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To assess the adherence to medication therapy for secondary prevention and achievement of 
treatment goals in persons with coronary heart disease (CHD) in a general population. 
Methods 
This project used data from the seventh wave of the Tromsø Study, alone and linked with data 
from the Norwegian Prescription database (NorPD). Participants self-reporting CHD were 
included (n = 1483). In Paper I, the associations between guideline adherence and 
achievement of treatment goals were assessed using logistic regression. Paper II validated the 
self-reported medication use by comparing by it to pharmacy dispensings from NorPD. In 
Paper III medication adherence was calculated based on pharmacy dispensings from NorPD, 
and the associations between medication adherence and blood pressure and low-density-
lipoprotein (LDL)-cholesterol were explored using linear regressions. 
Results 
Use of lipid-lowering drugs (LLDs) was reported by 76% of the study population, 
antihypertensive drugs by 72% and acetylsalicylic acid (ASA) by 66%. Agreement between 
self-reported medication use and pharmacy dispensings was high for all three medication 
groups (kappa ≥0.61). Average medication adherence (proportion of days covered) was 0.94 
for both LLDs and antihypertensive drugs and 0.97 for ASA. The recommended treatment 
goal for LDL-cholesterol was reached by 9% of the population. Achieving this treatment goal 
was associated with use of LLDs. Lower LDL-cholesterol was also associated with higher 
adherence to LLDs. The blood pressure goal was reached by 58% of the population, but 
achieving this goal was not significantly associated with using antihypertensive drugs. There 
was also no statistically significant association between adherence to antihypertensive drugs 
and lower systolic or diastolic blood pressure.  
Conclusions 
Use of and adherence to medications for secondary prevention of CHD was high, but 
achievement of treatment goals for blood pressure and especially LDL-cholesterol was low. 
Our results indicate that the lipid-lowering and antihypertensive therapy is not sufficiently 
intense. The prescription level might be a potential target to improve achievement of 
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1.1 This thesis 
This thesis investigates the use of medications for secondary prevention of coronary heart 
disease (CHD) and achievement of treatment goals for blood pressure and low-density-
lipoprotein (LDL)-cholesterol in a general population with CHD. The project consists of three 
papers using data from the seventh wave of the Tromsø Study (Tromsø 7) linked with data 
from the Norwegian Prescription Database (NorPD) and included participants with self-
reported CHD. In the first paper we described the use of antihypertensive drugs, lipid-
lowering drugs (LLDs) and acetylsalicylic acid (ASA) among these participants and their 
achievement of treatment goals for blood pressure and LDL-cholesterol. We also assessed the 
association between use of antihypertensive drugs and achievement of the treatment goal for 
blood pressure as well as between use of LLDs and achieving the treatment goal for LDL-
cholesterol. In the second paper we validated the self-reported use of antihypertensive drugs, 
LLDs and ASA by comparing the self-reported information with dispensing data from NorPD 
and explored different methods of defining current medication use in NorPD. In the third 
paper, we calculated proportion of days covered (PDC) as a measure of medication adherence 
to antihypertensive drugs, LLDs and ASA based on dispensing data from NorPD and assessed 
the association between adherence to antihypertensive drugs and systolic and diastolic blood 
pressure, and between adherence to LLDs and LDL-cholesterol levels. 
1.2 Coronary heart disease 
CHD, also called coronary artery disease or ischemic heart disease, is a major cause of death 
worldwide (1). In developed countries, the age-standardized CHD mortality rate has 
decreased over the last decades and is now surpassed by cancer as the most common cause of 
death in several countries, including Norway (2). Reduced mortality is a result of better CHD 
prevention and improved acute treatment (3, 4). As more patients survive acute CHD events, 
the prevalence of persons living with CHD rises. Having suffered a CHD event increases the 
risk of experiencing a new event (5), and as the number of persons surviving CHD events 
increases, optimal secondary prevention treatment is becoming increasingly important in a 




1.2.1 Disease mechanism, revascularization procedures and risk factors 
of CHD 
CHD occurs as a result of reduced oxygen supply to the heart (6). This is usually caused by a 
blockage of the coronary arteries, thus preventing blood from flowing to the heart. The most 
common cause of the blockage is build-ups of cholesterol-rich fatty deposits on the inner 
walls of the coronary arteries (6, 7). A partial blockage of the arteries leads to angina pectoris 
(AP), while a complete blockage or severely reduced blood flow results in a myocardial 
infarction (MI) (8).  
A method used to open the blocked coronary arteries is percutaneous coronary intervention 
(PCI). The procedure involves leading a guide catheter through the arteries from the wrist or 
groin to the coronary arteries (9). Then a thin guidewire with a deflated balloon is led in 
through the catheter to the blockage. At the blockage the balloon is inflated to press the 
plaque blocking the artery towards the artery walls thus widening the coronary artery’s 
diameter and restoring the blood flow to the heart. The balloon is then deflated and removed. 
In the PCI process, it is common to insert a stent in the blocked area of the coronary artery to 
ensure that the artery stays open. The stent can either be bare metal or drug-eluting. Drug-
eluting stents contain medications that inhibit growth of new tissue in the area around the 
stent, thereby preventing new blockage of the stented artery, known as restenosis (9, 10). 
In some cases coronary artery bypass graft surgery (CABG) is preferred over PCI as a method 
of restoring blood flow to the heart (10). This surgery is conducted by moving blood vessels 
from the chest cavity, thighs or legs and connect them between the coronary arteries and the 
aorta, bypassing the blocked area (11).  
Persons with CHD have increased risk of new cardiovascular events and death. Secondary 
prevention is therefore important to lower this risk. The major modifiable risk factors for 
CHD include hyperlipidemia, hypertension, smoking, unhealthy diet, diabetes and low 
physical activity (6, 12, 13). Secondary prevention of CHD targets these risk factors, both 
through lifestyle changes and pharmacological treatment. Lifestyle modifications, including 
smoking cessation, increased physical activity and adopting a healthier diet are highly 




stress the importance of using medications to lower cholesterol and blood pressure, and 
antiplatelet drugs to prevent blood clotting (12, 13). 
1.2.2 Medications used for secondary prevention of CHD 
The most common medications used for secondary prevention of CHD are described below. 
Lipid-lowering drugs (LLDs) 
Statins 
The most prescribed LLDs worldwide are statins. These are also specifically recommended as 
the first choice of lipid-lowering treatment by clinical practice guidelines in Europe (14). 
Statins are recommended to all patients with CHD. There are six different statins authorized 
for sale in Norway; atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and 
simvastatin, whereof simvastatin and atorvastatin are the most used (15). 
Statins’ mode of action is through inhibition of hydroxymethylglutaryl-coenzyme A (HMG-
CoA) reductase and they are therefore also known as HMG-CoA reductase inhibitors (16). 
HMG-CoA reductase is important for formation of precursors of several biological 
substances, including cholesterol. Reduced cholesterol formation leads to an increase in LDL-
receptors in the liver and hence increased uptake of LDL-cholesterol from the blood and 
increased metabolism in the liver. This reduces blood concentrations of total cholesterol, 
LDL-cholesterol, triglycerides and apolipoprotein B, and increases concentrations of high-
density lipoprotein (HDL)-cholesterol (16). 
Other LLDs 
If statins are not tolerated or insufficient to lower lipids to the recommended level, 
substitution with or addition of other LLDs such as ezetimibe is possible. Other substances 
such as cholesteryl ester transfer protein inhibitors, bile acid sequestrants and nicotinic acid 
can also contribute to reduction of lipids but are not commonly used (16).  
Ezetimibe binds to a protein that transports cholesterol from the intestine, thus inhibiting 
absorption of cholesterol (14). This leads to increased expression of LDL-receptors in the 
liver, hence increasing the cholesterol-lowering effect. A combination of ezetimibe and a 




In the last decade a new class of LLD has been developed, known as proprotein convertase 
subtilisin/kexin type 9 (PCSK9)-inhibitors (18). PCSK9 is an enzyme that binds to the liver’s 
LDL-receptors and leads to their degradation (16). Fewer LDL-receptors results in less LDL-
cholesterol being absorbed into the liver and hence higher concentrations in the blood. 
PCSK9-inhibitors bind to PCSK9 and thereby prevent the degradation of the LDL-receptor 
and thus more LDL-cholesterol is being removed from the blood (18). Though PCSK9-
inhibitors are found to be highly effective, their use is limited due to their high costs (19).  
Antihypertensive drugs 
Angiotensin-converting enzyme (ACE)-inhibitors and angiotensin receptor blockers (ARBs) 
 ACE-inhibitors and ARBs are among the most used antihypertensive drugs in Norway as 
well as the rest of the world (15, 20). They are especially recommended for those with a 
combination of hypertension and diabetes because of their advantageous effects against 
nephropathy, as well as for patients with reduced left ventricular function (20, 21).  
Both ACE-inhibitors and ARBs exhibit their main effect by inhibiting the activity of 
angiotensin II, ACE-inhibitors by inhibiting the enzyme ACE which converts angiotensin I to 
angiotensin II, and ARBs by blocking the angiotensin II type 1 receptor (21). Angiotensin II 
is a potent vasoconstrictor peptide, hence its inhibition leads to vasodilatation and reduction 
in total peripheral resistance. Release of aldosterone is also dependent of angiotensin II, and 
by reducing aldosterone release, more blood flows through the kidneys and more sodium and 
water is excreted (22). Lower blood volume reduces blood pressure.  
Beta-blockers 
Beta-blockers have for a long time been recommended as a part of the standard treatment of 
secondary prevention of CHD. Their effect on reducing risk of sudden death or reinfarction 
has been thoroughly documented. However, the studies documenting this effect are from a 
time before optimalization of revascularization procedures which were described in section 
1.2.1 (23, 24). It is now therefore debatable whether beta-blockers should be recommended to 
all patients after an MI, or if the recommendation only should include the patients at highest 
risk, where the effect is shown to be strongest (24, 25). Currently, there are ongoing studies 





Irrespective of whether beta-blockers should be routinely used for secondary prevention of 
CHD, it does have a role in antihypertensive treatment. Beta-blockers bind reversibly to beta-
adrenergic receptors (21). This leads to many different effects in many different sites in the 
body. For blood pressure reduction, several mechanisms are involved, leading to reduction in 
cardiac output, vasodilatation, decreased heart rate and a reduction in the hearts contractility 
and need of oxygen (21).  
Calcium-channel blockers (CCBs) 
CCBs inhibit movement of calcium ions through calcium channels in vascular smooth muscle 
and the heart (21). Their effect on the vascular smooth muscle leads to vasodilation, while the 
CCBs with direct effects on the heart contribute to reduced heart rate and contraction. 
Dihydropyridines, which are the most used CCBs for hypertension, mainly affect vascular 
smooth muscles, while the CCBs with more specific effect on heart rate and contractility are 
mainly used for other indications than hypertension (21).  
Thiazides 
Thiazides bind to the distal tubular sodium/chloride cotransporter in nephrons, thus inhibiting 
reabsorption of sodium and chloride and resulting in their excretion (21). This also increases 
excretion of water, which lowers the volume of blood plasma and in that way reduces blood 
pressure. Thiazides also have an additional vasodilating function, which contributes to 
reduced blood pressure.  
Other antihypertensive drugs 
In addition to the antihypertensive drug classes mentioned above, other medications with 
antihypertensive effects exist but are not as much used, at least not for the indication of 
hypertension (20). However, if combining the above-mentioned drug classes does not give the 
required antihypertensive effect, addition of a potassium-sparing diuretic, also known as an 
aldosterone antagonist or mineralocorticoid receptor antagonist, is usually the next step (20). 
These work by binding to mineralocorticoid receptors and thereby inhibit binding of 
aldosterone (21). Reduction of blood pressure is thus caused by reduced reabsorption of 






Acetylsalicylic acid (ASA)  
European guidelines for secondary prevention of CHD recommend ASA as the first-line 
choice of antiplatelet drug (12, 13). ASA has been shown to effectively reduce serious 
cardiovascular events and death, but due to its potential of increasing the risk of major 
bleeding, it is only recommended as secondary, and not primary, prevention (27). In low 
doses ASA binds irreversibly to the enzyme cyclooxygenase-1 (COX-1) in blood platelets, 
and hence inhibits the formation of thromboxane A2 which again reduces the platelets’ ability 
to aggregate (28).  
Other antiplatelet drugs  
If ASA is not tolerated, adenosine-diphosphate (ADP) receptor antagonists, especially 
clopidogrel, can be alternatives. ADP-receptor antagonists inhibit the purinergic receptor 
P2Y12 (28). Inhibition of P2Y12 deactivates glycoprotein IIb/IIIa which again leads to 
decreased thromboxane formation and hence reduced platelet aggregation.  
The first 12 months after MI or PCI, dual antiplatelet therapy (DAPT) is recommended (12, 
13, 29). This consists of ASA combined with an ADP-receptor antagonist, usually 
clopidogrel. DAPT has documented effect on prevention of new coronary events and death, 
but also increases the risk of major bleeding. As the risk of major bleeding is proportionally 
related to its duration of use, the ADP-receptor antagonist is recommended to be discontinued 
after 12 months, while treatment with ASA continues indefinitely. The optimal duration of 
DAPT is however still to be determined (29). 
1.2.3 Treatment goals in European guidelines 
The Joint European Societies (JES) have published guidelines on secondary prevention of 
CHD throughout the last twenty-seven years. The first Joint Task Force, consisting of the 
European Society of Cardiology (ESC), the European Atherosclerosis Society (EAS) and the 
European Society of Hypertension (ESH), published the first guideline in 1994 (30). The 
sixth, and most recent, guideline from the JES was published in 2016 (13). All editions of the 
guidelines have focused on the treatment of modifiable risk factors for CHD: cholesterol, 
blood pressure, diabetes control, smoking, body weight and physical activity.  
The most recent guidelines from 2016 (13) recommend that all persons with CHD stop 




body weight (BMI of 20-25 kg/m2), and attain moderate aerobic physical activity at least 150 
minutes or vigorous physical activity at least 75 minutes a week. In persons with CHD who 
also have diabetes, glycated hemoglobin (HbA1c) <7.0% (<53 mmol/mol) should be aimed 
for. As this project focused on blood pressure and cholesterol, treatment goals for these are 
described in more detail below. 
Blood pressure 
As hypertension is a major risk factor of recurrent CHD events, as well as other conditions 
such as heart failure, stroke, atrial fibrillation and renal failure, blood pressure control is very 
important in high-risk patients. The recommended treatment goal for persons with CHD has 
generally been stable since the JES guidelines from 1994 (see Table 1). All the six guidelines 
recommend a blood pressure of <140/90 mmHg, except for the one from the Fourth Joint 
Task Force from 2007. In these guidelines the recommendations for persons with established 
CVD was a blood pressure of <130/80 mmHg if feasible (31).  
The risk of death from cardiovascular diseases is found to increase from systolic blood 
pressure levels of 115 mmHg and diastolic blood pressure levels of 75 mmHg and upwards 
(32). The results of the Systolic Blood Pressure Intervention Trial (SPRINT) from 2015 found 
that reducing systolic blood pressure to <120 mmHg showed reduced rates of the combined 
outcome of death from any cause and fatal and non-fatal major cardiovascular events 
compared to a systolic blood pressure goal of <140 mmHg (33). More serious adverse effects 
were however found in the intervention group. The participants and study personnel were not 
blinded to study-group assignment and this may have affected the results. Evidence from 
reliable randomized controlled trials concerning the optimal treatment target for blood 
pressure among persons with CHD is scarce. The guidelines agree that there is sufficient 
evidence to recommend lowering blood pressure to below 140/90 mmHg but request more 
research before deciding to recommend even lower blood pressure targets (12, 13).  
Effects of blood pressure reduction are in some studies found to be greater in patients with 
diabetes than in the general population. The treatment goal for blood pressure could therefore 
differ from that for the general CHD population. However, also in diabetes patients there is 
little evidence from randomized controlled studies on which to base the recommendations. 




compared intensive blood pressure lowering treatment that targeted a systolic blood pressure 
<120 mmHg and standard therapy targeting a systolic blood pressure of <140 mmHg. The 
trial did not find any significant difference in the rate of the composite outcome of major 
cardiovascular events (34). Increased rate of adverse effects was seen in the intensive 
treatment group.  
Though risk of adverse effects in the elderly is a concern, there is now evidence that blood 
pressure lowering treatment in elderly hypertensive persons, including those >80 years of age, 
is as beneficial as treatment in younger patients (35). However, as the frailest elderly persons 
are not usually included in studies, it is unknown whether these results are generalizable to 
them. In the 2016 guidelines on cardiovascular disease prevention it is therefore 
recommended to lower systolic blood pressure to 140-150 mmHg in elderly >60 years of age 
who have a systolic blood pressure ≥160 mmHg, so long as this is tolerated by the individual 
patient (13).  
Cholesterol 
As atherosclerosis is known to cause CHD, lipid control is very important in secondary 
prevention of CHD. The JES guidelines from 1994 started with a recommendation of 
reducing total cholesterol to <5.5 mmol/L (30) (see Table 1). In the next guideline from 1998, 
this was reduced to <5.0 and a separate treatment goal for LDL-cholesterol was introduced at 
<3.0 mmol/L (36). The most recent guidelines from 2012 and 2016 focus mainly on LDL-
cholesterol and recommend LDL-cholesterol levels based on total cardiovascular risk. 
Persons with moderate risk are recommended an LDL-cholesterol of <3 mmol/L, those with 
high risk an LDL-cholesterol of <2.5 mmol/L or a reduction of at least 50% from baseline. 
Those at very high risk, which includes all with established CHD, are recommended an LDL-
cholesterol of <1.8 mmol/L or a reduction of at least 50% from baseline (12, 13). In newer 
guidelines from ESC, including the 2019 ESC Guidelines for the diagnosis and management 
of chronic coronary syndromes and the 2019 ESC/EAS Guidelines for the management of 
dyslipidemias, the treatment goal for LDL-cholesterol is reduced even further to <1.4 mmol/L 
and at least 50% reduction from baseline (14, 37). There is even a suggestion of reducing 
LDL-cholesterol to <1.0 mmol/L in those who have experienced two cardiovascular events in 
two years (37). Though the treatment goal has continuously been lowered, reaching these 














































































































































































































































































































































































































































































































































































































































































































































































































































































1.2.4 Adherence to prescription guidelines and achievement of 
treatment goals 
The EUROpean Action on Secondary Prevention through Intervention to Reduce Events 
(EUROASPIRE) surveys have assessed lifestyle, risk factors and use of medications for 
secondary prevention of CHD in Europe. The results from the first survey were published in 
1997 and explored medication use and achievement of treatment goals based on the first JES 
guideline from 1994 (39). Since then, four more surveys have been conducted: 
EUROASPIRE II (40), III (41), IV (42) and V (43). Comparisons of the EUROASPIRE 
surveys have found that the proportion of CHD patients using medications for secondary 
prevention has increased, as well as the proportion having total cholesterol, LDL-cholesterol 
and blood pressure control (44-46). However, there is still a large proportion of CHD patients 
that do not reach the recommended treatment goals, especially the treatment goal for LDL-
cholesterol. The most recent survey, EUROASPIRE V, conducted in 2016-2017, found that 
although 93% used antiplatelet drugs, 95% antihypertensive drugs and 84% LLDs, only 58% 
had a blood pressure <140/90 mmHg (<140/85 if diabetic) and 29% had an LDL-cholesterol 
of <1.8 mmol/L (43).  
Though the number of countries being included in the EUROASPIRE surveys has increased 
from nine in EUROASPIRE I to twenty-seven in EUROASPIRE V, Norway has not been 
included in any of the surveys. Prescription of secondary preventive medications after acute 
myocardial infarction in Norway in 2009-2013 has been described by Halvorsen et al (47). 
They found that 91% of the patients were discharged with a prescription of antiplatelet drugs, 
90% with a prescription of statins, 82% with beta-blockers and 60% with ACE-inhibitors or 
ARBs. After 12 months 84% of the patients were still being dispensed ASA and statins, while 
77% and 57% were being dispensed beta-blocker and ACE-inhibitors or ARBs respectively 
(47).  
Secondary prevention of CHD and achievement of treatment goals have also been 
investigated in Norway through the NOR-COR study (48). The NOR-COR study was 
conducted at the two Norwegian hospitals in Drammen and Vestfold in the southeast of 
Norway and included 1127 patients discharged from the hospitals in 2011-2014 after an acute 
MI, CABG or PCI. At follow-up 2-36 months after discharge 93% were found to use 




high use of secondary preventive medications, 46% had a blood pressure of ≥140/90 mmHg 
(140/80 mmHg if diabetic) and 57% had an LDL-cholesterol concentration of ≥1.8 mmol/L at 
follow-up (49). The results from both EUROASPIRE and NOR-COR show that though 
medication use for secondary prevention after a CHD event is high, achievement of the 
treatment goals for blood pressure and LDL-cholesterol are far from optimal. 
1.3 Measuring medication use 
To assess adherence to prescription guidelines, medication use needs to be determined. 
Several methods exist for determining use of medications for secondary prevention of CHD. 
The most frequently used methods include self-report and assessment of prescribed 
medications based on either medical or pharmacy records (50-53). 
1.3.1 Self-report 
Self-reported medication use is usually collected either by questionnaires or interviews (51, 
52), and in some cases medication inventories (54). For medication inventories participants 
are asked to bring along the medications they use or show them to the investigator when 
being interviewed at home.  
Self-administered questionnaires are common tools for measuring medication use. They are 
structured instruments that allow collection of information from a large number of persons 
(52). There are some limitations to using questionnaires. To collect information about 
medication use, the persons answering the questionnaires are required to state and remember 
all of their medications. Some respondents may have problems remembering or may be 
unwilling to report all the medications they use, and others may even report medications they 
know they ought to be using but do not use (55). 
Interviews are also applied as a way of measuring medication use. They can have a strict 
structure similar to self-administered questionnaires or be in more flexible forms. During less 
rigid interviews additional information can be obtained and questions can be adjusted 
individually to each of the respondents (51). They also allow for more clarification of the 
questions and result in higher completeness than structured questionnaires (52). Despite of its 




(52), and also affected by the same problems concerning recall and potential unwillingness to 
report actual medication use (55). 
1.3.2 Prescriptions 
In contrast to self-reported medication use, information about prescriptions is collected 
objectively and non-differentially. This can be done by examining medical records or 
assessing prescription databases, covering prescribed and/or dispensed medications (50, 52, 
53). 
Examining medical records to define if medications are prescribed and used according to 
guidelines is not uncommon. Though it does give a clear indication of which medications 
have been prescribed to the patients, it does not account for primary non-adherence (53). The 
same is true for databases only including information about prescriptions and not dispensings.  
Prescriptions that have been dispensed are more likely to be used (53). Databases containing 
information about dispensed medications are therefore more reliable sources when defining 
medication use. However, many such databases are incomplete, as they are based on claims 
from selected insurance companies or pharmacies (56). Other potential limitations arise when 
the medications examined are available over-the-counter (OTC) or as free samples distributed 
by health care professionals (53).  
Scandinavian national prescription databases do not have these limitations, as they are 
complete databases including all dispensed medications from all national pharmacies to all 
ambulatory individuals irrespective of reimbursement (57). Another advantage is that these 
registries can be linked to other databases, health surveys and other clinical studies using the 
unique national identity number assigned to all citizens.  
Even when using complete prescription databases, defining which medications are in use at a 
certain timepoint is a challenge. The two most common methods of defining medication use 
at a certain date are fixed-time window, also called fixed look-back period, and the legend-
time method, also known as legend-duration or medication-on-hand (58, 59). While fixed-
time window defines a medication in use as having a prescription dispensed within a defined 
time period before the date of interest, legend-time method uses the amount dispensed to 




medications used daily with regular dosages. For medications with varying use or dosages, 
more complex methods like for instance reverse waiting time distribution (60) might be 
needed.  
Another limitation of using dispensing data to define medication use is that it is not possible 
to confirm that the dispensed medication is actually taken or whether it is taken but not as 
indicated by the prescriber (53). 
1.3.3 Validity 
As all the measurement methods have limitations, none of them can provide information 
about the true medication use. To consider the validity of the different methods of examining 
medication use, studies have compared the different data sources. Since there is no absolute 
gold standard for measuring medication use, some studies have only looked at agreement 
between self-report and dispensing data (61-69), while others have also assessed validity 
using either self-report, dispensing data or both as reference standards (58, 70-81).  
When investigating medications used on a chronic basis, agreement between self-report and 
pharmacy dispensing data is generally found to be high (68). For medications used as needed, 
agreement tends to be lower. Cardiovascular drugs are used on a daily basis, and self-reported 
use of these medications is generally found to have high agreement with prescription or 
dispensing data (65, 66, 68). 
Most studies comparing self-reported and dispensed LLDs find substantial to almost perfect 
agreement with kappa-values of 0.67-0.95 (61, 62, 69, 71-75). Studies assessing validity 
using dispensing data as the reference source find high validity of self-reported LLDs with 
sensitivities of 87-97% and specificities of 88-99% (70, 73-75). 
Agreement between self-reported use and dispensing data concerning antihypertensive drugs 
as a group is mostly found to be substantial with kappa-values of 0.61-0.71 (63, 72, 74). 
However, one study finds only moderate agreement (77), while others find agreement to be 
almost perfect (71, 73). Sensitivity of self-reported antihypertensive use is generally found to 




Low-dose ASA is available OTC in most countries, which makes validating self-reported use 
difficult. Lower agreement and validity than for LLDs and antihypertensive drugs would 
therefore be expected. Despite this, most studies having investigated agreement and validity 
of self-reported ASA generally find at least substantial agreement with dispensing data (63, 
73, 79).  
Although self-reported use of LLDs, antihypertensive drugs and antiplatelet drugs is mostly 
found to have substantial agreement with dispensing data or quite high validity, the results 
vary. Studies have included diverse populations and assess medication use by different 
methods. In addition, none of the studies have investigated medication use solely for 
secondary prevention of CHD.  
1.4 Medication adherence 
In addition to establish which medications that are used, adherence to these medications is an 
important factor to achieve the best possible CHD preventive effect. The World Health 
Organization (WHO) defines adherence as “The extent to which a person’s behavior – taking 
medication, following a diet, and/or executing lifestyle changes, corresponds with agreed 
recommendations from a health care provider” (82).  
Other terms have sometimes been used interchangeably with adherence, namely compliance 
and concordance (83). There are however subtle differences between the terms, particularly 
regarding the relationship between the patient and the health care provider. Compliance is 
often defined as “the extent to which the patient’s behavior matches the prescriber’s 
recommendations” (83), and thereby describes the relationship between the health care 
provider and the patient as hierarchical, where the prescriber decides on the treatment and the 
patient is expected to follow it without question. Concordance, on the other hand, focuses on 
the process of reaching a consensus about the treatment between the patient and health care 
provider and was originally defined as “a new approach to the prescribing and taking of 
medicines. It is an agreement reached after negotiation between a patient and a health care 
professional that respects the beliefs and wishes of the patient in determining whether, when 
and how medicines are to be taken. Although reciprocal, this is an alliance in which the health 
care professionals recognize the primacy of the patient's decisions about taking the 




to 2009 found that nearly all publications used the term compliance from mid-1970, before 
adherence became increasingly used from mid-1980s and was the most used term from the 
mid-2000s (84). Concordance was used occasionally from the late the 1990s, with a top about 
2006-2008 before declining again in 2009.  
To simplify the comparison between studies exploring adherence, a taxonomy for adherence 
was described in 2012 (84). This taxonomy divides the adherence process into three phases: 
initiation, implementation and discontinuation. Initiation signifies the start of the treatment 
and can either be measured as a binary measure, starts treatment or not, or as time from 
prescription to initiation. Implementation is the extent to which a person actually follows the 
prescribed dosing regimen from initiation to discontinuation. Discontinuation marks the end 
of treatment, hence the last dose taken after which no more doses are registered. Persistence is 
the time measured from initiation until discontinuation (84).  
There is no optimal way of measuring adherence as this would require a feasible method of 
ascertaining whether the prescribed dosage regimen is indeed followed by the patient, 
including if, when and how the doses are ingested. The most reliable method of assessing 
adherence is directly observed therapy (85), but this method is generally not practical in most 
settings. Other direct approaches to adherence measurement include therapeutic drug 
monitoring and the use of ingestible sensors or addition of biological markers to the 
medication formulations (85-87). Indirect measurement methods are more widely utilized. 
The most common ways of measuring adherence are through pharmacy dispensing records or 
self-report, either in form of interviews, diaries or questionnaires. Other indirect methods 
include pill counts, measuring clinical responses or using electronic drug monitors (85, 86). 
Pharmacy dispensing records can be used to calculate a range of adherence and persistence 
measures, including measures of medication availability, discontinuation/continuation, 
switching, medication gaps and refill compliance (88). Measures that assess medication 
availability are most applied, and of these measures medication possession ratio (MPR) and 
proportion of days covered (PDC) are the most common approaches (89). These methods are 
similar, and the names are sometimes used interchangeably, though there are subtle 
differences between them. The most commonly used cut-off to define participants as being 




considered arbitrary and is often used to be able to compare results between studies. There has 
been some research finding that for medications used for cardiovascular disease (CVD), those 
with a PDC ≥0.80 have a lower risk of hospitalizations and cardiovascular events than those 
with a PDC <0.80 and therefore this cut-off could be considered reasonable for these 
medications (91, 92). However, another study insist that the cut-off depends on which 
medication is studied and that the optimal cut-off varies between medications, also those in 
the same groups such as statins (93). 
1.4.1 Adherence to medications used for CHD and associations with 
clinical outcomes 
Comparing results from studies examining adherence to medications used for CHD is 
complicated by use of different methods of measuring and calculating adherence. All studies 
do however agree that adherence to medications used for secondary prevention is suboptimal 
and hence has potential for improvement. A systematic review from 2015 found that 
medication adherence for secondary prevention of CHD within one year of hospital discharge 
ranged from 54% to 86% (94), while a meta-analysis from 2012 found a summery estimate of 
adherence of 66% for those using cardiovascular drugs for secondary prevention (95). 
Non-adherence to medications used for prevention of CHD has been found to increase the risk 
of cardiovascular death and other major cardiovascular events (96-99). Increased healthcare 
costs are also found among those who are non-adherent compared to those defined as 
adherent (97).  
1.4.2 Barriers to adherence for medications used for CHD and 
interventions to overcome them 
The WHO has classified barriers to optimal medication adherence into five categories: 
patient-related factors, health system/health care team-related factors, condition-related 
factors, therapy-related factors and socioeconomic-related factors (82). Examples of patient-
level factors are forgetting to take medications, intentionally avoiding taking medications e.g. 
because of side-effects, low health literacy and health beliefs and attitudes (86, 100, 101). 
Factors related to the health care system or health care team include problems obtaining the 
medications, e.g. because the drug is unavailable (drug shortage), or that the medication is 




disease and level of disability, while therapy-related barrier could be prescription of complex 
medication regimes, e.g. high dosing frequency or polypharmacy (82, 101). Socioeconomic 
factors have not consistently been found to affect adherence, but factors that could influence 
medication adherence include education, income and literacy (82, 101). 
Most interventions aiming to increase adherence to medications used for CHD have targeted 
patient-level barriers and have included patient education or counselling, reminders or 
medication aids and providing psychosocial support (102, 103). A meta-analysis including 
sixteen studies examining interventions to improve adherence to multiple cardiovascular 
medications in CHD patients found that the interventions significantly improved medication 
adherence in their pooled results, and that there were no significant differences between 
intervention types (102).  
Adherence interventions do however not necessarily lead to lower blood pressure and LDL-
cholesterol. Even in studies finding significantly improved adherence to antihypertensive 
drugs or LLDs in the intervention group compared to the control group, blood pressure and 
LDL-cholesterol control is often not significantly improved (104-108).  
1.5 Summary 
CHD is one of the leading causes of morbidity and mortality worldwide. As more patients 
survive acute CHD events, optimal secondary prevention is increasingly important for a 
growing chronic CHD population and thus for public health. Despite this, risk factor control, 
including blood pressure and LDL-cholesterol levels, in this patient group remains 
suboptimal. The proportion of users of medications for secondary prevention, including 
antihypertensive drugs, LLDs and ASA, during the first years after the CHD event has 
increased and is now generally found to be high. Guideline adherence and achievement of 
treatment goals for blood pressure and LDL-cholesterol have however not been thoroughly 
explored in general populations with chronic CHD, as opposed to in the first few years after 
the CHD event (43, 49), and the association between use of, and adherence to, these 










The overall aim of the thesis was to assess the adherence to medication therapy for secondary 
prevention and achievement of treatment goals in persons with CHD in a general population. 
 
The specific objectives were:  
 
Paper I 
Describe and compare adherence to prescription guidelines for persons with CHD and explore 
its association with treatment goal achievement for blood pressure and LDL-cholesterol.  
 
Paper II 
Validate self-reported use of medications for secondary prevention of CHD by comparing 
self-report with pharmacy dispensing data and explore different methods for defining 
medication use in a prescription database. 
 
Paper III 
Describe adherence to medications used for secondary prevention of CHD and explore its 










3.1 Data sources 
3.1.1 The Tromsø Study 
The Tromsø Study is an epidemiological population-based health study that has been 
conducted seven times between 1974 and 2016. The study population consists of inhabitants 
in the municipality of Tromsø, Norway, a town with approximately 73,000 inhabitants in 
2016.  
This project used data from the seventh wave of the Tromsø Study (Tromsø 7). Tromsø 7 was 
conducted in 2015-2016 and invited all inhabitants in the municipality ≥ 40 years (n = 
32,591) to participate. The response rate was 65% (n = 21,083).  
The participants of Tromsø 7 received an invitation and a questionnaire (Q1) in paper-format 
by mail. The invitation included a username and password for Q1 for those who preferred to 
fill it in digitally. Links to a second questionnaire (Q2) and a graphical index of pain 
questionnaire were also included in the invitation, and these were only available 
electronically. Participants could fill in the questionnaires at home or the examination site 
where they could get assistance if needed. The invitation to Tromsø 7 is included in Appendix 
1 (Norwegian only). English translations of the questionnaires are available at the Tromsø 
Study’s webpage (109) and the pages relevant for this project are included in Appendix 2 and 
3. 
At attendance all the participants went through a health examination, consisting of 
anthropometric measurements (height, weight, waist and hip circumference), and 
measurement of blood pressure, heart rate and oxygen saturation. Blood samples for analysis 
of blood lipids, HbA1c, creatinine and more were also taken. 
3.1.2 The Norwegian Prescription Database (NorPD) 
The NorPD contains information about all prescriptions dispensed at Norwegian pharmacies 
since 1st of January 2004, irrespective of reimbursement (110). All pharmacies in Norway are 




ambulatory care. Deliveries of medications to nursing homes and other medical institutions 
are also registered in NorPD, but not on an individual level. OTC medications are not 
included in the database, unless dispensed by prescription. 
Prescription records stored in the database includes information about the prescriber, the 
patient for whom the medication was prescribed, the pharmacy where the prescription was 
dispensed, and the medications dispensed. About the prescriber, NorPD contains information 
about gender, month and year of birth, profession and specialty, while information about the 
patient include gender, month and year of birth, potential month and year of death as well as 
place of residence. Name, license number, municipality and county are registered about the 
pharmacy. Information about the medications dispensed include brand names, strength, 
package sizes, number of packages, anatomical therapeutic chemical (ATC) codes, number of 
defined daily doses (DDDs), codes of reimbursement, dispensing dates and prices (110). 
Areas of application and prescribed dose are also registered in the database, however, these 
are in free-text and not yet available for research. 
3.2 Study design 
This project was a cross-sectional study with a retrospective component. Paper I was a pure 
cross-sectional study. Paper II and Paper III included a retrospective component by including 
prescriptions dispensed before attendance in Tromsø 7. 
3.3 Study population 
The study population consisted of participants in Tromsø 7 who reported having previous MI 
(n = 753), previous PCI and/or CABG (n = 1226) and previous or current AP (n = 466). Some 
participants had more than one disease, making the total study population consist of 1483 
participants. 
In paper I, the study population was subdivided into these disease groups for some of the 
analyses: all participants reporting previous MI (n = 753), participants previous reporting PCI 
or CABG but not MI (n = 604) and participants reporting AP but not previous MI, PCI or 




3.4 Medication use for secondary prevention of CHD 
We included medications recommended for secondary prevention of CHD based on the 
European Guidelines on cardiovascular disease prevention in clinical practice from 2012 (12). 
This included low-dose ASA, antihypertensive drugs (ACE-inhibitors, ARBs, beta-blockers, 
CCBs, thiazides and other antihypertensives) and LLDs (mainly statins). 
3.4.1 Self-reported medication use from Tromsø 7 (Paper I and Paper II) 
Self-reported current medication use for secondary prevention of CHD was based on 
questionnaire data from Tromsø 7. Current users of LLDs were defined as those answering 
“currently” to the question “Do you use, or have you used cholesterol lowering drugs?” or 
writing down the name of an LLD when asked to state the names of all the medications they 
had used regularly the previous four weeks. Users of antihypertensive drugs were defined as 
those answering “currently” when asked “Do you use, or have you used blood pressure 
lowering drugs?” or writing down the name of an antihypertensive drug. ASA-users were 
defined as those denoting a name for a medication containing ASA or answering “yes” when 
asked “If you have used analgesics and anti-inflammatory medication regularly in the past 
year - did you use “Baby” or low dose Acetylsalicylic acid (75 mg or 160 mg per tablet, i.e. 
Acetylsalicylic acid®/Albyl-E®/Asasantin Retard®)?”.  
Medication names were coded to their ATC-codes by trained personnel. The ATC-codes were 
used to categorize the medications from generic substances into the medication classes 
antihypertensive drugs and LLDs, and their subgroups; ACE inhibitors, ARBs, beta-blockers, 
CCBs, thiazides, other or unknown antihypertensives, and statins and other or unknown 
LLDs.  
3.4.2 Medication use based on pharmacy dispensings from NorPD 
(Paper II and Paper III) 
Current medication use was defined in three different ways in Paper II; one using a fixed-time 
window of 180 days, and two using legend-time methods assuming a daily dosage of either 
one dosage unit (usually one tablet) or one DDD. A fixed-time window of 180 days was 
chosen because LLDs, antihypertensive drugs and ASA are used chronically on a daily basis 




approximately 90 days, and we also wanted to account for stockpiling and poor medication 
adherence. The assumption about a daily dosage of either one dosage unit or one DDD was 
made because the prescribed dosage was not available from NorPD. As the medications 
considered here are used daily with as little complicated regimen as possible, one dosage unit 
daily should be a fair assumption. We also performed the analyses assuming one DDD as this 
daily dosage should be the average dosage used for the individual generic substances, as 
stated in the definition of a DDD; “the assumed average maintenance dose per day for a drug 
used for its main indication in adults” (111). One dosage unit or one DDD has been assumed 
as daily dosage for these medications in some previous Nordic studies where prescribed 
dosage has not been available (68, 112).  
Persistent prevalent medication users were defined in Paper III as participants using the 
relevant medications for more than 365 days before attending Tromsø 7, thereby excluding 
incident medication users who started using the medications during the 365 days before 
attending Tromsø 7 and non-persistent medication users who did not have any supplies of the 
medications available within 180 days before attendance.  
3.5 Blood pressure and LDL-cholesterol measurements and 
treatment goals (Paper I and Paper III) 
Blood pressure was measured with an automated digital device (Dinamap ProCare 300 
monitor, GE Healthcare, Norway). Three consecutive measurements were taken with one-
minute intervals and after two minutes of seated rest. Blood pressure was defined as the mean 
of the last two measurements. If only the third measurement was missing (n = 2), the second 
measurement was used. When both the second and third measurement, but not the first, was 
missing (n = 1), the first measurement was used.  
LDL-cholesterol was collected and analysed by trained personnel using enzymatic 
colorimetric methods with commercial kits on a Cobas 8000 c702 (Roche Diagnostics GmbH, 
Mannheim, Germany) from non-fasting venous blood samples. The analysis was performed at 
the Department of Laboratory Medicine, University Hospital of North Norway, Tromsø, 




Treatment goals for blood pressure and LDL-cholesterol were defined in accordance with the 
European Guidelines on cardiovascular disease prevention in clinical practice from 2012 (12) 
(see Table 1 in section 1.2.3). For blood pressure, the treatment goal was considered achieved 
if the participants had a systolic blood pressure below 140 mmHg and a diastolic blood 
pressure below 90 mmHg, or, if they had diabetes, 80 mmHg. Treatment goal for LDL-
cholesterol was considered achieved for participants who had an LDL-cholesterol of below 
1.8 mmol/l.  
3.6 Covariates (Paper I and Paper III) 
Self-reported variables concerning age, sex, body mass index (BMI), relevant comorbidities, 
diet, physical activity, use of health services, alcohol consumption, smoking and use of 
smokeless tobacco were collected from the questionnaires in Tromsø 7. In Paper I these 
variables were used to calculate a propensity score which then was used to match participants 
using LLDs and antihypertensive drugs with participants who did not.  
In Paper III the variables concerning alcohol consumption, smoking and use of smokeless 
tobacco, diet and physical activity were summarized in two variables containing gradients of 
lifestyle using multidimensional scaling.  
3.7 Statistical analysis 
3.7.1 Paper I 
We used chi square tests to examine the relationship between achievement of both of the 
treatment goals for blood pressure and LDL-cholesterol and use of a combination of LLDs, 
antihypertensive drugs and ASA, and between achievement of both treatment goals and 
disease group.  
Propensity score matched logistic regression was used to explore the association between use 
of antihypertensive drugs and achievement of treatment goal for blood pressure, and the 
association between use of LLDs and achievement of treatment goal for LDL-cholesterol. 
Propensity score matching is a method used to reduce bias by balancing the distribution of 
covariates between the exposed and unexposed groups (113). Due to the high number of 




matching. This was done using multiple imputation by chained equations (MICE), a 
commonly used imputation method which can handle various variable types and skip patterns 
of questions in a survey (114). The imputation method was set based on the properties of the 
variables; predictive mean matching was used to impute numeric variables, logistic regression 
for binary categorical variables, proportional odds model for ordered categorical variables and 
polytomous logistic regression for unordered categorical variables. In the imputation process, 
more variables than those to be used in the propensity score matched logistic regression were 
included in order to improve the imputations. Taking into consideration the large dataset, 
amount of missing data in all variables and computer resources, ten imputed datasets were 
created with fifty iterations.  
Descriptive statistics were done in SPSS version 25.0 for Windows (IBM Corp, 2017), while 
chi square test, multiple imputation and propensity score matched logistic regression were 
performed in R (R Core Team (2019)) using the packages mice and MatchIt.mice.  
3.7.2 Paper II 
Agreement between Tromsø 7 and NorPD was measured by percent observed agreement and 
Cohen’s kappa. Cohen’s kappa is the percent agreement corrected for chance. Agreement was 
considered poor for kappa-values <0.00, slight for kappa-values of 0.00-0.20, fair for kappa-
values of 0.21-0.40, moderate for kappa-values of 0.41-0.60, substantial for kappa-values of 
0.61-0.80 and almost perfect when kappa-values were 0.81-1.00, as described by Landis and 
Koch (115).  
To determine the validity of the self-reported medication use, sensitivity and specificity were 
calculated using NorPD as the reference standard. Sensitivity was defined as the proportion of 
medication users defined by NorPD who were also defined as medication users by self-report 
(medication users in both sources divided by medication users in NorPD). Specificity was 
defined as the proportion of non-users defined by NorPD who did not self-report medication 
use (non-users in both sources divided by non-users in NorPD). Predictive values were also 
calculated. Positive predictive value (PPV) was the proportion of self-reported medication 
users who were also registered as users in NorPD (medication users in both sources divided 




who were not self-reported medication users who were also not registered as users in NorPD 
(non-users in both sources divided by those not self-reporting medication use).  
All analyses were conducted using SPSS version 25.0 for Windows (IBM Corp, 2017). 
Confidence intervals (CIs) were calculated in VassarStats (http://vassarstats.net/). 
3.7.3 Paper III 
Adherence was measured for persistent prevalent medication users as PDC, calculated as 
continuous multiple-interval measure of medication availability (CMA)7 using the R-package 
AdhereR (116). CMA7 is defined as “number of gap days for all event intervals extracted 
from the total time interval; (accounting for carry over from before the observation window 
and within the observation window, and excluding the supply left at the observation window 
end)” (116). The observation window was set to 365 days before attending Tromsø 7 until the 
attendance date, with a follow-up window from 01 January 2004 until 31 December 2016 
which is the whole period from which we had information from NorPD.  
Multivariable linear regression models were used to explore the association between non-
adherence to LLDs, age, sex, lifestyle, BMI, current and previous diabetes and LDL-
cholesterol and between non-adherence to antihypertensive drugs, age, sex, lifestyle, BMI, 
current and previous diabetes and systolic and diastolic blood pressure. Adherence was 
reversed and log-transformed (1.1 – log(PDC)) in the analyses because of the skewness in 
these variables. The analyses were done as complete case analyses, hence removing the 
participants with missing values in the relevant variables. 
All analyses were performed using R (R Core Team (2021)) using the packages AdhereR and 
vegan.  
3.8 Ethics 
The study was approved by the Regional Committee for Medical and Health Research Ethics 
of North Norway (2015/1775) and had an approved Data Protection Impact Assessment from 
UiT The Arctic University of Norway. The approvals are included in Appendix 4 and 5 
(Norwegian only). All participants in the Tromsø Study have given written informed consent 









4.1 Paper I 
Among the total population with self-reported CHD in Tromsø 7, 72% reported using 
antihypertensive drugs, 76% LLDs, and 66% ASA. Use of both LLDs and ASA was reported 
by 59%, and 49% reported using all three medication groups. The use of all these medications 
was highest in participants who had had a previous MI and lowest in those who only had AP. 
The treatment goal for blood pressure was reached by 58% of the study population. 
Achievement of the treatment goal was similar across the disease groups, but highest among 
participants with AP, where 62% had the recommended blood pressure, and lowest among 
those with PCI/CABG where the proportion was 56%.  
Nine percent of the study population reached the treatment goal for LDL-cholesterol. Highest 
achievement of the treatment goal was found for participants with previous MI, where 11% 
had the recommended LDL-cholesterol, while the lowest achievement was found among 
those with only AP, where the proportion was 3%.  
As so few participants reached the treatment goal for LDL-cholesterol, the proportion who 
achieved the treatment goals for both blood pressure and LDL-cholesterol was 6%. 
There was a statistically significant association between using all three recommended 
medication classes and achieving both treatment goals. The proportion reaching both 
treatment goals was 9% among participants who used all three classes of drugs and 3% 
among those who did not use all three (p < 0.001). Hence adherence to prescription guidelines 
gave higher achievement of treatment goals. 
There was also an association between CHD disease group and achievement of both treatment 
goals with the proportion reaching both treatment goals being 6% among participants with a 
previous MI, 6% among those with PCI and/or CABG and 1% among those with AP (p = 
0.04). 
Using LLDs was significantly associated with achieving the treatment goal for LDL-




not significantly associated with achieving the treatment goal for blood pressure (OR = 1.3, 
95% CI 0.7-2.6). 
4.2 Paper II 
Agreement between Tromsø 7 and NorPD for use of LLDs, antihypertensive drugs and ASA 
was substantial, with percent agreement over 80% for all medication groups, and kappa-
values over 0.61. PPVs were high for all three medication classes, over 0.90 when using 
fixed-time window, which shows that when participants reported using these medications, the 
likelihood that they had them dispensed was high. Sensitivity was also high for all three main 
medication classes, indicating that a high proportion of those registered as users in NorPD 
also self-reported use of these medications in Tromsø 7.  
Concerning the methods for defining current medication use in the NorPD, fixed-time 
window seemed to be the best with the highest kappa-values, specificity and positive 
predictive values; and sensitivity and negative predictive values comparable to the legend-
time methods. Comparing the two legend-time methods showed that using the assumption of 
one unit a day generally gave higher values than assuming one DDD a day.  
4.3 Paper III 
Medication adherence was high. The average PDC was 0.94 for LLDs and antihypertensive 
drugs, and 0.97 for ASA. Eighty-eight percent of participants using LLDs, 92% of those using 
antihypertensive drugs and 95% of those using ASA had a PDC of 0.80 or higher. 
Non-adherence to LLDs, female sex, lifestyle and current diabetes were significantly 
associated with increased LDL-cholesterol. Higher age was associated with increased systolic 







5.1 Discussion of main findings 
5.1.1 Guideline adherence  
Adherence to prescription guidelines was found to be relatively high in our study population, 
with 76% reporting using LLDs, 72% antihypertensive drugs and 66% ASA. However, this is 
lower than what has been found in previous studies, such as the STABILITY (STabilization 
of Atherosclerotic plaque By Initiation of darapLadIb TherapY) (117) and CLARIFY 
(prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY 
disease) (118) studies, the newest EUROASPIRE surveys (42, 43), and Norwegian studies 
such as NOR-COR (49) and the study by Halvorsen et al. from 2016 (47).  
One reason for the lower guideline adherence in Tromsø 7 is the difference in study 
populations. Persons with CHD are in most studies included based on hospital records and 
within short time after their CHD event. The EUROASPIRE surveys recruited CHD patients 
from large academic hospitals and their follow-up occurred 6 months to 2-4 years after 
discharge (39-43). NOR-COR included CHD patients based on hospital discharge lists from 
the hospitals in Drammen and Vestfold within the last three years before the study (48), while 
the study by Halvorsen et al assessed medication use 12 months after MI (47). The 
STABILITY and CLARIFY studies both included persons with CHD from broader time 
perspective but had additional inclusion and exclusion criteria used to define their study 
populations, such as including patients only if they fulfilled at least one of these criteria: ≥60 
years, having diabetes mellitus, low HDL-cholesterol, being a smoker, having renal 
dysfunction or polyvascular disease (117), or excluding persons that had been admitted to the 
hospital for CVD within three months before inclusion, or persons with serious conditions 
that may hamper their participation over time (118). Our study population was selected from a 
general population. There would therefore on average be a longer time span between the CHD 
events and participation in Tromsø 7 for the participants in our study than in the studies 
mentioned above. Among the participants in our study population who reported how old they 
were when they first had an MI (n = 636), PCI (n = 841), CABG (n = 497) or AP (n = 350), 
the time mean between the first CHD event and attendance in Tromsø 7 was 11.2 years for 




Persistence with medication therapy for secondary prevention of CHD is known to diminish 
over time (112, 119, 120), and our results could be a consequence of that. Persons with CHD 
in a general population are not studied to the same degree as CHD patients in the first years 
after their diagnosis. The need for studies investigating this population in long-term using 
population-based studies has been acknowledged (121). As the prevalence of CHD is 
increasing due to more persons surviving their initial CHD event, this is an important 
population to follow in a public health view, and our findings contribute to the field by 
increasing the knowledge about this population.  
5.1.2 Validation of self-reported medication use 
To assess guideline adherence to secondary prevention of CHD we used the participants’ self-
reported current use of LLDs, antihypertensive drugs and ASA. To examine if these responses 
corresponded with which medications were available to the participants, we performed the 
validation study comparing their responses with pharmacy dispensings from NorPD. We 
found substantial to almost perfect agreement for the three medication classes, with kappa-
values of 0.81 for antihypertensive drugs, 0.78 for LLDs and 0.69 for ASA when using the 
fixed-time window method for defining current medication use in NorPD. This method gave 
higher agreement, positive predictive values and specificity compared to either of the legend-
time methods and was our preferred method for comparison when it comes to these 
medications.  
Our results are in line with previous studies comparing self-reported medication use and 
pharmacy dispensing data, especially for LLDs (61, 62, 69, 71, 72, 74, 75) and 
antihypertensive drugs (63, 64, 71-74, 76, 78). Comparing our results to studies that have 
examined the individual LLD and antihypertensive drug classes, our results are similar for 
statins (63, 65), ACE-inhibitors/ARBs (61, 62, 65, 66, 80), CCBs (61, 62, 65, 66, 81), 
thiazides (76, 80) and mostly also for beta-blockers (61, 62, 64-66, 80, 81). A Finnish study 
by Haapea et al. found only moderate agreement for beta-blockers with a kappa-value of 0.55 
but this can be explained by the fact that not all beta-blockers are reimbursed, and the Finnish 
registry only contains information about reimbursed medications (67).  
Our results concerning agreement and validity of self-reported ASA were lower than for 




from New Zealand (63) and France (65), but lower than in two studies from Scotland (73) and 
Canada (79). This is surprising as low-dose ASA is only available on prescription in Norway 
but available OTC in most other countries. We therefore expected higher agreement and 
validity measures in our material than in similar studies from other countries, such as is the 
case with one Australian study (80).  
Our results show PPVs over 0.90 for all medication groups and subgroups, thus indicating 
that we can be quite certain that the participants with CHD who report using these 
medications are actual medication users. NPVs are lower for some of the medications, 
particularly ASA and statins. We can therefore not be as confident that participants who do 
not report use of these medications are actual non-users.  
For LLDs and antihypertensive drugs, sensitivity was high with values of 0.94-0.98, 
indicating that the Tromsø 7 questionnaire captures most of the users of these medications. 
Specificity was slightly lower, 0.88 for antihypertensive drugs and 0.78 for LLDs. No 
threshold exists for determining whether self-reported use of medications can be considered to 
be valid, and this has to be considered in each study situation (55). The implications the 
slightly lower specificity would have for Paper I are that some of the participants may have 
been misclassified as users of LLDs and antihypertensive drugs. This could have weakened 
the associations between use of LLDs and achievement of treatment goal for LDL-cholesterol 
and between use of antihypertensive drugs and achievement of treatment goal for blood 
pressure. The effect would however be expected to be small, as the proportion of participants 
that used LLDs and antihypertensive drugs was much larger than the proportion of non-users. 
The conclusion would not have changed, as the association between use of antihypertensive 
drugs and achievement of treatment goal for blood pressure was already found to be non-
significant. The association between use of LLDs and achievement of treatment goal for 
LDL-cholesterol was strong, and even if some participants had been misclassified, most 
would have been correctly classified as LLD-users and the association would most likely have 
remained statistically significant.  
5.1.3 Medication adherence  
As we already found good adherence to prescription guidelines and that the reported 




was the next step. We found a very high medication adherence for all three medication 
classes, with mean PDC of 0.94 for LLDs and antihypertensive drugs and 0.97 for ASA.  
Adherence to cardiovascular medications is often found to be insufficient and lower than what 
we have found in this project (94, 122-125). Comparing studies examining adherence is 
complicated by the differing ways of measuring, calculating and defining adherence (126, 
127). In our adherence study we have only looked at secondary prevention of CHD and only 
included prevalent persistent medication users in the implementation phase of the adherence 
process (84). These should be expected to have a high adherence. A study by Thornley et al. 
indicates this, by showing that 82% of the patients who had been dispensed statins three 
months before hospital admission had a statin dispensing ratio of ≥0.80 in the year after 
hospital discharge compared with only 44% of the patients who initiated statin treatment after 
the hospital admission (125).  
Adherence to LLDs used for secondary prevention has been found to be higher than for 
primary prevention (128), and the same can be assumed for antihypertensive drugs and ASA. 
Our results are more comparable to studies that have investigated adherence to medications 
used for secondary prevention of CHD using dispensing data to define adherence by MPR or 
PDC, than studies that have included both primary and secondary prevention or used other 
methods for adherence measurements. Studies that have used MPR or PDC to assess 
adherence to medications used for secondary prevention of CHD report mean MPR or PDC 
values of 0.82-0.88 for LLDs, 0.91 for dual antiplatelet therapy (DAPT) and 0.33-0.84 for 
various antihypertensive drugs (122, 123). The proportion of persons with an MPR or PDC 
≥0.80 was reported to be 76.5%-79.8% for LLDs, 88.1% for DAPT and 11.9%-52.7% for the 
various antihypertensive drugs (122, 129).  
Non-persistence and poor implementation tend to be highest close to initiation of treatment 
(112). Persons that persist with treatment, generally have a higher implementation adherence. 
Medication adherence for secondary prevention is commonly measured in the first months or 
years after discharge from hospital after the CHD event. Not that much is known about 
medication adherence in persons with CHD in a general population with varying time since 
their CHD diagnosis. Ensuring that these persons persist with their medication therapy and 




therefore add to what is already known about medication adherence to secondary prevention 
of CHD.  
Despite the high adherence to LLDs and antihypertensive drugs found in our study, few had 
reached the recommended treatment goals for LDL-cholesterol and blood pressure. Though 
sustaining a high medication adherence is important, these results suggest that initiating a 
complex and resource-demanding intervention to increase adherence in this population is 
probably inutile. Conversations with persons with CHD about the importance of adherence 
and their individual barriers to adherence could simply be conducted upon their visits to their 
GP’s office or pharmacies.  
5.1.4 Reduction of blood pressure and LDL-cholesterol and treatment 
goal achievement 
In our study population we found that 58% had a blood pressure <140/90 mmHg (<140/80 
mmHg if diabetic) and only 9% had an LDL-cholesterol <1.8 mmol/L. Achievement of the 
treatment goal for LDL-cholesterol was associated with using LLDs, and lower LDL-
cholesterol was found to be associated with higher adherence to LLDs. This is in line with 
what has been found in the Norwegian NOR-COR study (130). Contrary to the results for 
LDL-cholesterol, the same associations were not seen for blood pressure, where there was no 
statistically significant association between using antihypertensive drugs and achieving the 
treatment goal for blood pressure, or any significant association between adherence to 
antihypertensive drugs and lower blood pressure. This finding also correlates well with 
findings from NOR-COR (131). 
The proportion achieving the treatment goal for blood pressure in our study population is in 
line with what has been found in other studies. In the STABILITY study, 54% were found to 
have blood pressure control (blood pressure of <140/90 mmHg or 130/80 mmHg if diabetic) 
(117) and similar results were found for central and western Europe in the CLARIFY study 
(118). Kotseva et al. reported that 58% achieved the treatment goal for blood pressure in the 
newest EUROASPIRE study, EUROASPIRE V (43). The results from NOR-COR are also in 
accordance with ours with 54% of their study population reaching the treatment goal (49). 
The proportion achieving blood pressure control has been similar throughout all the 
EUROASPIRE surveys (39-43), with a small increase from EUROASPIRE III to 




that age-adjusted mean systolic and diastolic blood pressure in the general population had 
decreased from when Tromsø 2 was conducted in 1979-1980 to Tromsø 6 in 2007-2008 
(132). Achievement of treatment goals for those with validated MI also increased. Among 
participants in Tromsø 4 who had a first-ever MI between 1994 and 2008, 46.2% had reached 
the treatment goal for blood pressure (<140/90 mmHg or <130/80 mmHg if diabetic) at 
participation in Tromsø 6 in 2007-2008, while among participants in Tromsø 6 who had a 
first-ever MI between 2007 and 2016, 52.7% had achieved the treatment goal at attendance in 
Tromsø 7 in 2015-2016 (133). 
Consistent with our results, previous studies have found the treatment goal achievement for 
LDL-cholesterol to be lower than for blood pressure, however not as low as the 9% that was 
found in our study population. In EUROASPIRE V, 29% achieved the treatment goal for 
LDL-cholesterol of <1.8 mmol (43), while the proportion in the NOR-COR study was 43% 
(49). A higher proportion reached the LDL-cholesterol treatment goal in the STABILITY and 
CLARIFY studies. However, both these studies set the treatment goal for LDL-cholesterol at 
<2.6 mmol/L (117, 118). 
Our results may partly be explained by our study population differing from those above, as 
mentioned in chapter 4.1.1. This may especially affect the comparison of achievement of the 
treatment goal for LDL-cholesterol, as the guideline recommendations have gradually 
lowered this treatment goal. Since most of the participants in our study population have had a 
coronary event several years ago, they may not have been followed up according to the newer 
guidelines. From 2019 a new and even lower treatment goal for LDL-cholesterol was 
presented. ESC/EAS guidelines for the management of dyslipidemias and ESC guidelines on 
chronic coronary syndrome now recommend an LDL-cholesterol of <1.4 mmol/L in addition 
to a reduction in LDL-cholesterol of ≥50% from baseline (14, 37). If this is to be obtainable, 
especially considering the low achievement of the previous treatment goal of <1.8 mmol/L, 
more effort needs to be focused on optimizing the existing treatment with LLDs.  
5.1.5 How to improve medication therapy and treatment goal 
achievement among persons with CHD? 
For persons with CHD to have an optimal treatment with LLDs and antihypertensive drugs, 
they need to start using these medications, keep using them and use sufficiently high dosages 




adherence to LLDs, antihypertensive drugs and ASA is high, there is always room for 
improvement.  
According to the self-reported medication use in Tromsø 7, 24% did not use LLDs, 28% did 
not use antihypertensive drugs and 34% did not use ASA. The proportion defined as non-
users in NorPD was similar for LLDs and antihypertensive drugs; 25% were defined as not 
having used LLDs and antihypertensive drugs at least one year before Tromsø 7. For ASA, 
the proportion of non-users was lower in NorPD, where 24% were defined as not having used 
ASA during the last year. Of the total study population, 12% did not have any dispensings for 
either LLDs, antihypertensive drugs or ASA, indicating possible non-initiators, while the 
remaining non-users at least one year before attendance in Tromsø 7 according to NorPD had 
at some point used these medications but discontinued treatment. Reasons for non-initiation 
and non-persistence should be explored and interventions to increase initiation and 
persistence are needed.  
We have found high adherence among prevalent users persistent to the treatment regimen, 
however, this could still be optimized, especially for LLDs. Side-effects are commonly 
associated with suboptimal adherence and persistence. It is therefore important to discuss 
experienced side-effects with the patients and adjust treatment accordingly, either by change 
of medication or dosage, or by encouraging patients to attempt using the medications for a 
longer time if these are side-effects that are known to diminish over time. 
To increase achievement of treatment goals for blood pressure and LDL-cholesterol, our 
results suggest that further optimizing medication adherence probably is not enough. 
Treatment of both blood pressure and LDL-cholesterol may need to be intensified. For 
treatment with LLDs this initially includes increasing dosages of statins, switching to more 
potent statins such as atorvastatin or rosuvastatin (134), or adding another LLD, i.e. ezetimibe 
(17). All patients may not reach the treatment goals, even with high dosages of the most 
potent statins in combination with ezetimibe, especially if the goal to reach is lowered to 1.4 
mmol/L (135). New treatments to lower LDL-cholesterol include PCSK9-inhibitors. These 
have been shown to be effective, especially in combination with statins, and could be 
considered in cases where other treatments have failed. However, due to the high costs of 




For antihypertensive drugs, the most recent recommendations are to start with combination 
therapy when hypertension is diagnosed, as combinations of several classes of 
antihypertensives is found to have a better effect compared to monotherapy (20). Adding a 
new antihypertensive drug from another antihypertensive class when treatment is insufficient 
is also found to be better than increasing dosages of preexisting antihypertensive drugs, to 
increase effect while avoiding intolerable side-effects. In our project, we found that 51% of 
those who reported using antihypertensive drugs, reported using antihypertensive drugs from 
more than one antihypertensive class. This shows great potential for optimizing treatment of 
hypertension by adding antihypertensive drugs from other antihypertensive classes. Resistant 
hypertension may still occur despite optimal treatment. Treatment with antihypertensive drugs 
from three different classes, usually an ACE-inhibitor/ARB combined with a CCB and a 
diuretic such as a thiazide, at the highest tolerable doses and optimal medication adherence 
without reaching recommended treatment goals is considered resistant hypertension (20). 
Patients with resistant hypertension are normally treated with additional antihypertensive 
drugs from other antihypertensive groups, most commonly an aldosterone antagonist. More 
research is still required to determine the effect and safety of other potential non-
pharmacological treatments such as renal denervation or carotid baroreceptor stimulation, and 
these are therefore not usually recommended (20). 
As most of this study population has not been diagnosed with CHD recently, they are 
generally followed up in primary care by their general practitioner (GP). Previous studies 
have found that many GPs lack knowledge about current treatment goals in secondary 
prevention of CHD (136, 137). This has also been seen in Norway, where GPs expressed lack 
of knowledge of treatment guidelines, strategies for adjusting medical treatment and how to 
handle side-effects, in addition to finding it challenging to reach the treatment goals, and talk 
to patients about it (138). Interventions targeting GPs therefore seems to have a great potential 
for improving secondary prevention of CHD.  
Improved communication between hospitals and GPs concerning treatment follow-up after a 
CHD event could contribute to better follow-up of CHD patients. In the Norwegian study, 
GPs requested clearer instructions from the hospital to the GPs concerning optimal treatment 
including suggestions for titration of relevant medications and individualized treatment goals 




To optimize treatment of CHD patients that have had their disease for a longer time, all GPs 
should be updated on the topic of secondary prevention of CHD. One possible method to 
achieve this could be a campaign as a part of the Norwegian Academic Detailing Program 
(KUPP) (139). The program is run by the Regional Drug Information and Pharmacovigilance 
Centers (RELIS) and the Clinical Pharmacological departments at the four university 
hospitals in Norway and is funded by the Ministry of Health and Care Services. The academic 
detailing is performed by trained pharmacists and physicians visiting GPs one-to-one in the 
GPs’ offices. The sessions last about 20 minutes and the most important topics regarding 
medication use in specific therapeutic areas are discussed (139). Previous campaigns have 
included the topics non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, opioids for 
chronic pain, menopausal hormone therapy and treatment of diabetes type 2 (140). The 
academic detailing intervention on better use of NSAIDs resulted in a significant reduction in 
prescription of diclofenac and an increased prescription of naproxen (141), indicating that this 
is an effective intervention.  
Closer collaboration between GPs and community pharmacists could also optimize patient 
care. Physician-pharmacist collaborative management has shown effect on blood pressure 
control among persons with hypertension and HbA1c reduction in diabetes patients (142). A 
study from Norway concluded that few GPs supported an active role for pharmacists and that 
to achieve an optimal collaboration between community pharmacists and GPs, the two 
professions’ knowledge about each other needs to be increased (143).  
Community pharmacists can contribute in the follow-up of medication treatment, especially 
in encouraging correct use of medications, and increase adherence and persistence. The 
intervention Medisinstart that was implemented and tested in Norwegian pharmacies in 2014-
2015 was found to increase adherence to recently initiated medications for CVD (144). 
Medisinstart is offered to patients with a first-time prescription of an antihypertensive drug, 
LLD or anticoagulant drug and consists of two consultations with a pharmacist focusing on 
correct use of the new medication and how to handle side-effects and forgotten dosages. A 
randomized controlled trial assessing the effect of the intervention found an increase in self-
reported adherence and decreased concerns about medications (144). The effect was strongest 
for statins. Though this service is only offered to new medication users, there is a potential for 




recommendations for lifestyle modifications such as smoking cessation and weight loss which 
are also important factors in secondary prevention of CHD.  
5.2 Methodological challenges 
A study’s validity is influenced by measurement errors. These measurement errors can be 
either random or systematic. Both the internal and external validity of a study will vary 
depending on the degree of particularly systematic errors. 
5.2.1 Random error 
Random error is the proportion of variance in a measurement that is not connected to any 
other variables and can be regarded as happened by chance (145). While systematic errors 
will distort estimates and associations in a particular direction, random error affects all 
subgroups non-differentially (146). Random error is more likely to affect the study’s power, 
thus making it more difficult to demonstrate associations that truly exist, but this can usually 
be controlled for by including a sufficient number of measurements.  
Analyses of LDL-cholesterol and HbA1c in our study could have been subject to smaller 
measurement errors, but as the same equipment, procedures and laboratory were used, these 
would most likely be random errors and not affected by systematic bias. In the first five 
waves of the Tromsø Study, LDL-cholesterol was calculated from Friedewald’s formula, 
while in Tromsø 7, it was measured by direct enzymatic colorimetric methods. We became 
aware of this change after the publication of Paper I, and a correction has been published to 
that effect (147). The use of direct enzymatic colorimetric methods is an advantage, as the use 
of Friedewald’s formula has been shown to underestimate the true LDL-cholesterol 
concentration (148), thus rendering our results more reliable. 
5.2.2 Internal validity 
Internal validity describes to which degree the study is free from systematic error (145), and 
thus whether the study results apply to the study population. The methods used to select the 
study population, collect information and conduct the analyses affect the internal validity of a 
study. Internal validity also depends on identification and measurement of potential 
confounders and choice of exposure windows (145).  




The study population in this project consisted of participants in Tromsø 7 who self-reported 
previous MI, PCI, CABG and/or AP (n = 1483). Self-reported diagnoses could be biased, 
hence the validity of the true disease status of our study population may be questioned. To 
attempt to validate our study population, it was possible to compare it to a local CVD registry 
existing in connection to the Tromsø Study. This registry contains information about 
participants with certain or probable previous MI based on their medical journal. According to 
this registry, 670 of the 753 (89%) who reported an MI in our study, were registered with a 
previous MI. Among our total study population (n = 1483), 1186 participants (80%) were 
included in the registry. Since the registry only includes cases with certain or probable MI, all 
participants with PCI, CABG or AP cannot be expected to be registered. These participants 
could still have CHD, even though they have not had an MI.  
The local CVD registry is limited by not being completely updated at the time we received the 
data from it. The registry also only includes data from the University Hospital of North 
Norway, and myocardial infarctions treated at other hospitals are not included. This implies 
that not being registered in the CVD registry does not exclude having a true MI diagnosis. 
Comparison with the local CVD registry makes us fairly sure that the participants in our study 
population are persons with CHD. However, there may be more participants in Tromsø 7 with 
a CHD diagnosis than those we included. This is probably not a major issue, as severe 
diagnoses such as CHD are more likely to be recalled, and also not as sensitive as e.g. mental 
disorders or sexually transmitted diseases, and hence more likely to be reported by the 
participants (55).  
A recent study by Hopstock et al. investigated treatment goal achievement and use of 
medications for secondary prevention among persons with validated MI and/or stroke who 
had participated in Tromsø 7 and at least one of the previous six waves or the Tromsø Study 
(n = 904) (149). They found that 55.2% achieved the treatment goal for blood pressure and 
9.0% the treatment goal for LDL-cholesterol, while 75.9% used antihypertensive drugs and 
81.0% LLDs. Their study population should be partly overlapping with ours, but with cases 
validated in the local CVD registry, and also including participants who have had a stroke and 




would likely that have gotten the same results if we had included persons with validated 
instead of self-reported CHD.  
Collection of information 
Information bias  
Information bias derives from systematic differences in the collection, recall, recording or 
handling of information and is common in observational studies, especially those using self-
reported data (150). The major types of information bias include recall bias, reporting bias 
and observer bias (150). 
Recall bias occurs when participants do not accurately remember past experiences or events 
and hence do not report them correctly (145, 151). This could lead to systematic errors as 
poor recall may be more common among some participants than others, such as the elderly, 
less educated or those with lower socioeconomic status (151). Self-reported medication use 
may have been underestimated in Paper I due to recall bias, but the problem is found to be 
smaller for medications used regularly such as medications used for secondary prevention of 
CHD, compared with medications used as needed (55). The results from the validation study 
(Paper II) also indicated that this is of minor concern. Recall bias could also have affected the 
selection of the study population as discussed above, and if so, may have affected the external 
validity of the study. 
Reporting bias can be defined as selectively revealing or suppressing information or study 
results (145). It is most commonly used to describe scientific misconduct, for instance by not 
publishing negative results (152), but the term reporting bias also refers to the situations in 
which participants in a study select whether or not to report particularly sensitive information 
such as sexual experiences or medical history (145). Self-reported lifestyle measures such as 
diet, smoking, alcohol consumption and physical activity could be affected by reporting bias. 
Smokers may hesitate to admit that they smoke or how many cigarettes they smoke daily. 
Participants may also estimate that they have a healthier diet and exert more physical activity 
than they actually do.  
Observer bias occurs when there is a systematic difference between a true value and an 
observed value because of the failure of an observer to measure a phenomenon accurately 




which could vary between observers, and if the differences are systematic this could introduce 
bias. Inadequate training in the use of measurement devices could introduce such bias (153). 
In the Tromsø Study, measurement of height, weight and blood pressure could potentially be 
affected by this, however, the impact should be low as the personnel conducting the 
examinations have been trained and follow standard procedures.  
Blood pressure measurement could also be affected by apprehension bias. Apprehension bias 
occurs when a study participant responds differently when being observed (154). White-coat 
hypertension is a well-known example of this effect (155). Going through a health 
examination could make the participants anxious which in turn could raise the blood pressure, 
thus giving recorded measurements higher than their normal blood pressure. This could 
potentially have led us to overestimate blood pressure and hence underestimate the proportion 
reaching the blood pressure treatment goal. 
Missing data 
Information bias can be introduced depending on the handling of missing data (150). Missing 
data happens as a result of participants not answering all the questions in a questionnaire or 
not completing clinical examinations. Of the data sources used in this project, missing data is 
mainly a problem in the data from the Tromsø Study.  
The pattern of missing data is usually classified as missing completely at random, missing at 
random and missing not at random. Missing completely at random indicates that there are no 
systematic differences between missing values and the observed data (145). Data is missing at 
random when the systematic difference between missing and observed data can be explained 
by differences in observed data, e.g. if missingness in a question about depression is higher 
among male participants without being dependent on their depression status. In the case of 
data missing not at random, there are systematic differences between the missing and 
observed data that cannot be explained by the observed data (145), e.g. if missingness about 
depression is highest among the most depressed participants. 
Analyzing datasets with missing data can be handled by either excluding participants with 
missing data or imputing values for the missing data (156). In this project, both methods were 
used. Analyses in paper III were done as complete-case analyses, meaning that participants 




induced bias if the participants with missing data were different from those with complete 
data. It also leaves us with a smaller study population and loss of precision. However, the 
proportion of participants with missing data was about 10%, so not very large and should not 
greatly reduce the validity of our results (156).  
Multiple imputation was done in Paper I for variables used to calculate the propensity score. 
This is a method that retains the uncertainty about the missing data by creating several 
datasets with several imputed values for the missing data (114). To attempt to avoid inducing 
bias in the multiple imputation analyses, we included as many variables as possible in the 
imputation model. All variables that were available to us in the dataset from Tromsø 7 were 
included if the proportion of missing in the variable was less than 50%. Higher proportions of 
missing than this led to difficulties completing the multiply imputed datasets using the mice 
package in R. All variables included in the multiple imputations were reported in the 
supplementary of Paper I. 
For some variables used throughout the project, single imputation was also used where the 
imputed value seemed reasonable. In both Paper I and Paper III, participants were assumed to 
have diabetes if they reported using any antidiabetic drug. Those not reporting having 
diabetes nor reporting use of antidiabetics were considered to not have diabetes in Paper III, 
while in Paper I this was subject to multiple imputation. Use of LLDs, antihypertensive drugs 
or ASA was coded as “no” if the data was missing. This is because we included both 
prespecified and open-ended questions to determine medication use, and not reporting any 
medications in the open-ended question indicated no use of these medications.  
For variables concerning smoking, alcohol consumption and use of health services, we 
combined several variables concerning the same issue to reduce the amount of missing data. 
An example is that if participants reported current smoking on any of the three variables 
concerning smoking, they would be considered a current smoker. Similarly, if participants did 
not report current smoking but previous smoking, they were considered previous smokers. 
When the remaining participants reported never having smoked, they were considered non-
smokers.  
Missing data is generally not a problem in the data from NorPD. The only cases in which this 




therefore is impossible. This is a minor problem as it occurs very rarely. Proportions of 
prescriptions without a valid personal identification number has decreased from 3.7% in 
2004, through 2% in 2005-2007 and 1.4% in 2008-2009, to less than 1% in 2010-2017 (157). 
This could potentially have led us to underestimate validity of medication use and medication 
adherence but has most likely not affected our results at all.  
Statistical methods  
Propensity score analysis 
Propensity score analysis methods are used to reduce bias in effect estimates in observational 
studies (158). The propensity score is calculated as the probability of the exposure based on 
the included covariates. Different propensity score methods can be used to balance the 
covariate distributions between the exposed and non-exposed in an analysis, the most 
common being matching, inverse probability of treatment weighting, stratification and 
covariate adjustment using the propensity score (158).  
Compared to multivariable regression where covariates are adjusted for by including them in 
the regression analysis, propensity score analyses have some advantages. One is that the 
balancing of covariates is done separately from the outcome analysis and is therefore 
performed independently and without knowledge of the outcome (113). Another advantage is 
that propensity score allows for more variables to be included as covariates than what is 
recommended in normal regression analyses, and thus fewer covariates needs to be included 
in the outcome analyses. And lastly, the included covariates need not be assumed to be 
confounders as all variables that are assumed to affect the outcome could be included in the 
propensity score, irrespective of whether they also affect the exposure (113).  
Some challenges were encountered during the analyses. Due to the high proportion of users of 
LLDs and antihypertensive drugs, the matching process could not be done in a one-to-one 
ratio, as that would have led us to exclude too many of the participants using the medications. 
The best solution was therefore to do the matching with replacement, thus allowing the non-
users to be matched with several of the medication users. This could have introduced bias, so 
we performed a sensitivity analysis using a one-to-one matching, which did not substantially 
change the results. Another challenge encountered was that covariates may not have been 




After matching the standardized mean difference (SMD) is recommended to be lower than 0.1 
(159) or at least lower than 0.25 (160). For some covariates in our analysis, SMDs were larger 
than this. In retrospect, we should have considered including these covariates in the outcome 
analysis as well as in the propensity score in order to completely adjust for them. The 
covariate that had the highest SMD values was age. This indicates that the users of 
antihypertensive drugs were older than non-users. In Paper III we found that older age was 
highly significantly associated with higher blood pressure. If we had included age as a 
covariate in our outcome analysis in Paper I, it would therefore most likely have diminished 
the association between use of antihypertensive drugs and achieving the treatment goal for 
blood pressure. As this association was found to be small and not statistically significant, it 
would not have changed the result substantially.  
Agreement measures 
Agreement between two information sources can be calculated by different measures. In 
Paper II we chose to report both percent agreement and Cohen’s kappa. Cohen’s kappa is the 
most commonly used measure to determine agreement between self-reported medication use 
and dispensing data from pharmacies, and by using this, our results could be compared with 
other studies. Though commonly used, the method does have some flaws. The kappa statistic 
is sensitive to prevalence and bias, leading to kappa paradoxes which give artificially low 
kappa coefficients (161). Adjusted versions of Cohen’s kappa have been developed, such as 
prevalence-adjusted bias-adjusted kappa (PABAK) (162), and this measure has been used in 
some studies but to a limited degree. Its superiority to the normal Cohen’s kappa statistic is 
also debatable (163). In Paper II we supplied both percent agreement and the numbers of 
medication users in both sources, neither sources and either one of the sources, making it 
possible for readers to calculate any other agreement measure. 
Proportion of days covered 
Pharmacy dispensing data is one of the most commonly used data sources for determining 
adherence. PDC is one of the most used adherence measures based on pharmacy dispensing 
data and is calculated as the sum of the days covered with medication supplies divided by the 
number of days in the observation period (89). Though it is sometimes used interchangeably 
with MPR or MPR capped at one, there are differences in these two measures. MPR is 




divided by the number of days in the period (89). Contrary to PDC, this implies that MPR can 
exceed 1, as the sum of the days’ supply can be larger than the number of days in the period 
unlike the number of days covered which cannot be more than the total number of days in the 
period. Another limitation with MPR is that it may allow for retroactive compensation, 
meaning that as the formula for MPR adds together all supplies in the period, this may allow 
for oversupply later in the period to compensate for gaps early in the period (164) which 
would overestimate the adherence measure. PDC is based on treatment episodes, and only 
take into consideration medications available from the day they have been dispensed at the 
pharmacy (89). 
As with other adherence measures based on pharmacy dispensing data, PDC also has some 
limitations. First, we can only assume that the dispensed medication is actually ingested. 
Also, since PDC represents the average adherence over the chosen time period, we cannot 
determine when the missed doses occurred or if the doses were taken on time (e.g. in the 
morning) (85). Missing several consecutive doses could have a worse treatment outcome than 
missing the same number of doses spread out over time. Using a set observation window 
rather than a period between a set first and last dispensing also complicates the interpretation 
of a low PDC-value. It makes it more difficult to know whether the low value is caused by 
poor implementation adherence or non-persistence (164). In our analyses we chose to handle 
this by excluding participants with no supplies available the last 180 days of the observation 
window to ensure that we mainly were capturing poor implementation adherence without 
influence of non-persistence. This also correlates with the definitions from Paper II, where 
participants without any medications dispensed within 180 days before attending Tromsø 7 
were considered non-users of the medications. 
Our observation window was set to one year before attendance in Tromsø 7 to assess 
adherence before the measurements of blood pressure and LDL-cholesterol, and to include 
enough dispensings to get a reliable measure of PDC. Vollmer et al found that at least 9 
months of dispensing is needed for this when the average supplies from one dispensing covers 
2-3 months (165). Incident medication users thus had to be excluded.  
Since we cannot be certain that the dispensed medications are actually taken, PDC will only 




possession. Our calculation of PDC based on NorPD may therefore have overestimated the 
true medication adherence. However, compared to using the two questions regarding 
medication non-adherence available in Tromsø 7, our results showed lower adherence. One of 
the questions in Tromsø 7 asked “How many times a week do you forget to take your 
medicines?” and the other “How many times a week do you decide to miss out your 
medicines?”. Of the 1151 (77.6% of the total study population) who answered the first 
question, 97.3% answered that they forget to take their medications one time a week or less, 
which is comparable to less than 80% of the time. For the second question, of the 1120 
(75.5% of the study population) who answered the question, 99.1% said that they decided to 
miss out on their medications once a week or less. This indicates even higher adherence than 
what was estimated based on NorPD, in accordance with previous research showing that self-
reported adherence tend to overestimate actual adherence (166). These questions would 
however give an indication of whether non-adherence was intentional or not, which is not 
possible to explore using pharmacy dispensing data. 
Confounding 
Confounding occurs as a result of a factor being independently associated with both exposure 
and outcome, thus potentially causing distorted associations (167). Observed confounded 
associations could thereby be partially or completely explained by these factors, called 
confounders. Confounders arise when there are mutual causes of the studied exposure and 
outcome (145). To attain valid results, confounders must be adjusted for. The best way to 
reduce confounding is through randomization (167). However, as this is not possible in 
observational studies, confounders have to be controlled for in the analyses, most commonly 
through stratification or multiple-regression techniques (168). In paper I we controlled for 
confounders by using propensity score matching, and in paper III through multivariable 
regression. As in all observational studies, there is however always a possibility of there being 
other unmeasured confounders that have not been accounted for.  
5.2.3 External validity 
External validity, or generalizability, is described as the degree to which the results of a study 
can be applied to populations that did not participate in the study (145). If a study is 
externally valid, unbiased inferences can be made regarding other specific populations beyond 




population, in which the population systematically differs from participants in the study, is 
considered as selection bias. A more correct definition of selection bias rather imply a lack of 
internal validity, by describing selection bias as an association between an exposure and an 
outcome influenced by the procedures used to select individuals into the study or analysis. If 
this selection conditions on a factor that is affected by, or a cause of, the exposure and the 
outcome, selection bias could arise (145). This type of selection bias is usually not a major 
issue in cross-sectional studies based on general population health surveys such as the Tromsø 
Study. 
Generalizability or external validity implies to which degree the population studied is 
sufficiently similar to other populations to be representative for these populations.  
The population invited to participate in the Tromsø Study are inhabitants in the municipality 
of Tromsø. The municipality includes a university town and had about 73 000 inhabitants at 
the time Tromsø 7 was conducted. Enrollment in the Tromsø Study has differed between the 
different waves conducted. In Tromsø 7, all inhabitants ≥40 years (n = 32 591) were invited 
to participate and 65% (n = 21 083) attended. Though this is a fair attendance rate compared 
to other health surveys (169), that almost one third of the invitees chose not to attend could 
give rise to concern. More women (67.0%) attended Tromsø 7 compared to men (62.4%) and 
attendance was highest in the age groups between 60 and 75 years (109). In previous waves of 
the Tromsø Study it has been seen that non-attendees are more likely to be younger, male and 
single compared to those who do attend (170). There are also indications that persons that 
have participated in more than one of the waves may have lower mortalities than non-
attendees. This is in line with what has been found in another similar Norwegian health 
survey, HUNT (171). In the HUNT study they also found that non-participants had higher 
prevalences of CVD, diabetes and psychiatric disorders, in addition to lower socio-economic 
status and higher mortality (172). This is likely to also apply to the Tromsø Study. Our study 
population may therefore be slightly healthier than general CHD populations. As the study 
population is based on self-report, the participants may also be more conscious of their own 
disease than the general CHD population. Validity of CHD in the study population was 




Previous waves of the Tromsø Study have considered it representative for a Northern 
European, urban, Caucasian population (173). Our study population consisted of persons with 
CHD. Non-participation and possible non-survival of those with poorest health indicate that 
our results may need to be restricted to relatively healthy persons living with a diagnosis of 
CHD. Access to and affordability of medications and other health care resources varies 
between countries, hence our results are probably more relevant for countries with similar 
health care systems as Norway, such as the other Nordic and possibly Northern European 
countries.  
5.3 Ethical considerations 
Informed consent is of great importance when conducting medical research. When 
participating in research projects, potential participants should be given adequate information 
about the study and its potential harms and benefits (174). Participation in the Tromsø Study 
supplied benefits for the participants by providing them with some results of their 
examinations, including height, weight, BMI, hemoglobin, blood pressure, cholesterol and if 
the results indicated that they may have diabetes. If any test results showed the need for 
further follow-up of GPs or specialists, this would be mentioned and reference to a specialist 
would be provided. With the invitation to participate in Tromsø 7 a comprehensive study 
information brochure was included (see Appendix 1). The brochure included information both 
about which tests would be performed and how the data would be handled. It also mentioned 
the potential for linkage to other registries, including NorPD. At attendance, participants 
signed a written informed consent based on the information in the brochure. This consent can 
be retracted at any time at the participants’ request. Tromsø 7 has been approved by Regional 
Committee for Medical and Health Research Ethics of North Norway (2014/940).  
NorPD is a pseudonymized health registry containing information about all dispensed 
prescriptions from Norwegian pharmacies to individuals (110). This information includes the 
individuals’ sex and age. Pseudonymization implies that name and national personal identity 
number are replaced by a pseudonym. This pseudonym makes it possible to follow 
individuals over time and link it to other data sources without knowing the individuals’ 
identity. Statistics Norway is responsible for the pseudonymizing process, and when linking 
NorPD with other data sources they provide the key used for the linking of the individuals’ 




informed consent. Withdrawal is not possible, but each individual has the right to access the 
information registered about themselves. Though registration in health registries like NorPD 
may not benefit each individual directly, it is important for attaining valid research results for 
the whole population. Valid research based on complete health registries is used to improve 









The project results showed that adherence to medication therapy for secondary prevention in 
persons with CHD in a general population was high, but achievement of treatment goals for 
blood pressure and especially LDL-cholesterol was low. Use of, and adherence to, LLDs was 
statistically significantly associated with achieving the treatment goal for LDL-cholesterol 
and with lower LDL-cholesterol. Similar associations were not found between use of or 
adherence to antihypertensive drugs and achieving the treatment goal for blood pressure or 
lower systolic or diastolic blood pressure. 
This implicates that treatment of LDL-cholesterol could be optimized by ensuring that all 
CHD patients that are eligible for LLD treatment should initiate such treatment and be 
encouraged to adhere to the prescribed therapy. As so few reach the treatment goal for LDL-
cholesterol this will probably be insufficient to reduce LDL-cholesterol to the recommended 
level. More intensive treatment of both hypertension and hypercholesterolemia is most likely 
needed. However, this should be further explored in future research.  
Our results show that most persons with chronic CHD follow the treatment they are 
prescribed. A potential intervention to improve secondary prevention to CHD should 
probably be aimed at the prescription level, making sure that these persons receive treatment 
optimal to reach the recommended treatment goals. This may be achievable through education 
of and reminders to general practitioners and enhanced collaboration between health 
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Adherence to prescription guidelines 
and achievement of treatment goals 
among persons with coronary heart disease 
in Tromsø 7
Elisabeth Pedersen1* , Beate Hennie Garcia1, Kjell H. Halvorsen1, Anne Elise Eggen2, Henrik Schirmer3,4 and 
Marit Waaseth1 
Abstract 
Background: Adherence to clinical practice guidelines for coronary heart disease (CHD) reduces morbidity, mortality 
and treatment costs. We aimed to describe and compare adherence to prescription guidelines for persons with CHD, 
and explore its association with treatment goal achievement.
Method: We included all participants reporting myocardial infarction, angina, percutaneous coronary intervention 
and/or coronary artery bypass surgery in the seventh wave of the Tromsø Study (2015–2016, n = 1483). Medica-
tion use and treatment goal measures (blood pressure, low-density lipoprotein (LDL)-cholesterol and HbA1c) were 
compared to clinical practice guidelines on secondary CHD prevention. Propensity score matched logistic regression 
was used to assess the association between the use of antihypertensive drugs and achievement of treatment goal for 
blood pressure, and the use of lipid-lowering drugs (LLDs) and achievement of treatment goal for LDL-cholesterol.
Results: The prevalence of pharmacological CHD treatment was 76% for LLDs, 72% for antihypertensive drugs and 
66% for acetylsalicylic acid. The blood pressure goal (< 140/90 mmHg, < 140/80 mmHg if diabetic) was achieved by 
58% and the LDL-cholesterol goal (< 1.8 mmol/l or < 70 mg/dL) by 9%. There was a strong association between using 
LLDs and achieving the treatment goal for LDL-cholesterol (OR 14.0, 95% CI 3.6–54.7), but not between using antihy-
pertensive drugs and blood pressure goal achievement (OR 1.4, 95% CI 0.7–2.7).
Conclusion: Treatment goal achievement of LDL-cholesterol and blood pressure was low, despite the relatively high 
use of LLDs and antihypertensive drugs. Further research is needed to find the proper actions to increase achieve-
ment of the treatment goals.
Keywords: Coronary heart disease, Prescription guidelines, Blood pressure, Antihypertensive agents, Lipid-lowering 
drugs, Low-density lipoprotein (LDL)-cholesterol
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Background
Coronary heart disease (CHD) is one of the leading 
causes of deaths worldwide and a common cause of hos-
pital admissions [1, 2]. The major modifiable risk factors 
are high blood pressure and cholesterol levels, tobacco 
smoking, diabetes mellitus, low physical activity, obe-
sity, and unhealthy diet [3]. Over the recent decades, 
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the world has witnessed a substantial reduction in CHD 
morbidity and mortality which is partially attributed to 
strategies based on lowering of blood pressure and cho-
lesterol, as well as successful acute treatment [4, 5].
Clinical practice guidelines for CHD promote risk 
factor reduction, both in terms of lifestyle changes and 
medication use. Lipid-lowering drugs (LLDs), antihyper-
tensive drugs and acetylsalicylic acid (ASA) comprise the 
recommended secondary prevention after both myocar-
dial infarction (MI) and coronary artery intervention like 
percutaneous coronary intervention (PCI) or coronary 
artery bypass surgery (CABG) [6]. Adherence to these 
prescription guidelines has been shown to prevent pre-
mature mortality, reduce morbidity and healthcare costs, 
and improve the patient’s quality of life [6].
The European survey of cardiovascular disease preven-
tion and diabetes (EUROASPIRE) is the largest European 
CHD survey, and it has evaluated the implementation of 
clinical guidelines in CHD patients five times since 1995–
1996 [7]. The most recent EUROASPIRE survey showed 
that > 80% of CHD patients use antihypertensive drugs 
and LLDs. The survey also showed that achievement of 
the recommended treatment goals is low, where 58% of 
the patients reach the treatment goal for blood pressure 
and 29% the treatment goal for low-density lipoprotein 
(LDL)-cholesterol. Similar results have also been found 
in a Norwegian study, where 93% used both antihyper-
tensive drugs and LLDs, while 54% reached the treatment 
goal for blood pressure and 43% reached the treatment 
goal for LDL-cholesterol [8].
Studies have shown an increase in treatment goal 
achievement in line with a decrease in blood pressure 
and cholesterol in the general population [9–13], but 
mainly describe adherence to clinical prescription guide-
lines and treatment goal achievement on an aggregated 
and not an individual level. Associations between treat-
ment goal achievement and adherence to guidelines con-
cerning prescription have also not been explored.
The aim of this study was to describe and compare 
adherence to prescription guidelines for persons with 
CHD and explore its association with treatment goal 
achievement for blood pressure and LDL-cholesterol.
Methods
Study setting and study population
The Tromsø Study is a Norwegian population-based epi-
demiological health study that has been conducted seven 
times from 1974 to 2016 [14]. The population of the 
Tromsø Study consists of inhabitants in the municipal-
ity of Tromsø in North Norway, a university town with 
approximately 70  000 inhabitants, and it is considered 
representative for a white, urban Northern European 
population [15].
The current study is a cross-sectional study apply-
ing data collected from participants in the seventh wave 
of the Tromsø Study (Tromsø 7). Tromsø 7 was con-
ducted in 2015 and 2016 and invited all inhabitants in the 
municipality aged 40  years or older (n = 32,591) to par-
ticipate. Response rate was 65% (n = 21,083). Participants 
answered several questionnaires, donated blood samples 
and went through a range of anthropometric measure-
ments (height, weight, body circumferences and clinical 
examinations). Links to the questionnaires can be found 
at the Tromsø Study’s webpage [16]. We included persons 
who self-reported CHD in the mandatory questionnaire, 
i.e. previous MI, present or previous angina pectoris (AP) 
and/or previous PCI or CABG. Participants with self-
reported diabetes or reporting use of antidiabetic drugs 
and those with self-reported hypertension were defined 
as subgroups in some analyses.
We included a total of 1483 (7.0%) participants with 
CHD; 753 with previous MI, 466 with AP and 1226 with 
previous PCI and/or CABG, some of them indicating 
more than one disease (Fig.  1). We divided our study 
population into three subgroups; previous MI (n = 753), 
PCI or CABG but no previous MI (n = 604) and only 
AP with no previous MI, PCI or CABG (n = 126). Of the 
1483 participants with CHD, 214 (14%) had diabetes, and 
827 (56%) reported having hypertension.
Data extraction
We extracted information about blood pressure measure-
ments from clinical examinations, LDL-cholesterol and 
HbA1c from blood samples and self-reported data from 
questionnaires. The questionnaire data included infor-
mation about present and previous diseases, medication 
use, health concerns, use of health services, diet, physi-
cal activity, smoking status, alcohol consumption and 
socio-demography.
Prevalent users of LLDs, antihypertensive drugs and 
antidiabetic drugs were defined by two approaches; (1) 
by including those who replied “currently” when asked 
“Do you use, or have you used cholesterol lowering drugs/
blood pressure lowering drugs/insulin or tablets for dia-
betes?” (answering options were “currently”, “previously, 
not now” and “never used”) or (2) mentioning the brand 
name of medications within these drug classes when 
asked to write down the brand names for all medications 
used regularly during the previous four weeks. Prevalent 
ASA use was defined as answering “yes” when asked “If 
you have used analgesics and anti-inflammatory medica-
tion regularly in the past year—did you use “Baby” or low 
dose acetylsalicylic acid (ASA) Acetylsalisylsyre® Albyl-E® 
Asasantin Retard® (75/160  mg per tablet)?” (answering 
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options were “yes” and “no”), or mentioning a brand 
name for ASA when asked to write down brand names 
for all the medications used regularly during the previous 
four weeks.
Brand names were recoded by trained personnel using 
the anatomical therapeutic chemical (ATC) classification 
system and categorised into medication groups. LLDs 
included statins and other LLDs. Antihypertensive drugs 
included angiotensin converting enzyme (ACE) inhibi-
tors, angiotensin receptor blockers (ARBs), beta-block-
ers, calcium channel blockers (CCBs), thiazides, other 
diuretics and other antihypertensives (Additional file  1: 
Table S1).
In Tromsø 7, blood pressure was measured with 
an automated digital device (Dinamap ProCare 300 
monitor, GE Healthcare, Norway) [9]. Three consecu-
tive measurements were taken. Blood pressure was 
defined as the mean of the last two measurements. If 
only the third measurement was missing (n = 2), the 
second measurement was used. When both the sec-
ond and third measurement, but not the first, was 
missing (n = 1), the first measurement was used. LDL-
cholesterol was collected and analyzed by trained per-
sonnel using enzymatic colorimetric methods with 
commercial kits on a Cobas 8000 c702 (Roche Diag-
nostics GmbH, Mannheim, Germany) from non-fasting 
venous blood samples. The analysis was performed at 
the Department of Laboratory Medicine, University 
Hospital of North Norway, Tromsø, Norway (ISO certi-










Fig. 1 Distribution of participants across coronary heart disease groups in Tromsø 7. AP, angina pectoris; CABG, coronary artery bypass surgery; MI, 
myocardial infarction; PCI, percutaneous coronary intervention
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Treatment goal achievement and medication use were 
assessed based on the European Guidelines on cardio-
vascular disease prevention in clinical practice from 2012 
(Table 1) [6]. At the time of data collection, there were no 
Norwegian clinical guidelines for secondary prevention 
of CHD.
Statistical method
Descriptive statistics are presented as frequencies with 
proportions (%) (categorical variables) and means with 
standard deviation (SD) (continuous variables).
Chi square tests were used to examine the relation-
ship between achievement of treatment goals for blood 
pressure and LDL-cholesterol and use of LLDs, antihy-
pertensive drugs and ASA, and between achievement of 
treatment goals and disease group. Significance level was 
set to 5%.
Logistic regression was used to explore the association 
between use of antihypertensive drugs and achievement 
of treatment goal for blood pressure, as well as the asso-
ciation between use of LLDs and achievement of treat-
ment goal for LDL-cholesterol. Participants with missing 
measurements for blood pressure (n = 3) and LDL-cho-
lesterol (n = 11) were excluded from the respective analy-
ses. Propensity score matching was used to control for 
confounding from covariates including age, sex, body 
mass index (BMI), relevant comorbidities, diet, physical 
activity, use of health services, alcohol consumption and 
smoking (including use of smokeless tobacco) (for more 
information about the variables included, see Additional 
file 1: Table S2). The matching method used was nearest 
neighbour matching, and the procedure was performed 
with replacement and a caliper of 0.2.
Due to the high proportion of missing values in some 
of the covariates, imputation was needed to perform 
the analyses. If a factor was described by more than one 
variable (e.g. use of health services, tobacco, alcohol), 
these variables were combined. For instance, a partici-
pant reporting current smoking on at least one ques-
tion regarding smoking habits would be categorised as 
a smoker. Multiple imputation by chained equations 
was then performed using the R packages mice and 
MatchIt.mice (see Additional file 1: Table S3 for variables 
included). Predictive mean matching was used to impute 
numeric variables, logistic regression for binary categori-
cal variables, proportional odds model for ordered cat-
egorical variables and polytomous logistic regression for 
unordered categorical variables. Ten imputated datasets 
where created with 50 iterations. The analyses were then 
performed with the within approach, which means that 
the propensity score matching and logistic regression was 
performed in each imputed dataset and the results subse-
quently pooled together to an overall result. We used the 
non-imputed dataset for the descriptive analyses and chi 
square tests, and the imputed datasets for the regression 
analyses.
All descriptive statistical analyses were performed 
using SPSS version 25.0 (IBM Corp, 2017). Chi square 
tests, multiple imputation, propensity score matching 
and logistic regression were conducted using R (R Core 
Table 1 Recommendations in guidelines on cardiovascular disease prevention by the European Society of Cardiology in 2012 [6]





Antihypertensive drugs (if hypertension)
 ACE inhibitor/ARB (first choice for diabetics)
 Beta-blockers




 < 140/90 mmHg (< 140/80 mmHg if diabetic)
LDL-cholesterol
 < 1.8 mmol/l (< 70 mg/dL)
HbA1c (if diabetic)
 < 7%
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Team (2019). R: A language and environment for statis-
tical computing. R Foundation for Statistical Comput-
ing, Vienna, Austria. URL https:// www.R- proje ct. org/).
Ethics
The study was approved by the Norwegian Data Protec-
tion Authority and the Regional Committee for Medi-
cal and Health Research Ethics of North Norway. All 
participants in the Tromsø Study have given written 
informed consent for their data to be used in research.
Results
The basic characteristics of the study population and 
across the three CHD disease groups are shown in 
Table 2.
Use of medications for CHD was highest among par-
ticipants with previous MI and lowest among those with 
AP only, see Fig. 2. Of those with hypertension (n = 827), 
92% used antihypertensive drugs. Among users of anti-
hypertensive drugs, the drug classes included beta-block-
ers (63%), ACE-inhibitors or ARBs (49%), CCBs (22%), 
thiazides (16%), other (17%) and unknown (9%) antihy-
pertensive drugs (for ATC-classification of medication 
Table 2 Characteristics of the study population
AP, angina pectoris; BMI, body mass index; CABG, coronary artery bypass graft; CHD, coronary heart disease; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; MI, myocardial infarction; PCI, percutaneous coronary intervention; sd, standard deviation
* Self-reported relevant comorbidities for coronary heart disease, present or previous diseases. For diabetes: present disease or use of any antidiabetic drug
† To convert to mg/dL, multiply with 38.67
‡ To convert to mg/dL, multiply with 88.57





PCI and/or CABG, but 
no MI
(n = 604)




 Women 446 (30.1) 174 (23.1) 203 (33.6) 69 (54.8)
Age, mean (sd) 68.7 (10.8) 69.2 (10.1) 69.2 (10.6) 63.0 (13.7)
Smoking, n (%)
 Daily smoking 182 (12.3) 96 (12.7) 67 (11.1) 19 (15.1)
 Smoked previously 860 (58.0) 472 (62.7) 334 (55.3) 54 (42.9)
Self-reported health, n (%)
 Excellent/good 705 (47.5) 343 (45.6) 311 (51.5) 51 (40.5)
 Neither good nor bad 602 (40.6) 318 (42.2) 232 (38.4) 52 (41.3)
 Bad/very bad 153 (10.3) 79 (10.5) 53 (8.8) 21 (16.7)
Comorbidities*, n (%)
 Hypertension 827 (55.8) 433 (57.5) 328 (54.3) 66 (52.4)
 Heart failure 231 (15.6) 126 (16.7) 94 (15.6) 11 (8.7)
 Atrial fibrillation 283 (19.1) 138 (18.3) 111 (18.4) 34 (27.0)
 Stroke 123 (8.3) 65 (8.6) 49 (8.1) 9 (7.1)
 Diabetes 214 (14.4) 123 (16.3) 80 (13.2) 11 (8.7)
 Renal disease 114 (7.7) 68 (9.0) 35 (5.6) 11 (8.7)
 Cancer 189 (12.7) 101 (13.4) 77 (12.7) 11 (8.7)
Medications, mean number of products (sd) 4.0 (2.9) 4.3 (3.0) 3.8 (2.8) 3.0 (2.9)
Clinical measurements, mean (sd)
 Systolic blood pressure, mmHg 136 (20.9) 135 (21.7) 137 (19.9) 133 (20.3)
 Diastolic blood pressure, mmHg 74 (9.9) 75 (10.0) 74 (9.6) 76 (10.1)
 Total cholesterol, mmol/l† 4.6 (1.1) 4.5 (1.1) 4.7 (1.1) 5.6 (1.3)
 LDL-cholesterol, mmol/l† 2.9 (1.0) 2.7 (1.0) 2.9 (1.0) 3.7 (1.2)
 HDL-cholesterol, mmol/l† 1.4 (0.4) 1.4 (0.4) 1.5 (0.5) 1.5 (0.4)
 Triglycerides, mmol/l‡ 1.6 (1.0) 1.7 (1.0) 1.5 (0.8) 1.8 (0.9)
 HbA1c, % 6.1 (0.9) 6.1 (1.0) 6.0 (0.8) 5.8 (0.5)
 Glucose, mmol/l§ 6.0 (2.1) 6.2 (2.3) 6.0 (1.9) 5.6 (1.3)
 BMI, kg/m2 28.4 (4.5) 28.5 (4.4) 28.1 (4.4) 28.7 (5.2)
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groups, see Additional file 1: Table S1). Fifty-one percent 
used two or more medications from different antihy-
pertensive drug classes. The most frequent class of LLD 
was statins (79% of LLD users), while 20% did not report 
which LLD they used. As 98% of those using LLDs in 
Norway use statins [17], these were assumed to be sta-
tin users. Among the LLD-users, 3% used another LLD 
in combination with a statin, while 1% used another LLD, 
but not a statin.
Blood pressure goal achievement 
(< 140/90  mmHg, < 140/80  mmHg in persons with dia-
betes) was highest among those with AP only and low-
est among those without MI but previous PCI or CABG, 
see Fig. 3a. Among those reporting having hypertension, 
49% reached the treatment goal for blood pressure. For 
comparison, Fig. 3a also includes the proportion having a 
blood pressure < 150/90 mmHg.
LDL-cholesterol goal achievement (< 1.8  mmol/l 
or < 70  mg/dL) was highest among those with previous 
MI and lowest among those with AP only, see Fig.  3b. 
For comparison, Fig.  3b also includes the proportions 
having LDL-cholesterol < 2.5  mmol/L (< 97  mg/dL) 
and < 3.0 mmol/L (< 116 mg/dL), the recommended treat-
ment goals for persons at high and moderate risk of CHD 
respectively.
Thirty-eight percent of the study population did not 
reach any of the two treatment goals and 6% reached both 
(Fig. 3c). In the study population, 5% were completely in 















Fig. 2 Proportion of participants using medications for CHD in total and across the CHD disease groups. AP, angina pectoris; ASA, acetylsalicylic 
acid; CABG, coronary artery bypass surgery; CHD, coronary heart disease; LLD, lipid-lowering drug; MI, myocardial infarction; PCI, percutaneous 
coronary intervention
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accordance with the guidelines, i.e. using ASA and LLDs 
and achieving both treatment goals. The proportion 
reaching both treatment goals was 9% (62) among those 
who used all three classes of drugs and 3% (21) among 
those who did not use all three (p < 0.001). Regarding 
CHD disease group, the proportion reaching both treat-
ment goals was 6% (48) among those with a previous 
MI, 6% (34) among those with PCI and/or CABG and 
1% (1) among those with AP (p = 0.04). Characteristics 
of participants achieving and not achieving the recom-
mended treatment goals for LDL-cholesterol and blood 
pressure among those using LLDs and antihypertensive 
drugs are shown in Table 3.
Among the participants with diabetes (n = 214), 
50% achieved the treatment goal for blood pres-
sure (< 140/80  mmHg) and 14% for LDL-cholesterol 
(< 1.8 mmol/L or < 70 mg/dL). Treatment goal for HbA1c 
(< 7%) was reached by 43% (for results on treatment goal 









Treatment goal <150/90 mmHg









Treatment goal <2.5 mmol/l (<97 mg/dL) <3.0 mmol/l (<116 mg/dL)









Fig. 3 Proportion of participants achieving the treatment goals, in total and across the CHD disease groups. a Blood pressure, treatment 
goal < 140/90 mmHg (< 140/80 mmHg if diabetic). The panel also shows the proportion with blood pressure close to treatment goal. b Low-density 
lipoprotein (LDL)-cholesterol, treatment goal < 1.8 mmol/l (< 70 mg/dL). The panel also shows the proportion with LDL-cholesterol < 2.5 mmol/l 
(< 97 mg/dL, treatment goal for persons at high risk of CHD) and < 3.0 mmol/l (< 116 mg/dL, treatment goal for persons at moderate risk of CHD). 
c both treatment goals (y-axis 0–10%). AP, angina pectoris; CABG, coronary artery bypass surgery; CHD, coronary heart disease; MI, myocardial 
infarction; PCI, percutaneous coronary intervention
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achievement for HbA1c in the different CHD disease 
groups, see Additional file  1: Table  S4). All three treat-
ment goals were reached by 4%.
Logistic regression with propensity score matching 
showed that use of LLDs was significantly associated 
with treatment goal achievement for LDL-cholesterol, 
while the use of antihypertensive drugs among partici-
pants with hypertension was not associated with treat-
ment goal achievement for blood pressure, see Table  4. 
Results from the propensity score matching can be found 
in Additional file 1: Tables S5 and S6.
Discussion
We have identified that a relatively high proportion of 
persons with CHD adhere to the recommended prescrip-
tion guidelines. However, fewer of the participants in our 
study use LLDs, antihypertensive drugs and ASA com-
pared to what has been found in other studies [7, 8, 18, 
Table 3 Characteristics of participants achieving and not achieving treatment goals among LLD and antihypertensive drug users
Percentages are calculated for columns
AP, angina pectoris; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft; CHD, coronary heart disease; HDL, high-density lipoprotein; LDL, 
low-density lipoprotein; LLD, lipid-lowering drugs; MI, myocardial infarction; PCI, percutaneous coronary intervention; sd, standard deviation
* Self-reported relevant comorbidities for coronary heart disease, present or previous diseases
† To convert to mg/dL, multiply with 38.67
‡ To convert to mg/dL, multiply with 88.57
§ To convert to mg/dL, multiply with 18.02
Users of LLDs
(n = 1133)
















 Women 29 (21.3) 262 (26.4) 123 (32.5) 132 (34.6)
Age, mean (sd) 69.7 (9.5) 69.4 (9.8) 68.0 (9.7) 71.6 (9.6)
Smoking, n (%)
 Daily smoking 15 (11.0) 114 (11.5) 52 (13.7) 29 (7.5)
 Smoked previously 79 (58.1) 617 (62.3) 218 (57.5) 236 (61.8)
Self-reported health, n (%)
 Excellent/good 56 (41.2) 478 (48.2) 157 (41.4) 161 (42.1)
 Neither good nor bad 68 (50.0) 403 (40.7) 175 (46.2) 177 (46.3)
 Bad/very bad 9 (6.6) 99 (10.0) 44 (11.6) 40 (10.4)
Comorbidities*, n (%)
 Heart failure 20 (14.7) 176 (17.8) 72 (19.0) 65 (17.0)
 Atrial fibrillation 23 (16.9) 181 (18.3) 84 (22.1) 76 (19.9)
 Stroke 12 (8.8) 90 (9.1) 45 (11.9) 46 (12.0)
 Diabetes 28 (20.6) 147 (14.8) 72 (19.0) 74 (19.4)
 Renal disease 7 (5.2) 71 (7.1) 25 (6.6) 40 (10.5)
 Cancer 18 (13.2) 124 (12.5) 44 (11.6) 60 (15.8)
 Medications, mean number of products (sd) 5.3 (2.9) 4.4 (2.8) 5.0 (2.9) 5.0 (2.9)
Clinical measurements, mean (sd)
 Systolic blood pressure, mmHg 133 (18.5) 136 (21.0) 123 (11.7) 155 (15.4)
 Diastolic blood pressure, mmHg 73 (9.2) 74 (9.8) 71 (8.5) 79 (9.6)
 Total cholesterol, mmol/l† 3.3 (0.6) 4.5 (0.9) 4.4 (1.0) 4.6 (1.1)
 LDL-cholesterol, mmol/l† 1.5 (0.2) 2.7 (0.8) 2.7 (0.9) 2.8 (1.0)
 HDL-cholesterol, mmol/l† 1.5 (0.6) 1.4 (0.4) 1.4 (0.4) 1.4 (0.4)
 Triglycerides, mmol/l‡ 1.5 (1.6) 1.6 (0.9) 1.7 (0.9) 1.7 (1.1)
 HbA1c, % 6.3 (1.0) 6.1 (0.9) 6.1 (1.0) 6.1 (1.0)
 Glucose, mmol/l§ 6.5 (2.7) 6.0 (2.1) 6.2 (2.3) 6.2 (2.2)
 BMI, kg/m2 28.4 (4.6) 28.4 (4.3) 29.2 (4.6) 28.9 (4.4)
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19]. The newest EUROASPIRE survey from 2019 found a 
proportion of use of 84% for LLDs, 95% for antihyperten-
sive drugs and 93% for antiplatelet drugs [7]. The results 
from The NORwegian CORonary (NOR-COR) Preven-
tion Study, STabilization of Atherosclerotic plaque By 
Initiation of darapLadIb TherapY (STABILITY) study and 
the prospeCtive observational LongitudinAl RegIstry oF 
patients with stable coronary arterY disease (CLARIFY) 
study are also similar to that of the EUROASPIRE [8, 18, 
19]. Unlike our study, most of these studies attain their 
information about medication use from medical journals 
and the studies are usually conducted within a limited 
time frame after discharge from the hospital. As far as 
we know, ours is the first study to focus on persons with 
CHD in a general population, independent of time since 
diagnosis, and to investigate the participants’ own self-
reported use of medications.
Compared with other studies, the use of ASA and other 
antiplatelet drugs in our study is especially low [7, 8, 18, 
19]. The guidelines recommend use of ASA as secondary 
prevention for those who have had an MI, PCI or CABG, 
i.e., not including persons with only AP. In the current 
study, 70% within this subpopulation (n = 1357) used 
ASA, which is lower than what has been reported previ-
ously [7, 8]. Including other antiplatelet drugs increased 
the proportion of users to 71%, while the proportion of 
users of any antithrombotic drug (antiplatelets or antico-
agulants) was 78%. Although there will always be some 
who cannot use antithrombotics, this user prevalence is 
lower than expected.
Despite high prevalence of use of antihypertensive 
drugs and LLDs, achievement of treatment goals was 
low, especially for LDL-cholesterol. This is also compa-
rable to what has been found in other studies, though 
the level of achievement for LDL-cholesterol was lower 
in our study [7, 8, 20, 21]. Since our study population 
is defined as participants already having heart disease, 
they are considered to have a very high cardiovascular 
(CVD) risk, and the guidelines therefore recommend 
a treatment goal for LDL-cholesterol at < 1.8  mmol/L 
(< 70  mg/dL) or a reduction of ≥ 50% for LDL-choles-
terol when the target cannot be reached [6]. As this is a 
cross-sectional study, we do not know the participants’ 
cholesterol levels at treatment initiation and are there-
fore not able to determine whether they have had a 50% 
reduction in LDL-cholesterol. However, even when 
applying a threshold of < 3 mmol/L (< 116 mg/dL), only 
62% achieve the treatment goal (Fig. 3b). This indicates 
that many participants were far from reaching the rec-
ommended treatment goal.
The proportion of participants using antihypertensive 
drugs and achieving the treatment goals for blood pres-
sure was comparable to what has been found in other 
studies [7–9, 18, 19]. These studies do not however 
explore the relationship between the two. We did not 
find a statistically significant relationship between using 
antihypertensive drugs and achieving the treatment goal 
for blood pressure. One plausible explanation for this 
is that participants who had been prescribed antihy-
pertensive drugs probably had a higher baseline blood 
pressure than those who were not prescribed antihyper-
tensive drugs. If so, some of the participants using anti-
hypertensive drugs may have experienced a reduction in 
blood pressure, though not enough to reach the recom-
mended treatment goal. Non-adherence could also be 
a potential explanation why we do not detect a statisti-
cally significant difference in achievement of treatment 
goal between participants using and not using antihy-
pertensive drugs. Another possibility is that our popula-
tion is too small, as so few persons with hypertension 
were not using antihypertensive drugs. This affects the 
propensity score matching, and makes it difficult to 
achieve comparable groups that are similar enough on 
all variables used in the propensity score. Further stud-
ies using a larger hypertensive population is therefore 
needed to confirm these results.
Of the three CHD disease groups, persons with previ-
ous MI, PCI or CABG have a higher risk of new major 
coronary events and require a closer follow-up than per-
sons with only self-reported AP. We found that among 
participants within the PCI or CABG group, fewer per-
sons reached the treatment goals for both blood pres-
sure and LDL-cholesterol and fewer of these persons 
used LLDs, antihypertensive drugs and ASA compared to 
those with previous MI (Figs. 2 and 3). This suggests that 
these persons need closer follow-up.
Strengths and limitations
We have used data from the Tromsø Study, a reliable 
population-based data source where measurements 
Table 4 Pooled results from the logistic regression analyses of 
the propensity score matched multiple imputed datasets
Number of cases varied between datasets and can be found in Additional file 1: 
Tables S5 and S6
Exposure variable Outcome variable Odds ratio 95% 
confidence 
interval
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of blood pressure and cholesterol were performed by 
trained personnel and with standardized procedures and 
instruments. The Tromsø Study has a high attendance 
rate and is considered representative for an urban, white 
Northern European population [15].
Measurements of blood pressure and LDL-choles-
terol were done objectively, which is also a strength of 
the study. So is the use of multiple imputation to avoid 
bias due to missing values and propensity score match-
ing to control for confounding. Propensity score match-
ing appropriately balances the covariates between treated 
and untreated participants and makes it possible to 
include more covariates than in a conventional multivari-
able logistic regression.
The major limitation in this study is that we do not 
have any information about blood pressure and LDL-
cholesterol at treatment initiation, which restricts us to 
investigating the participants’ blood pressure and LDL-
cholesterol at the time of their attendance in Tromsø 7.
We also lack information about the participants’ medi-
cation adherence; hence we do not know if the par-
ticipants actually take their medication as prescribed. 
Non-adherence is likely to reduce their achievement of 
treatment goals.
Another limitation of the study is that most variables 
are self-reported, including CHD diagnosis and use of 
medications. We may have underestimated adherence to 
treatment guidelines through inclusion of some partici-
pants that are not actual CHD patients, or exclusion of 
participants who did not recall a previous CHD event. 
Such misclassification is less likely for life threatening 
conditions like MI, and although there may be some who 
reported MI when they have had a PCI/CABG (or vice 
versa), the extent would be limited and should not note-
worthy alter the study results. Self-reported medication 
use could make the results susceptible to recall bias. For 
medications used for chronic conditions such as CHD, 
self-reported use of medications have shown good to 
very good agreement with prescription data [22], sug-
gesting that recall bias should be a minor problem in our 
study.
A disadvantage with the statistical methods is that pro-
pensity score matching does not use all the observations. 
This is especially a problem when the groups of treated 
and untreated are very unevenly distributed, as in our 
study population (76% use LLDs and 92% of those with 
hypertension use antihypertensive drugs). To include as 
many observations as possible we performed matching 
with replacement. This procedure may introduce bias 
as several participants among medication users can be 
matched with the same non-user, and some may not be 
matched to anyone at all. However, a re-analysis with-
out replacement gave very similar result, suggesting our 
results are valid (for results from this sensitivity analy-
sis, see Additional file  1: Table  S7). As propensity score 
matching only controls for measured confounders, our 
results might still be affected by unmeasured variables, 
which are only controllable through randomization.
Conclusion
Despite high adherence to prescription guidelines and a 
strong association between use of LLDs and treatment 
goal achievement, the proportion who reaches the treat-
ment goals is low among persons with CHD in a general 
population. Further research should include longitudi-
nal studies to explore dosage regimens and medication 
adherence among persons with CHD over time.
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Following publication of the original article [1], the 
authors would like to correct some information in the 
fourth paragraph under ‘Data extraction’ in the methods 
section. We have found that the LDL-cholesterol concen-
trations included in the study were measured directly, 
not calculated from total cholesterol.
The information originally read:
Serum total cholesterol was analysed by CHOD-
PAP enzymatic colorimetric methods with commercial 
kits (Roche Diagnostics GmbH, Mannheim, Germany) 
from non-fasting blood samples. The analysis was 
performed at the Department of Laboratory Medi-
cine, University Hospital of North Norway, Tromsø, 
Norway. LDL-cholesterol concentration was then 
calculated according to Friedewald’s formula: LDL-cho-
lesterol = total cholesterol − high-density lipoprotein 
cholesterol − (0.45 × triglycerides).
The information should read:
LDL-cholesterol was collected and analyzed by trained 
personnel using enzymatic colorimetric methods with 
commercial kits on a Cobas 8000 c702 (Roche Diagnos-
tics GmbH, Mannheim, Germany) from non-fasting 
venous blood samples. The analysis was performed at the 
Department of Laboratory Medicine, University Hospi-
tal of North Norway, Tromsø, Norway (ISO certification 
NS-EN ISO 15189:2012).
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Supplementary table 1: Overview of ATC-codes included in the three medication categories 
recommended for CHD based on the European Society of Cardiology: Guidelines on 
cardiovascular disease prevention in clinical practice (version 2012) (6) 
Medication ATC-codes 
Acetylsalicylic acid1 
 Acetylsalicylic acid B01AC06 
Lipid lowering drugs 
 Statins C10AA, C10BA 
 Other lipid lowering drugs C10AC, C10AX 
 Unknown lipid lowering drugs2  
Antihypertensive drugs 
 ACE inhibitors and ARBs C09 
 Beta-blockers C07 
 Calcium channel blockers C08, C09BB, C09DB, C09DX01, C09DX03 
 Thiazides C03A, C03EA, C07B, C09BA, C09DA, C09DX01, C09DX03 
 Other antihypertensives2 C02, C03C, C03D, C03EA, C03X  
 Unknown antihypertensives2  
1 Also includes “yes” to question “If you have used analgesics and anti-inflammatory medication regularly in the past year - did you use 
“Baby” or low dose acetylsalicylic acid (ASA) Acetylsalisylsyre® Albyl-E® Asasantin Retard® (75/160 mg per tablet)?” 
2 When, instead of brand name, the participants in free text reported using medication interpretable as “blood pressure lowering”, “diuretics” 





Supplementary table 2: Variables included as covariates in propensity score 
Variable name Variable explanation Coding 
AGE Number of years at attendance 
date 
Number 
SEX_T7 Sex 1 :  Male 
0 :  Female 
BMI Body mass index Number 
HEART_FAILURE_T7 Have you ever had, or do you 
have heart failure? 
0 :  No 
1 :  Yes, now 
2 :  Yes, previously 
ATRIAL_FIBRILLATION_T7 Have you ever had, or do you 
have atrial fibrillation? 
0 :  No 
1 :  Yes, now 
2 :  Yes, previously 
STROKE_T7 Do you have, or have you had a 
cerebral stroke/brain 
haemorrhage? 
0 :  No 
2 :  Yes, previously 
KIDNEY_DISEASE_T7 Do you have, or have you had a 
kidney disease, not including 
urinary tract infection (UTI)? 
0 :  No 
1 :  Yes, now 
2 :  Yes, previously 
CANCER_T7 Have you ever had, or do you 
have cancer? 
0 :  No 
1 :  Yes, now 
2 :  Yes, previously 
DIABETES_impu_new1 Do you have, or have you had 
diabetes? 
0 :  No 
1 :  Yes, now 
2 :  Yes, previously 
Cons_GP_Times_impu1 If you have visited a general 
practitioner (GP) the past year, 
how many visits have you made? 
Number 
Cons_Emergency_Times_impu1 If you have visited an emergency 
room the past year, how many 
visits have you made? 
Number 
Cons_Hospital_Times_impu1 If you have been admitted to a 
hospital the past year, how many 
times? 
Number 
Cons_Specialist_Times_impu1 If you have visited another 
medical specialist than a general 
practitioner (GP) or a 
psychologist or psychiatrist (not 
at a hospital) the past year, how 
many visits have you made? 
Number 
Cons_Clinic_Times_impu1 Have you during the past year 
visited a hospital out-patient 
clinic, other than psychiatric 
department? 
Number 
Alcohol_frequency_impu1 How often do you usually drink 
alcohol? 
1 :  Never 
2 :  Monthly or less 
frequently 
3 :  2-4 times a month 
4 :  2-3 times a week 
5 :  4 or more times a week 
Alcohol_units_impu1 How many units of alcohol (1 
beer, glass of wine or drink) do 
you usually drink when you drink 
alcohol? 
1 :  1-2 
2 :  3-4 
3 :  5-6 
4 :  7-9 
5 :  10 or more 
Alcohol_units_6_impu1 How often do you drink 6 units 
alcohol or more in one occasion? 
1 :  Never 




3 :  Monthly 
4 :  Weekly 
5 :  Daily or almost daily 
Smoke_impu1 Do you/did you smoke 
daily/sometimes? 
1 :  Now, daily 
2 :  Now, sometimes 
3 :  Previously 
4 :  Never 
Snuff_chewing_tobacco_impu1 Have you used or do you use 
snuff or chewing tobacco 
daily/sometimes? 
1 :  Now, daily 
2 :  Now, sometimes 
3 :  Previously 
4 :  Never 
Cod_liver_oil_omega3_impu1 Do you use cod liver oil or cod 
liver oil capsules or Omega 3 
capsules (fish oil, seal oil)? 
0 :  No 
1 :  Sometimes 
2 :  Daily during the winter 
season 
3 :  Daily 
FRUIT_UNITS_T7 How many units of fruit or 
vegetables do you eat per day 
(average). (E.g. an apple, bowl of 
salad)? 
Number 
RED_MEAT_T7 How often do you usually eat red 
meat (all products from beef, 
mutton, pork)? 
1 :  0-1 times per month 
2 :  2-3 times per month 
3 :  1-3 times per week 
4 :  4-6 times per week 
5 :  Once a day or more 
FRUITS_VEG_BERRY_T7 How often do you usually eat 
fruits, vegetables and berries? 
1 :  0-1 times per month 
2 :  2-3 times per month 
3 :  1-3 times per week 
4 :  4-6 times per week 
5 :  Once a day or more 
LEAN_FISH_T7 How often do you usually eat lean 
fish (cod, saithe)? 
1 :  0-1 times per month 
2 :  2-3 times per month 
3 :  1-3 times per week 
4 :  4-6 times per week 
5 :  Once a day or more 
FAT_FISH_T7 How often do you usually eat fat 
fish (salmon, trout, redfish, 
mackerel, herring, halibut)? 
1 :  0-1 times per month 
2 :  2-3 times per month 
3 :  1-3 times per week 
4 :  4-6 times per week 
5 :  Once a day or more 
PHYS_ACTIVITY_LEISURE_T7 Describe your exercise and 
physical exertion in leisure time 
over the last year. If your activity 
varies throughout the year, give 
an average. 
1 :  Reading, watching 
TV/screen or other sedentary 
activity? 
2 :  Walking, cycling, or 
other forms of exercise at least 4 
hours a week? (including 
walking or cycling to place of 
work, Sunday-walking, etc.) 
3 :  Participation in 
recreational sports, heavy 
gardening, snow shoveling etc at 
least 4 hours a week. 
4 :  Participation in hard 
training or sports competitions, 
regularly several times a week? 
EXERCISE_T7 How often do you exercise (i.e 
walking, skiing, swimming or 
training/sports)? 
1 :  Never 
2 :  Less than once a week 
3 :  Once a week 
4 :  2-3 times a week 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary table 4: Achievement of treatment goal for HbA1c for participants with diabetes 






for HbA1c,  
n (%) 
Coronary heart disease 214 91 (42.5) 
Myocardial infarction 123 50 (40.7) 
Percutaneous coronary intervention/ 
Coronary artery bypass surgery 
80 34 (42.5) 





Supplementary table 5: Results from propensity score matching of the ten imputed datasets for the logistic regression 
analysis of the association between use of lipid-lowering drugs and achieving the treatment goal for LDL-cholesterol 
Dataset 1 
 Before matching After matching 
 Not LLD 
user 
LLD user SMD Not LLD 
user 
LLD user SMD 
n 345 1127  252 1126  
AGE, mean (SD) 66.34 
(13.45) 





SEX_T7, n (%)   0.390   0.209 
 1 193 (55.9) 836 (74.2)  163 
(64.7) 
836 (74.2)  





HEART_FAILURE_T7, n (%)   0.197   0.145 
 0 283 (82.0) 841 (74.6)  202 
(80.2) 
840 (74.6)  
 1 30 (8.7) 114 (10.1)  23 (9.1) 114 (10.1)  
 2 32 (9.3) 172 (15.3)  27 (10.7) 172 (15.3)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.142   0.067 
 0 236 (68.4) 842 (74.7)  181 
(71.8) 
842 (74.8)  
 1 65 (18.8) 164 (14.6)  41 (16.3) 163 (14.5)  
 2 44 (12.8) 121 (10.7)  30 (11.9) 121 (10.7)  
STROKE_T7, n (%)   0.074   0.038 
 2 41 (11.9) 162 (14.4)  33 (13.1) 162 (14.4)  
KIDNEY_DISEASE_T7, n (%)   0.137   0.128 
 0 282 (81.7) 977 (86.7)  207 
(82.1) 
977 (86.8)"  
 1 35 (10.1) 87 (7.7)  26 (10.3) 86 (7.6)  
 2 28 (8.1) 63 (5.6)  19 (7.5) 63 (5.6)  
CANCER_T7, n (%)   0.022   0.050 
 0 279 (80.9) 920 (81.6)  201 
(79.8) 
919 (81.6)  
 1 24 (7.0) 73 (6.5)  17 (6.7) 73 (6.5)  
 2 42 (12.2) 134 (11.9)  34 (13.5) 134 (11.9)  
DIABETES_impu_new, n (%)   0.096   0.064 
 0 274 (79.4) 889 (78.9)  200 
(79.4) 
888 (78.9)  
 1 51 (14.8) 192 (17.0)  39 (15.5) 192 (17.1)  
 2 20 (5.8) 46 (4.1)  13 (5.2) 46 (4.1)  
Cons_GP_Times_impu, mean 
(SD) 
4.44 (6.03) 4.25 (5.31) 0.035 4.33 
(5.90) 
4.19 (5.01) 0.025 
Cons_Emergency_Times_impu, 
mean (SD) 
0.44 (0.88) 0.31 (0.74) 0.165 0.37 
(0.76) 
0.31 (0.74) 0.083 
Cons_Hospital_Times_impu, 
mean (SD) 
0.43 (1.26) 0.43 (0.90) 0.009 0.43 
(1.35) 
0.42 (0.90) 0.005 
Cons_Specialist_Times_impu, 
mean (SD) 
0.63 (1.85) 0.47 (2.49) 0.073 0.53 
(1.67) 
0.47 (2.49) 0.026 
Cons_Clinic_Times_impu, 
mean (SD) 
1.74 (7.48) 1.14 (4.74) 0.095 1.60 
(7.14) 
1.14 (4.75) 0.075 
Alcohol_frequency_impu, n (%)   0.150   0.142 
 1 34 (9.9) 121 (10.7)  23 (9.1) 121 (10.7)  
 
 
 2 85 (24.6) 209 (18.5)  60 (23.8) 208 (18.5)  
 3 129 (37.4) 462 (41.0)  94 (37.3) 462 (41.0)  
 4 69 (20.0) 243 (21.6)  53 (21.0) 243 (21.6)  
 5 28 (8.1) 92 (8.2)  22 (8.7) 92 (8.2)  
Alcohol_units_impu, n (%)   0.069   0.071 
 0 36 (10.4) 119 (10.6)  23 (9.1) 119 (10.6)  
 1 174 (50.4) 542 (48.1)  126 
(50.0) 
541 (48.0)  
 2 102 (29.6) 367 (32.6)  78 (31.0) 367 (32.6)  
 3 33 (9.6) 99 (8.8)  25 (9.9) 99 (8.8)  
Alcohol_units_6_impu, n (%)   0.117   0.146 
 1 188 (54.5) 662 (58.7)  133 
(52.8) 
662 (58.8)  
 2 116 (33.6) 364 (32.3)  89 (35.3) 363 (32.2)  
 3 32 (9.3) 77 (6.8)  23 (9.1) 77 (6.8)  
 4 7 (2.0) 21 (1.9)  5 (2.0) 21 (1.9)  
 5 2 (0.6) 3 (0.3)  2 (0.8) 3 (0.3)  
Smoke_impu, n (%)   0.305   0.245 
 1 57 (16.5) 139 (12.3)  43 (17.1) 139 (12.3)  
 2 12 (3.5) 19 (1.7)  7 (2.8) 19 (1.7)  
 3 167 (48.4) 711 (63.1)  129 
(51.2) 
710 (63.1)  
 4 109 (31.6) 258 (22.9)  73 (29.0) 258 (22.9)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.037   0.053 
 1 22 (6.4) 67 (5.9)  17 (6.7) 67 (6.0)  
 2 1 (0.3) 2 (0.2)  1 (0.4) 2 (0.2)  
 3 19 (5.5) 57 (5.1)  13 (5.2) 57 (5.1)  







  0.100   0.089 
 0 261 (75.7) 824 (73.1)  189 
(75.0) 
823 (73.1)  
 1 44 (12.8) 144 (12.8)  34 (13.5) 144 (12.8)  
 2 15 (4.3) 46 (4.1)  10 (4.0) 46 (4.1)  
 3 25 (7.2) 113 (10.0)  19 (7.5) 113 (10.0)  
FRUIT_UNITS_T7, mean (SD) 1.72 (1.35) 1.96 (1.71) 0.157 1.73 
(1.39) 
1.92 (1.28) 0.143 
RED_MEAT_T7, n (%)   0.066   0.095 
 1 24 (7.0) 74 (6.6)  14 (5.6) 74 (6.6)  
 2 76 (22.0) 250 (22.2)  54 (21.4) 250 (22.2)  
 3 216 (62.6) 723 (64.2)  167 
(66.3) 
722 (64.1)  
 4 26 (7.5) 68 (6.0)  16 (6.3) 68 (6.0)  
 5 3 (0.9) 12 (1.1)  1 (0.4) 12 (1.1)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.095   0.110 
 1 4 (1.2) 12 (1.1)  1 (0.4) 12 (1.1)  
 2 15 (4.3) 45 (4.0)  10 (4.0) 45 (4.0)  
 3 66 (19.1) 259 (23.0)  54 (21.4) 259 (23.0)  
 4 101 (29.3) 313 (27.8)  79 (31.3) 312 (27.7)  
 5 159 (46.1) 498 (44.2)"  108 
(42.9) 
498 (44.2)  
 
 
LEAN_FISH_T7, n (%)   0.231   0.102 
 1 24 (7.0) 28 (2.5)  10 (4.0) 28 (2.5)  
 2 50 (14.5) 153 (13.6)  38 (15.1) 153 (13.6)  
 3 224 (64.9) 801 (71.1)  175 
(69.4) 
800 (71.0)  
 4 41 (11.9) 134 (11.9)  27 (10.7) 134 (11.9)  
 5 6 (1.7) 11 (1.0)  2 (0.8) 11 (1.0)  
FAT_FISH_T7, n (%)   0.151   0.098 
 1 49 (14.2) 113 (10.0)  31 (12.3) 112 (9.9)  
 2 116 (33.6) 392 (34.8)  81 (32.1) 392 (34.8)  
 3 153 (44.3) 550 (48.8)  125 
(49.6) 
550 (48.8)  
 4 19 (5.5) 54 (4.8)  10 (4.0) 54 (4.8)  
 5 8 (2.3) 18 (1.6)  5 (2.0) 18 (1.6)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.108   0.048 
 1 86 (24.9) 232 (20.6)  55 (21.8) 231 (20.5)  
 2 179 (51.9) 625 (55.5)  140 
(55.6) 
625 (55.5)  
 3 72 (20.9) 247 (21.9)  53 (21.0) 247 (21.9)  
 4 8 (2.3) 23 (2.0)  4 (1.6) 23 (2.0)  
EXERCISE_T7, n (%)   0.175   0.144 
 1 45 (13.0) 107 (9.5)  29 (11.5) 107 (9.5)  
 2 54 (15.7) 142 (12.6)  39 (15.5) 142 (12.6)  
 3 51 (14.8) 155 (13.8)  38 (15.1) 155 (13.8)  
 4 111 (32.2) 434 (38.5)  82 (32.5) 433 (38.5)  
 5 84 (24.3) 289 (25.6)  64 (25.4) 289 (25.7)  
Dataset 2 
 Before matching After matching 
 Not LLD 
user 
LLD user SMD Not LLD 
user 
LLD user SMD 
n 345 1127  261 1124  
AGE, mean (SD) 66.34 
(13.45) 





SEX_T7, n (%)   0.390   0.247 
 1 193 (55.9) 836 (74.2)  164 
(62.8) 
834 (74.2)  





HEART_FAILURE_T7, n (%)   0.182   0.147 
 0 282 (81.7) 838 (74.4)  210 
(80.5) 
837 (74.5)  
 1 25 (7.2) 104 (9.2)  20 (7.7) 103 (9.2)  
 2 38 (11.0) 185 (16.4)  31 (11.9) 184 (16.4)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.140   0.081 
 0 236 (68.4) 840 (74.5)  187 
(71.6) 
839 (74.6)  
 1 65 (18.8) 162 (14.4)  45 (17.2) 161 (14.3)  
 2 44 (12.8) 125 (11.1)  29 (11.1) 124 (11.0)"  
STROKE_T7, n (%)   0.069   0.062 
 2 43 (12.5) 167 (14.8)  33 (12.6) 166 (14.8)  
KIDNEY_DISEASE_T7, n (%)   0.173   0.155 
 
 
 0 278 (80.6) 977 (86.7)  213 
(81.6) 
976 (86.8)  
 1 40 (11.6) 99 (8.8)  28 (10.7) 97 (8.6)  
 2 27 (7.8) 51 (4.5)  20 (7.7) 51 (4.5)  
CANCER_T7, n (%)   0.039   0.083 
 0 277 (80.3) 922 (81.8)  206 
(78.9) 
919 (81.8)  
 1 28 (8.1) 84 (7.5)  20 (7.7) 84 (7.5)  
 2 40 (11.6) 121 (10.7)  35 (13.4) 121 (10.8)  
DIABETES_impu_new, n (%)   0.065   0.087 
 0 273 (79.1) 887 (78.7)  209 
(80.1) 
886 (78.8)  
 1 54 (15.7) 194 (17.2)  38 (14.6) 192 (17.1)  
 2 18 (5.2) 46 (4.1)  14 (5.4) 46 (4.1)  
Cons_GP_Times_impu, mean 
(SD) 
3.99 (4.80) 4.15 (5.05) 0.034 3.98 
(4.32) 
4.09 (4.73) 0.026 
Cons_Emergency_Times_impu, 
mean (SD) 
0.41 (0.89) 0.29 (0.71) 0.149 0.37 
(0.79) 
0.29 (0.71) 0.105 
Cons_Hospital_Times_impu, 
mean (SD) 
0.42 (1.24) 0.43 (0.90) 0.010 0.41 
(1.33) 
0.43 (0.90) 0.012 
Cons_Specialist_Times_impu, 
mean (SD) 
0.49 (1.39) 0.46 (2.52) 0.016 0.44 
(1.18) 
0.46 (2.52) 0.010 
Cons_Clinic_Times_impu, 
mean (SD) 
1.45 (4.89) 1.22 (4.78) 0.048 1.32 
(2.84) 
1.22 (4.78) 0.025 
Alcohol_frequency_impu, n (%)   0.152   0.151 
 1 34 (9.9) 121 (10.7)  28 (10.7) 121 (10.8)  
 2 85 (24.6) 209 (18.5)  60 (23.0) 208 (18.5)  
 3 128 (37.1) 462 (41.0)  96 (36.8) 461 (41.0)  
 4 69 (20.0) 243 (21.6)  50 (19.2) 243 (21.6)  
 5 29 (8.4) 92 (8.2)  27 (10.3) 91 (8.1)  
Alcohol_units_impu, n (%)   0.074   0.078 
 0 36 (10.4) 119 (10.6)  30 (11.5) 119 (10.6)  
 1 176 (51.0) 542 (48.1)  130 
(49.8) 
539 (48.0)  
 2 101 (29.3) 367 (32.6)  76 (29.1) 367 (32.7)  
 3 32 (9.3) 99 (8.8)  25 (9.6) 99 (8.8)  
Alcohol_units_6_impu, n (%)   0.107   0.095 
 1 188 (54.5) 662 (58.7)  147 
(56.3) 
661 (58.8)  
 2 120 (34.8) 362 (32.1)  86 (33.0) 360 (32.0)  
 3 28 (8.1) 75 (6.7)  20 (7.7) 75 (6.7)  
 4 6 (1.7) 23 (2.0)  5 (1.9) 23 (2.0)  
 5 3 (0.9) 5 (0.4)  3 (1.1) 5 (0.4)  
Smoke_impu, n (%)   0.305   0.243 
 1 57 (16.5) 139 (12.3)  45 (17.2) 139 (12.4)  
 2 12 (3.5) 19 (1.7)  7 (2.7) 19 (1.7)  
 3 167 (48.4) 711 (63.1)  134 
(51.3) 
709 (63.1)  
 4 109 (31.6) 258 (22.9  75 (28.7) 257 (22.9)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.053   0.062 
 1 22 (6.4) 67 (5.9)  16 (6.1) 67 (6.0)  
 2 1 (0.3) 1 (0.1)  1 (0.4) 1 (0.1)  
 3 19 (5.5) 58 (5.1)  14 (5.4) 58 (5.2)  
 
 
 4 303 (87.8) 1001 (88.8)  230 
(88.1) 
998 (88.8)  
Cod_liver_oil_omega3_impu, n 
(%) 
  0.099   0.045 
 0 261 (75.7) 825 (73.2)  195 
(74.7) 
823 (73.2)  
 1 44 (12.8) 142 (12.6)  33 (12.6) 142 (12.6)  
 2 15 (4.3) 47 (4.2)  10 (3.8) 47 (4.2)  
 3 25 (7.2) 113 (10.0)  23 (8.8) 112 (10.0)  
FRUIT_UNITS_T7, mean (SD) 1.80 (1.49) 1.98 (1.72) 0.112 1.82 
(1.54) 
1.94 (1.26) 0.085 
RED_MEAT_T7, n (%)   0.088   0.122 
 1 24 (7.0) 72 (6.4)  18 (6.9) 72 (6.4)  
 2 73 (21.2) 253 (22.4)  53 (20.3) 253 (22.5)  
 3 218 (63.2) 721 (64.0)  169 
(64.8) 
719 (64.0)  
 4 27 (7.8) 67 (5.9)  20 (7.7) 67 (6.0)  
 5 3 (0.9) 14 (1.2)  1 (0.4) 13 (1.2)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.097   0.080 
 1 3 (0.9) 12 (1.1)  2 (0.8) 12 (1.1)  
 2 14 (4.1) 49 (4.3)  9 (3.4) 49 (4.4)  
 3 65 (18.8) 253 (22.4)  54 (20.7) 253 (22.5)  
 4 103 (29.9) 313 (27.8)  73 (28.0) 312 (27.8)  
 5 160 (46.4) 500 (44.4)  123 
(47.1) 
498 (44.3)  
LEAN_FISH_T7, n (%)   0.223   0.124 
 1 23 (6.7) 28 (2.5)  12 (4.6) 28 (2.5)  
 2 50 (14.5) 151 (13.4)  37 (14.2) 151 (13.4)  
 3 229 (66.4) 802 (71.2)  180 
(69.0) 
800 (71.2)  
 4 36 (10.4) 133 (11.8)  30 (11.5) 132 (11.7)  
 5 7 (2.0) 13 (1.2)  2 (0.8) 13 (1.2)  
FAT_FISH_T7, n (%)   0.156   0.065 
 1 51 (14.8) 113 (10.0)  29 (11.1) 112 (10.0)  
 2 116 (33.6) 393 (34.9)  88 (33.7) 393 (35.0)  
 3 156 (45.2) 551 (48.9)  130 
(49.8) 
549 (48.8)  
 4 15 (4.3) 54 (4.8)  10 (3.8) 54 (4.8)  
 5 7 (2.0) 16 (1.4)  4 (1.5) 16 (1.4)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.069   0.050 
 1 79 (22.9) 241 (21.4)  57 (21.8) 238 (21.2)  
 2 182 (52.8) 623 (55.3)  139 
(53.3) 
623 (55.4)  
 3 75 (21.7) 242 (21.5)  59 (22.6) 242 (21.5)  
 4 9 (2.6) 21 (1.9)  6 (2.3) 21 (1.9)  
EXERCISE_T7, n (%)   0.176   0.127 
 1 43 (12.5) 102 (9.1)  26 (10.0) 102 (9.1)  
 2 54 (15.7) 143 (12.7)  41 (15.7) 142 (12.6)  
 3 51 (14.8) 153 (13.6)  36 (13.8) 153 (13.6)  
 4 111 (32.2) 437 (38.8)  87 (33.3) 435 (38.7)  




 Before matching After matching 
 Not LLD 
user 
LLD user SMD Not LLD 
user 
LLD user SMD 
n 345 1127  259 1127  
AGE, mean (SD) 66.34 
(13.45) 
69.41 (9.72) 0.261 68.00 
(12.72) 
69.41 (9.72 0.124 
SEX_T7, n (%)   0.390   0.212 
 1 193 (55.9) 836 (74.2)  167 
(64.5) 
836 (74.2)  





HEART_FAILURE_T7, n (%)   0.191   0.190 
 0 279 (80.9) 844 (74.9)  213 
(82.2) 
844 (74.9)  
 1 33 (9.6) 104 (9.2)  20 (7.7) 104 (9.2)  
 2 33 (9.6) 179 (15.9)  26 (10.0) 179 (15.9)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.153   0.093 
 0 238 (69.0) 844 (74.9)  187 
(72.2) 
844 (74.9)  
 1 69 (20.0) 162 (14.4)  46 (17.8) 162 (14.4)  
 2 38 (11.0) 121 (10.7)  26 (10.0) 121 (10.7)  
STROKE_T7, n (%)   0.065   0.048 
 2 42 (12.2) 162 (14.4)  33 (12.7) 162 (14.4)  
KIDNEY_DISEASE_T7, n (%)   0.143   0.090 
 0 282 (81.7) 976 (86.6)  216 
(83.4) 
976 (86.6)  
 1 36 (10.4) 96 (8.5)  27 (10.4) 96 (8.5)  
 2 27 (7.8) 55 (4.9)  16 (6.2) 55 (4.9)  
CANCER_T7, n (%)   0.028   0.053 
 0 280 (81.2) 919 (81.5)  206 
(79.5) 
919 (81.5)  
 1 24 (7.0) 83 (7.4)  22 (8.5) 83 (7.4)  
 2 41 (11.9) 125 (11.1)  31 (12.0) 125 (11.1)  
DIABETES_impu_new, n (%)   0.114   0.106 
 0 274 (79.4) 887 (78.7)  208 
(80.3) 
887 (78.7)  
 1 52 (15.1) 200 (17.7)  38 (14.7) 200 (17.7)  
 2 19 (5.5) 40 (3.5)  13 (5.0) 40 (3.5)  
Cons_GP_Times_impu, mean 
(SD) 
4.33 (6.06) 4.14 (4.77) 0.036 3.99 
(5.30) 
4.14 (4.77) 0.028 
Cons_Emergency_Times_impu, 
mean (SD) 
0.39 (0.81) 0.30 (0.73) 0.116 0.31 
(0.72) 
0.30 (0.73) 0.008 
Cons_Hospital_Times_impu, 
mean (SD) 
0.48 (1.43) 0.43 (0.91) 0.040 0.42 
(1.26) 
0.43 (0.91) 0.012 
Cons_Specialist_Times_impu, 
mean (SD) 
0.61 (1.78) 0.48 (2.56) 0.059 0.62 
(1.74) 
0.48 (2.56) 0.061 
Cons_Clinic_Times_impu, 
mean (SD) 
1.12 (2.48) 1.07 (4.17) 0.012 1.18 
(2.61) 
1.07 (4.17) 0.030 
Alcohol_frequency_impu, n (%)   0.152   0.146 
 1 34 (9.9) 121 (10.7)  23 (8.9) 121 (10.7)  
 2 85 (24.6) 209 (18.5)  62 (23.9) 209 (18.5)  
 3 128 (37.1) 462 (41.0)  101 
(39.0) 
462 (41.0)  
 
 
 4 69 (20.0) 243 (21.6)  50 (19.3) 243 (21.6)  
 5 29 (8.4) 92 (8.2)  23 (8.9) 92 (8.2)  
Alcohol_units_impu, n (%)   0.074   0.078 
 0 36 (10.4) 119 (10.6)  24 (9.3) 119 (10.6)  
 1 175 (50.7) 541 (48.0)  132 
(51.0) 
541 (48.0)  
 2 101 (29.3) 367 (32.6)  78 (30.1) 367 (32.6)  
 3 33 (9.6) 100 (8.9)  25 (9.7) 100 (8.9)  
Alcohol_units_6_impu, n (%)   0.129   0.126 
 1 187 (54.2) 664 (58.9)  139 
(53.7) 
664 (58.9)  
 2 121 (35.1) 363 (32.2)  93 (35.9) 363 (32.2)  
 3 28 (8.1) 74 (6.6)  20 (7.7) 74 (6.6)  
 4 6 (1.7) 23 (2.0)  5 (1.9) 23 (2.0)  
 5 3 (0.9) 3 (0.3)  2 (0.8) 3 (0.3)  
Smoke_impu, n (%)   0.305   0.195 
 1 57 (16.5) 139 (12.3)  37 (14.3) 139 (12.3)  
 2 12 (3.5) 19 (1.7)  8 (3.1) 19 (1.7)  
 3 167 (48.4) 711 (63.1)  140 
(54.1) 
711 (63.1)  
 4 109 (31.6) 258 (22.9)  74 (28.6) 258 (22.9)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.054   0.072 
 1 22 (6.4) 67 (5.9)  16 (6.2) 67 (5.9)  
 2 1 (0.3) 1 (0.1)  1 (0.4) 1 (0.1)  
 3 19 (5.5) 57 (5.1)  11 (4.2) 57 (5.1)  







  0.109   0.106 
 0 259 (75.1) 821 (72.8)  196 
(75.7) 
821 (72.8)  
 1 46 (13.3) 142 (12.6)  34 (13.1) 142 (12.6)  
 2 14 (4.1) 44 (3.9)  9 (3.5) 44 (3.9)  
 3 26 (7.5) 120 (10.6)  20 (7.7) 120 (10.6)  
FRUIT_UNITS_T7, mean (SD) 1.72 (1.33) 1.97 (1.71) 0.164 1.76 
(1.42) 
1.97 (1.71) 0.131 
RED_MEAT_T7, n (%)   0.079   0.075 
 1 24 (7.0) 75 (6.7)  19 (7.3) 75 (6.7)  
 2 79 (22.9) 256 (22.7)  65 (25.1) 256 (22.7)  
 3 213 (61.7) 718 (63.7)  159 
(61.4) 
718 (63.7)  
 4 26 (7.5) 65 (5.8)  14 (5.4) 65 (5.8)  
 5 3 (0.9) 13 (1.2)  2 (0.8) 13 (1.2)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.105   0.062 
 1 3 (0.9) 12 (1.1)  2 (0.8) 12 (1.1)  
 2 13 (3.8) 45 (4.0)  9 (3.5) 45 (4.0)  
 3 65 (18.8) 258 (22.9)  56 (21.6) 258 (22.9)  
 4 101 (29.3) 312 (27.7)  77 (29.7) 312 (27.7)  
 5 163 (47.2) 500 (44.4)  115 
(44.4) 
500 (44.4)  
LEAN_FISH_T7, n (%)   0.218   0.095 
 1 23 (6.7) 28 (2.5)  9 (3.5) 28 (2.5)  
 
 
 2 55 (15.9) 155 (13.8)  42 (16.2) 155 (13.8)  
 3 227 (65.8) 799 (70.9)  176 
(68.0) 
799 (70.9)  
 4 36 (10.4) 133 (11.8)  29 (11.2) 133 (11.8)  
 5 4 (1.2) 12 (1.1)  3 (1.2) 12 (1.1)  
FAT_FISH_T7, n (%)   0.145   0.135 
 1 52 (15.1) 117 (10.4)  38 (14.7) 117 (10.4)  
 2 116 (33.6) 390 (34.6)  86 (33.2) 390 (34.6)  
 3 157 (45.5) 548 (48.6)  121 
(46.7) 
548 (48.6)  
 4 14 (4.1) 54 (4.8)  10 (3.9) 54 (4.8)  
 5 6 (1.7) 18 (1.6)  4 (1.5) 18 (1.6)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.078   0.081 
 1 83 (24.1) 236 (20.9)  63 (24.3) 236 (20.9)  
 2 180 (52.2) 622 (55.2)  136 
(52.5) 
622 (55.2)  
 3 75 (21.7) 246 (21.8)  55 (21.2) 246 (21.8)  
 4 7 (2.0) 23 (2.0)  5 (1.9) 23 (2.0)  
EXERCISE_T7, n (%)   0.179   0.177 
 1 45 (13.0) 107 (9.5)  31 (12.0) 107 (9.5)  
 2 53 (15.4) 141 (12.5)  40 (15.4) 141 (12.5)  
 3 52 (15.1) 154 (13.7)  39 (15.1) 154 (13.7)  
 4 110 (31.9) 436 (38.7)  80 (30.9) 436 (38.7)  
 5 85 (24.6) 289 (25.6)  69 (26.6) 289 (25.6)  
Dataset 4 
 Before matching After matching 
 Not LLD 
user 
LLD user SMD Not LLD 
user 
LLD user SMD 
n 345 1127  244 1126  
AGE, mean (SD) 66.34 
(13.45) 





SEX_T7, n (%)   0.390   0.285 
 1 193 (55.9) 836 (74.2)  149 
(61.1) 
836 (74.2)  





HEART_FAILURE_T7, n (%)   0.212   0.150 
 0 280 (81.2) 840 (74.5)  197 
(80.7) 
839 (74.5)  
 1 32 (9.3) 99 (8.8)  16 (6.6) 99 (8.8)  
 2 33 (9.6) 188 (16.7)  31 (12.7) 188 (16.7)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.151   0.137 
 0 236 (68.4) 843 (74.8)  173 
(70.9) 
843 (74.9)  
 1 67 (19.4) 161 (14.3)  47 (19.3) 160 (14.2)  
 2 42 (12.2) 123 (10.9)  24 (9.8) 123 (10.9)  
STROKE_T7, n (%)   0.072   0.082 
 2 42 (12.2) 165 (14.6)  29 (11.9) 165 (14.7)  
KIDNEY_DISEASE_T7, n (%)   0.124   0.035 
 0 284 (82.3) 978 (86.8)  209 
(85.7) 
978 (86.9)  
 1 37 (10.7) 90 (8.0)  21 (8.6) 89 (7.9)  
 
 
 2 24 (7.0) 59 (5.2)  14 (5.7) 59 (5.2)  
CANCER_T7, n (%)   0.035   0.049 
 0 279 (80.9) 919 (81.5)  196 
(80.3) 
918 (81.5)  
 1 27 (7.8) 78 (6.9)  16 (6.6) 78 (6.9)  
 2 39 (11.3) 130 (11.5)  32 (13.1) 130 (11.5)  
DIABETES_impu_new, n (%)   0.064   0.056 
 0 276 (80.0) 889 (78.9)  195 
(79.9) 
888 (78.9)  
 1 53 (15.4) 195 (17.3)  38 (15.6) 195 (17.3)  
 2 16 (4.6) 43 (3.8)  11 (4.5) 43 (3.8)  
Cons_GP_Times_impu, mean 
(SD) 
4.59 (6.65) 4.18 (5.04) 0.070 4.31 
(6.35) 
4.17 (5.03) 0.024 
Cons_Emergency_Times_impu, 
mean (SD) 
0.39 (0.96) 0.30 (0.73) 0.104 0.31 
(0.89) 
0.30 (0.73) 0.011 
Cons_Hospital_Times_impu, 
mean (SD) 
0.44 (1.25) 0.43 (0.90) 0.004 0.39 
(1.33) 
0.43 (0.90) 0.033 
Cons_Specialist_Times_impu, 
mean (SD) 
0.54 (1.62) 0.44 (2.44) 0.051 0.48 
(1.39) 
0.44 (2.44) 0.018 
Cons_Clinic_Times_impu, 
mean (SD) 
1.04 (2.38) 1.09 (4.16) 0.014 1.02 
(2.49) 
1.09 (4.16) 0.021 
Alcohol_frequency_impu, n (%)   0.150   0.133 
 1 34 (9.9) 121 (10.7)  25 (10.2) 121 (10.7)  
 2 85 (24.6) 209 (18.5)  58 (23.8) 208 (18.5)  
 3 129 (37.4) 462 (41.0)  94 (38.5) 462 (41.0)  
 4 69 (20.0) 243 (21.6)  47 (19.3) 243 (21.6)  
 5 28 (8.1) 92 (8.2)  20 (8.2) 92 (8.2)  
Alcohol_units_impu, n (%)   0.076   0.061 
 0 36 (10.4) 121 (10.7)  26 (10.7) 121 (10.7)  
 1 176 (51.0) 540 (47.9)  123 
(50.4) 
539 (47.9)  
 2 101 (29.3) 367 (32.6)  73 (29.9) 367 (32.6)  
 3 32 (9.3) 99 (8.8)  22 (9.0) 99 (8.8)  
Alcohol_units_6_impu, n (%)   0.103   0.065 
 1 187 (54.2) 662 (58.7)  137 
(56.1) 
662 (58.8)  
 2 122 (35.4) 366 (32.5)  84 (34.4) 365 (32.4)  
 3 27 (7.8) 74 (6.6)  16 (6.6) 74 (6.6)  
 4 7 (2.0) 22 (2.0)  6 (2.5) 22 (2.0)  
 5 2 (0.6) 3 (0.3)  1 (0.4) 3 (0.3)  
Smoke_impu, n (%)   0.305   0.271 
 1 57 (16.5) 139 (12.3)  39 (16.0) 139 (12.3)  
 2 12 (3.5) 19 (1.7)  4 (1.6) 19 (1.7)  
 3 167 (48.4) 711 (63.1)  122 
(50.0) 
710 (63.1)  
 4 109 (31.6) 258 (22.9)  79 (32.4) 258 (22.9)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.034   0.096 
 1 22 (6.4) 67 (5.9)  12 (4.9) 67 (6.0)  
 2 1 (0.3) 2 (0.2)  1 (0.4) 2 (0.2)  
 3 19 (5.5) 58 (5.1)  9 (3.7) 58 (5.2)  
 4 303 (87.8) 1000 (88.7)  222 
(91.0) 





  0.091   0.081 
 0 260 (75.4) 825 (73.2)  181 
(74.2) 
824 (73.2)  
 1 45 (13.0) 145 (12.9)  35 (14.3) 145 (12.9)  
 2 14 (4.1) 43 (3.8)  8 (3.3) 43 (3.8)  
 3 26 (7.5) 114 (10.1)  20 (8.2) 114 (10.1)  
FRUIT_UNITS_T7, mean (SD) 1.74 (1.35) 1.95 (1.71) 0.142 1.76 
(1.28) 
1.92 (1.28) 0.127 
RED_MEAT_T7, n (%)   0.068   0.090 
 1 24 (7.0) 70 (6.2)  14 (5.7) 70 (6.2)  
 2 78 (22.6) 251 (22.3)  57 (23.4) 251 (22.3)  
 3 214 (62.0) 722 (64.1)  156 
(63.9) 
721 (64.0)  
 4 26 (7.5) 71 (6.3)  16 (6.6) 71 (6.3)  
 5 3 (0.9) 13 (1.2)  1 (0.4) 13 (1.2)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.124   0.091 
 1 5 (1.4) 13 (1.2)  4 (1.6) 13 (1.2)  
 2 14 (4.1) 44 (3.9)  11 (4.5) 44 (3.9)  
 3 62 (18.0) 258 (22.9)  48 (19.7) 258 (22.9)  
 4 101 (29.3) 313 (27.8)  71 (29.1) 312 (27.7)  
 5 163 (47.2) 499 (44.3)  110 
(45.1) 
499 (44.3)  
LEAN_FISH_T7, n (%)   0.217   0.101 
 1 23 (6.7) 28 (2.5)  9 (3.7) 28 (2.5)  
 2 53 (15.4) 150 (13.3)  37 (15.2) 150 (13.3)  
 3 224 (64.9) 800 (71.0)  166 
(68.0) 
799 (71.0)  
 4 41 (11.9) 135 (12.0)  30 (12.3) 135 (12.0)  
 5 4 (1.2) 14 (1.2)  2 (0.8) 14 (1.2)  
FAT_FISH_T7, n (%)   0.156   0.124 
 1 50 (14.5) 114 (10.1)  28 (11.5) 113 (10.0)  
 2 114 (33.0) 389 (34.5)  74 (30.3) 389 (34.5)  
 3 158 (45.8) 553 (49.1)  124 
(50.8) 
553 (49.1)  
 4 14 (4.1) 53 (4.7)  11 (4.5) 53 (4.7)  
 5 9 (2.6) 18 (1.6)  7 (2.9) 18 (1.6)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.073   0.024 
 1 82 (23.8) 234 (20.8)  52 (21.3) 233 (20.7)  
 2 180 (52.2) 615 (54.6)  134 
(54.9) 
615 (54.6)  
 3 76 (22.0) 253 (22.4)  53 (21.7) 253 (22.5)  
 4 7 (2.0) 25 (2.2)  5 (2.0) 25 (2.2)  
EXERCISE_T7, n (%)   0.166   0.126 
 1 43 (12.5) 104 (9.2)  27 (11.1) 104 (9.2)  
 2 53 (15.4) 143 (12.7)  33 (13.5) 143 (12.7)  
 3 52 (15.1) 156 (13.8)  40 (16.4) 156 (13.9)  
 4 111 (32.2) 434 (38.5)  81 (33.2) 433 (38.5)  
 5 86 (24.9) 290 (25.7)  63 (25.8) 290 (25.8)  
Dataset 5 
 Before matching After matching 
 
 
 Not LLD 
user 
LLD user SMD Not LLD 
user 
LLD user SMD 
n 345 1127  249 1126  
AGE, mean (SD) 66.34 
(13.45) 





SEX_T7, n (%)   0.390   0.243 
 1 193 (55.9) 836 (74.2)  157 
(63.1) 
836 (74.2)  





HEART_FAILURE_T7, n (%)   0.190   0.133 
 0 282 (81.7) 838 (74.4)  199 
(79.9) 
837 (74.3)  
 1 27 (7.8) 104 (9.2)  18 (7.2) 104 (9.2)  
 2 36 (10.4) 185 (16.4)  32 (12.9) 185 (16.4)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.123   0.125 
 0 239 (69.3) 839 (74.4)  174 
(69.9) 
839 (74.5)  
 1 64 (18.6) 162 (14.4)  47 (18.9) 161 (14.3)  
 2 42 (12.2) 126 (11.2)  28 (11.2) 126 (11.2)  
STROKE_T7, n (%)   0.074   0.007 
 2 43 (12.5) 169 (15.0)  38 (15.3) 169 (15.0)  
KIDNEY_DISEASE_T7, n (%)   0.144   0.156 
 0 281 (81.4) 977 (86.7)  202 
(81.1) 
977 (86.8)  
 1 39 (11.3) 91 (8.1)  27 (10.8) 90 (8.0)  
 2 25 (7.2) 59 (5.2)  20 (8.0) 59 (5.2)  
CANCER_T7, n (%)   0.025   0.101 
 0 278 (80.6) 919 (81.5)  193 
(77.5) 
918 (81.5)  
 1 26 (7.5) 81 (7.2)  21 (8.4) 81 (7.2)  
 2 41 (11.9) 127 (11.3)  35 (14.1) 127 (11.3)  
DIABETES_impu_new, n (%)   0.043   0.084 
 0 275 (79.7) 891 (79.1)  195 
(78.3) 
890 (79.0)  
 1 57 (16.5) 200 (17.7)  42 (16.9) 200 (17.8)  
 2 13 (3.8) 36 (3.2)  12 (4.8) 36 (3.2)  
Cons_GP_Times_impu, mean 
(SD) 
4.28 (5.56) 4.31 (5.47) 0.005 4.27 
(5.41) 
4.29 (5.43) 0.004 
Cons_Emergency_Times_impu, 
mean (SD) 
0.43 (0.87) 0.30 (0.73) 0.165 0.34 
(0.74) 
0.30 (0.73) 0.061 
Cons_Hospital_Times_impu, 
mean (SD) 
0.43 (1.27) 0.44 (0.92) 0.003 0.42 
(1.14) 
0.43 (0.91) 0.015 
Cons_Specialist_Times_impu, 
mean (SD) 
0.51 (1.43) 0.44 (2.45) 0.033 0.47 
(1.34) 
0.44 (2.45) 0.012 
Cons_Clinic_Times_impu, 
mean (SD) 
1.32 (4.93) 1.19 (4.81) 0.027 1.50 
(5.66) 
1.19 (4.82) 0.059 
Alcohol_frequency_impu, n (%)   0.150   0.145 
 1 34 (9.9) 121 (10.7)  27 (10.8) 121 (10.7)  
 2 85 (24.6) 209 (18.5)  58 (23.3) 208 (18.5)  
 3 129 (37.4) 462 (41.0)  100 
(40.2) 
462 (41.0)  
 4 69 (20.0) 243 (21.6)  43 (17.3) 243 (21.6)  
 
 
 5 28 (8.1) 92 (8.2)  21 (8.4) 92 (8.2)  
Alcohol_units_impu, n (%)   0.075   0.112 
 0 36 (10.4) 119 (10.6)  27 (10.8) 119 (10.6)  
 1 175 (50.7) 542 (48.1)  127 
(51.0) 
541 (48.0)  
 2 101 (29.3) 367 (32.6)  69 (27.7) 367 (32.6)  
 3 33 (9.6) 99 (8.8)  26 (10.4) 99 (8.8)  
Alcohol_units_6_impu, n (%)   0.091   0.115 
 1 189 (54.8) 664 (58.9)  140 
(56.2) 
664 (59.0)  
 2 120 (34.8) 364 (32.3)  83 (33.3) 363 (32.2)  
 3 27 (7.8) 74 (6.6)  20 (8.0) 74 (6.6)  
 4 7 (2.0) 21 (1.9)  6 (2.4) 21 (1.9)  
 5 2 (0.6) 4 (0.4)  0 (0.0) 4 (0.4)  
Smoke_impu, n (%)   0.305   0.197 
 1 57 (16.5) 139 (12.3)  39 (15.7) 139 (12.3)  
 2 12 (3.5) 19 (1.7)  5 (2.0) 19 (1.7)  
 3 167 (48.4) 711 (63.1)  133 
(53.4) 
710 (63.1)  
 4 109 (31.6) 258 (22.9)  72 (28.9) 258 (22.9)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.053   0.080 
 1 22 (6.4) 68 (6.0)  15 (6.0) 68 (6.0)  
 2 1 (0.3) 1 (0.1)  1 (0.4) 1 (0.1)  
 3 19 (5.5) 57 (5.1)  10 (4.0) 57 (5.1)  







  0.075   0.054 
 0 260 (75.4) 823 (73.0)  187 
(75.1) 
822 (73.0)  
 1 43 (12.5) 145 (12.9)  31 (12.4) 145 (12.9)  
 2 14 (4.1) 44 (3.9)  9 (3.6) 44 (3.9)  
 3 28 (8.1) 115 (10.2)  22 (8.8) 115 (10.2)  
FRUIT_UNITS_T7, mean (SD) 1.74 (1.35) 1.98 (1.76 0.152 1.76 
(1.41) 
1.95 (1.35) 0.135 
RED_MEAT_T7, n (%)   0.055   0.032 
 1 23 (6.7) 73 (6.5)  17 (6.8) 73 (6.5)  
 2 80 (23.2) 255 (22.6)  55 (22.1) 255 (22.6)  
 3 214 (62.0) 720 (63.9)  158 
(63.5) 
719 (63.9)  
 4 24 (7.0) 65 (5.8)  16 (6.4) 65 (5.8)  
 5 4 (1.2) 14 (1.2)  3 (1.2) 14 (1.2)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.101   0.121 
 1 4 (1.2) 13 (1.2)  2 (0.8) 13 (1.2)  
 2 15 (4.3) 47 (4.2)  13 (5.2) 47 (4.2)  
 3 64 (18.6) 255 (22.6)  46 (18.5) 255 (22.6)  
 4 101 (29.3) 313 (27.8)  69 (27.7) 312 (27.7)  
 5 161 (46.7) 499 (44.3)  119 
(47.8) 
499 (44.3)  
LEAN_FISH_T7, n (%)   0.241   0.102 
 1 24 (7.0) 28 (2.5)  10 (4.0) 28 (2.5)  
 2 53 (15.4) 153 (13.6)  35 (14.1) 153 (13.6)  
 
 
 3 223 (64.6) 800 (71.0)  171 
(68.7) 
799 (71.0)  
 4 38 (11.0) 134 (11.9)  29 (11.6) 134 (11.9)  
 5 7 (2.0) 12 (1.1)  4 (1.6) 12 (1.1)  
FAT_FISH_T7, n (%)   0.138   0.110 
 1 50 (14.5) 115 (10.2)  27 (10.8) 114 (10.1)  
 2 116 (33.6) 389 (34.5)  82 (32.9) 389 (34.5)  
 3 157 (45.5) 550 (48.8)  126 
(50.6) 
550 (48.8)  
 4 15 (4.3) 55 (4.9)  8 (3.2) 55 (4.9)  
 5 7 (2.0) 18 (1.6)  6 (2.4) 18 (1.6)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.077   0.077 
 1 81 (23.5) 237 (21.0)  58 (23.3) 236 (21.0)  
 2 176 (51.0) 615 (54.6)  127 
(51.0) 
615 (54.6)  
 3 77 (22.3) 244 (21.7)  56 (22.5) 244 (21.7)  
 4 11 (3.2) 31 (2.8)  8 (3.2) 31 (2.8)  
EXERCISE_T7, n (%)   0.169   0.180 
 1 42 (12.2) 103 (9.1)  33 (13.3) 103 (9.1)  
 2 53 (15.4) 143 (12.7)  35 (14.1) 143 (12.7)  
 3 54 (15.7) 153 (13.6)  35 (14.1) 153 (13.6)  
 4 112 (32.5) 435 (38.6)  78 (31.3) 434 (38.5)  
 5 84 (24.3) 293 (26.0)  68 (27.3) 293 (26.0)  
Dataset 6 
 Before matching After matching 
 Not LLD 
user 
LLD user SMD Not LLD 
user 
LLD user SMD 
n 345 1127  248 1127  
AGE, mean (SD) 66.34 
(13.45) 





SEX_T7, n (%)   0.390   0.236 
 1 193 (55.9) 836 (74.2)  157 
(63.3) 
836 (74.2)  





HEART_FAILURE_T7, n (%)   0.190   0.160 
 0 282 (81.7) 841 (74.6)  201 
(81.0) 
841 (74.6)  
 1 31 (9.0) 116 (10.3)  21 (8.5) 116 (10.3)  
 2 32 (9.3) 170 (15.1)  26 (10.5) 170 (15.1)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.133   0.073 
 0 240 (69.6) 840 (74.5)  177 
(71.4) 
840 (74.5)  
 1 66 (19.1) 161 (14.3)  41 (16.5) 161 (14.3)  
 2 39 (11.3) 126 (11.2)  30 (12.1) 126 (11.2)  
STROKE_T7, n (%)   0.052   0.036 
 2 44 (12.8) 164 (14.6)  33 (13.3) 164 (14.6)  
KIDNEY_DISEASE_T7, n (%)   0.145   0.086 
 0 283 (82.0) 978 (86.8)  208 
(83.9) 
978 (86.8)  
 1 36 (10.4) 98 (8.7)  25 (10.1) 98 (8.7)  
 2 26 (7.5) 51 (4.5)  15 (6.0) 51 (4.5)  
 
 
CANCER_T7, n (%)   0.019   0.076 
 0 280 (81.2) 922 (81.8)  198 
(79.8) 
922 (81.8)  
 1 27 (7.8) 87 (7.7)  18 (7.3) 87 (7.7)  
 2 38 (11.0) 118 (10.5)  32 (12.9) 118 (10.5)  
DIABETES_impu_new, n (%)   0.104   0.114 
 0 273 (79.1) 887 (78.7)  196 
(79.0) 
887 (78.7)  
 1 52 (15.1) 196 (17.4)  37 (14.9) 196 (17.4)  
 2 20 (5.8) 44 (3.9)  15 (6.0) 44 (3.9)  
Cons_GP_Times_impu, mean 
(SD) 
4.19 (5.30) 4.14 (4.62) 0.009 4.28 
(5.72) 
4.14 (4.62) 0.027 
Cons_Emergency_Times_impu, 
mean (SD) 
0.39 (0.81) 0.30 (0.72) 0.129 0.34 
(0.73) 
0.30 (0.72) 0.066 
Cons_Hospital_Times_impu, 
mean (SD) 
0.43 (1.26) 0.43 (0.91) 0.002 0.47 
(1.41) 
0.43 (0.91) 0.033 
Cons_Specialist_Times_impu, 
mean (SD) 
0.60 (1.69) 0.52 (2.67) 0.033 0.55 
(1.47) 
0.52 (2.67) 0.013 
Cons_Clinic_Times_impu, 
mean (SD) 
1.29 (4.79) 1.28 (5.18) 0.001 1.25 
(5.35) 
1.28 (5.18) 0.006 
Alcohol_frequency_impu, n (%)   0.150   0.159 
 1 34 (9.9) 121 (10.7)  25 (10.1) 121 (10.7)  
 2 85 (24.6) 209 (18.5)  62 (25.0) 209 (18.5)  
 3 129 (37.4) 462 (41.0)  92 (37.1) 462 (41.0)  
 4 69 (20.0) 243 (21.6)  49 (19.8) 243 (21.6)  
 5 28 (8.1) 92 (8.2)  20 (8.1) 92 (8.2)  
Alcohol_units_impu, n (%)   0.074   0.038 
 0 36 (10.4) 119 (10.6)  25 (10.1) 119 (10.6)  
 1 175 (50.7) 541 (48.0)  121 
(48.8) 
541 (48.0)  
 2 101 (29.3) 367 (32.6)  78 (31.5) 367 (32.6)  
 3 33 (9.6) 100 (8.9)  24 (9.7) 100 (8.9)  
Alcohol_units_6_impu, n (%)   0.078   0.100 
 1 191 (55.4) 663 (58.8)  139 
(56.0) 
663 (58.8)  
 2 118 (34.2) 363 (32.2)  82 (33.1) 363 (32.2)  
 3 26 (7.5) 75 (6.7)  21 (8.5) 75 (6.7)  
 4 8 (2.3) 22 (2.0)  4 (1.6) 22 (2.0)  
 5 2 (0.6) 4 (0.4)  2 (0.8) 4 (0.4)  
Smoke_impu, n (%)   0.305   0.198 
 1 57 (16.5) 139 (12.3)  39 (15.7) 139 (12.3)  
 2 12 (3.5) 19 (1.7)  7 (2.8) 19 (1.7)  
 3 167 (48.4) 711 (63.1)  133 
(53.6) 
711 (63.1)  
 4 109 (31.6) 258 (22.9)  69 (27.8) 258 (22.9)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.053   0.067 
 1 22 (6.4) 67 (5.9)  16 (6.5) 67 (5.9)  
 2 1 (0.3) 1 (0.1)  1 (0.4) 1 (0.1)  
 3 19 (5.5) 58 (5.1)  13 (5.2) 58 (5.1)  







  0.085   0.118 
 
 
 0 261 (75.7) 820 (72.8)  188 
(75.8) 
820 (72.8)  
 1 43 (12.5) 146 (13.0)  33 (13.3) 146 (13.0)  
 2 14 (4.1) 47 (4.2)  10 (4.0) 47 (4.2)  
 3 27 (7.8) 114 (10.1)  17 (6.9) 114 (10.1)  
FRUIT_UNITS_T7, mean (SD) 1.70 (1.34) 1.96 (1.71) 0.169 1.81 
(1.44) 
1.96 (1.71) 0.099 
RED_MEAT_T7, n (%)   0.089   0.115 
 1 23 (6.7) 70 (6.2)  11 (4.4) 70 (6.2)  
 2 76 (22.0) 255 (22.6)  57 (23.0) 255 (22.6)  
 3 214 (62.0) 723 (64.2)  158 
(63.7) 
723 (64.2)  
 4 28 (8.1) 67 (5.9)  20 (8.1) 67 (5.9)  
 5 4 (1.2) 12 (1.1)  2 (0.8) 12 (1.1)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.108   0.083 
 1 3 (0.9) 13 (1.2)  2 (0.8) 13 (1.2)  
 2 17 (4.9) 46 (4.1)  10 (4.0) 46 (4.1)  
 3 65 (18.8) 257 (22.8)  50 (20.2) 257 (22.8)  
 4 99 (28.7) 312 (27.7)  75 (30.2) 312 (27.7)  
 5 161 (46.7) 499 (44.3)  111 
(44.8) 
499 (44.3)  
LEAN_FISH_T7, n (%)   0.261   0.169 
 1 28 (8.1) 28 (2.5)  13 (5.2) 28 (2.5)  
 2 51 (14.8) 152 (13.5)  36 (14.5) 152 (13.5)  
 3 224 (64.9) 797 (70.7)  173 
(69.8) 
797 (70.7)  
 4 37 (10.7) 134 (11.9)  24 (9.7) 134 (11.9)  
 5 5 (1.4) 16 (1.4)  2 (0.8) 16 (1.4)  
FAT_FISH_T7, n (%)   0.180   0.122 
 1 55 (15.9) 114 (10.1)  34 (13.7) 114 (10.1)  
 2 118 (34.2) 389 (34.5)  82 (33.1) 389 (34.5)  
 3 152 (44.1) 549 (48.7)  118 
(47.6) 
549 (48.7)  
 4 15 (4.3) 54 (4.8)  11 (4.4) 54 (4.8)  
 5 5 (1.4) 21 (1.9)  3 (1.2) 21 (1.9)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.096   0.142 
 1 84 (24.3) 235 (20.9)  63 (25.4) 235 (20.9)  
 2 176 (51.0) 621 (55.1)  122 
(49.2) 
621 (55.1)  
 3 75 (21.7) 243 (21.6)  54 (21.8) 243 (21.6)  
 4 10 (2.9) 28 (2.5)  9 (3.6) 28 (2.5)  
EXERCISE_T7, n (%)   0.186   0.194 
 1 46 (13.3) 105 (9.3)  32 (12.9) 105 (9.3)  
 2 53 (15.4) 144 (12.8)  37 (14.9) 144 (12.8)  
 3 51 (14.8) 154 (13.7)  36 (14.5) 154 (13.7)  
 4 109 (31.6) 436 (38.7)  75 (30.2) 436 (38.7)  
 5 86 (24.9) 288 (25.6)  68 (27.4) 288 (25.6)  
Dataset 7 
 Before matching After matching 
 Not LLD 
user 
LLD user SMD Not LLD 
user 
LLD user SMD 
n 345 1127  250 1127  
 
 
AGE, mean (SD) 66.34 
(13.45) 





SEX_T7, n (%)      0.238 
 1 193 (55.9) 836 (74.2)  0.390 158 
(63.2) 
836 (74.2)  





HEART_FAILURE_T7, n (%)   0.182   0.115 
 0 281 (81.4) 839 (74.4)  198 
(79.2) 
839 (74.4)  
 1 29 (8.4) 110 (9.8)  21 (8.4) 110 (9.8)  
 2 35 (10.1) 178 (15.8)  31 (12.4) 178 (15.8)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.138   0.128 
 0 238 (69.0) 844 (74.9)  173 
(69.2) 
844 (74.9)  
 1 66 (19.1) 164 (14.6)  46 (18.4) 164 (14.6)  
 2 41 (11.9) 119 (10.6)  31 (12.4) 119 (10.6)  
STROKE_T7, n (%)   0.060   0.041 
 2 42 (12.2) 160 (14.2)  32 (12.8) 160 (14.2)  
KIDNEY_DISEASE_T7, n (%)   0.144   0.151 
 0 281 (81.4) 977 (86.7)  203 
(81.2) 
977 (86.7)  
 1 39 (11.3) 92 (8.2)  30 (12.0) 92 (8.2)  
 2 25 (7.2) 58 (5.1)  17 (6.8) 58 (5.1)  
CANCER_T7, n (%)   0.046   0.092 
 0 278 (80.6) 921 (81.7)  200 
(80.0) 
921 (81.7)  
 1 30 (8.7) 84 (7.5)  25 (10.0) 84 (7.5)  
 2 37 (10.7) 122 (10.8)  25 (10.0) 122 (10.8)  
DIABETES_impu_new, n (%)   0.135   0.096 
 0 273 (79.1) 887 (78.7)  197 
(78.8) 
887 (78.7)  
 1 53 (15.4) 205 (18.2)  41 (16.4) 205 (18.2)  
 2 19 (5.5) 35 (3.1)  12 (4.8) 35 (3.1)  
Cons_GP_Times_impu, mean 
(SD) 
4.48 (5.93) 4.11 (4.67) 0.069 4.22 
(5.19) 
4.11 (4.67) 0.024 
Cons_Emergency_Times_impu, 
mean (SD) 
0.39 (0.81) 0.31 (0.73) 0.107 0.34 
(0.78) 
0.31 (0.73) 0.047 
Cons_Hospital_Times_impu, 
mean (SD) 
0.44 (1.28) 0.43 (0.96) 0.012 0.36 
(1.01) 
0.43 (0.96) 0.076 
Cons_Specialist_Times_impu, 
mean (SD) 
0.66 (2.14) 0.52 (2.68) 0.055 0.66 
(2.27) 
0.52 (2.68) 0.057 
Cons_Clinic_Times_impu, 
mean (SD) 
1.26 (4.77) 1.17 (4.76) 0.019 1.32 
(5.44) 
1.17 (4.76) 0.029 
Alcohol_frequency_impu, n (%)   0.157   0.150 
 1 34 (9.9) 121 (10.7)  23 (9.2) 121 (10.7)  
 2 86 (24.9) 209 (18.5)  59 (23.6) 209 (18.5)  
 3 128 (37.1) 462 (41.0)  91 (36.4) 462 (41.0)  
 4 69 (20.0) 243 (21.6)  53 (21.2) 243 (21.6)  
 5 28 (8.1) 92 (8.2)  24 (9.6) 92 (8.2)  
Alcohol_units_impu, n (%)   0.074   0.074 
 0 36 (10.4) 119 (10.6)  23 (9.2) 119 (10.6)  
 
 
 1 175 (50.7) 541 (48.0)  127 
(50.8) 
541 (48.0)  
 2 101 (29.3) 367 (32.6)  76 (30.4) 367 (32.6)  
 3 33 (9.6) 100 (8.9)  24 (9.6) 100 (8.9)  
Alcohol_units_6_impu, n (%)   0.090   0.111 
 1 190 (55.1) 664 (58.9)  139 
(55.6) 
664 (58.9)  
 2 119 (34.5) 362 (32.1)  83 (33.2) 362 (32.1)  
 3 27 (7.8) 77 (6.8)  19 (7.6) 77 (6.8)  
 4 7 (2.0) 21 (1.9)  7 (2.8) 21 (1.9)  
 5 2 (0.6) 3 (0.3)  2 (0.8) 3 (0.3)  
Smoke_impu, n (%)   0.305   0.197 
 1 57 (16.5) 139 (12.3)  37 (14.8) 139 (12.3)  
 2 12 (3.5) 19 (1.7)  9 (3.6) 19 (1.7)  
 3 167 (48.4) 711 (63.1)  136 
(54.4) 
711 (63.1)  
 4 109 (31.6) 258 (22.9)  68 (27.2) 258 (22.9)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.054   0.086 
 1 22 (6.4) 67 (5.9)  18 (7.2) 67 (5.9)  
 2 1 (0.3) 1 (0.1)  1 (0.4) 1 (0.1)  
 3 19 (5.5) 57 (5.1)  14 (5.6) 57 (5.1)  







  0.074   0.039 
 0 259 (75.1) 822 (72.9)  186 
(74.4) 
822 (72.9)  
 1 43 (12.5) 143 (12.7)  30 (12.0) 143 (12.7)  
 2 15 (4.3) 47 (4.2)  9 (3.6) 47 (4.2)  
 3 28 (8.1) 115 (10.2)  25 (10.0) 115 (10.2)  
FRUIT_UNITS_T7, mean (SD) 1.72 (1.33) 1.97 (1.72) 0.165 1.74 
(1.38) 
1.97 (1.72) 0.150 
RED_MEAT_T7, n (%)   0.079   0.089 
 1 24 (7.0) 72 (6.4)  14 (5.6) 72 (6.4)  
 2 80 (23.2) 254 (22.5)  58 (23.2) 254 (22.5)  
 3 212 (61.4) 721 (64.0)  155 
(62.0) 
721 (64.0)  
 4 26 (7.5) 67 (5.9)  20 (8.0) 67 (5.9)  
 5 3 (0.9) 13 (1.2)  3 (1.2) 13 (1.2)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.091   0.029 
 1 5 (1.4) 14 (1.2)  3 (1.2) 14 (1.2)  
 2 16 (4.6) 43 (3.8)  10 (4.0) 43 (3.8)  
 3 66 (19.1) 254 (22.5)  55 (22.0) 254 (22.5)  
 4 99 (28.7) 316 (28.0)  68 (27.2) 316 (28.0)  
 5 159 (46.1) 500 (44.4)  114 
(45.6) 
500 (44.4)  
LEAN_FISH_T7, n (%)   0.225   0.181 
 1 22 (6.4) 26 (2.3)  11 (4.4) 26 (2.3)  
 2 52 (15.1) 153 (13.6)  43 (17.2) 153 (13.6)  
 3 224 (64.9) 799 (70.9)  161 
(64.4) 
799 (70.9)  
 4 40 (11.6) 136 (12.1)  30 (12.0) 136 (12.1)  
 
 
 5 7 (2.0) 13 (1.2)  5 (2.0) 13 (1.2)  
FAT_FISH_T7, n (%)   0.163   0.125 
 1 52 (15.1) 114 (10.1)  33 (13.2) 114 (10.1)  
 2 115 (33.3) 388 (34.4)  85 (34.0) 388 (34.4)  
 3 158 (45.8) 553 (49.1)  120 
(48.0) 
553 (49.1)  
 4 13 (3.8) 55 (4.9)  8 (3.2) 55 (4.9)  
 5 7 (2.0) 17 (1.5)  4 (1.6) 17 (1.5)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.085   0.105 
 1 84 (24.3) 242 (21.5)  60 (24.0) 242 (21.5)  
 2 175 (50.7) 610 (54.1)  123 
(49.2) 
610 (54.1)  
 3 76 (22.0) 249 (22.1)  62 (24.8) 249 (22.1)  
 4 10 (2.9) 26 (2.3)  5 (2.0) 26 (2.3)  
EXERCISE_T7, n (%)   0.182   0.121 
 1 45 (13.0) 101 (9.0)  25 (10.0) 101 (9.0)  
 2 54 (15.7) 146 (13.0)  40 (16.0) 146 (13.0)  
 3 51 (14.8) 155 (13.8)  38 (15.2) 155 (13.8)  
 4 112 (32.5) 436 (38.7)  86 (34.4) 436 (38.7)  
 5 83 (24.1) 289 (25.6)  61 (24.4) 289 (25.6)  
Dataset 8 
 Before matching After matching 
 Not LLD 
user 
LLD user SMD Not LLD 
user 
LLD user SMD 
n 345 1127  251 1127  
AGE, mean (SD) 66.34 
(13.45) 





SEX_T7, n (%)   0.390   0.252 
 1 193 (55.9) 836 (74.2)  157 
(62.5) 
836 (74.2)  





HEART_FAILURE_T7, n (%)   0.191   0.118 
 0 281 (81.4) 838 (74.4)  197 
(78.5) 
838 (74.4)  
 1 31 (9.0) 114 (10.1)  25 (10.0) 114 (10.1)  
 2 33 (9.6) 175 (15.5)  29 (11.6) 175 (15.5)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.155   0.114 
 0 233 (67.5) 837 (74.3)  176 
(70.1) 
837 (74.3)  
 1 68 (19.7) 164 (14.6)  47 (18.7) 164 (14.6)  
 2 44 (12.8) 126 (11.2)  28 (11.2) 126 (11.2)  
STROKE_T7, n (%)   0.045   0.024 
 2 44 (12.8) 161 (14.3)  38 (15.1) 161 (14.3)  
KIDNEY_DISEASE_T7, n (%)   0.129   0.127 
 0 283 (82.0) 976 (86.6)  206 
(82.1) 
976 (86.6)  
 1 36 (10.4) 93 (8.3)  29 (11.6) 93 (8.3)  
 2 26 (7.5) 58 (5.1)  16 (6.4) 58 (5.1)  
CANCER_T7, n (%)   0.072   0.079 
 0 278 (80.6) 921 (81.7)  200 
(79.7) 
921 (81.7)  
 
 
 1 32 (9.3) 83 (7.4)  24 (9.6) 83 (7.4)  
 2 35 (10.1) 123 (10.9)  27 (10.8) 123 (10.9)  
DIABETES_impu_new, n (%)   0.056   0.048 
 0 275 (79.7) 889 (78.9)  197 
(78.5) 
889 (78.9)  
 1 58 (16.8) 207 (18.4)  45 (17.9) 207 (18.4)  
 2 12 (3.5) 31 (2.8)  9 (3.6) 31 (2.8)  
Cons_GP_Times_impu, mean 
(SD) 
4.34 (6.24) 4.12 (4.59) 0.040 4.48 
(6.87) 
4.12 (4.59) 0.061 
Cons_Emergency_Times_impu, 
mean (SD) 
0.41 (0.84) 0.30 (0.72) 0.148 0.41 
(0.79) 
0.30 (0.72) 0.152 
Cons_Hospital_Times_impu, 
mean (SD) 
0.47 (1.29) 0.43 (0.90) 0.033 0.52 
(1.42) 
0.43 (0.90) 0.077 
Cons_Specialist_Times_impu, 
mean (SD) 
0.63 (1.82) 0.48 (2.57) 0.067 0.65 
(1.91) 
0.48 (2.57) 0.072 
Cons_Clinic_Times_impu, 
mean (SD) 
1.14 (2.55) 1.19 (4.79) 0.013 1.23 
(2.70) 
1.19 (4.79) 0.008 
Alcohol_frequency_impu, n (%)   0.150   0.108 
 1 34 (9.9) 121 (10.7)  26 (10.4) 121 (10.7)  
 2 85 (24.6) 209 (18.5)  57 (22.7) 209 (18.5)  
 3 129 (37.4) 462 (41.0)  98 (39.0) 462 (41.0)  
 4 69 (20.0) 243 (21.6)  49 (19.5) 243 (21.6)  
 5 28 (8.1) 92 (8.2)  21 (8.4) 92 (8.2)  
Alcohol_units_impu, n (%)   0.075   0.095 
 0 36 (10.4) 119 (10.6)  25 (10.0) 119 (10.6)  
 1 176 (51.0) 540 (47.9)  132 
(52.6) 
540 (47.9)  
 2 101 (29.3) 367 (32.6)  74 (29.5) 367 (32.6)  
 3 32 (9.3) 101 (9.0)  20 (8.0) 101 (9.0)  
Alcohol_units_6_impu, n (%)   0.104   0.083 
 1 190 (55.1) 663 (58.8)  142 
(56.6) 
663 (58.8)  
 2 119 (34.5) 364 (32.3)  84 (33.5) 364 (32.3)  
 3 27 (7.8) 74 (6.6)  19 (7.6) 74 (6.6)  
 4 6 (1.7) 22 (2.0)  4 (1.6) 22 (2.0)  
 5 3 (0.9) 4 (0.4)  2 (0.8) 4 (0.4)  
Smoke_impu, n (%)   0.305   0.170 
 1 57 (16.5) 139 (12.3)  41 (16.3) 139 (12.3)  
 2 12 (3.5) 19 (1.7)  5 (2.0) 19 (1.7)  
 3 167 (48.4) 711 (63.1)  138 
(55.0) 
711 (63.1)  
 4 109 (31.6) 258 (22.9)  67 (26.7) 258 (22.9)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.054   0.073 
 1 22 (6.4) 67 (5.9)  17 (6.8) 67 (5.9)  
 2 1 (0.3) 1 (0.1)  1 (0.4) 1 (0.1)  
 3 19 (5.5) 57 (5.1)  12 (4.8) 57 (5.1)  







  0.101   0.087 
 0 261 (75.7) 821 (72.8)  190 
(75.7) 
821 (72.8)  
 1 44 (12.8) 143 (12.7)  32 (12.7) 143 (12.7)  
 
 
 2 14 (4.1) 46 (4.1)  8 (3.2) 46 (4.1)  
 3 26 (7.5) 117 (10.4)  21 (8.4) 117 (10.4)  
FRUIT_UNITS_T7, mean (SD) 1.71 (1.33) 1.97 (1.72) 0.168 1.69 
(1.35) 
1.97 (1.72) 0.181 
RED_MEAT_T7, n (%)   0.043   0.046 
 1 23 (6.7) 70 (6.2)  16 (6.4) 70 (6.2)  
 2 79 (22.9) 255 (22.6)  58 (23.1) 255 (22.6)  
 3 215 (62.3) 719 (63.8)  156 
(62.2) 
719 (63.8)  
 4 24 (7.0) 69 (6.1)  17 (6.8) 69 (6.1)  
 5 4 (1.2) 14 (1.2)  4 (1.6) 14 (1.2)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.107   0.069 
 1 4 (1.2) 13 (1.2)  3 (1.2) 13 (1.2)  
 2 17 (4.9) 44 (3.9)  12 (4.8) 44 (3.9)  
 3 65 (18.8) 257 (22.8)  54 (21.5) 257 (22.8)  
 4 102 (29.6) 313 (27.8)  75 (29.9) 313 (27.8)  
 5 157 (45.5) 500 (44.4)  107 
(42.6) 
500 (44.4)  
LEAN_FISH_T7, n (%)   0.225   0.074 
 1 23 (6.7) 26 (2.3)  8 (3.2) 26 (2.3)  
 2 53 (15.4) 152 (13.5)  37 (14.7) 152 (13.5)  
 3 227 (65.8) 803 (71.3)  176 
(70.1) 
803 (71.3)  
 4 38 (11.0) 134 (11.9)  27 (10.8) 134 (11.9)  
 5 4 (1.2) 12 (1.1)  3 (1.2) 12 (1.1)  
FAT_FISH_T7, n (%)   0.175   0.125 
 1 54 (15.7) 115 (10.2)  31 (12.4) 115 (10.2)  
 2 116 (33.6) 387 (34.3)  85 (33.9) 387 (34.3)  
 3 155 (44.9) 552 (49.0)  124 
(49.4) 
552 (49.0)  
 4 13 (3.8) 55 (4.9)  7 (2.8) 55 (4.9)  
 5 7 (2.0) 18 (1.6)  4 (1.6) 18 (1.6)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.080   0.061 
 1 79 (22.9) 241 (21.4)  56 (22.3) 241 (21.4)  
 2 179 (51.9) 617 (54.7)  130 
(51.8) 
617 (54.7)  
 3 77 (22.3) 247 (21.9)  60 (23.9) 247 (21.9)  
 4 10 (2.9) 22 (2.0)  5 (2.0) 22 (2.0)  
EXERCISE_T7, n (%)   0.169   0.168 
 1 43 (12.5) 106 (9.4)  32 (12.7) 106 (9.4)  
 2 55 (15.9) 142 (12.6)  38 (15.1) 142 (12.6)  
 3 51 (14.8) 157 (13.9)  40 (15.9) 157 (13.9)  
 4 111 (32.2) 433 (38.4)  86 (34.3) 433 (38.4)  
 5 85 (24.6) 289 (25.6)  55 (21.9) 289 (25.6)  
Dataset 9 
 Before matching After matching 
 Not LLD 
user 
LLD user SMD Not LLD 
user 
LLD user SMD 
n 345 1127  259 1126  
AGE, mean (SD) 66.34 
(13.45) 





SEX_T7, n (%)   0.390   0.237 
 
 
 1 193 (55.9) 836 (74.2)  164 
(63.3) 
836 (74.2)  





HEART_FAILURE_T7, n (%)   0.172   0.155 
 0 279 (80.9) 841 (74.6)  206 
(79.5) 
840 (74.6)  
 1 30 (8.7) 105 (9.3)  25 (9.7) 105 (9.3)  
 2 36 (10.4) 181 (16.1)  28 (10.8) 181 (16.1)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.133   0.100 
 0 237 (68.7) 841 (74.6)  182 
(70.3) 
841 (74.7)  
 1 62 (18.0) 159 (14.1)  42 (16.2) 158 (14.0)  
 2 46 (13.3) 127 (11.3)  35 (13.5) 127 (11.3)  
STROKE_T7, n (%)   0.054   0.046 
 2 43 (12.5) 161 (14.3)  33 (12.7) 161 (14.3)  
KIDNEY_DISEASE_T7, n (%)   0.141   0.131 
 0 281 (81.4) 975 (86.5)  212 
(81.9) 
975 (86.6)  
 1 39 (11.3) 88 (7.8)  28 (10.8) 87 (7.7)  
 2 25 (7.2) 64 (5.7)  19 (7.3) 64 (5.7)  
CANCER_T7, n (%)   0.024   0.038 
 0 279 (80.9) 921 (81.7)  208 
(80.3) 
920 (81.7)  
 1 27 (7.8) 82 (7.3)  21 (8.1) 82 (7.3)  
 2 39 (11.3) 124 (11.0)  30 (11.6) 124 (11.0)  
DIABETES_impu_new, n (%)   0.124   0.100 
 0 275 (79.7) 886 (78.6)  205 
(79.2) 
885 (78.6)  
 1 49 (14.2) 196 (17.4)  39 (15.1) 196 (17.4)  
 2 21 (6.1) 45 (4.0)  15 (5.8) 45 (4.0)  
Cons_GP_Times_impu, mean 
(SD) 
4.24 (5.14) 4.09 (4.47) 0.031 4.11 
(5.06) 
4.09 (4.47) 0.005 
Cons_Emergency_Times_impu, 
mean (SD) 
0.41 (0.85) 0.32 (0.77) 0.114 0.36 
(0.77) 
0.32 (0.77) 0.052 
Cons_Hospital_Times_impu, 
mean (SD) 
0.47 (1.41) 0.43 (0.90) 0.039 0.42 
(1.27) 
0.42 (0.90) 0.003 
Cons_Specialist_Times_impu, 
mean (SD) 
0.60 (1.60) 0.46 (2.49) 0.067 0.57 
(1.58) 
0.46 (2.49) 0.052 
Cons_Clinic_Times_impu, 
mean (SD) 
1.00 (2.33) 1.24 (5.29) 0.059 0.99 
(2.21) 
1.25 (5.29) 0.062 
Alcohol_frequency_impu, n (%)   0.152   0.141 
 1 34 (9.9) 121 (10.7)  26 (10.0) 121 (10.7)  
 2 85 (24.6) 209 (18.5)  62 (23.9) 208 (18.5)  
 3 128 (37.1) 462 (41.0)  100 
(38.6) 
462 (41.0)  
 4 69 (20.0) 243 (21.6)  49 (18.9) 243 (21.6)  
 5 29 (8.4) 92 (8.2)  22 (8.5) 92 (8.2)  
Alcohol_units_impu, n (%)   0.072   0.084 
 0 37 (10.7) 119 (10.6)  27 (10.4) 119 (10.6)  
 1 175 (50.7) 542 (48.1)  127 
(49.0) 
541 (48.0)  
 2 101 (29.3) 367 (32.6)  77 (29.7) 367 (32.6)  
 
 
 3 32 (9.3) 99 (8.8)  28 (10.8) 99 (8.8)  
Alcohol_units_6_impu, n (%)   0.094   0.108 
 1 190 (55.1) 664 (58.9)  140 
(54.1) 
664 (59.0)  
 2 120 (34.8) 364 (32.3)  91 (35.1) 363 (32.2)  
 3 27 (7.8) 75 (6.7)  22 (8.5) 75 (6.7)  
 4 6 (1.7) 21 (1.9)  5 (1.9) 21 (1.9)  
 5 2 (0.6) 3 (0.3)  1 (0.4) 3 (0.3)  
Smoke_impu, n (%)   0.305   0.190 
 1 57 (16.5) 139 (12.3)  42 (16.2) 139 (12.3)  
 2 12 (3.5) 19 (1.7)  7 (2.7) 19 (1.7)  
 3 167 (48.4) 711 (63.1)  140 
(54.1) 
710 (63.1)  
 4 109 (31.6) 258 (22.9)  70 (27.0) 258 (22.9)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.054   0.076 
 1 22 (6.4) 67 (5.9)  18 (6.9) 67 (6.0)  
 2 1 (0.3) 1 (0.1)  1 (0.4) 1 (0.1)  
 3 19 (5.5) 57 (5.1)  12 (4.6) 57 (5.1)  







  0.113   0.138 
 0 262 (75.9) 818 (72.6)  193 
(74.5) 
817 (72.6)  
 1 43 (12.5) 148 (13.1)  38 (14.7) 148 (13.1)  
 2 15 (4.3) 45 (4.0)  11 (4.2) 45 (4.0)  
 3 25 (7.2) 116 (10.3)  17 (6.6) 116 (10.3)  
FRUIT_UNITS_T7, mean (SD) 1.71 (1.34) 1.97 (1.72) 0.167 1.77 
(1.42) 
1.93 (1.29) 0.118 
RED_MEAT_T7, n (%)   0.047   0.041 
 1 23 (6.7) 69 (6.1)  16 (6.2) 69 (6.1)  
 2 77 (22.3) 254 (22.5)  55 (21.2) 254 (22.6)  
 3 218 (63.2) 721 (64.0)  167 
(64.5) 
720 (63.9)  
 4 24 (7.0) 70 (6.2)  18 (6.9) 70 (6.2)  
 5 3 (0.9) 13 (1.2)  3 (1.2) 13 (1.2)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.108   0.084 
 1 4 (1.2) 12 (1.1)  3 (1.2) 12 (1.1)  
 2 15 (4.3) 45 (4.0)  8 (3.1) 45 (4.0)  
 3 64 (18.6) 258 (22.9)  53 (20.5) 258 (22.9)  
 4 102 (29.6) 311 (27.6)  77 (29.7) 310 (27.5)  
 5 160 (46.4) 501 (44.5)  118 
(45.6) 
501 (44.5)  
LEAN_FISH_T7, n (%)   0.225   0.155 
 1 23 (6.7) 27 (2.4)  12 (4.6) 27 (2.4)  
 2 53 (15.4) 153 (13.6)  43 (16.6) 153 (13.6)  
 3 224 (64.9) 801 (71.1)  174 
(67.2) 
800 (71.0)  
 4 39 (11.3) 132 (11.7)  27 (10.4) 132 (11.7)  
 5 6 (1.7) 14 (1.2)  3 (1.2) 14 (1.2)  
FAT_FISH_T7, n (%)   0.139   0.124 
 1 51 (14.8) 116 (10.3)  35 (13.5) 115 (10.2)  
 
 
 2 116 (33.6) 390 (34.6)  87 (33.6) 390 (34.6)  
 3 157 (45.5) 548 (48.6)  121 
(46.7) 
548 (48.7)  
 4 15 (4.3) 55 (4.9)  10 (3.9) 55 (4.9)  
 5 6 (1.7) 18 (1.6)  6 (2.3) 18 (1.6)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.096   0.081 
 1 83 (24.1) 229 (20.3)  61 (23.6) 228 (20.2)  
 2 181 (52.5) 626 (55.5)  138 
(53.3) 
626 (55.6)  
 3 72 (20.9) 247 (21.9)  55 (21.2) 247 (21.9)  
 4 9 (2.6) 25 (2.2)  5 (1.9) 25 (2.2)  
EXERCISE_T7, n (%)   0.186   0.129 
 1 44 (12.8) 100 (8.9)  28 (10.8) 100 (8.9)  
 2 55 (15.9) 144 (12.8)  41 (15.8) 144 (12.8)  
 3 51 (14.8) 157 (13.9)  36 (13.9) 157 (13.9)  
 4 111 (32.2) 437 (38.8)  88 (34.0) 436 (38.7)  
 5 84 (24.3) 289 (25.6)  66 (25.5) 289 (25.7)  
Dataset 10 
 Before matching After matching 
 Not LLD 
user 
LLD user SMD Not LLD 
user 
LLD user SMD 
n 345 1127  251 1124  
AGE, mean (SD) 66.34 
(13.45) 





SEX_T7, n (%)   0.390   0.294 
 1 193 (55.9) 836 (74.2)  152 
(60.6) 
834 (74.2)  





HEART_FAILURE_T7, n (%)   0.204   0.158 
 0 283 (82.0) 832 (73.8)  202 
(80.5) 
831 (73.9)  
 1 27 (7.8) 114 (10.1)  20 (8.0) 114 (10.1)  
 2 35 (10.1) 181 (16.1)  29 (11.6) 179 (15.9)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.137   0.041 
 0 239 (69.3) 846 (75.1)  186 
(74.1) 
845 (75.2)  
 1 63 (18.3) 155 (13.8)  38 (15.1) 154 (13.7)  
 2 43 (12.5) 126 (11.2)  27 (10.8) 125 (11.1)  
STROKE_T7, n (%)   0.113   0.126 
 2 37 (10.7) 163 (14.5)  26 (10.4) 163 (14.5)  
KIDNEY_DISEASE_T7, n (%)   0.142   0.139 
 0 281 (81.4) 976 (86.6)  205 
(81.7) 
974 (86.7)  
 1 37 (10.7) 90 (8.0)  26 (10.4) 89 (7.9)  
 2 27 (7.8) 61 (5.4)  20 (8.0) 61 (5.4)  
CANCER_T7, n (%)   0.032   0.019 
 0 279 (80.9) 922 (81.8)  204 
(81.3) 
919 (81.8)  
 1 25 (7.2) 73 (6.5)  16 (6.4) 73 (6.5)  
 2 41 (11.9) 132 (11.7)  31 (12.4) 132 (11.7)  
DIABETES_impu_new, n (%)   0.070   0.101 
 
 
 0 281 (81.4) 893 (79.2)  208 
(82.9) 
892 (79.4)  
 1 51 (14.8) 195 (17.3)  34 (13.5) 193 (17.2)  
 2 13 (3.8) 39 (3.5)  9 (3.6) 39 (3.5)  
Cons_GP_Times_impu, mean 
(SD) 
4.18 (5.12) 4.13 (4.51) 0.011 4.15 
(5.28) 
4.11 (4.49) 0.008 
Cons_Emergency_Times_impu, 
mean (SD) 
0.39 (0.94) 0.30 (0.72) 0.113 0.29 
(0.65) 
0.30 (0.72) 0.002 
Cons_Hospital_Times_impu, 
mean (SD) 
0.43 (1.26) 0.44 (0.91) 0.002 0.45 
(1.39) 
0.44 (0.91) 0.013 
Cons_Specialist_Times_impu, 
mean (SD) 
0.64 (1.80) 0.50 (2.59) 0.063 0.51 
(1.38) 
0.50 (2.60) 0.005 
Cons_Clinic_Times_impu, 
mean (SD) 
1.44 (5.05) 1.13 (4.25) 0.065 1.19 
(3.01) 
1.13 (4.26) 0.016 
Alcohol_frequency_impu, n (%)   0.150   0.142 
 1 34 (9.9) 121 (10.7)  20 (8.0) 121 (10.8)  
 2 85 (24.6) 209 (18.5)  58 (23.1) 208 (18.5)  
 3 129 (37.4) 462 (41.0)  99 (39.4) 461 (41.0)  
 4 69 (20.0) 243 (21.6)  52 (20.7) 243 (21.6)  
 5 28 (8.1) 92 (8.2)  22 (8.8) 91 (8.1)  
Alcohol_units_impu, n (%)   0.075   0.096 
 0 36 (10.4) 120 (10.6)  21 (8.4) 120 (10.7)  
 1 176 (51.0) 540 (47.9)  127 
(50.6) 
537 (47.8)  
 2 101 (29.3) 367 (32.6)  78 (31.1) 367 (32.7)  
 3 32 (9.3) 100 (8.9)  25 (10.0) 100 (8.9)  
Alcohol_units_6_impu, n (%)   0.098   0.083 
 1 191 (55.4) 664 (58.9)  139 
(55.4) 
663 (59.0)  
 2 118 (34.2) 363 (32.2)  86 (34.3) 361 (32.1)  
 3 28 (8.1) 74 (6.6)  20 (8.0) 74 (6.6)  
 4 6 (1.7) 23 (2.0)  5 (2.0) 23 (2.0)  
 5 2 (0.6) 3 (0.3)  1 (0.4) 3 (0.3)  
Smoke_impu, n (%)   0.305   0.195 
 1 57 (16.5) 139 (12.3)  35 (13.9) 139 (12.4)  
 2 12 (3.5) 19 (1.7)  8 (3.2) 19 (1.7)  
 3 167 (48.4) 711 (63.1)  136 
(54.2) 
709 (63.1)  
 4 109 (31.6) 258 (22.9)  72 (28.7) 257 (22.9)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.054   0.069 
 1 22 (6.4) 67 (5.9)  12 (4.8) 67 (6.0)  
 2 1 (0.3) 1 (0.1)  0 (0.0) 1 (0.1)  
 3 19 (5.5) 57 (5.1)  12 (4.8) 57 (5.1)  
 4 303 (87.8) 1002 (88.9)  227 
(90.4) 
999 (88.9)  
Cod_liver_oil_omega3_impu, n 
(%) 
  0.098   0.063 
 0 260 (75.4) 822 (72.9)  189 
(75.3) 
819 (72.9)  
 1 44 (12.8) 144 (12.8)  30 (12.0) 144 (12.8)  
 2 15 (4.3) 45 (4.0)  10 (4.0) 45 (4.0)  
 3 26 (7.5) 116 (10.3)  22 (8.8) 116 (10.3)  
 
 
FRUIT_UNITS_T7, mean (SD) 1.75 (1.37) 1.97 (1.71) 0.141 1.81 
(1.46) 
1.92 (1.25) 0.080 
RED_MEAT_T7, n (%)   0.089    
 1 24 (7.0) 74 (6.6)  19 (7.6) 74 (6.6)  
 2 75 (21.7) 256 (22.7)  54 (21.5) 256 (22.8)  
 3 216 (62.6) 715 (63.4)  159 
(63.3) 
714 (63.5)  
 4 27 (7.8) 67 (5.9)  17 (6.8) 67 (6.0)  
 5 3 (0.9) 15 (1.3)  2 (0.8) 13 (1.2)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.114   0.124 
 1 3 (0.9) 12 (1.1)  3 (1.2) 12 (1.1)  
 2 18 (5.2) 47 (4.2)  12 (4.8) 47 (4.2)  
 3 64 (18.6) 257 (22.8)  45 (17.9) 257 (22.9)  
 4 100 (29.0) 310 (27.5)  73 (29.1) 309 (27.5)  
 5 160 (46.4) 501 (44.5)  118 
(47.0) 
499 (44.4)  
LEAN_FISH_T7, n (%)   0.240   0.112 
 1 24 (7.0) 27 (2.4)  11 (4.4) 27 (2.4)  
 2 52 (15.1) 153 (13.6)  34 (13.5) 153 (13.6)  
 3 223 (64.6) 803 (71.3)  176 
(70.1) 
800 (71.2)  
 4 40 (11.6) 133 (11.8)  28 (11.2) 133 (11.8)  
 5 6 (1.7) 11 (1.0)  2 (0.8) 11 (1.0)  
FAT_FISH_T7, n (%)   0.159   0.103 
 1 50 (14.5) 115 (10.2)  33 (13.1) 114 (10.1)  
 2 117 (33.9) 391 (34.7)  83 (33.1) 391 (34.8)  
 3 155 (44.9) 551 (48.9)  119 
(47.4) 
549 (48.8)  
 4 14 (4.1) 53 (4.7)  11 (4.4)  53 (4.7)  
 5 9 (2.6) 17 (1.5)  5 (2.0) 17 (1.5)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.088   0.055 
 1 84 (24.3) 237 (21.0)  51 (20.3) 234 (20.8)  
 2 178 (51.6) 622 (55.2)  137 
(54.6) 
622 (55.3)  
 3 74 (21.4) 242 (21.5)  55 (21.9) 242 (21.5)  
 4 9 (2.6) 26 (2.3)  8 (3.2) 26 (2.3)  
EXERCISE_T7, n (%)   0.176   0.157 
 1 44 (12.8) 105 (9.3)  30 (12.0) 105 (9.3)  
 2 54 (15.7) 141 (12.5)  38 (15.1) 140 (12.5)  
 3 52 (15.1) 158 (14.0)  33 (13.1) 158 (14.1)  
 4 111 (32.2) 435 (38.6)  81 (32.3) 433 (38.5)  
 5 84 (24.3) 288 (25.6)  69 (27.5) 288 (25.6)  





Supplementary table 6: Results from propensity score matching of the ten imputed datasets for the logistic regression 
analysis of the association between use of antihypertensive drugs and achieving the treatment goal for blood pressure among 
those with self-reported hypertension 
Dataset 1 














n 64 763  46 762  
AGE, mean (SD) 61.95 
(11.84) 
69.82 (9.82) 0.723 64.17 
(11.06) 
69.84 (9.81) 0.542 
SEX_T7, n (%)   0.013   0.113 
 1 43 (67.2) 508 (66.6)  33 (71.7) 507 (66.5)  
BMI, mean (SD) 28.99 (5.07) 28.99 (4.54) 0.001 28.53 (4.76) 28.99 (4.55) 0.100 
HEART_FAILURE_T7, n (%)   0.340   0.247 
 0 55 (85.9) 559 (73.3)  38 (82.6) 559 (73.4)  
 1 2 (3.1) 72 (9.4)  2 (4.3) 72 (9.4)  
 2 7 (10.9) 132 (17.3)  6 (13.0) 131 (17.2)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.216   0.239 
 0 40 (62.5) 544 (71.3)  30 (65.2) 544 (71.4)  
 1 11 (17.2) 121 (15.9)  6 (13.0) 120 (15.7)  
 2 13 (20.3) 98 (12.8)  10 (21.7) 98 (12.9)  
STROKE_T7, n (%)   0.135   0.002 
 2 8 (12.5) 132 (17.3)  8 (17.4) 132 (17.3)  
KIDNEY_DISEASE_T7, n (%)   0.235   0.229 
 0 53 (82.8) 654 (85.7)  38 (82.6) 653 (85.7)  
 1 4 (6.2) 70 (9.2)  3 (6.5) 70 (9.2)  
 2 7 (10.9) 39 (5.1)  5 (10.9) 39 (5.1)  
CANCER_T7, n (%)   0.205   0.193 
 0 56 (87.5) 620 (81.3)  40 (87.0) 619 (81.2)  
 1 4 (6.2) 51 (6.7)  3 (6.5) 51 (6.7)  
 2 4 (6.2) 92 (12.1)  3 (6.5) 92 (12.1)  
DIABETES_impu_new, n (%)   0.038   0.139 
 0 47 (73.4) 573 (75.1)  35 (76.1) 572 (75.1)  
 1 13 (20.3) 145 (19.0)  7 (15.2) 145 (19.0)  
 2 4 (6.2) 45 (5.9)  4 (8.7) 45 (5.9)  
Cons_GP_Times_impu, mean 
(SD) 
3.66 (3.32) 5.11 (6.78) 0.271 3.61 (2.84) 5.11 (6.79) 0.288 
Cons_Emergency_Times_impu, 
mean (SD) 
0.33 (0.64) 0.34 (0.80) 0.023 0.26 (0.57) 0.35 (0.80) 0.121 
Cons_Hospital_Times_impu, 
mean (SD) 
0.50 (1.62) 0.47 (1.01) 0.024 0.28 (0.58) 0.47 (1.01) 0.226 
Cons_Specialist_Times_impu, 
mean (SD) 
0.48 (0.96) 0.56 (3.04) 0.035 0.54 (1.03) 0.56 (3.04) 0.009 
Cons_Clinic_Times_impu, 
mean (SD) 
0.73 (1.34) 1.20 (3.54) 0.174 0.93 (1.51) 1.20 (3.54) 0.098 
Alcohol_frequency_impu, n (%)   0.160   0.283 
 1 7 (10.9) 79 (10.4)  2 (4.3) 79 (10.4)  
 2 14 (21.9) 160 (21.0)  10 (21.7) 160 (21.0)  
 3 26 (40.6) 285 (37.4)  18 (39.1) 284 (37.3)  
 4 10 (15.6) 166 (21.8)  9 (19.6) 166 (21.8)  
 5 7 (10.9) 73 (9.6)  7 (15.2) 73 (9.6)  
Alcohol_units_impu, n (%)   0.203   0.304 
 
 
 0 8 (12.5) 81 (10.6)  2 (4.3) 81 (10.6)  
 1 28 (43.8) 372 (48.8)  23 (50.0) 372 (48.8)  
 2 24 (37.5) 233 (30.5)  18 (39.1) 232 (30.4)  
 3 4 (6.2) 77 (10.1)  3 (6.5) 77 (10.1)  
Alcohol_units_6_impu, n (%)   0.296   0.290 
 1 33 (51.6) 448 (58.7)  23 (50.0) 447 (58.7)  
 2 27 (42.2) 237 (31.1)  20 (43.5) 237 (31.1)  
 3 2 (3.1) 55 (7.2)  2 (4.3) 55 (7.2)  
 4 1 (1.6) 18 (2.4)  1 (2.2) 18 (2.4)  
 5 1 (1.6) 5 (0.7)  0 (0.0) 5 (0.7)  
Smoke_impu, n (%)   0.230   0.255 
 1 4 (6.2) 86 (11.3)  3 (6.5) 86 (11.3)  
 2 1 (1.6) 12 (1.6)  0 (0.0) 12 (1.6)  
 3 37 (57.8) 465 (60.9)  29 (63.0) 464 (60.9)  
 4 22 (34.4) 200 (26.2)  14 (30.4) 200 (26.2)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.098   0.072 
 1 5 (7.8) 44 (5.8)  3 (6.5) 43 (5.6)  
 2 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  
 3 4 (6.2) 39 (5.1)  3 (6.5) 39 (5.1)  
 4 55 (85.9) 680 (89.1)  40 (87.0) 680 (89.2)  
Cod_liver_oil_omega3_impu, n 
(%) 
  0.239   0.141 
 0 41 (64.1) 560 (73.4)  31 (67.4) 560 (73.5)  
 1 11 (17.2) 101 (13.2)  8 (17.4) 101 (13.3)  
 2 5 (7.8) 27 (3.5)  2 (4.3) 26 (3.4)  
 3 7 (10.9) 75 (9.8)  5 (10.9) 75 (9.8)  
FRUIT_UNITS_T7, mean (SD) 1.81 (1.37) 2.06 (1.94) 0.144 2.04 (1.48) 2.05 (1.94) 0.005 
RED_MEAT_T7, n (%)   0.438   0.399 
 1 9 (14.1) 42 (5.5)  7 (15.2) 42 (5.5)  
 2 14 (21.9) 163 (21.4)  11 (23.9) 163 (21.4)  
 3 32 (50.0) 510 (66.8)  25 (54.3) 509 (66.8)  
 4 7 (10.9) 37 (4.8)  3 (6.5) 37 (4.9)  
 5 2 (3.1) 11 (1.4)  0 (0.0) 11 (1.4)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.253   0.201 
 1 0 (0.0) 8 (1.0)  0 (0.0) 8 (1.0)  
 2 5 (7.8) 31 (4.1)  2 (4.3) 31 (4.1)  
 3 12 (18.8) 151 (19.8)  8 (17.4) 151 (19.8)  
 4 14 (21.9) 212 (27.8)  11 (23.9) 212 (27.8)  
 5 33 (51.6) 361 (47.3)  25 (54.3) 360 (47.2)  
LEAN_FISH_T7, n (%)   0.406   0.299 
 1 7 (10.9) 20 (2.6)  3 (6.5) 20 (2.6)  
 2 8 (12.5) 100 (13.1)  7 (15.2) 100 (13.1)  
 3 43 (67.2) 531 (69.6)  32 (69.6) 530 (69.6)  
 4 4 (6.2) 99 (13.0)  4 (8.7) 99 (13.0)  
 5 2 (3.1) 13 (1.7)  0 (0.0) 13 (1.7)  
FAT_FISH_T7, n (%)   0.271   0.153 
 1 8 (12.5) 87 (11.4)  6 (13.0) 87 (11.4)  
 2 26 (40.6) 261 (34.2)  18 (39.1) 260 (34.1)  
 3 25 (39.1) 368 (48.2)  19 (41.3) 368 (48.3)  
 4 2 (3.1) 36 (4.7)  2 (4.3) 36 (4.7)  




T7, n (%) 
  0.295   0.194 
 1 14 (21.9) 169 (22.1)  8 (17.4) 169 (22.2)  
 2 37 (57.8) 409 (53.6)  27 (58.7) 409 (53.7)  
 3 9 (14.1) 170 (22.3)  9 (19.6) 169 (22.2)  
 4 4 (6.2) 15 (2.0)  2 (4.3) 15 (2.0)  
EXERCISE_T7, n (%)   0.217   0.443 
 1 6 (9.4) 88 (11.5)  1 (2.2) 88 (11.5)  
 2 10 (15.6) 90 (11.8)  9 (19.6) 90 (11.8)  
 3 11 (17.2) 123 (16.1)  6 (13.0) 123 (16.1)  
 4 18 (28.1) 276 (36.2)  16 (34.8) 276 (36.2)  
 5 19 (29.7) 186 (24.4)  14 (30.4) 185 (24.3)  
Dataset 2 














n 64 763  48 762  
AGE, mean (SD) 61.95 
(11.84) 
69.82 (9.82) 0.723 65.77 
(10.39) 
69.84 (9.81) 0.402 
SEX_T7, n (%)   0.013   0.041 
 1 43 (67.2) 508 (66.6)  31 (64.6) 507 (66.5)  
BMI, mean (SD) 28.99 (5.07) 28.99 (4.54) 0.001 28.83 (4.63) 28.99 (4.54) 0.035 
HEART_FAILURE_T7, n (%)   0.389   0.356 
 0 54 (84.4) 563 (73.8)  40 (83.3) 562 (73.8)  
 1 1 (1.6) 79 (10.4)  1 (2.1) 79 (10.4)  
 2 9 (14.1) 121 (15.9)  7 (14.6) 121 (15.9)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.266   0.185 
 0 39 (60.9) 546 (71.6)  31 (64.6) 546 (71.7)  
 1 11 (17.2) 122 (16.0)  8 (16.7) 122 (16.0)  
 2 14 (21.9) 95 (12.5)  9 (18.8) 94 (12.3)  
STROKE_T7, n (%)   0.089   0.075 
 2 9 (14.1) 132 (17.3)  7 (14.6) 132 (17.3)  
KIDNEY_DISEASE_T7, n (%)   0.180   0.013 
 0 53 (82.8) 655 (85.8)  41 (85.4) 654 (85.8)  
 1 4 (6.2) 61 (8.0)  4 (8.3) 61 (8.0)  
 2 7 (10.9) 47 (6.2)  3 (6.2) 47 (6.2)  
CANCER_T7, n (%)   0.179   0.208 
 0 56 (87.5) 618 (81.0)  42 (87.5) 617 (81.0)  
 1 3 (4.7) 53 (6.9)  3 (6.2) 53 (7.0)  
 2 5 (7.8) 92 (12.1)  3 (6.2) 92 (12.1)  
DIABETES_impu_new, n (%)   0.075   0.027 
 0 47 (73.4) 575 (75.4)  36 (75.0) 574 (75.3)  
 1 13 (20.3) 153 (20.1)  10 (20.8) 153 (20.1)  
 2 4 (6.2) 35 (4.6)  2 (4.2) 35 (4.6)  
Cons_GP_Times_impu, mean 
(SD) 
3.56 (3.00) 4.78 (5.61) 0.271 3.83 (3.11) 4.78 (5.62) 0.208 
Cons_Emergency_Times_impu, 
mean (SD) 
0.31 (0.59) 0.34 (0.79) 0.042 0.31 (0.59) 0.34 (0.79) 0.043 
Cons_Hospital_Times_impu, 
mean (SD) 
0.48 (1.61) 0.47 (1.01) 0.012 0.50 (1.77) 0.47 (1.01) 0.022 
Cons_Specialist_Times_impu, 
mean (SD) 





1.03 (2.30) 1.17 (3.51) 0.045 1.33 (2.58) 1.17 (3.51) 0.054 
Alcohol_frequency_impu, n (%)   0.180   0.307 
 1 6 (9.4) 79 (10.4)  2 (4.2) 79 (10.4)  
 2 14 (21.9) 160 (21.0)  10 (20.8) 160 (21.0)  
 3 26 (40.6) 285 (37.4)  22 (45.8) 284 (37.3)  
 4 10 (15.6) 166 (21.8)  8 (16.7) 166 (21.8)  
 5 8 (12.5) 73 (9.6)  6 (12.5) 73 (9.6)  
Alcohol_units_impu, n (%)   0.214   0.283 
 0 7 (10.9) 81 (10.6)  3 (6.2) 81 (10.6)  
 1 28 (43.8) 371 (48.6)  22 (45.8) 371 (48.7)  
 2 25 (39.1) 233 (30.5)  20 (41.7) 232 (30.4)  
 3 4 (6.2) 78 (10.2)  3 (6.2) 78 (10.2)  
Alcohol_units_6_impu, n (%)   0.296   0.391 
 1 34 (53.1) 449 (58.8)  27 (56.2) 449 (58.9)  
 2 27 (42.2) 237 (31.1)  20 (41.7) 236 (31.0)  
 3 2 (3.1) 55 (7.2)  1 (2.1) 55 (7.2)  
 4 1 (1.6) 18 (2.4)  0 (0.0) 18 (2.4)  
 5 0 (0.0) 4 (0.5)  0 (0.0) 4 (0.5)  
Smoke_impu, n (%)   0.230   0.243 
 1 4 (6.2) 86 (11.3)  4 (8.3) 86 (11.3)  
 2 1 (1.6) 12 (1.6)  0 (0.0) 12 (1.6)  
 3 37 (57.8) 465 (60.9)  28 (58.3) 464 (60.9)  
 4 22 (34.4) 200 (26.2)  16 (33.3) 200 (26.2)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.095   0.126 
 1 5 (7.8) 44 (5.8)  3 (6.2) 44 (5.8)  
 2 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  
 3 4 (6.2) 40 (5.2)  4 (8.3) 40 (5.2)  
 4 55 (85.9) 679 (89.0)  41 (85.4) 678 (89.0)  
Cod_liver_oil_omega3_impu, n 
(%) 
  0.221   0.155 
 0 41 (64.1) 557 (73.0)  33 (68.8) 557 (73.1)  
 1 11 (17.2) 102 (13.4)  9 (18.8) 101 (13.3)  
 2 5 (7.8) 30 (3.9)  2 (4.2) 30 (3.9)  
 3 7 (10.9) 74 (9.7)  4 (8.3) 74 (9.7)  
FRUIT_UNITS_T7, mean (SD) 1.83 (1.44) 2.09 (1.97) 0.151 1.92 (1.57) 2.08 (1.96) 0.093 
RED_MEAT_T7, n (%)   0.465   0.435 
 1 9 (14.1) 44 (5.8)  7 (14.6) 44 (5.8)  
 2 15 (23.4) 166 (21.8)  15 (31.2) 166 (21.8)  
 3 32 (50.0) 506 (66.3)  24 (50.0) 505 (66.3)  
 4 8 (12.5) 38 (5.0)  2 (4.2) 38 (5.0)  
 5 0 (0.0) 9 (1.2)  0 (0.0) 9 (1.2)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.206   0.205 
 1 0 (0.0) 8 (1.0)  0 (0.0) 8 (1.0)  
 2 4 (6.2) 32 (4.2)  3 (6.2) 32 (4.2)  
 3 12 (18.8) 152 (19.9)  10 (20.8) 152 (19.9)  
 4 15 (23.4) 213 (27.9)  11 (22.9) 213 (28.0)  
 5 33 (51.6) 358 (46.9)  24 (50.0) 357 (46.9)  
LEAN_FISH_T7, n (%)   0.396   0.255 
 1 7 (10.9) 21 (2.8)  3 (6.2) 20 (2.6)  
 2 9 (14.1) 103 (13.5)  7 (14.6) 103 (13.5)  
 3 43 (67.2) 531 (69.6)  33 (68.8) 531 (69.7)  
 
 
 4 5 (7.8) 97 (12.7)  5 (10.4) 97 (12.7)  
 5 0 (0.0) 11 (1.4)  0 (0.0) 11 (1.4)  
FAT_FISH_T7, n (%)   0.293   0.344 
 1 9 (14.1) 88 (11.5)  7 (14.6) 87 (11.4)  
 2 28 (43.8) 261 (34.2)  22 (45.8) 261 (34.3)  
 3 25 (39.1) 367 (48.1)  18 (37.5) 367 (48.2)  
 4 1 (1.6) 38 (5.0)  1 (2.1) 38 (5.0)  
 5 1 (1.6) 9 (1.2)  0 (0.0) 9 (1.2)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.279   0.163 
 1 14 (21.9) 176 (23.1)  12 (25.0) 176 (23.1)  
 2 37 (57.8) 404 (52.9)  26 (54.2) 404 (53.0)  
 3 9 (14.1) 166 (21.8)  8 (16.7) 165 (21.7)  
 4 4 (6.2) 17 (2.2)  2 (4.2) 17 (2.2)  
EXERCISE_T7, n (%)   0.213   0.348 
 1 6 (9.4) 91 (11.9)  3 (6.2) 91 (11.9)  
 2 10 (15.6) 92 (12.1)  10 (20.8) 92 (12.1)  
 3 12 (18.8) 122 (16.0)  8 (16.7) 122 (16.0)  
 4 18 (28.1) 274 (35.9)  13 (27.1) 274 (36.0)  
 5 18 (28.1) 184 (24.1)  14 (29.2) 183 (24.0)  
Dataset 3 














n 64 763  46 760  
AGE, mean (SD) 61.95 
(11.84) 
69.82 (9.82) 0.723 65.02 
(11.05) 
69.84 (9.82) 0.461 
SEX_T7, n (%)   0.013   0.064 
 1 43 (67.2) 508 (66.6)  32 (69.6) 506 (66.6)  
BMI, mean (SD) 28.99 (5.07) 29.01 (4.55) 0.003 28.88 (4.63) 29.02 (4.55) 0.030 
HEART_FAILURE_T7, n (%)   0.344   0.312 
 0 54 (84.4) 560 (73.4)  39 (84.8) 557 (73.3)  
 1 2 (3.1) 87 (11.4)  2 (4.3) 87 (11.4)  
 2 8 (12.5) 116 (15.2)  5 (10.9) 116 (15.3)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.228   0.263 
 0 40 (62.5) 541 (70.9)  29 (63.0) 540 (71.1)  
 1 11 (17.2) 129 (16.9)  7 (15.2) 129 (17.0)  
 2 13 (20.3) 93 (12.2)  10 (21.7) 91 (12.0)  
STROKE_T7, n (%)   0.093   0.124 
 2 9 (14.1) 133 (17.4)  6 (13.0) 133 (17.5)  
KIDNEY_DISEASE_T7, n (%)   0.169   0.061 
 0 53 (82.8) 654 (85.7)  39 (84.8) 651 (85.7)  
 1 5 (7.8) 70 (9.2)  4 (8.7) 70 (9.2)  
 2 6 (9.4) 39 (5.1)  3 (6.5) 39 (5.1)  
CANCER_T7, n (%)   0.177   0.307 
 0 56 (87.5) 619 (81.1)  42 (91.3) 616 (81.1)  
 1 3 (4.7) 58 (7.6)  2 (4.3) 58 (7.6)  
 2 5 (7.8) 86 (11.3)  2 (4.3) 86 (11.3)  
DIABETES_impu_new, n (%)   0.075   0.160 
 0 47 (73.4) 574 (75.2)  37 (80.4) 571 (75.1)  
 1 13 (20.3) 154 (20.2)  8 (17.4) 154 (20.3)  





4.86 (8.57) 4.91 (5.79) 0.007 5.52 (9.89) 4.91 (5.79) 0.076 
Cons_Emergency_Times_impu, 
mean (SD) 
0.34 (0.74) 0.34 (0.78) 0.009 0.35 (0.77) 0.34 (0.78) 0.012 
Cons_Hospital_Times_impu, 
mean (SD) 
0.47 (1.61) 0.48 (1.01) 0.006 0.52 (1.83) 0.48 (1.02) 0.030 
Cons_Specialist_Times_impu, 
mean (SD) 
0.56 (1.18) 0.56 (3.11) 0.001 0.74 (1.34) 0.56 (3.12) 0.074 
Cons_Clinic_Times_impu, 
mean (SD) 
1.06 (2.35) 1.18 (3.60) 0.037 1.28 (2.67) 1.18 (3.61) 0.033 
Alcohol_frequency_impu, n (%)   0.169   0.283 
 1 6 (9.4) 79 (10.4)  2 (4.3) 79 (10.4)  
 2 15 (23.4) 160 (21.0)  11 (23.9) 159 (20.9)  
 3 26 (40.6) 285 (37.4)  19 (41.3) 283 (37.2)  
 4 10 (15.6) 166 (21.8)  8 (17.4) 166 (21.8)  
 5 7 (10.9) 73 (9.6)  6 (13.0) 73 (9.6)  
Alcohol_units_impu, n (%)   0.203   0.142 
 0 8 (12.5) 81 (10.6)  4 (8.7) 80 (10.5)  
 1 28 (43.8) 372 (48.8)  21 (45.7) 371 (48.8)  
 2 24 (37.5) 233 (30.5)  17 (37.0) 232 (30.5)  
 3 4 (6.2) 77 (10.1)  4 (8.7) 77 (10.1)  
Alcohol_units_6_impu, n (%)   0.297   0.317 
 1 34 (53.1) 448 (58.7)  25 (54.3) 446 (58.7)  
 2 27 (42.2) 237 (31.1)  19 (41.3) 236 (31.1)  
 3 2 (3.1) 55 (7.2)  1 (2.2) 55 (7.2)  
 4 1 (1.6) 19 (2.5)  1 (2.2) 19 (2.5)  
 5 0 (0.0) 4 (0.5)  0 (0.0) 4 (0.5)  
Smoke_impu, n (%)   0.230   0.213 
 1 4 (6.2) 86 (11.3)  4 (8.7) 86 (11.3)  
 2 1 (1.6) 12 (1.6)  0 (0.0) 12 (1.6)  
 3 37 (57.8) 465 (60.9)  28 (60.9) 463 (60.9)  
 4 22 (34.4) 200 (26.2)  14 (30.4) 199 (26.2)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.098   0.152 
 1 5 (7.8) 44 (5.8)  2 (4.3) 44 (5.8)  
 2 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  
 3 4 (6.2) 39 (5.1)  4 (8.7) 39 (5.1)  
 4 55 (85.9) 680 (89.1)  40 (87.0) 677 (89.1)  
Cod_liver_oil_omega3_impu, n 
(%) 
  0.168   0.251 
 0 42 (65.6) 559 (73.3)  31 (67.4) 558 (73.4)  
 1 11 (17.2) 99 (13.0)  10 (21.7) 98 (12.9)  
 2 3 (4.7) 30 (3.9)  1 (2.2) 30 (3.9)  
 3 8 (12.5) 75 (9.8)  4 (8.7) 74 (9.7)  
FRUIT_UNITS_T7, mean (SD) 1.80 (1.38) 2.06 (1.94) 0.155 1.89 (1.51) 2.05 (1.94) 0.093 
RED_MEAT_T7, n (%)   0.452   0.346 
 1 9 (14.1) 45 (5.9)  7 (15.2) 45 (5.9)  
 2 14 (21.9) 162 (21.2)  10 (21.7) 162 (21.3)  
 3 33 (51.6) 509 (66.7)  27 (58.7) 506 (66.6)  
 4 8 (12.5) 38 (5.0)  2 (4.3) 38 (5.0)  
 5 0 (0.0) 9 (1.2)  0 (0.0) 9 (1.2)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.221   0.220 
 1 0 (0.0) 8 (1.0)  0 (0.0) 8 (1.1)  
 
 
 2 5 (7.8) 35 (4.6)  3 (6.5) 35 (4.6)  
 3 12 (18.8) 151 (19.8)  10 (21.7) 151 (19.9)  
 4 15 (23.4) 213 (27.9)  10 (21.7) 213 (28.0)  
 5 32 (50.0) 356 (46.7)  23 (50.0) 353 (46.4)  
LEAN_FISH_T7, n (%)   0.411   0.212 
 1 7 (10.9) 19 (2.5)  1 (2.2) 18 (2.4)  
 2 9 (14.1) 103 (13.5)  8 (17.4) 103 (13.6)  
 3 43 (67.2) 532 (69.7)  32 (69.6) 530 (69.7)  
 4 5 (7.8) 97 (12.7)  5 (10.9) 97 (12.8)  
 5 0 (0.0) 12 (1.6)  0 (0.0) 12 (1.6)  
FAT_FISH_T7, n (%)   0.297   0.240 
 1 8 (12.5) 87 (11.4)  7 (15.2) 86 (11.3)  
 2 29 (45.3) 261 (34.2)  18 (39.1) 259 (34.1)  
 3 25 (39.1) 369 (48.4)  19 (41.3) 369 (48.6)  
 4 1 (1.6) 37 (4.8)  1 (2.2) 37 (4.9)  
 5 1 (1.6) 9 (1.2)  1 (2.2) 9 (1.2)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.291   0.168 
 1 14 (21.9) 178 (23.3)  11 (23.9) 178 (23.4)  
 2 37 (57.8) 404 (52.9)  25 (54.3) 402 (52.9)  
 3 9 (14.1) 166 (21.8)  8 (17.4) 165 (21.7)  
 4 4 (6.2) 15 (2.0)  2 (4.3) 15 (2.0)  
EXERCISE_T7, n (%)   0.189   0.225 
 1 7 (10.9) 90 (11.8)  4 (8.7) 90 (11.8)  
 2 10 (15.6) 91 (11.9)  9 (19.6) 91 (12.0)  
 3 11 (17.2) 121 (15.9)  7 (15.2) 121 (15.9)  
 4 18 (28.1) 274 (35.9)  15 (32.6) 274 (36.1)  
 5 18 (28.1) 187 (24.5)  11 (23.9) 184 (24.2)  
Dataset 4 














n 64 763  45 761  
AGE, mean (SD) 61.95 
(11.84) 
69.82 (9.82) 0.723 63.98 
(10.44) 
69.85 (9.80) 0.580 
SEX_T7, n (%)   0.013   0.043 
 1 43 (67.2) 508 (66.6)  29 (64.4) 506 (66.5)  
BMI, mean (SD) 28.99 (5.07) 29.01 (4.55) 0.004 28.73 (4.66) 29.01 (4.54) 0.060 
HEART_FAILURE_T7, n (%)   0.301   0.324 
 0 54 (84.4) 567 (74.3)  37 (82.2) 566 (74.4)  
 1 2 (3.1) 74 (9.7)  1 (2.2) 74 (9.7)  
 2 8 (12.5) 122 (16.0)  7 (15.6) 121 (15.9)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.248   0.221 
 0 39 (60.9) 545 (71.4)  30 (66.7) 545 (71.6)  
 1 12 (18.8) 125 (16.4)  6 (13.3) 124 (16.3)  
 2 13 (20.3) 93 (12.2)  9 (20.0) 92 (12.1)  
STROKE_T7, n (%)   0.086   0.041 
 2 9 (14.1) 131 (17.2)  7 (15.6) 130 (17.1)  
KIDNEY_DISEASE_T7, n (%)   0.230   0.040 
 0 53 (82.8) 653 (85.6)  39 (86.7) 651 (85.5)  
 1 4 (6.2) 70 (9.2)  4 (8.9) 70 (9.2)  
 2 7 (10.9) 40 (5.2)  2 (4.4) 40 (5.3)  
 
 
CANCER_T7, n (%)   0.205   0.187 
 0 56 (87.5) 620 (81.3)  39 (86.7) 619 (81.3)  
 1 4 (6.2) 51 (6.7)  3 (6.7) 50 (6.6)  
 2 4 (6.2) 92 (12.1)  3 (6.7) 92 (12.1)  
DIABETES_impu_new, n (%)   0.067   0.176 
 0 47 (73.4) 577 (75.6)  36 (80.0) 576 (75.7)  
 1 13 (20.3) 149 (19.5)  6 (13.3) 148 (19.4)  
 2 4 (6.2) 37 (4.8)  3 (6.7) 37 (4.9)  
Cons_GP_Times_impu, mean 
(SD) 
3.72 (3.33) 4.95 (6.09) 0.250 3.91 (3.36) 4.94 (6.09) 0.208 
Cons_Emergency_Times_impu, 
mean (SD) 
0.30 (0.58) 0.33 (0.78) 0.045 0.24 (0.53) 0.33 (0.78) 0.127 
Cons_Hospital_Times_impu, 
mean (SD) 
0.48 (1.61) 0.45 (0.99) 0.024 0.47 (1.83) 0.45 (0.99) 0.009 
Cons_Specialist_Times_impu, 
mean (SD) 
0.47 (0.96) 0.57 (3.10) 0.044 0.51 (1.04) 0.57 (3.10) 0.026 
Cons_Clinic_Times_impu, 
mean (SD) 
0.83 (1.69) 1.16 (3.49) 0.121 1.07 (1.95) 1.15 (3.49) 0.030 
Alcohol_frequency_impu, n (%)   0.169   0.240 
 1 6 (9.4) 79 (10.4)  3 (6.7) 79 (10.4)  
 2 15 (23.4) 160 (21.0)  12 (26.7) 159 (20.9)  
 3 26 (40.6) 285 (37.4)  19 (42.2) 285 (37.5)  
 4 10 (15.6) 166 (21.8)  7 (15.6) 165 (21.7)  
 5 7 (10.9) 73 (9.6)  4 (8.9) 73 (9.6)  
Alcohol_units_impu, n (%)   0.214   0.260 
 0 7 (10.9) 81 (10.6)  4 (8.9) 81 (10.6)  
 1 28 (43.8) 371 (48.6)  19 (42.2) 371 (48.8)  
 2 25 (39.1) 233 (30.5)  19 (42.2) 231 (30.4)  
 3 4 (6.2) 78 (10.2)  3 (6.7) 78 (10.2)  
Alcohol_units_6_impu, n (%)   0.270   0.346 
 1 33 (51.6) 449 (58.8)  24 (53.3) 448 (58.9)  
 2 27 (42.2) 235 (30.8)  19 (42.2) 234 (30.7)  
 3 3 (4.7) 56 (7.3)  2 (4.4) 56 (7.4)  
 4 1 (1.6) 19 (2.5)  0 (0.0) 19 (2.5)  
 5 0 (0.0) 4 (0.5)  0 (0.0) 4 (0.5)  
Smoke_impu, n (%)   0.230   0.239 
 1 4 (6.2) 86 (11.3)  4 (8.9) 86 (11.3)  
 2 1 (1.6) 12 (1.6)  0 (0.0) 12 (1.6)  
 3 37 (57.8) 465 (60.9)  26 (57.8) 464 (61.0)  
 4 22 (34.4) 200 (26.2)  15 (33.3) 199 (26.1)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.095   0.077 
 1 5 (7.8) 44 (5.8)  3 (6.7) 44 (5.8)  
 2 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  
 3 4 (6.2) 40 (5.2)  3 (6.7) 39 (5.1)  
 4 55 (85.9) 679 (89.0)  39 (86.7) 678 (89.1)  
Cod_liver_oil_omega3_impu, n 
(%) 
  0.198   0.159 
 0 41 (64.1) 557 (73.0)  32 (71.1) 556 (73.1)  
 1 11 (17.2) 102 (13.4)  8 (17.8) 102 (13.4)  
 2 4 (6.2) 30 (3.9)  2 (4.4) 29 (3.8)  
 3 8 (12.5) 74 (9.7)  3 (6.7) 74 (9.7)  
FRUIT_UNITS_T7, mean (SD) 1.77 (1.39) 2.08 (1.95) 0.187 1.89 (1.56) 2.08 (1.95) 0.111 
RED_MEAT_T7, n (%)   0.411   0.275 
 
 
 1 9 (14.1) 43 (5.6)  4 (8.9) 42 (5.5)  
 2 14 (21.9) 165 (21.6)  13 (28.9) 165 (21.7)  
 3 33 (51.6) 510 (66.8)  26 (57.8) 509 (66.9)  
 4 7 (10.9) 36 (4.7)  1 (2.2) 36 (4.7)  
 5 1 (1.6) 9 (1.2)  1 (2.2) 9 (1.2)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.222   0.181 
 1 0 (0.0) 7 (0.9)  0 (0.0) 7 (0.9)  
 2 5 (7.8) 33 (4.3)  3 (6.7) 33 (4.3)  
 3 11 (17.2) 153 (20.1)  10 (22.2) 152 (20.0)  
 4 16 (25.0) 214 (28.0)  12 (26.7) 213 (28.0)  
 5 32 (50.0) 356 (46.7)  20 (44.4) 356 (46.8)  
LEAN_FISH_T7, n (%)   0.388   0.296 
 1 7 (10.9) 20 (2.6)  3 (6.7) 20 (2.6)  
 2 9 (14.1) 100 (13.1)  8 (17.8) 99 (13.0)  
 3 42 (65.6) 534 (70.0)  29 (64.4) 534 (70.2)  
 4 6 (9.4) 98 (12.8)  5 (11.1) 97 (12.7)  
 5 0 (0.0) 11 (1.4)  0 (0.0) 11 (1.4)  
FAT_FISH_T7, n (%)   0.288   0.304 
 1 9 (14.1) 88 (11.5)  8 (17.8) 88 (11.6)  
 2 26 (40.6) 260 (34.1)  18 (40.0) 259 (34.0)  
 3 26 (40.6) 369 (48.4)  17 (37.8) 369 (48.5)  
 4 1 (1.6) 37 (4.8)  1 (2.2) 37 (4.9)  
 5 2 (3.1) 9 (1.2)  1 (2.2) 8 (1.1)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.278   0.198 
 1 14 (21.9) 172 (22.5)  11 (24.4) 172 (22.6)  
 2 37 (57.8) 404 (52.9)  25 (55.6) 402 (52.8)  
 3 9 (14.1) 169 (22.1)  7 (15.6) 169 (22.2)  
 4 4 (6.2) 18 (2.4)  2 (4.4) 18 (2.4)  
EXERCISE_T7, n (%)   0.217   0.382 
 1 6 (9.4) 92 (12.1)  2 (4.4) 92 (12.1)  
 2 10 (15.6) 92 (12.1)  9 (20.0) 91 (12.0)  
 3 11 (17.2) 122 (16.0)  6 (13.3) 122 (16.0)  
 4 18 (28.1) 273 (35.8)  14 (31.1) 273 (35.9)  
 5 19 (29.7) 184 (24.1)  14 (31.1) 183 (24.0)  
Dataset 5 














n 64 763  47 760  
AGE, mean (SD) 61.95 
(11.84) 
69.82 (9.82) 0.723 64.17 
(10.77) 
69.86 (9.80) 0.553 
SEX_T7, n (%)   0.013   0.010 
 1 43 (67.2) 508 (66.6)  31 (66.0) 505 (66.4)  
BMI, mean (SD) 28.99 (5.07) 29.00 (4.54) 0.002 29.05 (5.18) 29.00 (4.55) 0.012 
HEART_FAILURE_T7, n (%)   0.263   0.228 
 0 54 (84.4) 563 (73.8)  39 (83.0) 561 (73.8)  
 1 4 (6.2) 85 (11.1)  3 (6.4) 84 (11.1)  
 2 6 (9.4) 115 (15.1)  5 (10.6) 115 (15.1)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.246   0.227 
 0 39 (60.9) 544 (71.3)  29 (61.7) 544 (71.6)  
 
 
 1 12 (18.8) 126 (16.5)  9 (19.1) 124 (16.3)  
 2 13 (20.3) 93 (12.2)  9 (19.1) 92 (12.1)  
STROKE_T7, n (%)   0.089   0.067 
 2 9 (14.1) 132 (17.3)  7 (14.9) 132 (17.4)  
KIDNEY_DISEASE_T7, n (%)   0.156   0.079 
 0 53 (82.8) 654 (85.7)  40 (85.1) 652 (85.8)  
 1 5 (7.8) 68 (8.9)  5 (10.6) 67 (8.8)  
 2 6 (9.4) 41 (5.4)  2 (4.3) 41 (5.4)  
CANCER_T7, n (%)   0.216   0.208 
 0 56 (87.5) 618 (81.0)  41 (87.2) 616 (81.1)  
 1 4 (6.2) 50 (6.6)  3 (6.4) 50 (6.6)  
 2 4 (6.2) 95 (12.5)  3 (6.4) 94 (12.4)  
DIABETES_impu_new, n (%)   0.045   0.028 
 0 47 (73.4) 575 (75.4)  36 (76.6) 574 (75.5)  
 1 14 (21.9) 156 (20.4)  9 (19.1) 154 (20.3)  
 2 3 (4.7) 32 (4.2)  2 (4.3) 32 (4.2)  
Cons_GP_Times_impu, mean 
(SD) 
4.00 (4.38) 4.99 (6.15) 0.186 4.30 (4.80) 4.97 (6.13) 0.123 
Cons_Emergency_Times_impu, 
mean (SD) 
0.28 (0.58) 0.33 (0.78) 0.075 0.26 (0.53) 0.33 (0.78) 0.118 
Cons_Hospital_Times_impu, 
mean (SD) 
0.47 (1.61) 0.46 (0.99) 0.006 0.43 (1.79) 0.46 (0.99) 0.024 
Cons_Specialist_Times_impu, 
mean (SD) 
0.55 (1.01) 0.53 (2.96) 0.009 0.62 (1.07) 0.53 (2.97) 0.040 
Cons_Clinic_Times_impu, 
mean (SD) 
1.11 (2.39) 1.20 (3.53) 0.028 1.32 (2.70) 1.19 (3.54) 0.040 
Alcohol_frequency_impu, n (%)   0.180   0.309 
 1 6 (9.4) 79 (10.4)  2 (4.3) 79 (10.4)  
 2 14 (21.9) 160 (21.0)  10 (21.3) 159 (20.9)  
 3 26 (40.6) 285 (37.4)  20 (42.6) 283 (37.2)  
 4 10 (15.6) 166 (21.8)  8 (17.0) 166 (21.8)  
 5 8 (12.5) 73 (9.6)  7 (14.9) 73 (9.6)  
Alcohol_units_impu, n (%)   0.158   0.322 
 0 7 (10.9) 81 (10.6)  2 (4.3) 81 (10.7)  
 1 28 (43.8) 371 (48.6)  21 (44.7) 370 (48.7)  
 2 24 (37.5) 234 (30.7)  20 (42.6) 232 (30.5)  
 3 5 (7.8) 77 (10.1)  4 (8.5) 77 (10.1)  
Alcohol_units_6_impu, n (%)   0.266   0.264 
 1 33 (51.6) 449 (58.8)  23 (48.9) 448 (58.9)  
 2 27 (42.2) 236 (30.9)  20 (42.6) 234 (30.8)  
 3 3 (4.7) 55 (7.2)  3 (6.4) 55 (7.2)  
 4 1 (1.6) 19 (2.5)  1 (2.1) 19 (2.5)  
 5 0 (0.0) 4 (0.5)  0 (0.0) 4 (0.5)  
Smoke_impu, n (%)   0.230   0.205 
 1 4 (6.2) 86 (11.3)  4 (8.5) 86 (11.3)  
 2 1 (1.6) 12 (1.6)  0 (0.0) 12 (1.6)  
 3 37 (57.8) 465 (60.9)  30 (63.8) 463 (60.9)  
 4 22 (34.4) 200 (26.2)  13 (27.7) 199 (26.2)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.093   0.117 
 1 5 (7.8) 45 (5.9)  4 (8.5) 45 (5.9)  
 2 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  
 3 4 (6.2) 39 (5.1)  3 (6.4) 39 (5.1)  





  0.193   0.126 
 0 41 (64.1) 555 (72.7)  33 (70.2) 553 (72.8)  
 1 11 (17.2) 103 (13.5)  7 (14.9) 102 (13.4)  
 2 4 (6.2) 30 (3.9)  3 (6.4) 30 (3.9)  
 3 8 (12.5) 75 (9.8)  4 (8.5) 75 (9.9)  
FRUIT_UNITS_T7, mean (SD) 1.84 (1.38) 2.10 (2.00) 0.147 2.02 (1.52) 2.09 (2.00) 0.041 
RED_MEAT_T7, n (%)   0.437   0.200 
 1 10 (15.6) 44 (5.8)  4 (8.5) 43 (5.7)  
 2 14 (21.9) 166 (21.8)  12 (25.5) 166 (21.8)  
 3 32 (50.0) 506 (66.3)  27 (57.4) 505 (66.4)  
 4 7 (10.9) 38 (5.0)  3 (6.4) 37 (4.9)  
 5 1 (1.6) 9 (1.2)  1 (2.1) 9 (1.2)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.222   0.252 
 1 0 (0.0) 9 (1.2)  0 (0.0) 9 (1.2)  
 2 4 (6.2) 29 (3.8)  4 (8.5) 29 (3.8)  
 3 12 (18.8) 152 (19.9)  9 (19.1) 151 (19.9)  
 4 15 (23.4) 214 (28.0)  12 (25.5) 214 (28.2)  
 5 33 (51.6) 359 (47.1)  22 (46.8) 357 (47.0)  
LEAN_FISH_T7, n (%)   0.436   0.249 
 1 8 (12.5) 19 (2.5)  2 (4.3) 18 (2.4)  
 2 9 (14.1) 101 (13.2)  6 (12.8) 100 (13.2)  
 3 42 (65.6) 536 (70.2)  35 (74.5) 536 (70.5)  
 4 4 (6.2) 97 (12.7)  3 (6.4) 97 (12.8)  
 5 1 (1.6) 10 (1.3)  1 (2.1) 9 (1.2)  
FAT_FISH_T7, n (%)   0.307   0.360 
 1 9 (14.1) 86 (11.3)  7 (14.9) 84 (11.1)  
 2 27 (42.2) 264 (34.6)  20 (42.6) 264 (34.7)  
 3 25 (39.1) 370 (48.5)  17 (36.2) 370 (48.7)  
 4 1 (1.6) 35 (4.6)  1 (2.1) 35 (4.6)  
 5 2 (3.1) 8 (1.0)  2 (4.3) 7 (0.9)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.287   0.089 
 1 14 (21.9) 171 (22.4)  11 (23.4) 170 (22.4)  
 2 37 (57.8) 401 (52.6)  26 (55.3) 400 (52.6)  
 3 9 (14.1) 173 (22.7)  9 (19.1) 172 (22.6)  
 4 4 (6.2) 18 (2.4)  1 (2.1) 18 (2.4)  
EXERCISE_T7, n (%)   0.253   0.319 
 1 5 (7.8) 90 (11.8)  3 (6.4) 89 (11.7)  
 2 11 (17.2) 91 (11.9)  10 (21.3) 91 (12.0)  
 3 12 (18.8) 122 (16.0)  6 (12.8) 122 (16.1)  
 4 18 (28.1) 273 (35.8)  15 (31.9) 272 (35.8)  
 5 18 (28.1) 187 (24.5)  13 (27.7) 186 (24.5)  
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n 64 763  49 759  
AGE, mean (SD) 61.95 
(11.84) 
69.82 (9.82) 0.723 65.08 
(10.80) 
69.88 (9.81) 0.465 
SEX_T7, n (%)   0.013   0.058 
 1 43 (67.2) 508 (66.6)  34 (69.4) 506 (66.7)  
 
 
BMI, mean (SD) 28.99 (5.07) 29.00 (4.54) 0.002 28.60 (4.62) 29.00 (4.54) 0.087 
HEART_FAILURE_T7, n (%)   0.353   0.291 
 0 55 (85.9) 557 (73.0)  41 (83.7) 553 (72.9)  
 1 2 (3.1) 78 (10.2)  2 (4.1) 78 (10.3)  
 2 7 (10.9) 128 (16.8)  6 (12.2) 128 (16.9)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.222   0.184 
 0 40 (62.5) 544 (71.3)  31 (63.3) 541 (71.3)  
 1 11 (17.2) 123 (16.1)  9 (18.4) 122 (16.1)  
 2 13 (20.3) 96 (12.6)  9 (18.4) 96 (12.6)  
STROKE_T7, n (%)   0.089   0.028 
 2 9 (14.1) 132 (17.3)  8 (16.3) 132 (17.4)  
KIDNEY_DISEASE_T7, n (%)   0.186   0.063 
 0 53 (82.8) 651 (85.3)  41 (83.7) 648 (85.4)  
 1 5 (7.8) 75 (9.8)  5 (10.2) 75 (9.9)  
 2 6 (9.4) 37 (4.8)  3 (6.1) 36 (4.7)  
CANCER_T7, n (%)   0.273   0.320 
 0 56 (87.5) 619 (81.1)  42 (85.7) 616 (81.2)  
 1 5 (7.8) 51 (6.7)  5 (10.2) 50 (6.6)  
 2 3 (4.7) 93 (12.2)  2 (4.1) 93 (12.3)  
DIABETES_impu_new, n (%)   0.069   0.065 
 0 47 (73.4) 575 (75.4)  37 (75.5) 571 (75.2)  
 1 14 (21.9) 147 (19.3)  10 (20.4) 147 (19.4)  
 2 3 (4.7) 41 (5.4)  2 (4.1) 41 (5.4)  
Cons_GP_Times_impu, mean 
(SD) 
3.34 (2.84) 4.90 (5.80) 0.340 3.69 (2.99) 4.90 (5.82) 0.261 
Cons_Emergency_Times_impu, 
mean (SD) 
0.28 (0.55) 0.33 (0.78) 0.065 0.24 (0.48) 0.33 (0.78) 0.125 
Cons_Hospital_Times_impu, 
mean (SD) 
0.48 (1.61) 0.46 (1.00) 0.015 0.47 (1.76) 0.47 (1.00) 0.003 
Cons_Specialist_Times_impu, 
mean (SD) 
0.53 (1.01) 0.64 (3.24) 0.045 0.61 (1.06) 0.64 (3.25) 0.011 
Cons_Clinic_Times_impu, 
mean (SD) 
0.69 (1.23) 1.16 (3.50) 0.181 0.80 (1.35) 1.16 (3.51) 0.138 
Alcohol_frequency_impu, n (%)   0.169   0.227 
 1 6 (9.4) 79 (10.4)  3 (6.1) 79 (10.4)  
 2 15 (23.4) 160 (21.0)  11 (22.4) 160 (21.1)  
 3 26 (40.6) 285 (37.4)  21 (42.9) 284 (37.4)  
 4 10 (15.6) 166 (21.8)  8 (16.3) 163 (21.5)  
 5 7 (10.9) 73 (9.6)  6 (12.2) 73 (9.6)  
Alcohol_units_impu, n (%)   0.187   0.281 
 0 7 (10.9) 82 (10.7)  3 (6.1) 82 (10.8)  
 1 29 (45.3) 371 (48.6)  23 (46.9) 370 (48.7)  
 2 24 (37.5) 233 (30.5)  20 (40.8) 230 (30.3)  
 3 4 (6.2) 77 (10.1)  3 (6.1) 77 (10.1)  
Alcohol_units_6_impu, n (%)   0.302   0.287 
 1 34 (53.1) 448 (58.7)  25 (51.0) 446 (58.8)  
 2 27 (42.2) 236 (30.9)  21 (42.9) 234 (30.8)  
 3 2 (3.1) 56 (7.3)  2 (4.1) 56 (7.4)  
 4 1 (1.6) 19 (2.5)  1 (2.0) 19 (2.5)  
 5 0 (0.0) 4 (0.5)  0 (0.0) 4 (0.5)  
Smoke_impu, n (%)   0.230   0.223 
 1 4 (6.2) 86 (11.3)  4 (8.2) 86 (11.3)  
 2 1 (1.6) 12 (1.6)  0 (0.0) 12 (1.6)  
 
 
 3 37 (57.8) 465 (60.9)  30 (61.2) 463 (61.0)  
 4 22 (34.4) 200 (26.2)  15 (30.6) 198 (26.1)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.092   0.038 
 1 5 (7.8) 44 (5.8)  3 (6.1) 43 (5.7)  
 2 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  
 3 4 (6.2) 41 (5.4)  3 (6.1) 41 (5.4)  
 4 55 (85.9) 678 (88.9)  43 (87.8) 675 (88.9)  
Cod_liver_oil_omega3_impu, n 
(%) 
  0.193   0.148 
 0 41 (64.1) 556 (72.9)  33 (67.3) 554 (73.0)  
 1 11 (17.2) 101 (13.2)  9 (18.4) 100 (13.2)  
 2 4 (6.2) 32 (4.2)  2 (4.1) 31 (4.1)  
 3 8 (12.5) 74 (9.7)  5 (10.2) 74 (9.7)  
FRUIT_UNITS_T7, mean (SD) 1.81 (1.37) 2.06 (1.94) 0.148 1.92 (1.48) 2.06 (1.94) 0.081 
RED_MEAT_T7, n (%)   0.503   0.377 
 1 11 (17.2) 43 (5.6)  7 (14.3) 41 (5.4)  
 2 14 (21.9) 163 (21.4)  12 (24.5) 163 (21.5)  
 3 32 (50.0) 508 (66.6)  27 (55.1) 506 (66.7)  
 4 7 (10.9) 38 (5.0)  3 (6.1) 38 (5.0)  
 5 0 (0.0) 11 (1.4)  0 (0.0) 11 (1.4)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.187   0.171 
 1 0 (0.0) 7 (0.9)  0 (0.0) 7 (0.9)  
 2 4 (6.2) 30 (3.9)  3 (6.1) 30 (4.0)  
 3 12 (18.8) 152 (19.9)  10 (20.4) 151 (19.9)  
 4 16 (25.0) 214 (28.0)  14 (28.6) 213 (28.1)  
 5 32 (50.0) 360 (47.2)  22 (44.9) 358 (47.2)  
LEAN_FISH_T7, n (%)   0.438   0.287 
 1 8 (12.5) 20 (2.6)  3 (6.1) 19 (2.5)  
 2 8 (12.5) 100 (13.1)  6 (12.2) 100 (13.2)  
 3 43 (67.2) 535 (70.1)  36 (73.5) 533 (70.2)  
 4 5 (7.8) 97 (12.7)  4 (8.2) 96 (12.6)  
 5 0 (0.0) 11 (1.4)  0 (0.0) 11 (1.4)  
FAT_FISH_T7, n (%)   0.336   0.344 
 1 8 (12.5) 84 (11.0)  7 (14.3) 83 (10.9)  
 2 29 (45.3) 260 (34.1)  21 (42.9) 259 (34.1)  
 3 24 (37.5) 370 (48.5)  18 (36.7) 369 (48.6)  
 4 1 (1.6) 38 (5.0)  1 (2.0) 38 (5.0)  
 5 2 (3.1) 11 (1.4)  2 (4.1) 10 (1.3)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.275   0.131 
 1 14 (21.9) 169 (22.1)  11 (22.4) 168 (22.1)  
 2 37 (57.8) 399 (52.3)  27 (55.1) 398 (52.4)  
 3 9 (14.1) 174 (22.8)  9 (18.4) 173 (22.8)  
 4 4 (6.2) 21 (2.8)  2 (4.1) 20 (2.6)  
EXERCISE_T7, n (%)   0.219   0.307 
 1 6 (9.4) 91 (11.9)  3 (6.1) 91 (12.0)  
 2 10 (15.6) 90 (11.8)  10 (20.4) 89 (11.7)  
 3 12 (18.8) 120 (15.7)  7 (14.3) 120 (15.8)  
 4 18 (28.1) 276 (36.2)  16 (32.7) 275 (36.2)  
 5 18 (28.1) 186 (24.4)  13 (26.5) 184 (24.2)  
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n 64 763  47 760  
AGE, mean (SD) 61.95 
(11.84) 
69.82 (9.82) 0.723 64.21 
(11.06) 
69.85 (9.81) 0.539 
SEX_T7, n (%)   0.013   0.013 
 1 43 (67.2) 508 (66.6)  31 (66.0) 506 (66.6)  
BMI, mean (SD) 28.99 (5.07) 28.99 (4.54) 0.001 28.64 (4.58) 28.99 (4.54) 0.077 
HEART_FAILURE_T7, n (%)   0.313   0.259 
 0 54 (84.4) 564 (73.9)  39 (83.0) 561 (73.8)  
 1 2 (3.1) 77 (10.1)  2 (4.3) 77 (10.1)  
 2 8 (12.5) 122 (16.0)  6 (12.8) 122 (16.1)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.236   0.179 
 0 39 (60.9) 544 (71.3)  31 (66.0) 543 (71.4)  
 1 12 (18.8) 121 (15.9)  7 (14.9) 121 (15.9)  
 2 13 (20.3) 98 (12.8)  9 (19.1) 96 (12.6)  
STROKE_T7, n (%)   0.187   0.129 
 2 7 (10.9) 133 (17.4)  6 (12.8) 132 (17.4)  
KIDNEY_DISEASE_T7, n (%)   0.151   0.062 
 0 53 (82.8) 652 (85.5)  41 (87.2) 650 (85.5)  
 1 5 (7.8) 69 (9.0)  4 (8.5) 68 (8.9)  
 2 6 (9.4) 42 (5.5)  2 (4.3) 42 (5.5)  
CANCER_T7, n (%)   0.179   0.222 
 0 56 (87.5) 620 (81.3)  41 (87.2) 617 (81.2)  
 1 3 (4.7) 45 (5.9)  3 (6.4) 45 (5.9)  
 2 5 (7.8) 98 (12.8)  3 (6.4) 98 (12.9)  
DIABETES_impu_new, n (%)   0.051   0.079 
 0 47 (73.4) 575 (75.4)  37 (78.7) 573 (75.4)  
 1 14 (21.9) 151 (19.8)  8 (17.0) 150 (19.7)  
 2 3 (4.7) 37 (4.8)  2 (4.3) 37 (4.9)  
Cons_GP_Times_impu, mean 
(SD) 
4.00 (4.50) 4.92 (5.50) 0.182 4.43 (4.97) 4.92 (5.51) 0.094 
Cons_Emergency_Times_impu, 
mean (SD) 
0.36 (0.70) 0.34 (0.78) 0.025 0.32 (0.66) 0.34 (0.79) 0.032 
Cons_Hospital_Times_impu, 
mean (SD) 
0.48 (1.61) 0.47 (1.01) 0.014 0.45 (1.78) 0.47 (1.01) 0.014 
Cons_Specialist_Times_impu, 
mean (SD) 
0.56 (1.18) 0.54 (2.96) 0.010 0.64 (1.29) 0.54 (2.96) 0.043 
Cons_Clinic_Times_impu, 
mean (SD) 
0.83 (1.53) 1.19 (3.56) 0.132 1.02 (1.71) 1.19 (3.57) 0.061 
Alcohol_frequency_impu, n (%)   0.171   0.232 
 1 6 (9.4) 79 (10.4)  3 (6.4) 79 (10.4)  
 2 14 (21.9) 160 (21.0)  8 (17.0) 159 (20.9)  
 3 27 (42.2) 285 (37.4)  22 (46.8) 284 (37.4)  
 4 10 (15.6) 166 (21.8)  9 (19.1) 166 (21.8)  
 5 7 (10.9) 73 (9.6)  5 (10.6) 72 (9.5)  
Alcohol_units_impu, n (%)   0.160   0.244 
 0 7 (10.9) 81 (10.6)  3 (6.4) 81 (10.7)  
 1 28 (43.8) 372 (48.8)  20 (42.6) 371 (48.8)  
 2 24 (37.5) 233 (30.5)  19 (40.4) 231 (30.4)  
 3 5 (7.8) 77 (10.1)  5 (10.6) 77 (10.1)  
Alcohol_units_6_impu, n (%)   0.274   0.270 
 
 
 1 33 (51.6) 448 (58.7)  27 (57.4) 447 (58.8)  
 2 27 (42.2) 235 (30.8)  17 (36.2) 233 (30.7)  
 3 3 (4.7) 57 (7.5)  3 (6.4) 57 (7.5)  
 4 1 (1.6) 18 (2.4)  0 (0.0) 18 (2.4)  
 5 0 (0.0) 5 (0.7)  0 (0.0) 5 (0.7)  
Smoke_impu, n (%)   0.230   0.249 
 1 4 (6.2) 86 (11.3)  4 (8.5) 86 (11.3)  
 2 1 (1.6) 12 (1.6)  0 (0.0) 12 (1.6)  
 3 37 (57.8) 465 (60.9)  27 (57.4) 462 (60.8)  
 4 22 (34.4) 200 (26.2)  16 (34.0) 200 (26.3)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.098   0.086 
 1 5 (7.8) 44 (5.8)  2 (4.3) 44 (5.8)  
 2 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  
 3 4 (6.2) 39 (5.1)  3 (6.4) 39 (5.1)  
 4 55 (85.9) 680 (89.1)  42 (89.4) 677 (89.1)  
Cod_liver_oil_omega3_impu, n 
(%) 
  0.210   0.175 
 0 41 (64.1) 557 (73.0)  31 (66.0) 555 (73.0)  
 1 12 (18.8) 101 (13.2)  9 (19.1) 100 (13.2)  
 2 4 (6.2) 29 (3.8)  2 (4.3) 29 (3.8)  
 3 7 (10.9) 76 (10.0)  5 (10.6) 76 (10.0)  
FRUIT_UNITS_T7, mean (SD) 1.80 (1.42) 2.07 (1.95) 0.161 1.98 (1.52) 2.06 (1.95) 0.049 
RED_MEAT_T7, n (%)   0.443   0.345 
 1 10 (15.6) 43 (5.6)  7 (14.9) 42 (5.5)  
 2 14 (21.9) 165 (21.6)  11 (23.4) 164 (21.6)  
 3 32 (50.0) 508 (66.6)  26 (55.3) 507 (66.7)  
 4 7 (10.9) 38 (5.0)  2 (4.3) 38 (5.0)  
 5 1 (1.6) 9 (1.2)  1 (2.1) 9 (1.2)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.233   0.266 
 1 0 (0.0) 8 (1.0)  0 (0.0) 8 (1.1)  
 2 4 (6.2) 31 (4.1)  2 (4.3) 30 (3.9)  
 3 12 (18.8) 153 (20.1)  10 (21.3) 153 (20.1)  
 4 14 (21.9) 213 (27.9)  9 (19.1) 213 (28.0)  
 5 34 (53.1) 358 (46.9)  26 (55.3) 356 (46.8)  
LEAN_FISH_T7, n (%)   0.434   0.353 
 1 8 (12.5) 19 (2.5)  3 (6.4) 16 (2.1)  
 2 9 (14.1) 100 (13.1)  9 (19.1) 100 (13.2)  
 3 42 (65.6) 534 (70.0)  31 (66.0) 534 (70.3)  
 4 4 (6.2) 96 (12.6)  4 (8.5) 96 (12.6)  
 5 1 (1.6) 14 (1.8)  0 (0.0) 14 (1.8)  
FAT_FISH_T7, n (%)   0.328   0.249 
 1 8 (12.5) 85 (11.1)  7 (14.9) 84 (11.1)  
 2 27 (42.2) 260 (34.1)  19 (40.4) 259 (34.1)  
 3 25 (39.1) 368 (48.2)  19 (40.4) 367 (48.3)  
 4 1 (1.6) 38 (5.0)  1 (2.1) 38 (5.0)  
 5 3 (4.7) 12 (1.6)  1 (2.1) 12 (1.6)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.279   0.168 
 1 14 (21.9) 173 (22.7)  10 (21.3) 172 (22.6)  
 2 37 (57.8) 400 (52.4)  27 (57.4) 400 (52.6)  
 3 9 (14.1) 171 (22.4)  8 (17.0) 169 (22.2)  
 4 4 (6.2) 19 (2.5)  2 (4.3) 19 (2.5)  
 
 
EXERCISE_T7, n (%)   0.234   0.312 
 1 6 (9.4) 93 (12.2)  3 (6.4) 92 (12.1)  
 2 11 (17.2) 90 (11.8)  9 (19.1) 90 (11.8)  
 3 11 (17.2) 120 (15.7)  7 (14.9) 120 (15.8)  
 4 18 (28.1) 275 (36.0)  14 (29.8) 275 (36.2)  
 5 18 (28.1) 185 (24.2)  14 (29.8) 183 (24.1)  
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n 64 763  47 762  
AGE, mean (SD) 61.95 
(11.84) 
69.82 (9.82) 0.723 65.79 
(10.75) 
69.86 (9.77) 0.396 
SEX_T7, n (%)   0.013   0.030 
 1 43 (67.2) 508 (66.6)  32 (68.1) 508 (66.7)  
BMI, mean (SD) 28.99 (5.07) 29.00 (4.54) 0.001 28.67 (4.79) 29.00 (4.54) 0.069 
HEART_FAILURE_T7, n (%)   0.379   0.334 
 0 54 (84.4) 565 (74.0)  38 (80.9) 564 (74.0)  
 1 1 (1.6) 76 (10.0)  1 (2.1) 76 (10.0)  
 2 9 (14.1) 122 (16.0)  8 (17.0) 122 (16.0)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.215   0.165 
 0 40 (62.5) 545 (71.4)  30 (63.8) 545 (71.5)  
 1 12 (18.8) 128 (16.8)  10 (21.3) 128 (16.8)  
 2 12 (18.8) 90 (11.8)  7 (14.9) 89 (11.7)  
STROKE_T7, n (%)   0.128   0.059 
 2 8 (12.5) 130 (17.0)  7 (14.9) 130 (17.1)  
KIDNEY_DISEASE_T7, n (%)   0.209   0.112 
 0 53 (82.8) 653 (85.6)  39 (83.0) 652 (85.6)  
 1 4 (6.2) 67 (8.8)  4 (8.5) 67 (8.8)  
 2 7 (10.9) 43 (5.6)  4 (8.5) 43 (5.6)  
CANCER_T7, n (%)   0.202   0.199 
 0 56 (87.5) 620 (81.3)  40 (85.1) 619 (81.2)  
 1 4 (6.2) 52 (6.8)  4 (8.5) 52 (6.8)  
 2 4 (6.2) 91 (11.9)  3 (6.4) 91 (11.9)  
DIABETES_impu_new, n (%)   0.089   0.041 
 0 46 (71.9) 576 (75.5)  35 (74.5) 575 (75.5)  
 1 15 (23.4) 151 (19.8)  10 (21.3) 151 (19.8)  
 2 3 (4.7) 36 (4.7)  2 (4.3) 36 (4.7)  
Cons_GP_Times_impu, mean 
(SD) 
4.22 (4.68) 5.06 (6.40) 0.149 4.79 (5.26) 5.05 (6.40) 0.045 
Cons_Emergency_Times_impu, 
mean (SD) 
0.28 (0.55) 0.34 (0.80) 0.085 0.23 (0.48) 0.34 (0.80) 0.161 
Cons_Hospital_Times_impu, 
mean (SD) 
0.47 (1.61) 0.45 (0.98) 0.017 0.47 (1.79) 0.45 (0.98) 0.015 
Cons_Specialist_Times_impu, 
mean (SD) 
0.66 (1.73) 0.58 (3.05) 0.031 0.72 (1.95) 0.58 (3.05) 0.056 
Cons_Clinic_Times_impu, 
mean (SD) 
0.95 (2.18) 1.32 (4.56) 0.103 1.21 (2.48) 1.32 (4.57) 0.029 
Alcohol_frequency_impu, n (%)   0.160   0.254 
 1 7 (10.9) 79 (10.4)  3 (6.4) 79 (10.4)  
 2 14 (21.9) 160 (21.0)  11 (23.4) 159 (20.9)  
 3 26 (40.6) 285 (37.4)  20 (42.6) 285 (37.4)  
 
 
 4 10 (15.6) 166 (21.8)  7 (14.9) 166 (21.8)  
 5 7 (10.9) 73 (9.6)  6 (12.8) 73 (9.6)  
Alcohol_units_impu, n (%)   0.205   0.234 
 0 8 (12.5) 81 (10.6)  4 (8.5) 81 (10.6)  
 1 28 (43.8) 371 (48.6)  21 (44.7) 371 (48.7)  
 2 24 (37.5) 233 (30.5)  19 (40.4) 232 (30.4)  
 3 4 (6.2) 78 (10.2)  3 (6.4) 78 (10.2)  
Alcohol_units_6_impu, n (%)   0.300   0.314 
 1 34 (53.1) 448 (58.7)  23 (48.9) 448 (58.8)  
 2 27 (42.2) 237 (31.1)  21 (44.7) 236 (31.0)  
 3 2 (3.1) 55 (7.2)  2 (4.3) 55 (7.2)  
 4 1 (1.6) 18 (2.4)  1 (2.1) 18 (2.4)  
 5 0 (0.0) 5 (0.7)  0 (0.0) 5 (0.7)  
Smoke_impu, n (%)   0.230   0.228 
 1 4 (6.2) 86 (11.3)  4 (8.5) 86 (11.3)  
 2 1 (1.6) 12 (1.6)  0 (0.0) 12 (1.6)  
 3 37 (57.8) 465 (60.9)  28 (59.6) 465 (61.0)  
 4 22 (34.4) 200 (26.2)  15 (31.9) 199 (26.1)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.095   0.052 
 1 5 (7.8) 44 (5.8)  3 (6.4) 44 (5.8)  
 2 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  
 3 4 (6.2) 40 (5.2)  2 (4.3) 40 (5.2)  
 4 55 (85.9) 679 (89.0)  42 (89.4) 678 (89.0)  
Cod_liver_oil_omega3_impu, n 
(%) 
  0.205   0.189 
 0 41 (64.1) 558 (73.1)  32 (68.1) 557 (73.1)  
 1 11 (17.2) 99 (13.0)  9 (19.1) 99 (13.0)  
 2 4 (6.2) 28 (3.7)  1 (2.1) 28 (3.7)  
 3 8 (12.5) 78 (10.2)  5 (10.6) 78 (10.2)  
FRUIT_UNITS_T7, mean (SD) 1.73 (1.41) 2.07 (1.96) 0.200 1.81 (1.54) 2.08 (1.96) 0.152 
RED_MEAT_T7, n (%)   0.461   0.346 
 1 9 (14.1) 45 (5.9)  5 (10.6) 45 (5.9)  
 2 15 (23.4) 162 (21.2)  13 (27.7) 162 (21.3)  
 3 32 (50.0) 508 (66.6)  25 (53.2) 508 (66.7)  
 4 8 (12.5) 39 (5.1)  4 (8.5) 38 (5.0)  
 5 0 (0.0) 9 (1.2)  0 (0.0) 9 (1.2)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.197   0.199 
 1 0 (0.0) 7 (0.9)  0 (0.0) 7 (0.9)  
 2 4 (6.2) 31 (4.1)  3 (6.4) 31 (4.1)  
 3 13 (20.3) 151 (19.8)  11 (23.4) 151 (19.8)  
 4 15 (23.4) 215 (28.2)  13 (27.7) 214 (28.1)  
 5 32 (50.0) 359 (47.1)  20 (42.6) 359 (47.1)  
LEAN_FISH_T7, n (%)   0.378   0.193 
 1 7 (10.9) 20 (2.6)  3 (6.4) 20 (2.6)  
 2 8 (12.5) 102 (13.4)  6 (12.8) 101 (13.3)  
 3 42 (65.6) 533 (69.9)  32 (68.1) 533 (69.9)  
 4 5 (7.8) 96 (12.6)  5 (10.6) 96 (12.6)  
 5 2 (3.1) 12 (1.6)  1 (2.1) 12 (1.6)  
FAT_FISH_T7, n (%)   0.335   0.353 
 1 9 (14.1) 88 (11.5)  8 (17.0) 87 (11.4)  
 2 26 (40.6) 260 (34.1)  19 (40.4) 260 (34.1)  
 3 25 (39.1) 367 (48.1)  17 (36.2) 367 (48.2)  
 
 
 4 1 (1.6) 38 (5.0)  1 (2.1) 38 (5.0)  
 5 3 (4.7) 10 (1.3)  2 (4.3) 10 (1.3)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.326   0.203 
 1 14 (21.9) 174 (22.8)  9 (19.1) 174 (22.8)  
 2 37 (57.8) 402 (52.7)  29 (61.7) 402 (52.8)  
 3 9 (14.1) 175 (22.9)  8 (17.0) 175 (23.0)  
 4 4 (6.2) 12 (1.6)  1 (2.1) 11 (1.4)  
EXERCISE_T7, n (%)   0.260   0.427 
 1 5 (7.8) 93 (12.2)  2 (4.3) 93 (12.2)  
 2 10 (15.6) 89 (11.7)  10 (21.3) 89 (11.7)  
 3 13 (20.3) 119 (15.6)  5 (10.6) 119 (15.6)  
 4 18 (28.1) 274 (35.9)  15 (31.9) 273 (35.8)  
 5 18 (28.1) 188 (24.6)  15 (31.9) 188 (24.7)  
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n 64 763  46 763  
AGE, mean (SD) 61.95 
(11.84) 
69.82 (9.82) 0.723 65.72 
(10.23) 
69.82 (9.82) 0.409 
SEX_T7, n (%)   0.013   0.064 
 1 43 (67.2) 508 (66.6)  32 (69.6) 508 (66.6)  
BMI, mean (SD) 28.99 (5.07) 29.00 (4.54) 0.002 28.63 (4.49) 29.00 (4.54) 0.082 
HEART_FAILURE_T7, n (%)   0.328   0.329 
 0 55 (85.9) 566 (74.2)  40 (87.0) 566 (74.2)  
 1 2 (3.1) 74 (9.7)  2 (4.3) 74 (9.7)  
 2 7 (10.9) 123 (16.1)  4 (8.7) 123 (16.1)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.215   0.127 
 0 40 (62.5) 543 (71.2)  31 (67.4) 543 (71.2)  
 1 11 (17.2) 122 (16.0)  7 (15.2) 122 (16.0)  
 2 13 (20.3) 98 (12.8)  8 (17.4) 98 (12.8)  
STROKE_T7, n (%)   0.096   0.126 
 2 9 (14.1) 134 (17.6)  6 (13.0) 134 (17.6)  
KIDNEY_DISEASE_T7, n (%)   0.226   0.102 
 0 53 (82.8) 655 (85.8)  40 (87.0) 655 (85.8)  
 1 4 (6.2) 68 (8.9)  3 (6.5) 68 (8.9)  
 2 7 (10.9) 40 (5.2)  3 (6.5) 40 (5.2)  
CANCER_T7, n (%)   0.198   0.164 
 0 56 (87.5) 618 (81.0)  40 (87.0) 618 (81.0)  
 1 2 (3.1) 51 (6.7)  2 (4.3) 51 (6.7)  
 2 6 (9.4) 94 (12.3)  4 (8.7) 94 (12.3)  
DIABETES_impu_new, n (%)   0.043   0.126 
 0 48 (75.0) 574 (75.2)  37 (80.4) 574 (75.2)  
 1 13 (20.3) 147 (19.3)  7 (15.2) 147 (19.3)  
 2 3 (4.7) 42 (5.5)  2 (4.3) 42 (5.5)  
Cons_GP_Times_impu, mean 
(SD) 
3.28 (2.58) 4.86 (5.76) 0.353 3.37 (2.78) 4.86 (5.76) 0.329 
Cons_Emergency_Times_impu, 
mean (SD) 
0.25 (0.53) 0.34 (0.77) 0.129 0.20 (0.45) 0.34 (0.77) 0.221 
Cons_Hospital_Times_impu, 
mean (SD) 





0.47 (0.96) 0.56 (3.06) 0.039 0.52 (1.03) 0.56 (3.06) 0.016 
Cons_Clinic_Times_impu, 
mean (SD) 
"0.77 (1.46) 1.19 (3.56) 0.158 0.91 (1.63) 1.19 (3.56) 0.102 
Alcohol_frequency_impu, n (%)   0.160   0.152 
 1 7 (10.9) 79 (10.4)  4 (8.7) 79 (10.4)  
 2 14 (21.9) 160 (21.0)  8 (17.4) 160 (21.0)  
 3 26 (40.6) 285 (37.4)  20 (43.5) 285 (37.4)  
 4 10 (15.6) 166 (21.8)  9 (19.6) 166 (21.8)  
 5 7 (10.9) 73 (9.6)  5 (10.9) 73 (9.6)  
Alcohol_units_impu, n (%)   0.201   0.187 
 0 8 (12.5) 81 (10.6)  5 (10.9) 81 (10.6)  
 1 28 (43.8) 371 (48.6)  19 (41.3) 371 (48.6)  
 2 24 (37.5) 234 (30.7)  18 (39.1) 234 (30.7)  
 3 4 (6.2) 77 (10.1)  4 (8.7) 77 (10.1)  
Alcohol_units_6_impu, n (%)   0.300   0.222 
 1 34 (53.1) 449 (58.8)  25 (54.3) 449 (58.8)  
 2 27 (42.2) 236 (30.9)  18 (39.1) 236 (30.9)  
 3 2 (3.1) 56 (7.3)  2 (4.3) 56 (7.3)  
 4 1 (1.6) 18 (2.4)  1 (2.2) 18 (2.4)  
 5 0 (0.0) 4 (0.5)  0 (0.0) 4 (0.5)  
Smoke_impu, n (%)   0.230   0.290 
 1 4 (6.2) 86 (11.3)  4 (8.7) 86 (11.3)  
 2 1 (1.6) 12 (1.6)  0 (0.0) 12 (1.6)  
 3 37 (57.8) 465 (60.9)  25 (54.3) 465 (60.9)  
 4 22 (34.4) 200 (26.2)  17 (37.0) 200 (26.2)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.093   0.043 
 1 5 (7.8) 45 (5.9)  3 (6.5) 45 (5.9)  
 2 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  
 3 4 (6.2) 39 (5.1)  2 (4.3) 39 (5.1)  
 4 55 (85.9) 679 (89.0)  41 (89.1) 679 (89.0)  
Cod_liver_oil_omega3_impu, n 
(%) 
  0.203   0.137 
 0 41 (64.1) 559 (73.3)  31 (67.4) 559 (73.3)  
 1 11 (17.2) 101 (13.2)  7 (15.2) 101 (13.2)  
 2 4 (6.2) 30 (3.9)  2 (4.3) 30 (3.9)  
 3 8 (12.5) 73 (9.6)  6 (13.0) 73 (9.6)  
FRUIT_UNITS_T7, mean (SD) 1.84 (1.48) 2.10 (1.96) 0.145 1.91 (1.50) 2.10 (1.96) 0.104 
RED_MEAT_T7, n (%)   0.427   0.358 
 1 9 (14.1) 46 (6.0)  6 (13.0) 46 (6.0)  
 2 15 (23.4) 161 (21.1)  12 (26.1) 161 (21.1)  
 3 33 (51.6) 506 (66.3)  27 (58.7) 506 (66.3)  
 4 7 (10.9) 39 (5.1)  1 (2.2) 39 (5.1)  
 5 0 (0.0) 11 (1.4)  0 (0.0) 11 (1.4)  
FRUITS_VEG_BERRY_T7, n 
(%) 
  0.204   0.233 
 1 0 (0.0) 8 (1.0)  0 (0.0) 8 (1.0)  
 2 4 (6.2) 30 (3.9)  2 (4.3) 30 (3.9)  
 3 13 (20.3) 152 (19.9)  12 (26.1) 152 (19.9)  
 4 15 (23.4) 213 (27.9)  10 (21.7) 213 (27.9)  
 5 32 (50.0) 360 (47.2)  22 (47.8) 360 (47.2)  
LEAN_FISH_T7, n (%)   0.444   0.224 
 1 8 (12.5) 19 (2.5)  1 (2.2) 19 (2.5)  
 
 
 2 8 (12.5) 102 (13.4)  6 (13.0) 102 (13.4)  
 3 43 (67.2) 534 (70.0)  35 (76.1) 534 (70.0)  
 4 5 (7.8) 97 (12.7)  4 (8.7) 97 (12.7)  
 5 0 (0.0) 11 (1.4)  0 (0.0) 11 (1.4)  
FAT_FISH_T7, n (%)   0.299   0.267 
 1 8 (12.5) 86 (11.3)  6 (13.0) 86 (11.3)  
 2 29 (45.3) 261 (34.2)  20 (43.5) 261 (34.2)  
 3 25 (39.1) 368 (48.2)  18 (39.1) 368 (48.2)  
 4 1 (1.6) 38 (5.0)  1 (2.2) 38 (5.0)  
 5 1 (1.6) 10 (1.3)  1 (2.2) 10 (1.3)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.306   0.161 
 1 14 (21.9) 178 (23.3)  10 (21.7) 178 (23.3)  
 2 37 (57.8) 401 (52.6)  25 (54.3) 401 (52.6)  
 3 9 (14.1) 170 (22.3)  9 (19.6) 170 (22.3)  
 4 4 (6.2) 14 (1.8)  2 (4.3) 14 (1.8)  
EXERCISE_T7, n (%)   0.258   0.390 
 1 5 (7.8) 93 (12.2)  2 (4.3) 93 (12.2)  
 2 10 (15.6) 91 (11.9)  9 (19.6) 91 (11.9)  
 3 12 (18.8) 119 (15.6)  8 (17.4) 119 (15.6)  
 4 18 (28.1) 275 (36.0)  13 (28.3) 275 (36.0)  
 5 19 (29.7) 185 (24.2)  14 (30.4) 185 (24.2)  
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n 64 763  46 760  
AGE, mean (SD) 61.95 
(11.84) 
69.82 (9.82) 0.723 64.76 
(11.33) 
69.87 (9.80) 0.482 
SEX_T7, n (%)   0.013   0.017 
 1 43 (67.2) 508 (66.6)  31 (67.4) 506 (66.6)  
BMI, mean (SD) 28.99 (5.07) 29.00 (4.54) 0.001 28.49 (4.64) 29.00 (4.54) 0.110 
HEART_FAILURE_T7, n (%)   0.385   0.327 
 0 55 (85.9) 565 (74.0)  38 (82.6) 562 (73.9)  
 1 1 (1.6) 73 (9.6)  1 (2.2) 73 (9.6)  
 2 8 (12.5) 125 (16.4)  7 (15.2) 125 (16.4)  
ATRIAL_FIBRILLATION_T7, 
n (%) 
  0.197   0.206 
 0 40 (62.5) 543 (71.2)  29 (63.0) 542 (71.3)  
 1 12 (18.8) 123 (16.1)  8 (17.4) 123 (16.2)  
 2 12 (18.8) 97 (12.7)  9 (19.6) 95 (12.5)  
STROKE_T7, n (%)   0.135   0.055 
 2 8 (12.5) 132 (17.3)  7 (15.2) 131 (17.2)  
KIDNEY_DISEASE_T7, n (%)   0.144   0.085 
 0 53 (82.8) 653 (85.6)  39 (84.8) 651 (85.7)  
 1 5 (7.8) 67 (8.8)  5 (10.9) 67 (8.8)  
 2 6 (9.4) 43 (5.6)  2 (4.3) 42 (5.5)  
CANCER_T7, n (%)   0.176   0.114 
 0 56 (87.5) 619 (81.1)  39 (84.8) 616 (81.1)  
 1 3 (4.7) 52 (6.8)  3 (6.5) 52 (6.8)  
 2 5 (7.8) 92 (12.1)  4 (8.7) 92 (12.1)  
DIABETES_impu_new, n (%)   0.093   0.117 
 0 46 (71.9) 574 (75.2)  35 (76.1) 572 (75.3)  
 
 
 1 14 (21.9) 155 (20.3)  8 (17.4) 155 (20.4)  
 2 4 (6.2) 34 (4.5)  3 (6.5) 33 (4.3)  
Cons_GP_Times_impu, mean 
(SD) 
3.89 (4.49) 4.80 (5.31) 0.185 4.22 (5.03) 4.79 (5.32) 0.111 
Cons_Emergency_Times_impu, 
mean (SD) 
0.27 (0.54) 0.33 (0.76) 0.092 0.26 (0.53) 0.33 (0.76) 0.101 
Cons_Hospital_Times_impu, 
mean (SD) 
0.47 (1.61) 0.45 (0.98) 0.013 0.54 (1.85) 0.45 (0.99) 0.062 
Cons_Specialist_Times_impu, 
mean (SD) 
0.80 (2.74) 0.56 (3.11) 0.082 0.98 (3.19) 0.53 (3.03) 0.145 
Cons_Clinic_Times_impu, 
mean (SD) 
0.66 (1.22) 1.15 (3.47) 0.188 0.78 (1.38) 1.15 (3.47) 0.138 
Alcohol_frequency_impu, n (%)   0.171   0.270 
 1 6 (9.4) 79 (10.4)  2 (4.3) 79 (10.4)  
 2 14 (21.9) 160 (21.0)  9 (19.6) 159 (20.9)  
 3 27 (42.2) 285 (37.4)  21 (45.7) 283 (37.2)  
 4 10 (15.6) 166 (21.8)  9 (19.6) 166 (21.8)  
 5 7 (10.9) 73 (9.6)  5 (10.9) 73 (9.6)  
Alcohol_units_impu, n (%)   0.162   0.305 
 0 7 (10.9) 81 (10.6)  2 (4.3) 81 (10.7)  
 1 28 (43.8) 371 (48.6)  21 (45.7) 370 (48.7)  
 2 24 (37.5) 233 (30.5)  19 (41.3) 231 (30.4)  
 3 5 (7.8) 78 (10.2)  4 (8.7) 78 (10.3)  
Alcohol_units_6_impu, n (%)   0.325   0.319 
 1 33 (51.6) 449 (58.8)  26 (56.5) 448 (58.9)  
 2 28 (43.8) 235 (30.8)  18 (39.1) 233 (30.7)  
 3 2 (3.1) 55 (7.2)  2 (4.3) 55 (7.2)  
 4 1 (1.6) 20 (2.6)  0 (0.0) 20 (2.6)  
 5 0 (0.0) 4 (0.5)  0 (0.0) 4 (0.5)  
Smoke_impu, n (%)   0.230   0.292 
 1 4 (6.2) 86 (11.3)  3 (6.5) 86 (11.3)  
 2 1 (1.6) 12 (1.6)  0 (0.0) 12 (1.6)  
 3 37 (57.8) 465 (60.9)  27 (58.7) 464 (61.1)  
 4 22 (34.4) 200 (26.2)  16 (34.8) 198 (26.1)  
Snuff_chewing_tobacco_impu, 
n (%) 
  0.093   0.090 
 1 5 (7.8) 45 (5.9)  2 (4.3) 45 (5.9)  
 2 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  
 3 4 (6.2) 39 (5.1)  3 (6.5) 39 (5.1)  
 4 55 (85.9) 679 (89.0)  41 (89.1) 676 (88.9)  
Cod_liver_oil_omega3_impu, n 
(%) 
  0.179   0.262 
 0 42 (65.6) 559 (73.3)  30 (65.2) 557 (73.3)  
 1 12 (18.8) 99 (13.0)  10 (21.7) 98 (12.9)  
 2 3 (4.7) 31 (4.1)  1 (2.2) 31 (4.1)  
 3 7 (10.9) 74 (9.7)  5 (10.9) 74 (9.7)  
FRUIT_UNITS_T7, mean (SD) 1.77 (1.38) 2.06 (1.97) 0.174 1.93 (1.50) 2.05 (1.96) 0.068 
RED_MEAT_T7, n (%)   0.440   0.281 
 1 10 (15.6) 46 (6.0)  6 (13.0) 46 (6.1)  
 2 14 (21.9) 160 (21.0)  11 (23.9) 159 (20.9)  
 3 32 (50.0) 511 (67.0)  26 (56.5) 510 (67.1)  
 4 7 (10.9) 36 (4.7)  2 (4.3) 35 (4.6)  





  0.257   0.241 
 1 0 (0.0) 9 (1.2)  0 (0.0) 9 (1.2)  
 2 5 (7.8) 30 (3.9)  3 (6.5) 30 (3.9)  
 3 11 (17.2) 153 (20.1)  9 (19.6) 152 (20.0)  
 4 15 (23.4) 212 (27.8)  10 (21.7) 212 (27.9)  
 5 33 (51.6) 359 (47.1)  24 (52.2) 357 (47.0)  
LEAN_FISH_T7, n (%)   0.452   0.275 
 1 8 (12.5) 19 (2.5)  3 (6.5) 18 (2.4)  
 2 9 (14.1) 100 (13.1)  6 (13.0) 99 (13.0)  
 3 42 (65.6) 533 (69.9)  32 (69.6) 532 (70.0)  
 4 5 (7.8) 99 (13.0)  5 (10.9) 99 (13.0)  
 5 0 (0.0) 12 (1.6)  0 (0.0) 12 (1.6)  
FAT_FISH_T7, n (%)   0.284   0.254 
 1 8 (12.5) 88 (11.5)  6 (13.0) 87 (11.4)  
 2 29 (45.3) 263 (34.5)  19 (41.3) 261 (34.3)  
 3 25 (39.1) 367 (48.1)  20 (43.5) 367 (48.3)  
 4 1 (1.6) 35 (4.6)  1 (2.2) 35 (4.6)  
 5 1 (1.6) 10 (1.3)  0 (0.0) 10 (1.3)  
PHYS_ACTIVITY_LEISURE_
T7, n (%) 
  0.280   0.141 
 1 14 (21.9) 166 (21.8)  10 (21.7) 165 (21.7)  
 2 37 (57.8) 405 (53.1)  27 (58.7) 404 (53.2)  
 3 9 (14.1) 173 (22.7)  8 (17.4) 172 (22.6)  
 4 4 (6.2) 19 (2.5)  1 (2.2) 19 (2.5)  
EXERCISE_T7, n (%)   0.222   0.263 
 1 6 (9.4) 93 (12.2)  3 (6.5) 93 (12.2)  
 2 10 (15.6) 88 (11.5)  8 (17.4) 87 (11.4)  
 3 12 (18.8) 120 (15.7)  7 (15.2) 120 (15.8)  
 4 18 (28.1) 274 (35.9)  15 (32.6) 273 (35.9)  
 5 18 (28.1) 188 (24.6)  13 (28.3) 187 (24.6)  





Supplementary table 7: Pooled results from the sensitivity analysis for the logistic regression analyses of 
the multiple imputed datasets, using propensity score matching without replacement*. 
Exposure variable Outcome variable Odds ratio 95 % confidence 
interval 
Use of lipid lowering 
drugs 
Achievement of treatment 





Achievement of treatment 
goal for blood pressure 
1.5 0.6-3.6 
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Abstract 
Objective: To validate self-reported use of medications for secondary prevention of coronary heart disease (CHD) in a population- 
based health study by comparing self-report with pharmacy dispensing data, and explore different methods for defining medication use 
in prescription databases. 
Study design and setting: Self-reported medication use among participants with CHD ( n = 1483) from the seventh wave of the 
Tromsø Study was linked with the Norwegian Prescription Database (NorPD). Cohen’s kappa, sensitivity, specificity, and positive and 
negative predictive values were calculated, using NorPD as the reference standard. Medication use in NorPD was defined in three ways; 
fixed-time window of 180 days, and legend-time method assuming a daily dose of one dosage unit or one defined daily dose (DDD). 
Results: Kappa-values for antihypertensive drugs, lipid-lowering drugs and acetylsalicylic acid all showed substantial agreement 
(kappa ≥0.61). Validity varied depending on the method used for defining medication use in NorPD. Applying a fixed-time window 
gave higher agreement, positive predictive values and specificity compared with the legend-time methods. 
Conclusion: Self-reported use of medication for secondary prevention of CHD shows high validity when com- 
pared with pharmacy dispensing data. For CHD medications, fixed-time window appears to be the most appropri- 
ate method for defining medication use in prescription databases. © 2021 The Author(s). Published by Elsevier Inc. 
This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
Keywords: Medication use; validation; agreement; population-based study; prescription database 
What this adds to what is known? What is new? 
Key findings 
• Self-reported use of lipid-lowering drugs, antihy- 
pertensive drugs and acetylsalicylic acid among 
patients with coronary heart disease showed high 
agreement when compared with pharmacy dispens- 
ing data. Using a fixed-time window to define cur- 
rent medication use gave higher agreement, positive 
predictive values and specificity compared with the 
legend-time methods. Abbreviations: ASA, acetylsalicylic acid; CHD, coronary heart dis- 
ease; DDD, defined daily dose; LLD, lipid-lowering drug; NorPD, Nor- 
wegian Prescription Database; NPV, negative predictive value; PPV, pos- 
itive predictive value. 
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0895-4356/© 2021 The Author(s). Published by Elsevier Inc. This is an open a
( http://creativecommons.org/licenses/by/4.0/ ) • Self-reported medication use for coronary heart dis- 
ease collected with a questionnaire combining pre- 
specified and open-ended questions gives a valid 
measure of medication use. 
• For coronary heart disease medication, a fixed-time 
window is better than legend-time methods in defin- 
ing current use from prescription data. If legend- 
time is used and the prescribed dose is unavailable, 
assuming a daily dose of one dosage unit is a better 
choice than one defined daily dose for these medi- 
cations. ccess article under the CC BY license 













































































What is the implication, what should change 
now? 
• Though a combination of self-report and prescrip- 
tion data classifies medication exposure most accu- 
rately, self-reported information on medication for 
secondary prevention of coronary heart disease has 
adequate validity to be used for epidemiological re- 
search if prescription data is unavailable. 
• When investigating current use of medications for 
coronary heart disease using prescription databases, 
fixed-time window appears to be a more appropriate 
method than the legend-time method. 
1. Introduction 
Medication use is an important factor in many epidemi-
ological studies, either as exposure or outcome. Poor mea-
surement of medication use can lead to over- or underes-
timation of true associations and risks [1] . 
There are several ways to measure medication use,
where self-reported use, e.g. questionnaires or interviews,
and pharmacy dispensing data are common methods. Un-
fortunately, no method provides information about the true
medication exposure. Self-reported use may be biased by
poor recall and underreporting of socially stigmatized med-
ication classes [2 , 3] . Despite being collected objectively
and nondifferentially, dispensing data cannot account for
secondary nonadherence, i.e., dispensed medication is not
necessarily used. It may also be prone to selection bias as
some data sources include only reimbursed medications,
and others are based on claims from selected insurance
companies or pharmacies [4–10] . A few countries, like
the Scandinavian countries, have complete prescription reg-
istries that include all prescription-based medications dis-
pensed from pharmacies [11] . 
Several studies have compared medication use measure-
ments from different data sources [4–10 , 12–17] . Most stud-
ies find good agreement and validity between self-reported
and dispensing data when investigating medications used
for long-term conditions. Results are less consistent for
medications used as needed [9 , 10 , 12 , 13] . Cardiovascular
medications, such as antihypertensive drugs, lipid-lowering
drugs (LLDs) and antiplatelet drugs, are normally used on
a daily basis, and agreement and validity between different
data sources are usually found to be high [4–7 , 9 , 10 , 12–17] .
However, few studies have investigated this in a popu-
lation with established coronary heart disease (CHD) or
compared data from complete prescription registries with
self-reported data from a large population study. 
A methodological concern with prescription registry
data entails defining “current medication use”. The two
most commonly applied methods are fixed-time window
and legend-time duration. Fixed-time window is most fre-
quently applied and defines participants as medication-users if they have been dispensed the medication within a
set time window before an index date [8 , 17] . The legend-
time method uses information from the last prescription
dispensed before the index date to calculate whether the
dispensed medication will last to the index date [8 , 17] .
Some studies have compared the two methods, but no con-
sensus have been reached concerning which is the most
appropriate for defining current medication use [8 , 12 , 18] . 
This study aimed to validate self-reported use of medi-
cations for secondary prevention of CHD in a population-
based health study by comparing self-report with pharmacy
dispensing data using the Norwegian Prescription Database
(NorPD) as the reference standard, and exploring different
methods for defining medication use in NorPD. 
2. Methods 
2.1. The Tromsø study 
The Tromsø Study is a population-based health study
that has been conducted seven times from 1974 to 2016
[19] . The study includes inhabitants in the municipality of
Tromsø, Norway, a town with approximately 73,000 inhab-
itants in 2016. The present study used data collected dur-
ing 2015-16 from the seventh wave of the Tromsø Study
(Tromsø 7), where all inhabitants ≥ 40 years ( n = 32,591)
were invited to participate. The response rate was 65% ( n
= 21,083). 
Participation in Tromsø 7 included answering two ques-
tionnaires, donating blood samples and going through clin-
ical examinations. Most questions about diseases and med-
ication use were posed in questionnaire 1, which could be
answered either on paper or electronically anytime between
invitation and attending the health examination. Links to
the questionnaires can be found at the Tromsø Study’s
webpage [19] . 
2.2. The Norwegian Prescription Database (NorPD) 
NorPD contains complete information about all pre-
scribed medications dispensed from Norwegian pharma-
cies to individuals since January 2004. Medications used
in hospitals/nursing homes and over-the-counter medica-
tions are not included. We included the following vari-
ables from NorPD: date of dispensing and information on
medications dispensed (including Anatomical Therapeutic
Chemical (ATC) code, and number of dosage units and de-
fined daily doses (DDDs) dispensed [20] ). DDD is defined
as “the assumed average maintenance dose per day for a
drug used for its main indication in adults” [20] . 
2.3. Study population 
From Tromsø 7, we included participants reporting es-
tablished CHD ( n = 1483). CHD was defined as reporting
either previous myocardial infarction, present or previous


















































































angina pectoris, previous percutaneous coronary interven-
tion or coronary artery bypass graft surgery. 
2.4. Medications included 
We included medications for secondary prevention
of CHD ( Fig. 1 ), which according to the prevailing
European guidelines in 2015/2016 was acetylsalicylic
acid (ASA), LLDs (mainly statins) and antihypertensive
drugs (angiotensin-converting enzyme (ACE)-inhibitors,
angiotensin receptor blockers (ARBs), beta-blockers,
calcium-channel blockers (CCBs), thiazides and other
antihypertensives) [21] . 
2.5. Defining medication use 
In Tromsø 7, medication use was self-reported through
i) questions about specific medication use and ii) partici-
pants listing the brand names for all medications used reg-
ularly the previous four weeks. We defined users of LLDs
and antihypertensive drugs as participants answering “cur-
rently” to the two specific questions “Do you use, or have
you used cholesterol-lowering drugs? ” and “Do you use,
or have you used blood pressure lowering drugs?”, (re-
sponse alternatives were “currently”, “previously, not now”
and “never used”) and/or listing the brand name of an LLD
or antihypertensive drug, respectively. We defined users
of ASA as participants answering “yes” when asked “If
you have used analgesics and anti-inflammatory medica-
tion regularly in the past year - did you use “Baby” or
low dose acetylsalicylic acid (ASA), i.e. Acetylsalisylsyre ®,
Albyl-E ®, Asasantin Retard ® (75/160 mg per tablet)?”
(response alternatives were “yes” and “no”), or denoting a
brand name for ASA. 
From NorPD, current use was defined by three ap-
proaches; one using a fixed-time window and two us-
ing the legend-time method ( Fig. 2 ). For all approaches,
index date was the day the participants completed the
Tromsø 7 questionnaire. Using a fixed-time window def-
inition, medication-users were participants who had been
dispensed at least one prescription within 180 days before
index date. A sensitivity analysis was performed using time
windows of 90 and 365 days. The legend-time method re-
quires knowledge about the duration of use. As prescribed
daily dose is not available in NorPD, we calculated the
duration supplied assuming the daily dose was equal to:
i) one dosage unit (e.g. tablet, capsule etc.), and ii) one
DDD. In both legend-time approaches, we added 10% to
the duration to account for imperfect adherence before as-
sessing whether the duration of the last dispensation cov-
ered the index date. Sensitivity analyses were performed
by not adding any additional units/DDDs, and by adding
20% additional units/DDDs. 2.6. Statistical analysis 
Data from Tromsø 7 was linked with NorPD data using
the unique national identity number assigned to all citizens
in Norway. NorPD performed the record linkage according
to standard procedures. Agreement between Tromsø 7 and
NorPD was measured by percent observed agreement and
Cohen’s kappa. Kappa-values were interpreted as proposed
by Landis and Koch: poor ( < 0.00), slight (0.00 to 0.20),
fair (0.21 to 0.40), moderate (0.41 to 0.60), substantial
(0.61 to 0.80), or almost perfect (0.81 to 1.00) [22] . 
To determine the validity of self-reported medication
use, we calculated sensitivity and specificity using NorPD
as the reference standard. Positive (PPV) and negative
(NPV) predictive values were also calculated. 
Analyses were conducted applying IBM SPSS 25 for
Windows. Confidence intervals were calculated using Vas-
sarStats [23 , 24] . Results are expressed as proportions and
kappa-values with 95% confidence intervals. 
2.7. Ethics 
The study was approved by the Regional Committee
for Medical and Health Research Ethics of North Norway
(2015/1775) and had an approved Data Protection Impact
Assessment from UiT The Arctic University of Norway.
All participants in the Tromsø Study have given written
informed consent for their data to be used in research. 
3. Results 
In the study population ( n = 1483), 70% were male
and mean age was 68.7 (standard deviation 10.8) years.
Medication use is shown in Table 1 . 
Agreement was substantial for antihypertensive drugs,
LLDs and ASA, with kappa-values ≥0.61 ( Table 2 ). An
exception was for ASA when using either of the legend-
time methods, in which case the kappa-value was 0.60.
The fixed-time window method gave higher agreement than
either of the legend-time methods, both in terms of per-
cent agreement and kappa. For antihypertensive drugs, the
kappa-value showed an almost perfect agreement when us-
ing a fixed-time window. 
Among participants where the two data sources did not
agree, more participants were identified as ASA-users in
NorPD than in Tromsø 7, while the result was opposite for
LLD-users ( Table 2 ). For antihypertensive drugs, more par-
ticipants were identified as users in NorPD than in Tromsø
7 when using a fixed-time window, but opposite when us-
ing the legend-time methods. 
PPV was high for all three main medication classes,
which shows that when participants report using these
medications, the likelihood that they had it dispensed is
high. Highest values were found using fixed-time window,
while legend-time with DDD gave the lowest values. NPV
was high for antihypertensive drugs and LLDs but lower
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Fig. 1. Overview of included ATC-codes and aggregation into medication groups. 
∗When, instead of brand name, the participants in free text reported using medication interpretable as “blood pressure lowering” or “cholesterol 
lowering”, it was registered under the respective medication category. 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ATC, anatomical therapeutic chemical classification sys- 
tem; CCB, calcium-channel blocker. 
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Fig. 2. The three different methods used to define medication users in NorPD. Index date is the day of questionnaire completion. Using fixed-time 
window, participants were defined as medication-users if they had a medication dispensed ≤180 days before index date. The legend-time methods 
defined a participant as user if the supply of medication most recently dispensed would last past the index date, assuming a daily dosage of either 
one unit (e.g., tablet) or one DDD. Medications A, B and C are in use according to fixed-time window; A and D are in use when applying legend-time 
with one unit a day; A and B are in use applying legend-time with one DDD a day. Medication E is not defined as in use by any of the methods. 
Abbreviations: DDD, defined daily dose; NorPD, Norwegian Prescription Database 
Table 1. Prevalence of use ( n (%)) of medications for secondary prevention of coronary heart disease in Tromsø 7 and the three approaches for 
defining medication use in NorPD ( n = 1483) 
Tromsø 7 NorPD, Fixed-time NorPD, Legend-time, Unit NorPD, Legend-time, DDD 
Antihypertensive drugs 1069 (72.1) 1087 (73.3) 1032 (69.6) 865 (58.3) 
Lipid-lowering drugs 1133 (76.4) 1074 (72.4) 960 (64.7) 928 (62.6) 
Acetylsalicylic acid 980 (66.1) 1098 (74.0) 991 (66.8) 991 (66.8) 





























for ASA. For NPV, the legend-time methods and especially
using DDDs gave the highest values, but the difference be-
tween methods was small. 
Sensitivity was also high for all three main medica-
tion classes. This indicates that a high proportion of those
registered as users in NorPD also self-reported use of
these medications in Tromsø 7. Specificity was lower than
the sensitivity for antihypertensive drugs and LLDs, but
higher for ASA. The specificity was lowest when using
the legend-time methods, and especially with one DDD as
the daily dosage. 
Among the antihypertensive drugs, an almost perfect
agreement was found for angiotensin-converting enzyme
(ACE)-inhibitors, angiotensin receptor blockers (ARBs)
and calcium-channel blockers (CCBs) when using fixed-
time window, while the legend-time methods gave substan-tial to almost perfect agreements ( Table 3 ). The kappa-
values for thiazides showed substantial agreement. For
beta-blockers, agreement was substantial when using fixed-
time window and legend-time method with one unit a
day, and fair with legend-time method with one DDD a
day. For statins, agreement was substantial when using the
fixed-time window method and fair with either legend-time
method. 
Sensitivity analyses showed higher agreement for a 180
days than a 90 days fixed-time window, and the main
analysis (with 10% extra added to the duration) for the
legend-time methods showed higher agreement than no
addition. Using a 365 days fixed-time window or adding
20% to the duration in the legend-time methods gave re-
sults similar to the main analysis (supplementary tables
A.1-A.3). 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































This study demonstrates high agreement between self-
reported use of CHD medications and pharmacy dispens-
ing data among participants with CHD in the seventh wave
of the Tromsø Study. High PPV was shown for all medi-
cations, especially when using a fixed-time window. This
indicates that participants reporting use of such medica-
tions can be presumed to be actual medication-users. Sen-
sitivity and specificity was also found to be high for the
investigated medication classes. This is in accordance with
previous studies [4-7 , 9 , 10 , 12 , 14–16] . 
Negative predictive values were also high for most med-
ication classes, showing that almost all who do not re-
port use of CHD medications are nonusers in NorPD as
well. Lower NPVs for statins and ASA suggest that among
participants not reporting use of these medications, some
have been dispensed such medications. It is possible that
these participants do not actually use statins or ASA, but
it is more likely that they have forgotten to report them in
the questionnaire, thereby being misclassified as nonusers
according to self-report. Predictive values are affected by
prevalence and the high prevalence of use in our study
population contributes to the high PPVs. 
In addition to lower NPV, ASA had a lower kappa-
value, as more participants were classified as ASA-users
by NorPD, and not by Tromsø 7. This was particularly
clear using fixed-time window, where 10.7% of the par-
ticipants were defined as medication-users in NorPD only,
while 2.6% were defined as users only in Tromsø 7. Un-
like for antihypertensive drugs and LLDs, we could only
include those who specified an ASA brand name, and we
would lose users who wrote “blood-thinning medication”.
As this could represent any antithrombotic drug, we could
not include these as ASA-users. We did include answers
to a prespecified question about use of low-dose ASA, but
this question was conditional on a positive answer to a
previous question (“Have you used analgesics and anti-
inflammatory medication regularly in the past year?”). So,
ASA-users did not have the same opportunity as LLD-
/antihypertensive drug-users to report their use, leading to
a likely underestimated agreement for ASA. 
Like ASA, statins had lower agreement and NPV than
the other medication classes. However, the values for all
LLDs combined were higher than for statins alone, es-
pecially when using fixed-time window. Many LLD-users
remember that they use LLDs, but might not report which
type. This again underlines the importance of including
the prespecified question about LLD-use in addition to the
open-ended question when evaluating use of statins. Inter-
estingly, LLDs is the only medication class with a higher
proportion of users defined in Tromsø 7 than in NorPD.
The number of users defined by Tromsø 7 alone is lower
when using a fixed-time window of 365 days, indicating
lower adherence among LLD-users. The lowest sensitivity was found for thiazides, indicat-
ing that the Tromsø 7 questionnaire does not identify all
thiazide-users. Only the open-ended question was used to
define thiazide-users, and we are therefore dependent on
the participants being specific when listing their medica-
tions. In Norway, thiazides are usually sold as part of a
combination product with another antihypertensive drug.
Self-reported use of combination products can be misclas-
sified as single active substances. The thiazide is usually
mentioned at the end of a brand name, e.g. “candesartan
hydrochlorothiazide”, leaving it easy to forget, and result-
ing in lower sensitivity for thiazides. 
The structure of the questions in a questionnaire can af-
fect how a participant reports medication use [25] . A study
by Klungel et al. [2] compared questions about medica-
tions for prespecified conditions with open-ended question
and concluded that prespecified indication alternatives gave
higher recall sensitivity. However, the open-ended ques-
tion and the question with prespecified indications did not
ask about the same medication type. Combining the in-
formation from different types of questions should yield
higher prevalence of medication use [25] . In our study, we
combined prespecified questions and an open-ended ques-
tion. Thereby we could capture participants who forgot to
list some of their medicines in the open-ended question
and participants who use antihypertensive drugs and LLDs
without understanding exactly what the medication is for.
The two questions might lead to different responses as the
prespecified questions ask about current medication use,
while the open-ended one asks about regular use in the last
four weeks. As CHD medications are used chronically, it
is reasonable to assume that both questions would capture
the participants’ recent use of these medications. 
It is not possible to define current use in a prescription
registry in the same way as in a questionnaire. NorPD
states that a medication was dispensed at a certain date
and amount, but not if, when or how the medication was
taken. Two main methods have been used when assess-
ing current medication use in pharmacy records: fixed-time
windows (also called fixed look-back periods) and legend-
time (also called legend-duration or medication-on-hand)
[18] . As there is no consensus on the best method for
defining current medication use in pharmacy records, it
has been recommended to compare different approaches
[18] . We chose to use both fixed-time window and legend-
time methods to define current medication use in NorPD.
A fixed-time window of 180 days was chosen because a
typical dispensing in Norway covers around 90 days of
use, and we added another 90 days to account for poor
adherence and stockpiling. For the same reason we added
10% to the units and DDDs before calculating whether
the dispensed duration would last to the index day when
using the legend-time method [2 , 12 , 15 , 17] . The sensitivity
analyses suggest that this was satisfactory. 


















































































Using one unit compared with one DDD to calculate
legend duration gave similar results for most of the medica-
tion classes. The sensitivity was slightly higher when using
DDDs, while using units generally gave higher agreement,
specificity and PPV. The differences were largest for beta-
blockers. This indicates that the DDD for beta-blockers is
higher than the most commonly prescribed dose of beta-
blockers in Norway. As most of the medications used for
secondary prevention of CHD are used as one unit daily,
this appears to be a better estimate for the prescribed daily
dosage than DDD. The only exception among the medica-
tion classes was calcium-channel blockers, where the DDD
gave slightly higher agreement, sensitivity and PPV than
the unit. This is not unexpected, as some calcium-channel
blockers are recommended to be taken more than once a
day. 
We used NorPD as the reference standard in calculat-
ing our validity measures. NorPD can be considered more
reliable than self-report as the registry has complete cov-
erage of dispensed medications used for secondary pre-
vention of CHD. These medications are also not available
over-the-counter in Norway. Using dispensing data as the
reference standard is common in validation studies [4–
6 , 9 , 10] . However, the choice of definition matters, and
careful considerations are needed when choosing fixed-
time or legend-time, and dosage unit or DDD as unit of
use. We found that for CHD medications used chronically,
a fixed-time window of 180 days gave the best results
with higher values of both percent agreement and kappa
as well as higher specificity and PPV for all medications.
Though sensitivity and NPV was higher for most medi-
cations when using the legend-time methods, the differ-
ences from fixed-time window were small. The fixed-time
window is also more easily applicable than the legend-
time method. Overall, using a fixed-time window could be
recommended for most studies investigating use of these
medications. For other medication classes this might be
different. 
5. Conclusion 
Self-reported information on current use of medications
for secondary prevention of coronary heart disease col-
lected with a questionnaire combining prespecified and
open-ended questions shows high validity compared with
pharmacy dispensing data. Though a combination with dis-
pensing data is preferable, this questionnaire provides a
sufficiently accurate classification of such medication ex-
posure should prescription data be unavailable. 
Validity and agreement measures varied depending on
the definition of medication use in NorPD. For CHD medi-
cations, using a fixed-time window gave better results than
the legend-time methods. However, this may vary depend-
ing on medication class, setting and data source. Funding 
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Purpose: To describe medication adherence to lipid-lowering drugs (LLDs), antihypertensive 
drugs and acetylsalicylic acid (ASA) among persons with coronary heart disease (CHD) and 
explore its association with low-density-lipoprotein (LDL)-cholesterol, and systolic and 
diastolic blood pressure. 
Methods: Based on record linkage between the seventh wave of the Tromsø study and the 
Norwegian Prescription Database, medication adherence was calculated as proportion of days 
covered (PDC) for persistent prevalent users in the time-period of 365 days before the 
attendance date. Multivariable linear regression models were used to assess the association 
between systolic and diastolic blood pressure and medication nonadherence to 
antihypertensive drugs, age, sex, lifestyle, body mass index (BMI), current and previous 
diabetes and between LDL-cholesterol and medication nonadherence to LLDs, age, sex, 
lifestyle, BMI, current and previous diabetes. 
Results: Mean PDC was 0.94 for LLDs and antihypertensive drugs and 0.97 for ASA. Among 
persons with PDC ≥0.80 for LLDs, 12.0% had an LDL-cholesterol <1.8 mmol/L. Blood 
pressure <140/90 mmHg (<140/80 mmHg if diabetes patient) was reached by 55.1% of those 
with a PDC ≥0.80 for antihypertensive drugs. Adherence to LLDs was associated with lower 
LDL-cholesterol, while neither systolic nor diastolic blood pressure were associated with 
adherence to antihypertensive drugs.  
Conclusion: Adherence to antihypertensive drugs, LLDs and ASA among persons with CHD 
was high despite low achievement of treatment goals for blood pressure and LDL-cholesterol. 
There was a statistically significant association between adherence to LLDs and LDL-
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Adherence to medications for secondary prevention of coronary heart disease (CHD) is 
important to achieve full effect of lipid-lowering drugs (LLDs), antihypertensive drugs and 
low-dose acetylsalicylic acid (ASA) and thereby to avoid new cardiovascular events [1-4].  
Lowering low-density-lipoprotein (LDL)-cholesterol and blood pressure reduces the risk of 
further morbidity and mortality of coronary heart disease [5, 6]. European guidelines for 
prevention of cardiovascular disease have recommended that patients with established CHD 
should have a blood pressure of <140/90 mmHg (<140/80 mmHg in patients with diabetes) 
and an LDL-cholesterol of <1.8 mmol/l (<70 mg/dL) [7, 8]. In the more recent guidelines 
concerning management of chronic coronary syndromes and those concerning 
hypercholesterolemia, the recommendations for persons with a very high risk of new coronary 
events are now further reduced to an LDL-cholesterol reduction of ≥50% from baseline and 
an LDL-cholesterol goal of <1.4 mmol/L (<55 mg/dL) [9, 10]. Risk factor control among 
persons with CHD is found to be suboptimal, also in population-based studies [11-14]. 
Achievement of the treatment goal for LDL-cholesterol is particularly low. Suboptimal 
medication adherence has been suggested as a possible explanation for the poor treatment 
goal achievement. Several studies have found an association between being adherent and 
achieving LDL-cholesterol or blood pressure control [15-19].  
Adherence to long-term therapies is generally found to be as low as 50% [20]. Although some 
studies have found slightly higher adherence to medications used for secondary prevention of 
CHD, there is still potential for improvement [1, 17, 21]. Being adherent is normally defined 
as having a measure of adherence (e.g. proportion of days covered (PDC) or medication 




studies have found that for medications used for cardiovascular diseases, a medication 
adherence of ≥80% is associated with fewer adverse coronary events [4].  
The medication adherence process can be divided into three separate phases: initiation, 
implementation and discontinuation. Initiation determines when the first dose is taken, 
implementation indicates to which extent patients’ actual dosing corresponds to the prescribed 
regiment and is often measured as a proportion, while discontinuation marks the last dose 
taken and thus the end of treatment [22]. Persistence is defined as the time between initiation 
and discontinuation.   
Few studies have assessed the association between medication adherence and LDL-
cholesterol and systolic and diastolic blood pressure as continuous measures. Adherence to 
LLDs, antihypertensive drugs and ASA among persistent prevalent medication users with 
CHD has also not been properly described.  
This study aims to describe medication adherence to LLDs, antihypertensive drugs and ASA 
among persons with CHD, focusing on the implementation phase of the adherence process, 
and explore its association with LDL-cholesterol serum concentrations, and systolic and 
diastolic blood pressure.  
Methods 
Data sources 
The data for this study was retrieved from the seventh wave of the Tromsø Study (Tromsø 7, 
conducted in 2015-6) and the Norwegian Prescription Database (NorPD).  
The Tromsø Study is a Norwegian population-based epidemiological health study that has 
been conducted seven times since 1974. The population of the Tromsø Study consists of 




approximately 73 000 inhabitants in 2016. Tromsø 7 invited all inhabitants in the municipality 
aged 40 years or older (n = 32,591). Attendance rate was 65% (n = 21,083).  
Data collection includes questionnaires, interviews, biological sampling, and clinical 
examinations from where we extracted blood pressure and anthropometric measurements 
(height and weight), LDL-cholesterol values, and self-reported diseases, lifestyle, and 
demographic information.  
Data from Tromsø 7 was linked with NorPD data using the unique national identity number 
assigned to all citizens in Norway. NorPD contains information on all prescriptions dispensed 
to individuals from Norwegian pharmacies. Medications given at hospitals, nursing homes, or 
over-the-counter is not included. We extracted the following variables: date of dispensing and 
information on medications dispensed, including Anatomical Therapeutic Chemical (ATC) 
code [23] and number of dosage units dispensed. Prescribed daily dosage is not available in 
NorPD and we therefore assumed a daily dosage of one dosage unit (e.g., tablet or capsule). 
Study population  
The study population consisted of participants reporting established CHD (n=1483), defined 
as previous myocardial infarction, present or previous angina pectoris, previous percutaneous 
coronary intervention or coronary artery bypass graft surgery. 
Medications included 
From NorPD, we included use of medications for secondary prevention of CHD based on the 
prevailing European clinical guidelines in 2015/2016. This included ASA, LLDs (mainly 
statins) and antihypertensive drugs (angiotensin converting enzyme (ACE) inhibitors, 
angiotensin receptor blockers (ARBs), beta-blockers, calcium channel blockers (CCBs), 
thiazides and other antihypertensives) [7]. ATC-codes for the medications included can be 
found in Online Resource 1. The number of participants using the different medication groups 





We calculated adherence to medication use as proportion of days covered (PDC), calculated 
as a continuous multiple-interval measure of medication availability (CMA) 7 in the R-
package AdhereR [24]. CMA7 is defined as “number of gap days for all event intervals 
extracted from the total time interval; (accounting for carry over from before the observation 
window and within the observation window, and excluding the supply left at the observation 
window end)” [24, 25]. The observation window was set from 365 days before the attendance 
date in Tromsø 7 until the attendance date (see Fig. 2). The follow-up window was set from 
the 1st of January 2004 until the 31st of December 2016 in order to utilize all available data 
from NorPD.  The medications supplied before the beginning of the observation window 
could then be carried over into the observation window if the days supplied extended into this 
period. Medication supplied from prescriptions filled before the end of the previous supplies 
were also carried forward to after the end of the previous days supplied. This was only done 
within the same 5th level ATC-code (chemical substance level) to avoid overestimating 
medication supplies in connection to switches of medications within the same medication 
group.  
Adherence calculations were done for persistent prevalent users, defined as participants who 
had used the medications from before the start of the observation window and had supplies 
available to cover days within 180 days before attendance in Tromsø 7. Incident and 
nonpersistent users were excluded (see Fig. 1 and 2). Incident users were defined as 
participants who had not filled any prescriptions for the relevant medications within 365 days 
before the first prescription in the observation window. These were excluded because they 
had too few dispensing of the relevant medications before attending Tromsø 7 for the 
calculated PDC to be reliable. Adherence estimations during short time intervals is found to 




window is long enough to last at least three dispensings or over 9 months [25]. In Norway, a 
typical dispensing of LLDs, antihypertensive drugs or ASA lasts about three months, hence 
four dispensings should cover one year. Nonpersistent users were defined as those not having 
any days covered with the relevant medications within 180 days before the attendance date. 
These were excluded from our analyses because discontinuation is a different step in the 
adherence process and those who discontinue treatment could therefore be different than those 
who have poor implementation [22]. In a previous study we have also considered those 
without medications dispensed within 180 days before attending Tromsø 7 as not being 
medication users at the time of attendance [26]. Our focus in the current study was thereby on 
the implementation phase within the adherence taxonomy [22].  
For users of several antihypertensive drugs and LLDs, a day was considered covered when at 
least one of the medications was available [19, 27]. See Fig. 1 for an overview of medication 
users per medication group, for subgroups see Online Resource 2.  
Measurement of LDL-cholesterol and blood pressure 
In Tromsø 7, blood pressure was measured by trained personnel using a digital automated 
device (Dinamap ProCare 300 monitor, GE Healthcare, Norway). Three measurements were 
taken with one-minute intervals and after two minutes of seated rest [12]. In the analyses, we 
used the mean of the two final measurements, except if the third measurement was missing (n 
= 2), then we only used the second measurement. If both the second and third measurement 
was missing (n = 1), we used the first measurement. Three participants did not have any blood 
pressure measurements registered and were excluded from the analyses examining blood 
pressure. Achieving the treatment goal for blood pressure was defined as having a blood 
pressure <140/90 mmHg (<140/80 mmHg in those with diabetes) [7].  
LDL-cholesterol was collected and analysed by trained personnel using enzymatic 




Mannheim, Germany) from non-fasting venous blood samples. The analysis was performed at 
the Department of Laboratory Medicine, University Hospital of North Norway, Tromsø, 
Norway (ISO certification NS-EN ISO 15189:2012) [12]. Eleven participants did not have 
any LDL-cholesterol measurements registered and were excluded from the analysis of LDL-
cholesterol. The treatment goal for LDL-cholesterol was set to <1.8 mmol/L based on the 
European guidelines from 2012 which were the prevailing guidelines at the time of Tromsø 7 
[7].  
Covariates 
Weight and height were measured with light clothing and no shoes to the nearest 0.1 
kilograms and 0.1 centimetres using the Jenix DS-102 height and weight scale (DongSahn 
Jenix, Seoul, Korea). We calculated body mass index (BMI) as weight in kilograms divided 
by height in metres squared. 
We collected variables concerning current or previous diabetes and lifestyle from 
questionnaires in Tromsø 7. Having a diagnosis of diabetes was defined as answering “yes, 
currently” or “previously, not now” when asked “Have you ever had, or do you have 
diabetes?” (answering options “no”, “yes, currently” and “previously, not now”) or reporting 
current use of antidiabetic drugs, either by reporting a brand name of an antidiabetic drug 
when asked to state the name of all medicines used regularly during the last 4 weeks, or 
checking off “now” when asked “Do you use or have you used tablets for diabetes/insulin?”. 
Participants were considered not having diabetes if they did not reply to whether they had 
diabetes and did not report using any antidiabetic drug.  
Two variables summarizing lifestyle were obtained using multidimensional scaling, computed 
with the R package vegan, applied to a multivariate dataset including variables concerning 
self-reported smoking, alcohol use, diet and physical activity. For more information about 





Descriptive statistics are presented as proportions and means with standard deviation (sd). We 
applied three multivariable linear regression models to assess the association between systolic 
and diastolic blood pressure and medication nonadherence to antihypertensive drugs, age, sex, 
lifestyle, BMI, current and previous diabetes (model i & ii) and between LDL-cholesterol and 
medication nonadherence to LLDs, age, sex, lifestyle, BMI, current and previous diabetes 
(model iii). Medication nonadherence was assessed as the adherence variables had to be 
reversed and log-transformed (1.1 – log(PDC)) in these analyses (skewness in variables). The 
analyses were done as complete case analyses, hence excluding participants with missing 
values in the relevant variables. Significance level was set to 5%.  
The analyses were conducted using R (R Core Team (2021), R: A language and environment 
for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL 
https://www.R-project.org/). 
Ethics 
The study was approved by the Regional Committee for Medical and Health Research Ethics 
of North Norway (2015/1775) and had an approved Data Protection Impact Assessment 
(DPIA) from UiT The Arctic University of Norway. All participants in the Tromsø Study 
have given written informed consent for their data to be used in research. 
Results 
Participants defined as persistent prevalent medication users were 1003 for LLDs, 1046 for 
antihypertensive drugs and 1042 for ASA (Fig. 1). The number of participants that had been 
dispensed prescriptions for all three medication groups was 701, while 113 participants had 
not had any dispensed prescriptions for any of three. Characteristics of the total study 




Medication adherence was high, with a mean PDC of ≥0.94 for all medication groups and 
subgroups (Table 2). The distribution of PDC in all medication groups is shown in Fig. 3.  
Treatment goals for both systolic and diastolic blood pressure (<140/90 mmHg, <140/80 
mmHg if diabetic) was reached for 54.7% of the antihypertensive drug users. The treatment 
goal for systolic blood pressure was reached by 56.8%, while 90.9% reached the goal for 
diastolic blood pressure. The proportion of participants reaching the blood pressure goal 
among participants with a PDC ≥0.80 (n = 963) was 55.1% compared to 49.4% among those 
with PDC <0.80 (n=83).  
For the LLD-users, the proportion reaching the treatment goal for LDL-cholesterol (<1.8 
mmol/L or <70 mg/dL) was 11.2%. The proportion of participants reaching the treatment goal 
among participants with a PDC ≥ 0.80 (n = 884) was 12.0% compared to 5.0% among those 
with a PDC < 0.80 (n = 119). 
The regression models (Table 3) show that an increased systolic blood pressure was 
significantly associated with higher age (β 0.31, p<.001), while an increased diastolic blood 
pressure was significantly associated with lower age (β -0.14, p<.001), male sex (β 0.09, 
p=.009) and lifestyle (β 0.10, p=.008). None of the blood pressure measurements were 
significantly associated with adherence to antihypertensive drug use. An increase in LDL 
cholesterol was significantly associated with nonadherence to LLDs (β 0.12, p<.001), female 
sex (β -0.12, p<.001), lifestyle (β 0.14, p<.001) and current diabetes (β -0.09, p=.009).  
The regression models indicated that the predictors explained 9.9% of the variance in systolic 
blood pressure (adjusted R2 = 0.099, F(8,930)= 13.91, p<.001), 6.3% of the variance in 
diastolic blood pressure (adjusted R2 = 0.063, F(8,930)= 8.84, p<.001) and 4.2% of the 
variance in LDL-cholesterol (adjusted R2 = 0.042, F(8,900)= 5.96, p<.001). 
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Discussion 
In this study we have identified a high medication adherence to antihypertensive drugs, lipid-
lowering drugs and acetylsalicylic acid among persons with CHD. Despite the high 
adherence, achievement of treatment goals for blood pressure and LDL-cholesterol was low. 
From the regression models, we found that adherence to LLDs was significantly associated 
with a lower LDL-cholesterol, but no significant association was identified between 
adherence to antihypertensive drugs and lower blood pressure. Sex and lifestyle were 
associated with both LDL-cholesterol and diastolic blood pressure, while age was associated 
with both systolic and diastolic blood pressure. 
Previous studies examining medication adherence to secondary prevention of CHD or 
cardiovascular disease using pharmacy dispensing data have also found high adherence for 
LLDs with mean PDC of 0.76 [28] or 79.8% having PDC ≥0.80 [17]. Also adherence to 
antihypertensive drugs is found to be high with mean PDC of 0.77 [15].  The medication 
adherence found in the present study is even higher than what has been seen in these studies. 
There could be several explanations for this. First, we have only selected persistent prevalent 
medication users to enable calculation of PDC for the whole year before attendance in 
Tromsø 7. Most previous studies have included new users in the first months or years after 
treatment initiation or included a combination of new and prevalent users. The highest 
discontinuation rates have been found to appear in the first year after treatment initiation, and 
persistent users tend to have higher adherence than those who are nonpersistent [29]. Second, 
disease severity has been associated with higher adherence, and thus we anticipate higher 
adherence to secondary prevention of CHD compared with primary prevention [28]. Third, 
NorPD covers all dispensed medications in these medication groups, irrespective of 




enables us to include all the medications that are actually available to the participants, which 
may not be the case in all other studies. Altogether, these patients seem to be highly adherent.  
Despite the low nonadherence to LLDs in this patient group, it was significantly associated 
with a higher LDL-cholesterol. This agrees with other studies showing that adherence to 
LLDs is associated with reaching the recommended treatment goals for LDL-cholesterol [17, 
18]. A Norwegian study by Munkhaugen et al also found that self-reported medication 
adherence to statins was associated with both lower LDL-cholesterol and achievement of the 
treatment goal for LDL-cholesterol [30]. Lowering LDL-cholesterol reduces the risk of a new 
coronary event [5]. In a previous study, we showed that only 9% of these participants reached 
the treatment goal of <1.8 mmol/L (<70 mg/dL) [11], which is surprising seen in the light of 
the high adherence shown in the current study. Even if more focus on the importance of 
adherence could lead to an increase in treatment goal achievement in this patient population, 
other actions such as increasing the prescribed daily dose of statins or adding ezetimibe, might 
also be necessary. In the current study we were not able to identify how much the LDL-
cholesterol had been reduced from baseline, or whether dose increase could be justified. 
Previous studies have shown a larger LDL-cholesterol reduction with more intense statin 
treatment [5, 31, 32], and a more intense treatment seems to be necessary in our population. 
However, it is important to keep in mind that higher dosages of statins are more prone to give 
side-effects, which again might negatively affect the participants’ adherence. Nocebo effects 
with statin treatment are also increasingly being recognized, further augmenting the risk of 
poor adherence and discontinuation of treatment [33, 34]. 
Neither systolic nor diastolic blood pressure were significantly affected by adherence to 
antihypertensive drugs in our analyses. This contrasts with other studies, where being 
adherent was associated with achieving blood pressure goals [15, 16, 19]. However, a 




antihypertensive drugs, based on self-report, and blood pressure control [35]. In the same 
study, increased blood pressure was found to be associated with older age and higher BMI. 
We have previously found that 42% of our study population did not reach the recommended 
blood pressure goal (140/90 mmHg or 140/80 mmHg if they also had diabetes) and that self-
reported use of antihypertensive drugs was not associated with achieving the treatment goal 
[11]. When we now have identified such a high adherence to these drugs among the persistent 
prevalent medication users in the same population, but no association with their blood 
pressure, a potential explanation could be that treatment intensity is too low. Our results also 
show the very clear association between higher age and higher blood pressure, which could be 
caused by arterial stiffening which increases with age and is associated with higher blood 
pressure [36]. It is also possible that elderly persons are not treated as intensely with 
antihypertensive drugs as those who are younger, which might be clinically sound. This has 
also been taken into account by the more recent European clinical guidelines from 2016 [8], 
contrary to the guidelines from 2012 [7] applied in this study. For patients over 60 years with 
a baseline systolic blood pressure over ≥160 mmHg, the new recommended systolic blood 
pressure goal is 140-150 mmHg. Treating hypertension in the oldest patients can be 
challenging, as they are usually more frail and more sensitive to potentially harmful side-
effects such as reduced kidney function and orthostatic hypotension, which could lead to falls. 
Although reducing blood pressure is very important in CHD patients, it might not be possible, 
or even appropriate, to bring all patients down to the recommended blood pressure goal. 
Though we have not assessed initiation and persistence in this study, Fig. 1 shows that about 
12% of the participants had no prescriptions dispensed for each of these medication groups 
throughout the whole follow-up window from 2004 until they attended Tromsø 7, indicating 
they either never had such medications prescribed, or that they never initiated treatment. Of 




discontinued antihypertensive treatment or LLDs and 13% discontinued ASA before 
attending Tromsø 7. The proportion discontinuing treatment is lower than what has been 
found in previous Nordic studies [29, 37, 38], indicating that our study population does have 
good persistence. However, those who discontinue or do not initiate treatment might have an 
even higher risk of new coronary events. It should be further investigated how to identify 
these patient groups and assessed whether a closer treatment follow-up is warranted. 
Strengths and limitations 
A strength of this study was the use of two reliable data sources; the Tromsø Study, a reliable 
population-based data source with high attendance rate, where measurements of blood 
pressure and cholesterol were performed by trained personnel using standardized procedures 
and instruments, and NorPD, which includes information about all dispensings from 
Norwegian pharmacies. Using a follow-up window from 2004, when NorPD was established, 
enabled us to capture as many days covered with medication supplies as possible in the 
observation window, and hence estimate how much medication the participants had available 
during the observation window. Furthermore, the medications studied herein are prescription-
only medications, we should therefore have captured all medications available to the 
participants. However, as we did not have any information about potential hospital stays, and 
medications dispensed to patients in hospitals are not included in NorPD, this could 
potentially lead to a slight underestimation of PDC.  
One limitation is that we did not have information about prescribed daily dose as this is not 
available in NorPD. We therefore assumed a daily dose of one dosage unit. As most 
medications used for secondary prevention of coronary heart disease are taken once daily this 
is a fair assumption, though some medications, particularly some antihypertensives, might 
have a higher daily dosage (units per day), and this would lead us to overestimate the PDC. 




that a daily dose of one dosage unit a day was a more accurate assumption than one defined 
daily dose (DDD) a day, which would have been the alternative [26]. 
As in other studies evaluating refill adherence, we cannot determine that having had the 
medications dispensed actually means that they have been consumed by the participants. We 
can however be quite certain that these medications are considered in use by the participants, 
as previously shown in the validation study [26].  
Finally, and perhaps most importantly, the proportions of variance in LDL-cholesterol, and in 
systolic and diastolic blood pressure, explained by our models were low (4.2-9.9%), 
indicating that other factors also contribute to the observed variance. As this is an 
observational study, our results might also have been influenced by unmeasured confounders.   
Conclusion 
Adherence to lipid-lowering drugs, antihypertensive drugs and acetylsalicylic acid among 
persons with coronary heart disease was high despite low achievement of treatment goals for 
blood pressure and LDL-cholesterol. Adherence to lipid-lowering drugs was significantly 
associated with lower LDL-cholesterol, while adherence to antihypertensive drugs was not 
significantly associated with either systolic or diastolic blood pressure. This suggests that 
these participants might not receive optimal medication treatment, and that perhaps dosages, 
or number or combinations of medications are insufficient. More research is needed to 
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Figure legends  
Fig. 1  Flowchart of medication users 
Fig. 2 Defining proportion of days covered for prevalent medication users 
Treatment period durations were defined by the number of medication units (e.g. tablets) 
dispensed at each treatment fill (dots). PDC was calculated for prevalent users based on 
treatment durations during the observation window (green). The mid panel shows one 
participant with 50 % adherence and one with perfect adherence according to PDC. Incident 
users (top) and nonpersistent users (bottom) were excluded 
Abbreviations: PDC, proportion of days covered 
Fig. 3 Distributions of proportion of days covered 





Table 1: Characteristics of the study population and the different subgroups 
  Study 
population 
n = 1483 
Users of  
lipid-lowering 
drugs 








n = 1042 
Age (years), mean (sd) 68.7 (10.8) 69.5 (9.6) 70.7 (9.8) 69.7 (9.7) 
Sex, n (%)         
 Male 1037 (69.9) 730 (72.8) 730 (69.8) 765 (73.4) 
BMI (kg/m2), mean (sd) 28.4 (4.5) 28.4 (4.3) 28.7 (4.5) 28.4 (4.3) 
Diabetes, n (%)         
 Current 204 (11.1) 160 (16.0) 172 (16.4) 158 (15.2) 
 Previous 21 (1.4) 14 (1.4) 15 (1.4) 11 (1.1) 
LDL-cholesterol (mmol/L), mean (sd) 2.9 (1.0) 2.6 (0.8) 2.7 (0.9) 2.7 (0.9) 
Systolic blood pressure (mmHg), mean (sd) 135.9 (20.9) 136.5 (20.7) 137.1 (21.1) 136.6 (20.4) 
Diastolic blood pressure (mmHg), mean (sd) 74.4 (9.9) 74.3 (9.7) 73.8 (9.7) 74.2 (9.8) 






Table 2: Adherence to antihypertensive drugs, lipid-lowering drugs, acetylsalicylic 
acid and subgroups 
  PDC, mean (sd) Proportion of 
participants with 
PDC ≥0.80, n (%) 
Antihypertensive drugs (n = 1046) 0.94 (0.10) 963 (92.1) 
 ACE-inhibitor (n = 215) 0.98 (0.07) 208 (96.7) 
 ARB (n = 371) 0.96 (0.10) 348 (93.8) 
 Beta-blocker (n = 759) 0.96 (0.10) 708 (93.3) 
 CCB (n = 269) 0.97 (0.08) 259 (96.3) 
 Thiazide (n = 229) 0.95 (0.12) 205 (89.5) 
Lipid-lowering drugs (n = 1003) 0.94 (0.12) 884 (88.1) 
 Statin (n = 987) 0.94 (0.12) 869 (88.0) 
Acetylsalicylic acid (n = 1042) 0.97 (0.08) 992 (95.2) 
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Medication adherence among persons with coronary 
heart disease and associations with blood pressure and 
low-density-lipoprotein-cholesterol 
Elisabeth Pedersena,*, Raul Primicerioa,b, Kjell H. Halvorsena, Anne Elise Eggenc, Beate Hennie 
Garciaa, Henrik Schirmerd,e, Marit Waasetha  
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dDepartment of Cardiology, Akershus University Hospital, Lørenskog, Norway 
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Content: 
1. Online resource 1: Overview of ATC-codes included in the three medication
categories
2. Online resource 2: Flowchart of medication users within medication subgroups
3. Online resource 3: Explanation for making and interpreting the lifestyle variables
Supplementary table 1: Overview of ATC-codes included in the three medication categories 
Medication ATC-codes 
Acetylsalicylic acid 
Acetylsalicylic acid B01AC06 
Lipid lowering drugs 
Statins C10AA, C10BA 
Other lipid lowering drugs C10AC, C10AX, C10 
Antihypertensive drugs 
ACE inhibitors C09A, C09B  
ARBs C09C, C09D 
Beta-blockers C07 
CCBs C08, C09BB, C09DB, C09DX01, C09DX03 
Thiazides C03A, C03EA, C07B, C09BA, C09DA, C09DX01, C09DX03 
Other antihypertensives C02, C03C, C03D, C03EA, C03X  
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; ATC, anatomical therapeutic chemical; CCB, 
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Supplementary 3: Lifestyle variables 
Explanation for making and interpreting the lifestyle variables:  
We constructed two variables containing a gradient of lifestyle including ordinal variables on 
alcohol consumption, smoking, diet and physical activity (see table below).  
The variables were made in R using the package “vegan” (see R code below). First the 
dissimilarity in the original variables were calculated using gower distance which is the 
preferred choice for heterogeneous variables. This distance matrix was then used to identify 
four clusters using hierarchical clustering. Next, multidimensional scaling was preformed on 
the distance matrix made earlier, giving the sets of points with distances equaling the 
dissimilarities in the different variables used (alcohol consumption, smoking, diet and 
physical activity, see table below). The points from the multidimensional scaling were saved 
as the two lifestyle variables used in further analyses. 
The points from the multidimensional scaling with colors indicating the clusters identified are 
shown in the figure below. To show the correlation with age, red isolines of age is added onto 
the plot. To see which of the original variables contribute to the dissimilarities in lifestyle we 
conducted a correspondence analysis as shown in the second plot in the figure. This shows 
that lifestyle variable 1 is influenced by especially alcohol consumption, but also consumption 
of read meat and smoking, so the participants represented by the blue and red colored clusters 
have a higher consumption of alcohol and red meat and are more likely to be smokers, while 
the opposite is shown for those in the green and orange clusters. Lifestyle variable 2 appears 
to be more influenced by intake of cod liver oil or omega 3, where those in the green and 
orange clusters more often take cod liver oil or omega 3.  
Figure: Plots of the first two dimensions of the multidimensional scaling analyses (left) and the correspondence analysis 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































#Including relevant variables  
Lifest<-pred_ext[,c(7, 31:36, 38:41, 43)] 
colnames(Lifest) <- c('AGE', 'ALCOHOL_FREQUENCY', 'ALCOHOL_UNITS', 
'ALCOHOL_6UNITS_FREQUENCY', 'SMOKING', 'SNUFF_CHEWING_TOBACCO', 
'OMEGA3', 'RED_MEAT', 'FRUIT_VEGETABLES', 'LEAN_FISH', 'FAT_FISH', 
'EXERCISE') 












#Running and plotting correspondence analysis to determine which variables contribute to the 
#lifestyle variables 
Lifest.ca<-cca(na.omit(Lifest[,-1])) 
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Vil du være med i 
Tromsøundersøkelsen?
Hva er Tromsøundersøkelsen?
Tromsøundersøkelsen er en folkehelseundersøkelse. 
Formålet er å samle inn opplysninger til forskning som 
gir økt kunnskap om helse og sykdom, og hvordan folke-
helsen kan forbedres gjennom forebygging og behandling. 
Tromsøundersøkelsen startet i 1974 med bakgrunn i den 
høye forekomsten av hjerte -og karsykdom i Nord-Norge. 
Siden den gang er undersøkelsen gjennomført med  
6-7 års mellomrom og dette er den sjuende runden. 
Ved å delta bidrar du til viktig forskning om forekomst, 
forebygging og behandling av sykdom, hva som fremmer 
god helse, og hva som er årsak til helseproblemer.
Ditt bidrag teller!
Forespørsel  
om deltakelse i 
Tromsøundersøkelsen
Hvorfor spør vi deg? 
Alle innbyggere i Tromsø kommune fra 40 år og oppover 
spørres om å delta. I tillegg inviterer vi ca.1000 personer i 
alderen 21-25 år. Hver deltaker er like viktig, enten du er 
ung eller gammel, frisk eller syk. 
Sammen med denne informasjonsbrosjyren finner du en 
invitasjon med praktiske opplysninger om undersøkelsen.
 
Det er gratis å delta i Tromsøundersøkelsen. Trenger du 
videre undersøkelse eller oppfølging av fastlegen eller  
spesialisthelsetjenesten, betaler du vanlig egenandel.
 
Slik foregår undersøkelsen
Alle deltakere inviteres til en hovedundersøkelse som 
omfatter spørreskjema, intervju, blodprøver og under- 
søkelser. Et helt tilfeldig utvalg av deltakere inviteres  
tilbake til en spesialundersøkelse som omfatter flere  
prøver og mer omfattende undersøkelser. Alle under- 
søkelsene gjennomføres av helsepersonell.
Tilbakemelding
Noen uker etter undersøkelsen får du et brev med noen 
resultater, det vil si høyde, vekt, BMI, hemoglobin, blod-
trykk, kolesterolnivå og om du har diabetes. Det gis ikke 
rutinemessig tilbakemelding om resultater av andre blod-
prøver eller målinger. Dersom prøveresultatet viser at det 
er nødvendig med oppfølging av lege eller henvisning til 
spesialist, vil du få råd om det. Ved behov for henvisning 
til spesialist, sørger vi for å sende henvisning. 
 
Du kan reservere deg mot å få vite resultatene av prøvene 
dine. Men hvis et prøveresultat krever rask legebehandling, 
vil du likevel bli kontaktet.
Du vil også få informasjon om undersøkelsen underveis 
gjennom aviser, sosiale medier (Facebook, Twitter m.m) 
samt på arrangementer som “Lørdagsuniversitetet” og 
“Forskningsdagene”.
Frivillig deltakelse
Det er frivillig å delta i Tromsøundersøkelsen.  
Om du sier ja til å delta, kan du når som helst trekke 
tilbake samtykket.
Hva er Tromsøundersøkelsen?
Tromsøundersøkelsen er en folkehelseundersøkelse. 
Formålet er å samle inn opplysninger til forskning som 
gir økt kunnskap om helse og sykdom, og hvordan folke-
helsen kan forbedres gjennom forebygging og behandling. 
Tromsøundersøkelsen startet i 1974 med bakgrunn i den 
høye forekomsten av hjerte -og karsykdom i Nord-Norge. 
Siden den gang er undersøkelsen gjennomført med  
6-7 års mellomrom og dette er den sjuende runden. 
Ved å delta bidrar du til viktig forskning om forekomst, 
forebygging og behandling av sykdom, hva som fremmer 
god helse, og hva som er årsak til helseproblemer.
Ditt bidrag teller!
Forespørsel  
om deltakelse i 
Tromsøundersøkelsen
Hvorfor spør vi deg? 
Alle innbyggere i Tromsø kommune fra 40 år og oppover 
spørres om å delta. I tillegg inviterer vi ca.1000 personer i 
alderen 21-25 år. Hver deltaker er like viktig, enten du er 
ung eller gammel, frisk eller syk. 
Sammen med denne informasjonsbrosjyren finner du en 
invitasjon med praktiske opplysninger om undersøkelsen.
 
Det er gratis å delta i Tromsøundersøkelsen. Trenger du 
videre undersøkelse eller oppfølging av fastlegen eller  
spesialisthelsetjenesten, betaler du vanlig egenandel.
 
Slik foregår undersøkelsen
Alle deltakere inviteres til en hovedundersøkelse som 
omfatter spørreskjema, intervju, blodprøver og under- 
søkelser. Et helt tilfeldig utvalg av deltakere inviteres  
tilbake til en spesialundersøkelse som omfatter flere  
prøver og mer omfattende undersøkelser. Alle under- 
søkelsene gjennomføres av helsepersonell.
Tilbakemelding
Noen uker etter undersøkelsen får du et brev med noen 
resultater, det vil si høyde, vekt, BMI, hemoglobin, blod-
trykk, kolesterolnivå og om du har diabetes. Det gis ikke 
rutinemessig tilbakemelding om resultater av andre blod-
prøver eller målinger. Dersom prøveresultatet viser at det 
er nødvendig med oppfølging av lege eller henvisning til 
spesialist, vil du få råd om det. Ved behov for henvisning 
til spesialist, sørger vi for å sende henvisning. 
 
Du kan reservere deg mot å få vite resultatene av prøvene 
dine. Men hvis et prøveresultat krever rask legebehandling, 
vil du likevel bli kontaktet.
Du vil også få informasjon om undersøkelsen underveis 
gjennom aviser, sosiale medier (Facebook, Twitter m.m) 
samt på arrangementer som “Lørdagsuniversitetet” og 
“Forskningsdagene”.
Frivillig deltakelse
Det er frivillig å delta i Tromsøundersøkelsen.  
Om du sier ja til å delta, kan du når som helst trekke 
tilbake samtykket.
Hva omfatter den sjuende 
Tromsøundersøkelsen?
Spørreskjema 
Deltakernes informasjon om egen helse er en svært viktig del av Tromsø- 
undersøkelsen. Vi ber deg derfor fylle ut to spørreskjema. Alle spørsmål  
kan besvares på nett. Det ene skjemaet er vedlagt i papirform, hvis du  
foretrekker det. Fyll det gjerne ut før du møter opp så sparer du tid under 
undersøkelsen. Hvis du trenger assistanse vil personalet hjelpe deg på 
undersøkelsen hvor det også er satt opp egne datamaskiner til dette.
Utfylte svar i spørreskjema er like viktig for forskningen som resultater  
fra blodprøver og kliniske undersøkelser.
Du kan delta på Tromsøundersøkelsen selv om du ikke ønsker å være  
med på alle deler av undersøkelsen.
Hva skal vi forske på? 
I denne runden av Tromsøundersøkelsen er det mer enn 50 prosjekter  
som skal forske på forekomst, forebygging og behandling av  
folkehelseproblemer.
 
Det skal blant annet forskes på hjerte- og karsykdommer, kreft, lunge- 
sykdommer, aldring og demens, fedme, diabetes, legemiddelbruk, psykisk 
helse, kronisk smerte, tannhelse, muskel- og skjelettplager, risikofaktorer 
som alkohol, fysisk aktivitet og kosthold, nyrer og urinveier, hudproblemer, 
miljøgifter, infeksjoner og antibiotikaresistens, nervesystemet, sosial ulikhet, 
samspill mellom arv og miljø, søvn og bruk av helsetjenester. 
Du finner mer informasjon om forskningen på vår internettside,  
www.tromsoundersokelsen.no
Hovedundersøkelsen  
Helsepersonell veileder deg gjennom  
undersøkelsen som varer ca. en time hvis  
du har fylt ut spørreskjemaene på forhånd.  
Du får også time til spesialundersøkelsen  
hvis du er valgt ut til denne.
Vi starter med noen enkle spørsmål knyttet  
til undersøkelsene du skal gjennomføre.  
Videre måler vi høyde, vekt, hofte- og livvidde, 
blodtrykk og puls. 
Det tas deretter prøver og gjøres noen  
kliniske undersøkelser: 
Blodprøve. Det tas blodprøver til bruk for 
forskning som samlet er mye mindre enn det  
en blodgiver gir. Det fryses ned prøver til bruk  
for senere analyser og forskning. Arvestoff  
(DNA/RNA) vil bli lagret til bruk for forskning.
Bakterieprøve fra nese og hals for å se etter  
gule stafylokokker, en bakterie som normalt  
finnes på hud og slimhinner hos mennesker, 
men som i enkelte tilfeller kan forårsake alvorlige 
infeksjoner. Prøvene tas med en fuktet vattpensel.
Spyttprøver til bruk for forskning knyttet til  
tannhelse, virusinfeksjon og kreft. 
Smertefølsomhet måles med to metoder.  
Først holder du hånden i kaldt vann i opptil 90 
sekunder,deretter får du en blodtrykksmansjett 
plassert rundt leggen som blåses opp. Underveis 
angir du hvor mye smerte du opplever, og kan 
avbryte testene når som helst hvis det blir for 
ubehagelig. 
Tannsjekk som omfatter et røntgenbilde av 
kjeven, registrering av hull i tennene og 
betennelsessykdom i tannkjøttet.
Fysisk aktivitet og kosthold. Utvalgte deltakere  
blir bedt om å registrere fysisk aktivitet ved bruk  
av aktivitetsmåler og registrering av kosthold i  
en periode. 
 
Du får også utdelt utstyr for innlevering av  
urin- og avføringsprøve hvis du er valgt ut til 
spesialundersøkelsen.
Spesialundersøkelsen
Et tilfeldig utvalg av deltakere inviteres til  
spesialundersøkelsen som gjennomføres noen 
uker etter hovedundersøkelsen. Denne varer 
totalt ca. 2 timer, avhengig av hvor mange  
deler du blir spurt om å være med på.
 
Ved oppmøte vil urinprøvene samles inn, og det tas 
noen nye blodprøver. Deler av blodprøvene fryses 
ned for senere forskning beskrevet i denne brosjyren.
 
Videre inviteres du til én eller flere av disse 
undersøkelsene:
EKG er en registrering av hjerterytmen  
som også kan gi informasjon om hjertesykdom.  
Ved registrering festes ledninger til kroppen. 
 
Kognitiv funksjon testes ved hjelp av enkle  
spørsmål knyttet til gjenkjenning av ord, kopling  
av symboler og tall samt grad av fingerbevegelighet.
Fysisk funksjon undersøkes ved å teste balanse,  
gange og gripestyrke. 
Ultralyd av halspulsåre gjøres for å se etter  
forkalkninger og innsnevringer av årene. Under- 
søkelsen kartlegger også blodforsyningen til hjernen.
Fotografering av øyebunnen gir bilder som både  
sier noe om synet og om tilstanden til blodkarene i 
kroppen. Det gis en øyendråpe i hvert øye en tid før 
fotografering for at pupillene skal utvide seg. Dette 
kan svi noe og synet kan forbigående bli noe uklart. 
Effekten går gradvis over, og er borte etter en time. 
I tillegg gjøres det en enkel synstest som du får svar 
på umiddelbart. 
Lungefunksjonen testes ved at du puster så hardt 
du klarer gjennom et munnstykke. Hvor mye  
luft som blåses ut pr. sekund, er et mål på lunge- 
funksjonen din. I tillegg vil det gjøres lydopptak  
av lungelyder og hjertelyder. 
Måling av beintetthet. Ved hjelp av ultralyd foretas 
det beintetthetsmåling som brukes til å undersøke 
risiko for beinskjørhet og brudd. 
Ultralyd av hjertet gjøres for å undersøke hjertets  
form og funksjon.
Hva omfatter den sjuende 
Tromsøundersøkelsen?
Spørreskjema 
Deltakernes informasjon om egen helse er en svært viktig del av Tromsø- 
undersøkelsen. Vi ber deg derfor fylle ut to spørreskjema. Alle spørsmål  
kan besvares på nett. Det ene skjemaet er vedlagt i papirform, hvis du  
foretrekker det. Fyll det gjerne ut før du møter opp så sparer du tid under 
undersøkelsen. Hvis du trenger assistanse vil personalet hjelpe deg på 
undersøkelsen hvor det også er satt opp egne datamaskiner til dette.
Utfylte svar i spørreskjema er like viktig for forskningen som resultater  
fra blodprøver og kliniske undersøkelser.
Du kan delta på Tromsøundersøkelsen selv om du ikke ønsker å være  
med på alle deler av undersøkelsen.
Hva skal vi forske på? 
I denne runden av Tromsøundersøkelsen er det mer enn 50 prosjekter  
som skal forske på forekomst, forebygging og behandling av  
folkehelseproblemer.
 
Det skal blant annet forskes på hjerte- og karsykdommer, kreft, lunge- 
sykdommer, aldring og demens, fedme, diabetes, legemiddelbruk, psykisk 
helse, kronisk smerte, tannhelse, muskel- og skjelettplager, risikofaktorer 
som alkohol, fysisk aktivitet og kosthold, nyrer og urinveier, hudproblemer, 
miljøgifter, infeksjoner og antibiotikaresistens, nervesystemet, sosial ulikhet, 
samspill mellom arv og miljø, søvn og bruk av helsetjenester. 
Du finner mer informasjon om forskningen på vår internettside,  
www.tromsoundersokelsen.no
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Helsepersonell veileder deg gjennom  
undersøkelsen som varer ca. en time hvis  
du har fylt ut spørreskjemaene på forhånd.  
Du får også time til spesialundersøkelsen  
hvis du er valgt ut til denne.
Vi starter med noen enkle spørsmål knyttet  
til undersøkelsene du skal gjennomføre.  
Videre måler vi høyde, vekt, hofte- og livvidde, 
blodtrykk og puls. 
Det tas deretter prøver og gjøres noen  
kliniske undersøkelser: 
Blodprøve. Det tas blodprøver til bruk for 
forskning som samlet er mye mindre enn det  
en blodgiver gir. Det fryses ned prøver til bruk  
for senere analyser og forskning. Arvestoff  
(DNA/RNA) vil bli lagret til bruk for forskning.
Bakterieprøve fra nese og hals for å se etter  
gule stafylokokker, en bakterie som normalt  
finnes på hud og slimhinner hos mennesker, 
men som i enkelte tilfeller kan forårsake alvorlige 
infeksjoner. Prøvene tas med en fuktet vattpensel.
Spyttprøver til bruk for forskning knyttet til  
tannhelse, virusinfeksjon og kreft. 
Smertefølsomhet måles med to metoder.  
Først holder du hånden i kaldt vann i opptil 90 
sekunder,deretter får du en blodtrykksmansjett 
plassert rundt leggen som blåses opp. Underveis 
angir du hvor mye smerte du opplever, og kan 
avbryte testene når som helst hvis det blir for 
ubehagelig. 
Tannsjekk som omfatter et røntgenbilde av 
kjeven, registrering av hull i tennene og 
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Fysisk aktivitet og kosthold. Utvalgte deltakere  
blir bedt om å registrere fysisk aktivitet ved bruk  
av aktivitetsmåler og registrering av kosthold i  
en periode. 
 
Du får også utdelt utstyr for innlevering av  
urin- og avføringsprøve hvis du er valgt ut til 
spesialundersøkelsen.
Spesialundersøkelsen
Et tilfeldig utvalg av deltakere inviteres til  
spesialundersøkelsen som gjennomføres noen 
uker etter hovedundersøkelsen. Denne varer 
totalt ca. 2 timer, avhengig av hvor mange  
deler du blir spurt om å være med på.
 
Ved oppmøte vil urinprøvene samles inn, og det tas 
noen nye blodprøver. Deler av blodprøvene fryses 
ned for senere forskning beskrevet i denne brosjyren.
 
Videre inviteres du til én eller flere av disse 
undersøkelsene:
EKG er en registrering av hjerterytmen  
som også kan gi informasjon om hjertesykdom.  
Ved registrering festes ledninger til kroppen. 
 
Kognitiv funksjon testes ved hjelp av enkle  
spørsmål knyttet til gjenkjenning av ord, kopling  
av symboler og tall samt grad av fingerbevegelighet.
Fysisk funksjon undersøkes ved å teste balanse,  
gange og gripestyrke. 
Ultralyd av halspulsåre gjøres for å se etter  
forkalkninger og innsnevringer av årene. Under- 
søkelsen kartlegger også blodforsyningen til hjernen.
Fotografering av øyebunnen gir bilder som både  
sier noe om synet og om tilstanden til blodkarene i 
kroppen. Det gis en øyendråpe i hvert øye en tid før 
fotografering for at pupillene skal utvide seg. Dette 
kan svi noe og synet kan forbigående bli noe uklart. 
Effekten går gradvis over, og er borte etter en time. 
I tillegg gjøres det en enkel synstest som du får svar 
på umiddelbart. 
Lungefunksjonen testes ved at du puster så hardt 
du klarer gjennom et munnstykke. Hvor mye  
luft som blåses ut pr. sekund, er et mål på lunge- 
funksjonen din. I tillegg vil det gjøres lydopptak  
av lungelyder og hjertelyder. 
Måling av beintetthet. Ved hjelp av ultralyd foretas 
det beintetthetsmåling som brukes til å undersøke 
risiko for beinskjørhet og brudd. 
Ultralyd av hjertet gjøres for å undersøke hjertets  
form og funksjon.
Personvern 
All informasjon du gir til Tromsøundersøkelsen 
behandles med respekt for personvern og privat-
liv, og i samsvar med lover og forskrifter.  
Alle medarbeidere som jobber med undersøkel-
sen har taushetsplikt. Opplysningene som samles 
inn skal bare brukes til godkjente forsknings- 
formål. Det vil ikke være mulig å identifisere  
deg når resultatene av forskningen publiseres.
 
UiT Norges arktiske universitet ved universitets-
direktøren er ansvarlig for behandlingen av  
personopplysninger. Tromsøundersøkelsen har 
konsesjon fra Datatilsynet. Regional komité for 
medisinsk og helsefaglig forskningsetikk i Nord-
Norge (REK nord) har gjort en etisk og helsefag-
lig vurdering av undersøkelsene som gjennom- 
føres, samt godkjent innsamlingen av prøver.
Hvilke data lagres i 
Tromsøundersøkelsen?
I Tromsøundersøkelsen lagres opplysninger 
gitt av deltakere i de forskjellige rundene av 
Tromsøundersøkelsen. Det lagres også opplys-
ninger om kreftdiagnoser og dødsårsaker fra 
Kreftregisteret og Dødsårsaksregisteret.  
For deltakere som har eller får diagnoser innen 
hjerte- og karsykdom, diabetes og beinbrudd, 
innhentes opplysninger fra sykejournalen i spesi-
alist- og primærhelsetjenesten som er nødvendig 
for å kvalitetssikre aktuelle diagnoser. Dette for 
å sikre forskning av høy kvalitet. Tilsvarende vil 
også kunne bli aktuelt for andre sykdommer det 
forskes på i Tromsøundersøkelsen. 
Hvordan lagres dine  
opplysninger og prøver?
Alle opplysningene og prøvene lagres uten navn 
og fødselsnummer. 
En kode knytter deg til dine opplysninger og 
prøver. Det er kun noen få autoriserte personer 
som kan finne tilbake til deg gjennom en egen 
kodenøkkel. 
 
De biologiske prøvene lagres i godkjent 
forskningsbiobank ved Institutt for samfunns-
medisin, UiT. Leder av Tromsøundersøkelsen 
er ansvarlig for biobanken. Den er registrert i 
Folkehelseinstituttets Biobankregister (nr 2397). 
Det biologiske materialet kan bare brukes etter 
godkjenning fra REK. 
Utlevering av opplysninger  
og prøver til forskere
Hvis du sier ja til å delta i studien, samtykker  
du til at dine opplysninger og prøver kan  
brukes videre i forskning på ubestemt tid.  
Medisinsk forskning forandrer seg hele tiden,  
og i fremtiden kan data bli brukt i forsknings-
prosjekter forutsatt at det er i samsvar med 
gjeldende lover og forskrifter.
Alle forskningsprosjekter som får data fra  
Tromsøundersøkelsen må være i samsvar med 
lover og forskrifter. Prosjektleder må tilhøre en 
kompetent forskningsinstitusjon. Den enkelte 
forsker vil kun få tilgang til personidentifiserende 
opplysninger etter å ha innhentet nødvendige 
godkjenninger fra REK, og/eller Datatilsynet. 
I noen forskningsprosjekter kan prøver og  
avidentifiserte opplysninger bli utlevert til andre 
land. Det vil skje i en slik form at våre utenlandske 
samarbeidspartnere ikke kan knytte prøvene opp 
mot deg som person.
 
I noen prosjekter kan det bli aktuelt å kontakte  
deg igjen for å samle inn flere data, f.eks. ved  
spørreskjema, intervju eller kliniske undersøkelser. 
Du vil da få ny informasjon og bes om nytt  
samtykke til det konkrete prosjektet. 
Videre bruk av opplysninger  
og prøver i forskning
Sammenstilling med  
andre registre 
I noen forskningsprosjekter vil opplysninger  
om deg kunne bli sammenstilt med: 
 
Opplysninger du har gitt i tidligere runder  
av Tromsøundersøkelsen hvis du har deltatt  
i Tromsøundersøkelsen før.  
 
Opplysninger fra barn, søsken, foreldre og beste-
foreldre som har deltatt i Tromsøundersøkelsen. 
Opplysninger om deg i nasjonale helseregistre 
som Reseptregisteret, Medisinsk fødselsregister, 
Kreftregisteret, Norsk pasientregister, Hjerte-  
og karregisteret, Dødsårsaksregisteret,  
infeksjonsregistre og andre nasjonale  
sykdoms- og kvalitetsregistre. 
Helseopplysninger om deg fra primær- og  
spesialisthelsetjenesten.  
Opplysninger om sosiale forhold som arbeid, 
utdanning, inntekt, boforhold osv. fra registre 
hos bl.a. Statistisk sentralbyrå og NAV. 
Slike sammenstillinger krever som regel  
forhåndsgodkjenning av offentlige instanser,  
som REK og/eller Datatilsynet. 
Rett til innsyn og sletting av dine 
opplysninger og prøver 
Hvis du sier ja til å delta i studien, har du rett  
til å få innsyn i hvilke opplysninger som er  
registrert om deg. Du har også rett til å få  
korrigert eventuelle feil i opplysningene vi har 
registrert. Dersom du trekker deg fra studien, 
kan du kreve å få slettet innsamlede prøver  
og opplysninger, med mindre opplysningene 
allerede er inngått i analyser eller er brukt i  
vitenskapelige artikler.
Finansiering
Tromsøundersøkelsen er finansiert av  
UiT Norges arktiske universitet, Helse Nord 
RHF, Universitetssykehuset Nord-Norge (UNN)  
samt ulike forskningsfond.
Forsikring
Deltakere i Tromsøundersøkelsen er forsikret 
gjennom Norsk Pasientskadeerstatning.
Samtykke til deltakelse i studien
Hvis du vil delta i den sjuende Tromsø-
undersøkelsen, må du gi skriftlig samtykke  
ved oppmøte. Personalet vil gi mer informasjon 
og svare deg dersom du har spørsmål i forbindelse 
med samtykket. 
Du kan når som helst trekke tilbake  
samtykket ditt.
Ved å delta i Tromsøundersøkelsen bidrar du til viktig forskning på sykdom 
og helse, oppbygging av fagmiljøer og bedre pasientbehandling.
Personvern 
All informasjon du gir til Tromsøundersøkelsen 
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liv, og i samsvar med lover og forskrifter.  
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Tromsøundersøkelsen. Det lagres også opplys-
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For deltakere som har eller får diagnoser innen 
hjerte- og karsykdom, diabetes og beinbrudd, 
innhentes opplysninger fra sykejournalen i spesi-
alist- og primærhelsetjenesten som er nødvendig 
for å kvalitetssikre aktuelle diagnoser. Dette for 
å sikre forskning av høy kvalitet. Tilsvarende vil 
også kunne bli aktuelt for andre sykdommer det 
forskes på i Tromsøundersøkelsen. 
Hvordan lagres dine  
opplysninger og prøver?
Alle opplysningene og prøvene lagres uten navn 
og fødselsnummer. 
En kode knytter deg til dine opplysninger og 
prøver. Det er kun noen få autoriserte personer 
som kan finne tilbake til deg gjennom en egen 
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medisin, UiT. Leder av Tromsøundersøkelsen 
er ansvarlig for biobanken. Den er registrert i 
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Det biologiske materialet kan bare brukes etter 
godkjenning fra REK. 
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prosjekter forutsatt at det er i samsvar med 
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lover og forskrifter. Prosjektleder må tilhøre en 
kompetent forskningsinstitusjon. Den enkelte 
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opplysninger etter å ha innhentet nødvendige 
godkjenninger fra REK, og/eller Datatilsynet. 
I noen forskningsprosjekter kan prøver og  
avidentifiserte opplysninger bli utlevert til andre 
land. Det vil skje i en slik form at våre utenlandske 
samarbeidspartnere ikke kan knytte prøvene opp 
mot deg som person.
 
I noen prosjekter kan det bli aktuelt å kontakte  
deg igjen for å samle inn flere data, f.eks. ved  
spørreskjema, intervju eller kliniske undersøkelser. 
Du vil da få ny informasjon og bes om nytt  
samtykke til det konkrete prosjektet. 
Videre bruk av opplysninger  
og prøver i forskning
Sammenstilling med  
andre registre 
I noen forskningsprosjekter vil opplysninger  
om deg kunne bli sammenstilt med: 
 
Opplysninger du har gitt i tidligere runder  
av Tromsøundersøkelsen hvis du har deltatt  
i Tromsøundersøkelsen før.  
 
Opplysninger fra barn, søsken, foreldre og beste-
foreldre som har deltatt i Tromsøundersøkelsen. 
Opplysninger om deg i nasjonale helseregistre 
som Reseptregisteret, Medisinsk fødselsregister, 
Kreftregisteret, Norsk pasientregister, Hjerte-  
og karregisteret, Dødsårsaksregisteret,  
infeksjonsregistre og andre nasjonale  
sykdoms- og kvalitetsregistre. 
Helseopplysninger om deg fra primær- og  
spesialisthelsetjenesten.  
Opplysninger om sosiale forhold som arbeid, 
utdanning, inntekt, boforhold osv. fra registre 
hos bl.a. Statistisk sentralbyrå og NAV. 
Slike sammenstillinger krever som regel  
forhåndsgodkjenning av offentlige instanser,  
som REK og/eller Datatilsynet. 
Rett til innsyn og sletting av dine 
opplysninger og prøver 
Hvis du sier ja til å delta i studien, har du rett  
til å få innsyn i hvilke opplysninger som er  
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1. HEALTH AND DISEASES
1.1  How do you in general consider your health to be?
Excellent Good
Neither  
good nor bad Bad Very bad
c c c c c
1.2  How is your health now compared to others of your age?
Excellent Good
Neither  
good nor bad Bad Very bad
c c c c c
1.3  Have you ever had, or do you have?  








High blood pressure  ...................................... c c c
Heart attack  ............................................................... c c
Heart failure  .............................................................. c c c
Atrial fibrillation  ................................................... c c c
Angina pectoris (heart cramp)  .......... c c c
Cerebral stroke /  
brain haemorrhage   ........................................ c c
Diabetes  ......................................................................... c c c
Kidney disease, not including  
urinary tract infection (UTI)  ................... c c c
Bronchitis / emphysema / COPD  ....... c c c
Asthma  ............................................................................. c c c
Cancer  ............................................................................... c c c
Rheumatoid Arthritis ..................................... c c c
Arthrosis  ......................................................................... c c c
Migraine  ......................................................................... c c c
Psychological problems for which 
you have sought help  .................................. c c c
1.4  Do you have persistent or constantly recurring pain that has 
lasted for three months or more?
c No c Yes
2. DENTAL HEALTH
2.1  How do you consider your own dental health to be? 
1 2 3 4 5
Very bad c c c c c Excellent
2.2  How satisfied or dissatisfied are you with your teeth or denture? 
Very  
dissatisfied
1 2 3 4 5 Very 
satisfiedc c c c c
3. USE OF HEALTH SERVICES




General practitioner (GP)  ............................................................................ c c
Emergency room  ................................................................................................... c c
Psychiatrist / Psychologist  ........................................................................... c c
Another medical specialist than a general  
practitioner (GP) or a psychologist or  
psychiatrist (not at a hospital)  ............................................................... c c
Dentist / dental services  ................................................................................ c c
Pharmacy (to buy / get advice about medicines /  
treatment)  ........................................................................................................................ c c
Physiotherapist  ........................................................................................................ c c
Chiropractor  ................................................................................................................. c c
Acupuncturist  ............................................................................................................ c c
CAM provider (homeopath, reflexologist, spiritual 
healer etc.)  ....................................................................................................................... c c
Traditional healer (helper, “reader” etc.)  .................................... c c
Have you during the past 12 months  
communicated with any of the services  
above by using the Internet?  ................................................................ c c




Hospital admission  ............................................................................................... c c
Visited an out-patient clinic:
Psychiatric out-patient clinic   ................................................................... c c
Other out-patient clinics (not psychiatric  
department)  .................................................................................................................. c c
The questionnaire will be optically read. Please, use blue  
or black inked pen only. Use block lettering. Refrain from 
the use of comma.
Date for filling in the questionnaire:
2015 – 2016
CONFIDENTIAL
4. USE OF MEDICIN






Blood pressure lowering drugs  ............. c c c
Cholesterol lowering drugs  ........................ c c c
Diuretics  ............................................................................... c c c
Drugs for heart disease (for example 
anticoagulants, antiarrhythmics,  
nitroglycerin)?  ................................................................. c c c
Insulin  ...................................................................................... c c c
Tablets for diabetes  ............................................... c c c
Drugs for hypothyroidism (Levaxin 
or thyroxine)? .................................................................. c c c
4.2  How often during the past four weeks have you used?  
Tick once for each line.
Not used  





week but  
not daily Daily
Painkillers on  
prescription  ....................... c c c c
Painkiller non- 
prescription  ........................ c c c c
Acid suppressive  
medication  .......................... c c c c
Sleeping pills  .................... c c c c
Tranquillizers  .................... c c c c
Antidepressants   ......... c c c c
4.3  State the name of all medicines, both those on prescription 
and non-prescription drugs, you have used regularly during the 
last 4 weeks. Do not include nonprescription vitamin-, mineral- and 
food supplements, herbs, naturopathic remedies etc.
If there is not enough space for all medicines, continue on a separate sheet.
5. DIET
5.1  Do you usually eat breakfast every day? 
c No c Yes
5.2  How many units of fruit or vegetables do you eat on average 
per day? One unit is by example one apple, one  
salad bowl.
Number of units   
5.3  How often do you eat these food items? 




















Red meat (All products  
from beef, mutton, pork)?  ............... c c c c c
Fruits, vegetables, and berries?  ..... c c c c c
Lean fish (Cod, Saithe)?  .................... c c c c c
Fat fish (salmon, trout, redfish, 
mackerel, herring, halibut)?  ........... c c c c c
5.4  How many glasses / containers of the following do you  
normally drink / eat? Tick once for each line.














Milk / Yogurt with  
probiotics (Biola, 
Cultura, Activia, 
Actimel, BioQ etc.)  .......... c c c c c
Fruit juice  ................................... c c c c c
Soft drinks with sugar  . c c c c c
Soft drinks with artifi-
cial sweeteners ..................... c c c c c
5.5  How many cups of coffee or tea do you usually drink daily?  
Put 0 for the types you do not drink daily.
Number of cups
Filtered coffee  ...........................................................................................................................................
Boiled coffee / french plunger coffee (coarsely ground coffee 




Cups of espresso-based coffee (from coffee-machines,  
capsules etc.)  ................................................................................................................................................
 
Black tea (e.g. Earl Grey, Black currant)  .......................................................................
 
Green tea / white tea / oolong tea  ...................................................................................
 
Herbal tea (e.g. rose hip tea, chamomile tea, Rooibos tea) .................
6. HEALTH ANXIETY
Not at all A little bit Moderately Quite a bit A great deal
6.1  Do you think there is something seriously wrong with your body? c c c c c
6.2  Do you worry a lot about your health? c c c c c
6.3  Is it hard for you to believe the doctor when he / she tells you 
there is nothing to worry about?
c c c c c
6.4  Do you often worry about the possibility that you have a serious 
illness?
c c c c c
6.5  If a disease is brought to your attention (e.g., on TV, radio, the 
internet, the newspapers, or by someone you know), do you worry 
about getting it yourself?
c c c c c
6.6  Do you find that you are bothered by many different symptoms? c c c c c
6.7  Do you have recurring thoughts about having a disease that is  
difficult to be rid ofom?
c c c c c
7. PHYSICAL ACTIVITY
7.1  If you are in paid or unpaid work, which statement describes 
your work best? Tick the most apprioate box.
c Mostly sedentary work? 
(e.g. office work, mounting))
c Work that requires a lot of walking  
(e.g. shop assistant, light industrial work, teaching)
c Work that requires a lot of walking and lifting  
(e.g. nursing, construction)
c Heavy manual labour
7.2  Describe your exercise and physical exertion in leisure time 
over the last year. If your activity varies throughout the year, give an 
average. Tick the most appropriate box.
c Reading, watching TV / screen or other sedentary activity?
c
Walking, cycling, or other forms of exercise at least 4 hours  
a week? (including walking or cycling to  place of work, Sunday-
walking etc.)
c Participation in recreational sports, heavy gardening, snow  
shoveling etc. at least 4 hours a week.
c Participation in hard training or sports competitions, regularly 
several times a week?
7.3  During the last week, how much time did you spend sitting on 
a typical week or weekend day? E.g., at a desk, while visiting friends, 
while watching TV / screen.
 
Hours sitting on a weekday (both work and leisure hours)
 
Hours on a weekend day 
8. ALCOHOL
8.1  How often do you drink alcohol?? 
c Never
c Monthly or less frequently 
c 2–4 times a month
c 2–3 times a week 
c 4 or more times a week
8.2  How many units of alcohol (1 beer, glass of wine or drink) do 
you usually drink when you drink alcohol?
1–2 3–4 5–6 7–9 10 or more
c c c c c
8.3  How often do you have six or more units of alcohol in one 
occasion??
c Never
c Less frequent than monthly 
c Monthly
c Weekly
c Daily or almost daily
9. TOBACCO and SNUFF
9.1  Do you / did you smoke daily?
c Never c Yes, now c Yes, previously
9.2  Have you used or do you use snuff or chewing tobacco daily?
c Never c Yes, now c Yes, previously
11. EDUCATION AND INCOME
11.1  What is the highest levels of education you have completed? 
Tick one box only.
c Primary / partly secondary education. (Up to 10 years of schooling)
c Upper secondary education: (a minimum of 3 years)
c Tertiary education, short: College / university less than 4 years
c Tertiary education, long: College / university 4 years or more
11.2  What was the household’s total taxable income last year? 
Include income from work, social benefits and similar.
c Less than  150 000 kr c 451 000–550 000 kr
c 150 000–250 000 kr c 551 000–750 000 kr
c 251 000–350 000 kr c 751 000 –1 000 000 kr
c 351 000–450 000 kr c More than 1 000 000 kr
12. FAMILY AND FRIENDS
12.1  Who do you live with? 
Yes No Number
Spouse / partner  ........................................................................................... c c
Other persons over 18 years  ....................................................... c c
Persons under 18 years  ...................................................................... c c
12.2  Do you have enough friends who can give you help and 
support when you need it?
c Yes c No
12.3  Do you have enough friends that you can talk confidentially 
with?
c Yes c No
12.4  How often do you take part in organised gatherings, e.g., sports 
clubs, political meetings, religious or other associations?
Never, or just a 
few times a year    




More than  
once a week
c c c c
13. WOMAN ONLY
13.1  How old were you when you first started menstruating? 
Age    
13.2  Are you pregnant at the moment?
c No c Yes c Uncertain
13.3  How many children have you given birth to? 
Number   
13.4  If you have given birth, how many months did you breast-
feed? Fill in for each child the birth year, birth weight and the 
number of months breast feeding. Fill in the best you can
Birth year
Birth weight  
in grams









14.1  Have you ever had an inflammation of your prostate / urine 
bladder?
c No c Yes
14.2  Have you ever had a vasectomy?
c No c Yes If yes: Which year was it
10. QUESTIONS ABOUT CANCER
10.1  Have you ever had
No Yes If yes: Age first time If yes: Age last time
A mammogram  ..................................................................................................................................................................... c c
Your PSA (Prostate Specific Antigen) level measured)  ...................................................... c c
A colon examination (colonoscopy, stool sample test)  ................................................... c c









grandfather Aunt Uncle Sibling
Breast cancer  ............. c c c c c c c c c c
Prostate cancer ....... c c c c c c
Colon cancer  ............. c c c c c c c c c c




Relevant questions from  











2.7 Biological children  
2.11 Is your mother alive? 
No Yes 
If Yes, skip to 2.9. 
If No: 
2.11.1 What was your mother’s age at death?
Age at death__ 
2.12 Is your father alive?
No  Yes 
If Yes, skip to 2.10. 
If No: 
2.12.1 What was your father’s age at death?
Age at death__
5 







4.1 What is your main occupation/activity? 





Disability benefit recipient/work assessment allowance 
Family income supplement 
Unemployed 
Student/military service 
4.2 I consider my occupation to have the following social status in society (if not 
currently employed, consider you latest occupation): 
Very high social status
Fairly high social status
Neither high nor low social status
Fairly low social status
Very low status
7 
5 ILLNESS AND WORRIES 
Have you had any of the following illnesses or worries? 
No Yes      Age first time
5.1 Have you had coronary artery bypass surgery? 
5.2 Have you had percutaneous coronary intervention? 
5.3 Do you have or have you had claudicatio intermittens? 
13 
9 MEMORY 
Please answer the questions below regarding your memory: 
(Tick once for each line) 
9.1 Has your memory declined?
No Yes 
If No on 9.1-9.4, skip to 10.1. 
If Yes on one or more on 9.1-9.4: 
9.1.1 Is your memory a problem in your daily life?
No  Yes
20 
17 PAINKILLERS AND ANTIINFLAMMATORIC MEDICINES 
17.1 Have you used analgesics and anti-inflammatory medication regularly in the 
past year?  (i.e. acetylsalicylic acid, paracetamol, ibuprofen, diclofenac, naproxen)?
These include both over-the-counter and prescription only medicines, also including acetylsalicylic acid, which is used in 
low dosage as a blood thinning drug.  
No     Yes
If No, skip to 18.1. 
If Yes: 
Which analgesics and anti-inflammatory medication have your used the past year? 
(Tick one or more) 
17.1.1 «Baby» or low dose of Acetylsalicylic acid 
(75 mg or 160 mg per tablet, i.e. Acetylsalicylic acid® i.e Albyl-E® Asasantin Retard®)
No  Yes
29 
18 MEDICINE INFORMATION 
18.1 Have you used medicines (nonprescription and prescription) regularly during the 
last 4 weeks? Do not include dietary supplements (vitamins, minerals, omega-3, herbs or other natural remedies) 
No  Yes 
If No, skip to 19.1. 
If Yes: 
Either because of forgetfulness, inconvenience or because they do not want to, it is common that people not always 
take the medicine they have been prescribed.  The following questions concern your habits when taking your 
medicine.  
18.1.14 How many times a week do you forget to take your medicines? 
Less than once a week
Once a week 
2-4 times a week 
5 times a week or more 
18.1.15 How many times a week do you decide to miss out your medicines? 
Less than once a week
Once a week 
2-4 times a week 
5 times a week or more 
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19 PHYSICAL ACTIVITY 
19.1 How often do you exercise? 
(i.e. walking, skiing, swimming or training/sports) 
Never 
Less than once a week 
Once a week 
2-3 times a week 
Approximately every day
If Never, skip to 20.1. 
If >Never: 
19.1.1 If you exercise - how hard do you exercise? 
Easy - you do not become shortwinded or sweaty 
You become shortwinded and sweaty 
Hard - you become exhausted  
19.1.2 For how long time do you exercise? (give an average) 
Less than 15 minutes
15-29 minutes  
30-60 minutes  
More than 1 hour 
32 
20 FOOD HABITS 
Do you use the following food supplements? 
(Tick once for each line) 
No Sometimes Daily during the winter season   Daily 
20.17 Cod liver oil or cod liver oil capsules 
20.18 Omega 3 capsules (fish oil, seal oil)   
45 
As exact as you can, give an estimate of your alcohol habits. Keep the past year in mind when filling in. 
31.1.1-31.1.8.2 
How often the past year have you: 
Never    Less than monthly Monthly Weekly  Daily
31.1.1.9 Not been able to stop drinking alcohol when first started? 
31.1.1.10 Failed to do what was normally expected from you because of drinking? 
31.1.1.11 Needed alcohol in the morning to get yourself going after a heavy drinking session? 
31.1.1.12 Had a feeling of guilt or remorse after drinking? 
31.1.1.13 Been unable to remember what happened the night before because you had been drinking? 
31.1.1.14 Drunk so much that you felt highly intoxicated (drunk)? 
How often the past year have you: 
Never    Yes, but not during the past year Yes, during the past year 
31.1.1.15 Have you or someone else been injured because of your drinking? 
31.1.1.16 Has a relative or friend or a doctor or another health worker been concerned about your 
drinking or suggested you cut down? 
47 
DAILY SMOKING 
33.1 Do you/did you smoke daily?
Never Yes, now   Yes, previously 
If Never, skip to 33.2 
If Yes, now or Yes, previously 
DAILY SMOKING  
33.1.1 How old were you when you began smoking daily?
Age__ 
33.1.2 How many years in all have you smoked daily?
Number of years__ 
33.1.3 How many cigarettes do you or did you usually smoke per day?
Number of cigarettes ____
If Yes, previously on 33.1:  
33.1.4 If you previously smoked daily, how long is it since you stopped?
Number of years__
OCCASIONAL SMOKING 
33.2 Do you smoke, or have you smoked sometimes, but not daily?
Never  Yes, now     Yes, previously 
If Never, skip to 33.3. 
If Yes, now or Yes, previously: 
OCCASIONAL SMOKING 
33.2.1 How many cigarettes do you or did you usually smoke per day?
Number of cigarettes__
DAILY USE OF SNUFF  
33.3 Have you used or do you use snuff or chewing tobacco?
Never   Yes, now   Yes, previously 
If Never, skip to 33.4. 
If Yes, now or Yes, previously? 
DAILY USE OF SNUFF 




33.3.2 How many years in all have you used snuff or chewing tobacco?
Number of years____
33.3.3 If you use or have used snuff - how many portions do/did you take in a week?
Number of portions ____
If Yes, previously on 33.3: 
DAILY USE OF SNUFF 
33.3.4 If you used snuff daily previously, how many years since you stopped?
Number of years__ 
OCCASIONAL SNUFF USE 
33.4 Do you use, or have you used snuff sometimes, but not daily?
Never   Yes, now   Yes, previously 
If Never, skip to 34.1  
If Yes, now or Yes, previously: 
OCCASIONAL SNUFF USE 
33.4.1 How many portions did you/do you usually take in a week?
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2015/1775  Identifikasjon av faktorer som kan hindre optimal legemiddelbehandling hos personer
med koronarsykdom i befolkningen 
 UiT Norges arktiske universitetForskningsansvarlig:
 Marit WaasethProsjektleder:
Vi viser til søknad om forhåndsgodkjenning av ovennevnte forskningsprosjekt. Søknaden ble behandlet av
Regional komité for medisinsk og helsefaglig forskningsetikk (REK nord) i møtet 15.10.2015. Vurderingen
er gjort med hjemmel i helseforskningsloven (hfl.) § 10, jf. forskningsetikkloven § 4.
Prosjektleders prosjektomtale
Informasjon om nytte og risiko ved legemiddelbehandlingen er viktig for å oppnå god etterlevelse, som igjen
er viktig for å nå behandlingsmål. Prosjektet vil identifisere faktorer som hindrer optimal
legemiddelbehandling. Det kan være faktorer knyttet til legemiddelbrukerne, f.eks. problemer med
etterlevelsen grunnet bekymring for bivirkninger, eller det kan være at legemiddelregimet ikke er i henhold
til behandlingsretningslinjene. Vi vil undersøke om oppnåelse av behandlingsmålene ved koronar
hjertesykdom (blodtrykk, lipider og blodsukker) har sammenheng med - Legemiddelregime blant
studiedeltakerne, samsvar med behandlingsretningslinjene - Legemiddelbrukernes etterlevelse, målt ved
spørreskjema og ved reseptuttak - Deltakernes syn på legemiddelinformasjonen de har mottatt, bekymringer
omkring legemiddelbruk og etterlevelse Med en svarprosent på 70 % og en prevalens av koronar
hjertesykdom på 8,4 %, forventes at ca. 1900 av 23 000 deltakere i Tromsø 7 har koronarsykdom.
Vurdering
Design
Man ønsker å bruke data fra deltakere i Tromsø 7 som har koronarsykdom og har avgitt
spørreskjemainformasjon, sosiodemografi, resultater fra analyser i biologisk materiale, antropometriske
målinger og kliniske undersøkelser. Disse data ønskes koblet opp mot reseptregisteret.
Vurdering av om det avgitte samtykke er dekkende for koblingen
Det fremgår av det avgitte samtykket at det kan gjøres koblinger mot Reseptregisteret, og forsking på
hjertesykdommer er et av hovedtema for Tromsøundersøkelsene. Komiteen anser således at det avgitte
samtykket er dekkende for det som skal gjøres i studien.
Vedtak
Med hjemmel i helseforskningslovens §§ 2 og 10 godkjennes prosjektet.
Sluttmelding og søknad om prosjektendring
Prosjektleder skal sende sluttmelding til REK nord på eget skjema senest 30.06.2031, jf. hfl. §
12. Prosjektleder skal sende søknad om prosjektendring til REK nord dersom det skal gjøres vesentlige
endringer i forhold til de opplysninger som er gitt i søknaden, jf. hfl. § 11.
Klageadgang
Du kan klage på komiteens vedtak, jf. forvaltningsloven § 28 flg. Klagen sendes til REK nord. Klagefristen
er tre uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av REK nord, sendes klagen videre til
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Marit Waaseth
 Universitetet i Tromsø
2015/1775 Identifikasjon av faktorer som kan hindre optimal legemiddelbehandling hos personer med
koronarsykdom i befolkningen
 Institutt for farmasiForskningsansvarlig institusjon:
 Marit Waaseth Prosjektleder:
Vi viser til søknad om prosjektendring datert 12.05.2016 for ovennevnte forskningsprosjekt. Søknaden er
behandlet av REK nord på fullmakt, med hjemmel i helseforskningsloven § 11.
Vurdering 
Vi viser til skjema for prosjektendring av 12.05.16 vedlagt revidert prosjektbeskrivelse.
Prosjektleder ber om å få utsatt startdato frem til 01.01.17. Bakgrunnen for dette skyldes at prosjektet ikke
har fått nødvendige midler til oppstart.
REK har ingen innvendinger til dette.
Videre søkes om det om koble data fra Tromsø 7 opp mot Tromsøundersøkelsens endepunktsregister for
kardiovaskulær sykdom. Registeret inneholder informasjon fra journaler ved Universitetssykehuset i
Nord-Norge.
Vurdering av om samtykke for Tromsø 7 er dekkende for koblingen
I samtykkeskrivet for Tromsø 7 er det samtykket til kobling av de innsamlede data opp mot sentrale register,
samt journaldata.
Ettersom endepunktsregisteret er et selvstendig register som inneholder journaldata, anser REK at den
omsøkte kobling ligger godt innenfor det avgitte samtykke. Samtykkeskrivet er dekkende for den omsøkte
kobling.
Etter fullmakt er det fatte slikt
Vedtak 
Med hjemmel i helseforskningsloven § 11, godkjennes prosjektendringene. 
Klageadgang
Du kan klage på komiteens vedtak, jf. forvaltningsloven § 28 flg. Klagen sendes til REK nord. Klagefristen
er tre uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av REK nord, sendes klagen videre til






Kopi til: thrina.loennechen@uit.no  
Region: Saksbehandler: Telefon:  Vår dato: Vår referanse:
REK nord Veronica Sørensen 77620758  07.03.2019 2015/1775/REK nord
 Deres dato: Deres referanse:
 27.02.2019
 
Vår referanse må oppgis ved alle henvendelser
Besøksadresse:







All post og e-post som inngår i
saksbehandlingen, bes adressert til REK
nord og ikke til enkelte personer
 
Kindly address all mail and e-mails to
the Regional Ethics Committee, REK
nord, not to individual staff
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 Universitetet i Tromsø
2015/1775 Identifikasjon av faktorer som kan hindre optimal legemiddelbehandling hos personer med
koronarsykdom i befolkningen
 Institutt for farmasi, UiT - Norges arktiske universitetForskningsansvarlig institusjon:
 Marit Waaseth Prosjektleder:
Vi viser til søknad om prosjektendring datert 27.02.2019 for ovennevnte forskningsprosjekt. Søknaden er
behandlet av  REK nord på fullmakt, med hjemmel i helseforskningsloven § 11.
Vurdering
Vi viser til skjema for prosjektendring av 27.02.19.
Endringen gjelder utvidelse av reseptuthenting fra ATC-gruppeC og B01AC06 til alle ACT koder, det søkes
også om å gå lengre tilbake i tid. Omsøkte periode for uthenting av data for reseptuttak vil være fra 1.1.2004
til 31.12.2016.
REK legger til grunn at man fortsatt tar utgangspunkt i deltakere fra Tromsø 7 som har koronarsykdom og
har avgitt spørreskjemainformasjon, sosiodemografi, resultater fra analyser i biologisk materiale,
antropometriske målinger og kliniske undersøkelser og at det er disse data som ønskes koblet opp mot
reseptregisteret.
Vurdering av om det avgitte samtykke er dekkende for koblingen
Det fremgår av det avgitte samtykket at det kan gjøres koblinger mot Reseptregisteret, og forsking på
hjertesykdommer er et av hovedtema for Tromsøundersøkelsene. Komiteen anser således at det avgitte
samtykket er dekkende for det som skal gjøres i studien.
 REK har ingen innvendinger til den omsøkte endringen.
Vedtak 
Med hjemmel i helseforskningsloven § 11 godkjennes prosjektendringen.
 
Klageadgang
Du kan klage på komiteens vedtak, jf. helseforskningsloven § 10 og forvaltningsloven § 28 flg. Klagen
sendes til REK nord. Klagefristen er tre uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av
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2015/1775 Identifikasjon av faktorer som kan hindre optimal legemiddelbehandling hos personer med
koronarsykdom i befolkningen
 Institutt for farmasi, UiT - Norges arktiske universitetForskningsansvarlig institusjon:
 Marit Waaseth Prosjektleder:
Vi viser til søknad om prosjektendring datert 17.6.2019. Søknaden er behandlet av Regional komité for
medisinsk og helsefaglig forskningsetikk (REK nord) ved sekretariatsleder, etter fullmakt gitt av komiteen
med hjemmel i forskningsetikkforskriften § 7, første ledd, tredje punktum. Søknaden er vurdert med
hjemmel i helseforskningsloven § 11.
Vurdering
Prosjektleder opplyser i endringssøknaden at endringen gjelder inklusjon av 2 nye prosjektmedarbeidere,
herunder en ph.d.-student og en mastergradsstudent. Endringen er begrunnet med at «noen må gjøre
analysene slik at prosjektet kommer godt i havn.»
REK har ingen innvendinger til den omsøkte endringen. Det forutsettes at prosjektet til
mastergradsstudenten ligger innenfor formålet til hovedprosjektet 2015/1775.
Etter fullmakt er det fattet slikt
Vedtak 
Med hjemmel i helseforskningsloven § 11 godkjennes prosjektendringen.
Vi gjør samtidig oppmerksom på at etter ny personopplysningslov må det også foreligge et
behandlingsgrunnlag etter personvernforordningen. Dette må forankres i egen institusjon.
Klageadgang
Du kan klage på REKs vedtak, jf. helseforskningsloven § 10 og forvaltningsloven § 28 flg. Klagen sendes til
REK nord. Klagefristen er tre uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av REK nord,
sendes klagen videre til Den nasjonale forskningsetiske komité for medisin og helsefag for endelig
vurdering.
Til informasjon bytter REK søknadsportal i sommer. Den nye portalen vil være klar i august. Se våre
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NSD – Personvernkonsekvensvurdering 
Prosjektopplysninger 
 
Prosjekttittel: Barriers to optimal medication therapy and treatment goal achievement 
among persons with coronary heart disease  
 
Behandlingsansvarlig: Universitetet i Tromsø 
 




Om konsekvensvurdering (DPIA) 
 
NSD har gjennomgått innholdet i meldeskjemaet. Det er vår vurdering at den planlagte 
behandlingen av personopplysninger vil innebære relativt høy risiko for de registrertes 
rettigheter og friheter, og dermed krever en personvernkonsekvensvurdering (DPIA), jf. 
personvernforordningen art. 35.  
 
Dette fordi den planlagte behandlingen av personopplysninger innebærer:  
 Behandling av særlige kategorier av personopplysninger 
 Behandling av personopplysninger i stor skala (stort antall registrerte, mengde 
opplysninger og lang varighet) 
 Sammenstilling av datasett  
 
På oppdrag fra UiT sin ledelse, har NSD i samråd med prosjektansvarlig og rådgivere ved 
institusjonen laget utkast til en DPIA som inneholder:  
1) En systematisk beskrivelse av den planlagte behandlingen av personopplysninger. 
2) Vurdering av om behandlingsaktivitetene er nødvendige og står i rimelig forhold til 
formålene.  
3) Analyse av risiko for de registrertes rettigheter og friheter.  
4) Planlagte tiltak for å håndtere risikoene.  
 
Ved å følge de planlagte tiltakene, mener NSD at personvernrisikoen er redusert i en slik 
grad at behandlingen kan gjennomføres i samsvar med personvernforordningen, uten 
forhåndsdrøfting med Datatilsynet.  
 
Behandlingsansvarlig institusjon (v/ledelsen) bestemmer om 
personvernkonsekvensvurderingen er tilfredsstillende utført, og om personvernrisikoen er 
redusert til et akseptabelt nivå slik at behandlingen kan gjennomføres, eller om det er 
nødvendig med forhåndsdrøfting (se del 6 – Ledelsens beslutning). Dette etter å ha rådført 
seg med sitt personvernombud og tatt hensyn til eventuelle adferdsnormer.  Vi oversender 
derfor vår vurdering til UiT og personvernombud for godkjenning. NSD ber om å få tilsendt 
endelig versjon av DPIA med ledelsens beslutning i signert form. 




Dersom behandling av personopplysninger igangsettes på grunnlag av DPIA, og deretter 
endres, minner vi om at endringene kan medføre behov for ny eller oppdatert DPIA. 
Prosjektansvarlig skal melde endringer til NSD, og institusjonen har ansvar for å påse at dette 
skjer. NSD vil ta kontakt hvert annet år. Ved melding om endringer i prosjektet, vil NSD bistå i 
vurderingen av om ny DPIA er nødvendig og utfører i så fall denne i samråd med UiT sin 
ledelse og personvernombud.  
 
Følgende personer har deltatt i personvernkonsekvensvurderingen:  
 
Navn Rolle/funksjon Virksomhet 
Trine Anikken Larsen Seniorrådgiver NSD Norsk senter for 
forskningsdata 
Marit Waaseth Prosjektleder og hovedveileder for 
PhD-student 
UiT Norges arktiske 
universitet 
Elisabeth Pedersen PhD-stipendiat og daglig ansvarlig UiT Norges arktiske 
universitet 
Anne Elise Eggen Vitenskapelig leder for den sjuende 
Tromsøundersøkelsen og biveileder 
for stipendiaten 
UiT Norges arktiske 
universitet 
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Personvernkonsekvensvurdering - DPIA 
1. Systematisk beskrivelse av planlagte 
behandlingsaktiviteter og formål 
 
Her følger en ren beskrivelse av den planlagte behandlingen av personopplysninger, slik den 
er oppgitt i meldeskjema med vedlegg. Vurdering av behandlingen følger i del 2 og 3.  
 
1.1 Bakgrunnen for DPIA i prosjektet 
 
Prosjektet fikk konsesjon av Datatilsynet i vedtak datert 14.03.2018. I etterkant av 
konsesjonsvedtaket har prosjektansvarlig ønsket å legge til variabelen ApotekKonsesjonNr 
fra Reseptregisteret. Variabelen forteller hvor mange apotek deltakerne benytter seg av.  
 
På grunn av en uklar formulering fra NSD sin side ble det oppfattet slik at kun personer med 
hjerte- og karsykdom skulle inngå som en del av utvalget, det vil si cirka 1800 personer. 
Dette ble også lagt til grunn i konsesjonsvedtaket fra Datatilsynet. Prosjektansvarlig ønsker 
imidlertid å benytte data fra samtlige av deltakerne fra den syvende runden av 
Tromsøundersøkelsen (Tromsø 7), det vil si til sammen 21 083 personer.  
 
Sammenholdt med at prosjektet behandler særlige kategorier (sensitive) personopplysninger 
om helse, at prosjektet har lang varighet (31.12.2030) og at utvalget består av en stor andel 




Formålet med prosjektet er å identifisere faktorer som hindrer optimal 
legemiddelbehandling. Det kan være faktorer knyttet til legemiddelbrukerne, f.eks. 
problemer med etterlevelsen grunnet bekymring for bivirkninger, eller det kan være at 
legemiddelregimet ikke er i henhold til behandlingsretningslinjene. Forskerne vil derfor 
undersøke om oppnåelse av behandlingsmålene ved koronar hjertesykdom (blodtrykk, 
lipider og blodsukker) har sammenheng med:  
 
- Legemiddelregime blant studiedeltakerne, samsvar med behandlingsretningslinjene 
- Legemiddelbrukernes etterlevelse, målt ved spørreskjema og ved reseptuttak 
- Deltakernes syn på legemiddelinformasjonen de har mottatt, bekymringer omkring 




Utvalget består av deltakere fra den syvende runden av Tromsøundersøkelsen (Tromsø 7). 
Dette vil totalt utgjøre 21 083 personer.  
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1.4 Type og omfang personopplysninger 
 
Prosjektet innebærer behandling av alminnelige personopplysninger og behandling av 
særlige kategorier (sensitive) personopplysninger om helse.  
 
Fra Tromsøundersøkelsen hentes det følgende opplysninger: Dato for deltakelse, 
sosiodemografi (fødselsår, kjønn, utdanning, jobbsituasjon), selvrapportert sykdom, plager 
og helsetilstand, legemiddelbruk, bruk av helsetjenester, livsstil (diett, røyk/snus, alkohol, 
fysisk aktivitet), familieforhold, behov for legemiddelinformasjon (type informasjon mottatt, 
hjelp til å ta medisin, informasjonsbehov), bekymringer angående legemidler, selvrapportert 
etterlevelse (glemmer/lar være å ta medisin), generell helsebekymring, antropometriske 
målinger (høyde, vekt, blodtrykk) og analyser i biologisk materiale (glukose, lipider). Det 
vises til detaljert variabelliste fra Tromsøundersøkelsen, se vedlegg 1.  
 
Fra Reseptregisteret hentes det opplysninger om følgende:  
- Forskriver: Fødselsår, kjønn, profesjon og spesialitet* 
- Pasient: Fødselsdato 
- Resept/ordinasjon: Utleveringsdato, utsalgspris og totale antall, reseptkategori, 
hjemmel og refusjonspunkt iht. blåreseptforskrift 
- Legemiddel: Produktnavn, informasjon om legemiddelets styrke, enheter og 
dosering, ATC-koder, varegrupper, tidspunkt for utlevering og apotekets utsalgspriser 
- I tillegg innhentes variabelen ApotekKonsesjonNr som var søkt i opprinnelig 
konsesjonssøknad til Datatilsynet i 2018, se vedlegg 3.  
 




Data skal hentes fra følgende registre: Tromsøundersøkelsen og Reseptregisteret. 
Opplysningene er samlet inn og administrert av Universitetet i Tromsø og FHI, og disse 
institusjonene vil utlevere data etter kontrakt.  
 
1.6 Hvordan personopplysningene skal behandles 
 
Behandling av personopplysninger innebærer sammenstilling/kobling av data. Allerede 
innhentede opplysninger fra Tromsø 7 undersøkelsen vil sammenstilles med utvalgte 
variabler fra Reseptregisteret. Utlevering og sammenstilling vil skje i henhold til Universitetet 
i Tromsø og FHI sine rutiner.  
 
1.7 Dataflyt: Lagringsenheter, kanaler for sending/deling, koblingsprosedyre 
 
Opplysningene er samlet inn og administrert av Universitetet i Tromsø og 
Folkehelseinstituttet (FHI), og disse institusjonene utleverer data til forskere etter kontrakt.  
 
Datafilene i Tromsøundersøkelsen oppbevares i EUTRO. EUTRO-personell klargjør filene, 
sender dem til Reseptregisteret for kobling og utleverer dem til forskerne etter at koblingen 
er foretatt. Forskerne får utlevert filer uten personnummer, personlige koder i 
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Tromsøundersøkelsen (perskey) eller koder som gjør at det mulig å identifisere personer 
eller koble filene til andre datamaterialer.  
 
Kobling av data vil skje i henhold til FHI/Reseptregisterets rutine for sammenstilling som 




Etter at sammenstillingen er utført vil koblingsnøkkelen oppbevares av SSB.  
 
Overføring av forskningsfiler fra Tromsøundersøkelsen følger oppsatte retningslinjer. Et 
fildelingsprogram med passordbeskyttelse (Uninett Filesender 2.0) vil bli brukt for å sende 
filene over internett.  
 
Filen (avidentifisert) vil bli levert til stipendiaten (Elisabeth Pedersen) etter Reseptregisterets 
prosedyrer, og hun vil jobbe med den på sin universitets-PC ved Institutt for farmasi, og ha 
den lagret på sitt universitetsserverområde. Eventuell videreformidling av data i filen vil kun 
skje til andre prosjektmedarbeidere (navngitt i dokumentet) ved hjelp av universitetets 
system for sikker filoverføring (dvs. med passord). For de fleste av medarbeiderne vil det 
være lite aktuelt å ha tilgang til dataene direkte. Hovedsakelig er det prosjektansvarlig og 
statistikerne (Frode Skjold og Raul Primicerio) som vil ha tilgang til data etter avtale med 
stipendiaten og ved sikker filoverføring fra henne. De andre vil kun få tabellresultater fra 
analysene til felles tolkning/vurdering. 
 
Det skal kun foretas én kobling. Dette innebærer at data hentes ut kun én gang fra både 
Tromsøundersøkelsen og Reseptregisteret.  
 
1.8 Hvem vil få tilgang til personopplysninger?  
 
I dette prosjektet vil følgende kategorier av mottakere ha tilgang til personopplysninger:  
Elisabeth Pedersen, Marit Waaseth, Anne Elise Eggen, Beate H. Garcia, Lars Småbrekke, Kjell 




Prosjektperioden er satt frem til 31.12.2030. Prosjektdata vil slettes ved prosjektslutt. 
 
Datamaterialet må være tilgjengelig inntil alle artiklene i doktorgradsprosjektet er publisert, 




REK har vurdert at prosjektet faller innenfor helseforskningslovens virkeområde 
(referansenummer 2015/1775). REK har i vedtak av 26.10.2015 (vedlegg 4), samt senere 
vedtak om prosjektendring datert 31.05.2016, godkjent prosjektet (vedlegg 5).  
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2. Vurdering av om behandlingsaktivitetene er nødvendige og står i 
rimelig forhold til formålene 
 
Prosjektets formål er å identifisere faktorer som hindrer optimal legemiddelbehandling. Det 
kan være faktorer knyttet til legemiddelbrukerne, f.eks. problemer med etterlevelsen 
grunnet bekymring for bivirkninger, eller det kan være at legemiddelregimet ikke er i 
henhold til behandlingsretningslinjene. Det skal undersøkes om oppnåelse av 
behandlingsmålene ved koronar hjertesykdom (blodtrykk, lipider og blodsukker) har 
sammenheng med:  
- Legemiddelregime blant studiedeltakerne, samsvar med behandlingsretningslinjene 
- Legemiddelbrukernes etterlevelse, målt ved spørreskjema og ved reseptuttak 
- Deltakernes syn på legemiddelinformasjon de har mottatt, bekymringer omkring 
legemiddelbruk og etterlevelse 
 
Utvalget hentes fra Tromsø 7 som er en delstudie under Tromsøundersøkelsen, og 
innbefatter personer med hjerte- og karsykdommer. Tromsøundersøkelsen er en prospektiv, 
populasjonsbasert helseundersøkelse som startet i 1974. Mer enn 45 000 personer har 
deltatt i en eller flere av de syv rundene av undersøkelsene som er gjennomført. Den store 
oppslutningen har sikret kvaliteten på helseundersøkelsen og de vitenskapelige resultatene.  
 
NSD vurderer samfunnsnytten i prosjektet til å være vesentlig og at behandlingsaktivitetene er 
nødvendige og står i rimelig forhold til formålene. 
 
2.1 Rettslig grunnlag for behandling av personopplysninger 
 
Prosjektet er basert på samtykke fra deltakerne i Tromsøundersøkelsen. Lovlig grunnlag for 
behandlingen vil dermed være den registrertes uttrykkelige samtykke, jf. 
personvernforordningen art. 6 nr. 1 a) og art. 9 nr. 2 bokstav a), jf. personopplysningsloven § 
10.  
 
Av informasjonsskrivet fremgår det at kan forskes på hjerte- og karsykdommer, og at 
opplysningene kan kobles mot Reseptregisteret. NSD vurderer informasjonsskrivet til å gi 





Formålet med behandlingen vurderes til å være spesifikk, uttrykkelig angitt og berettiget. 
Deltakerne har avgitt et bredt samtykke i forbindelse med deltakelse i 
Tromsøundersøkelsen. I informasjonsskrivet er det lagt opp til mulige koblinger mot ulike 
helseregistre i fremtiden. Så fremt denne koblingen gjøres i tråd med formålet som er 
beskrevet i prosjektet, vurderer NSD dette til at personopplysninger ikke viderebehandles til 
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NSD vurderer at personopplysningene som behandles i prosjektet er adekvate, relevante, 
nødvendige og begrenset til det som er nødvendig for formålet med behandlingen 
(dataminimering).  
 
For begrunnelser for variabler fra Tromsøundersøkelsen vises det her til vedlegg 2.  
 
Som begrunnelse for variabler som innhentes fra Reseptregisteret angir forskergruppen 
følgende:  
 
Forskriveropplysninger: Pasientforholdet og medication adherence kan tenkes å være 
påvirket av forskrivende leges spesialitet, alder og kjønn. Opplysningene vil bli benyttet i 
multivariate analyser, f.eks. korrespondanseanalyse, for å utforske og muligens identifisere 
adherencemønstre hos pasienter hos de ulike legegruppene. Profesjonsopplysningene vil 
benyttes for å ekskludere forskrivere som ikke er leger.  
 
Pasient: Informasjon om dødsmåned/år er nødvendig for å kunne ekskludere deltakere ved 
dødsfall, siden de ellers vil kunne fremstå som om de har avsluttet behandlingen, det vil si 
feilaktig tolkes som dårlig etterlevelse/adherence.  
 
Legemiddelopplysninger: Opplysningene anses nødvendige for vurdering av legemiddelbruk 
opp mot spørsmålene i Tromsøundersøkelsen.  
 
Variabelen ApotekKonsesjonNr: Variabelen angir hvor mange apotek deltakerne benytter 
seg av. Tidligere studie har funnet ut at antall apotek pasienten forholder seg til kan påvirke 





Prosjektperioden er begrenset til å vare frem til 31.12.2030. Tidsperioden vurderes å være 
begrenset til det som er nødvendig for å gjennomføre prosjektet. Datamaterialet skal slettes 




Kobling av data fra Reseptregisteret vil skje i henhold til FHI sine etablerte rutiner for 
sammenstilling som etablert av FHI.  
 
Overføringen av forskningsfiler fra Tromsøundersøkelsen følger oppsatte retningslinjer. Et 
fildelingsprogram med passordbeskyttelse (Uninett Filesender 2.0) brukes til å sende filene 
over internett. Når forskerne mottar filene vil disse oppbevares på en datamaskin beskyttet 
med brukernavn og passord. Denne er også sikret bak institusjonens brannmur. 
Forskningsfilene vil oppbevares på en datamaskin i nettverkssystem så lenge dataene 
analyseres. Tilgangen til datamaterialet er begrenset til åtte personer som er nevnt under 
punkt 1.9.  
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NSD vurderer dette til å være gode tiltak for å ivareta personopplysningssikkerheten i 
prosjektet.  
 
2.6 De registrertes rettigheter og friheter 
 
Personvernforordningen gir den registrerte en rekke rettigheter (art. 12-22). 
Behandlingsansvarlig har plikt til å informere den enkelte registrerte om behandlingen og 
tilrettelegge for at den registrerte kan utøve sine rettigheter. Rettighetene gjelder så lenge 
det behandles personopplysninger og det er mulig sikkert å identifisere den registrerte.  
 
I dette prosjektet vil deltakerne ha krav på å benytte seg av sin rett til innsyn, retting, 
sletting, begrensning og dataportabilitet. De registrerte kan utøve sine rettigheter ved å 
kontakte Tromsøundersøkelsen, hvorav kontaktinformasjon er oppgitt på prosjektets 
nettsted.  
3. Vurdering av risiko for de registrertes rettigheter og friheter 
 
NSD vil trekke frem konkrete risikoer i prosjektet:  
 
 Prosjektet vil behandle særlige kategorier av personopplysninger (sensitive 
opplysninger) om helseforhold.  
 Det skal innhentes data fra et stort utvalg (21 083 personer).  
 Prosjektet innebærer behandling av personopplysninger over lang tid (31.12.2030).  
 
 




 Data skal kun hentes ut én gang i løpet av prosjektperioden.  
 Tilgangen til datamaterialet er begrenset til en mindre gruppe med personer.  
 Sammenstilling av data fra Reseptregisteret skjer i henhold til Reseptregisterets 
rutine og koblingsnøkkel skal oppbevares av SSB.  
 Det ferdig koblede datamaterialet skal oppbevares på datamaskin beskyttet med 
brukernavn og passord, og i tillegg bak virksomhetens brannmur.  
 Forskningsfilene skal oppbevares på en datamaskin i virksomhetens nettverkssystem 
så lenge dataene er under analyse.  
 
4.2 Vurdering fra eget personvernombud 
 
Personvernombud (PVO) Joakim Bakkevold har kontrollert gjennomføringen av vurderingen 
av personvernkonsekvenser i henhold til GDPR artikkel 35. Etter personvernombudets 
vurdering medfører behandlingen av personopplysninger i prosjektet en høy risiko for de 
registrerte personers rettigheter og friheter og da i hovedsak deres personvernrettigheter. 
Det skal behandles i stor skala opplysninger som faller inn under særlige kategorier, 
Versjon 2 - 7.2.2019/TAL 
9 
 
helseopplysninger, som i utgangspunktet er forbudt, jf. GDPR artikkel 9 nr. 1. Behandlingen 
skal også foregå over lang tid.  
Vurderingen av personvernkonsekvensene inneholder en systematisk beskrivelse av den 
planlagte behandlingen av personopplysninger. Den inneholder en vurdering av om 
behandlingsaktivitetene er nødvendige og står i rimelig forhold til formålene. Den 
inneholder en analyse av risiko for de registrerte rettigheter og friheter og planlagte tiltak 
for å håndtere risikoene. Slik personvernombudet vurderer gjennomføringen av vurderingen 
av personvernkonsekvenser, så er den i tråd med kravene til innhold etter GDPR artikkel 35.  
Personvernombudet gir følgende råd: 
Prosjektet er vurdert av Datatilsynet etter tidligere personvernlovgivning og registrert hos 
NSD i det gamle meldingsarkivet. Behandlingsansvarlig representert av NSD bør oppdatere 
protokollbeskrivelsen av prosjektet, slik at den innholdsmessig blir i tråd med GDPR artikkel 
30.  
Behandlingsansvarlig bør klargjøre hvilke av universitetets systemer, nettverk og maskiner 
som skal benyttes i prosjektet til behandling og lagring av data. Dernest vurdere om disse er 
tilstrekkelig sikret i tråd med risikoen for de registrerte.      
Behandlingsansvarlig bør vurdere spesielt om omfanget, her antall registrerte, av 
behandlingen av personopplysninger i prosjektet er i tråd med prinsippet om 
dataminimering. Datatilsynet har i sin vurdering lagt til grunn at studiet omfatter cirka 1 800 
registrerte. Det riktige er 21 083.   
5. NSD sin samlede vurdering av personvernet 
 
NSD vurderer på grunnlag av ovennevnte tiltak at prosjektet håndterer de identifiserte 
risikoene på en akseptabel måte, og at personvernet således er tilstrekkelig ivaretatt.  
 
 
6. Godkjenning fra institusjonens ledelse 
 
Universitetsledelsen vil påpeke at tidligere konsesjon gitt av Datatilsynet var basert på 
feilaktig antall registrerte. Det presiseres at dette ikke har betydning for denne vurderingen, 
siden dette er en selvstendig vurdering som ikke bygger på Datatilsynets konsesjon. 
 
Ledelsen beslutter og begrunner: 
- DPIA er godkjent/validert: Behandlingen kan starte opp, under følgende 
forutsetninger: 
1. NSD må oppdatere protokollinformasjon om prosjektet 
2. Filen med komplett datagrunnlag (de 21 083 personene) må ha ekstra sikring 
ut over det som følger av hjemmeområdet (H:\), slik som kryptering 
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3. Denne filen, og eventuelle uttrekk fra denne, kan kun åpnes på UiT-eide 
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